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ii Executive summary
Background Infectious diseases cause a considerable burden to pop-
ulation health worldwide. Different types of surveillance systems have
been implemented to assess changes in disease frequency, to identify out-
breaks, and to detect newly emerging diseases aiming at early detection
of epidemics, disease control and prevention. Passive surveillance sys-
tems are mostly used, measuring the ‘incidence of notified cases’ rather
than the incidence (frequency) of disease at population level. Foodborne
pathogens, for example, do not always cause disease in infected indi-
viduals. Sick individuals – mostly presenting with acute gastroenteritis
(AG) – do not always seek healthcare. Of those approaching a physician,
aetiology of disease is investigated only in a fraction of patients. Finally,
not all cases with a positive laboratory finding for a notifiable pathogen
might be reported to the surveillance system. This “loss” of cases along
the so-called burden of illness pyramid – from infection to actual noti-
fication in the surveillance system –, or the factor of underestimation,
depends on the pathogen and the local health (care) system.
Two surveillance systems are implemented in Switzerland which are im-
portant for infectious disease surveillance and early detection: the Na-
tional Notification System for Infectious Diseases (NNSID) and the Swiss
Sentinel Surveillance Network (Sentinella). The NNSID is based on
the Epidemics Act and is the only mandatory surveillance system in
Switzerland covering the entire nation and involving all physicians and
diagnostic laboratories. The Epidemics Act defines which observations
have to be reported to the NNSID and stipulates the time frame for
reporting. Sentinella is a network where information from a subset of
voluntarily participating physicians is collected to study diseases and
health issues at the primary care level.
It was estimated that 31 foodborne hazards caused 33 million Disability
Adjusted Life Years (DALYs) and 600 million cases of illness worldwide
in 2010. In European countries, the incidence of AG was estimated at
0.3–1.5 disease episodes per person-year. Campylobacter spp. is the most
frequent, notifiable, bacterial foodborne disease, both in the European
Union (EU) and in Switzerland and showed increasing trends in the
past decade. In contrast, Salmonella spp. notifications were decreasing
in the EU and in Switzerland while enterohaemorrhagic Escherichia coli
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(EHEC) notifications were increasing in Switzerland but remained stable
in the EU.
In Switzerland, information on foodborne diseases is mostly restricted
to data obtained through the NNSID. Many factors contribute to un-
derestimation and hence, it is unclear how well notification rates reflect
disease incidence.
Objectives This work aimed at contributing to a better understand-
ing of the burden of illness pyramid for foodborne infections in Switzer-
land and, thus, contributing to improve infectious disease surveillance
and control. It sought to investigate the frequency of cases of food-
borne disease or AG at different levels of the burden of illness pyramid.
Further, it should describe trends and understand factors leading to case
registration. Finally, a better understanding of disease epidemiology will
lead to improvements in early disease detection and control.
Methods This research work consisted of several projects character-
ising different levels of the burden of illness pyramid from its tip to the
wide (population) base. In a first step, notification data of Campylobac-
ter , Salmonella and hepatitis A were analysed to describe trends since
1988. Considering that the number of tests conducted can (strongly)
influence the number of cases detected, we studied the trend in the pro-
portion of positive tests out of all tests performed – the positivity rate
– for Campylobacter , Salmonella and EHEC over a 10-year period. Per-
sonnel of diagnostic laboratories was consulted to assess current labor-
atory practices, focussing on the diagnosis of EHEC infections. Fur-
thermore, we conducted a qualitative study among Swiss general practi-
tioners (GPs) to understand physicians’ approaches towards anamnesis
(including diagnosis) and treatment of AG in general and campylobac-
teriosis in particular. Subsequently, these findings were complemented
by a study within Sentinella, where the number of patient consultations
due to AG at primary care level was assessed. Physicians reported all
first consultations due to AG including information on hospitalisation,
stool diagnostics, treatment and inability to work.
Findings of the aforementioned studies, expert consultations and pub-
licly available data were used to explore healthcare costs for AG and
campylobacteriosis in Switzerland for the first time. Four distinct pa-
tient management models were defined for which frequency and indi-
vidual case management costs were estimated. Extrapolations of these
results were used to assess total direct healthcare costs for Switzerland.
Finally, bringing together all study results of the above-mentioned stud-
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ies, we identified the need to understand the burden of AG at the basis –
at the level of the general population. Therefore, a study protocol to in-
vestigate the lowest level of the burden of illness pyramid – the incidence
and aetiology of AG at population-level – was developed.
Results Campylobacter case notifications increased between 1988
and 2013 while Salmonella case notifications decreased. Highest case
numbers for Campylobacter were recorded in 2012 with 8’480 cases. For
Salmonella, peak levels were observed in 1992 with 7’806 cases. While
showing inverse long-term trends, both pathogens follow a similar sea-
sonality pattern with higher case numbers during summer months. In
winter, a short but pronounced peak over Christmas and New Year
was observed for Campylobacter . Positivity rates for Campylobacter in-
creased from 2003 to 2012 while they decreased for Salmonella. At the
same time, the number of tests conducted increased for both pathogens.
Hepatitis A case notifications decreased between 1988 and 2016 in
Switzerland, similar to Salmonella. The strongest decline was observed
in the early 1990’s, starting even before active immunisation was intro-
duced in 1992. At the same time, there was a shift in reported risk
exposures for hepatitis A: Intravenous drug use was the most frequently
mentioned risk exposure at the beginning of reporting while, more re-
cently, contaminated food and beverages were mentioned predominantly
as possible sources of infection. Notification forms and content were
changed multiple times during this 29-year period.
Laboratory experts unanimously think that the increase in EHEC no-
tifications which is observed in the NNSID can be explained by the in-
troduction of multiplex gastrointestinal PCR panels. Those panels also
test for EHEC while traditional culture-based stool testing mostly con-
sidered Campylobacter spp., Salmonella spp. and Shigella spp. only.
Nevertheless, there was also an increase in positivity rate observed for
EHEC from 2007 to 2016 apart from an increase in testing frequency.
Preliminary analysis of surveillance data on testing frequency, which was
collected since the implementation of the new Epidemics Act in 2016,
reveals several issues regarding data quality related to the complex and
heterogeneous “laboratory landscape” in Switzerland.
AG case management of Swiss GPs is diverse. Nevertheless, four dis-
tinct strategies could be identified. The majority of patients is managed
with a “wait & see” approach based on the knowledge that AG is usually
self-limiting. Two of the four approaches include microbiological invest-
igation (stool testing), with antibiotic treatment started either before
or after availability of stool test results. Swiss GPs perceive AG and
xxi
ii Executive summary
campylobacteriosis as diseases of minor importance in their daily work
but acknowledge that they can be disturbing and debilitating for the
individual patient. Surveillance of AG in Sentinella revealed that 8.5%
of AG patients received antibiotic therapy, for 12.3% stool testing was
initiated and 86.3% of employees were not able to work. Extrapolation
of case numbers suggested an incidence of AG at primary care level of
2’146 first consultations per 100’000 inhabitants in Switzerland in 2014.
Direct healthcare costs of AG and campylobacteriosis in Switzerland
were estimated at e29–45 million in 2012. Of these, e8.3 million were
attributed to the 8’480 laboratory-confirmed campylobacteriosis patients
registered in the NNSID. It was estimated that 233’000–629’000 patients
consulted a physician without further stool testing resulting in health-
care costs of e9.0–24.2 million in 2012. Work-loss and other non-health-
care costs associated with AG and campylobacteriosis were not assessed
in this study. However, this socio-economic burden will be explored
in more detail in an upcoming study on the burden of gastroenteritis
in Switzerland (“BUGS study”). The BUGS study was developed to
explore the “true” incidence, burden of disease, aetiology and socio-eco-
nomic impact of AG in Switzerland; to finally understand the entire bur-
den of AG at population level and the level of underestimation of cases
notified to the NNSID. BUGS is a prospective cohort study weekly fol-
lowing up individuals of the general population during a 52-week period.
Furthermore, the presence of four pathogenic bacteria (Campylobacter ,
Salmonella, Shigella and EHEC) and of bacteria harbouring selected
antibiotic resistances (fluoroquinolone, extended-spectrum β-lactamase
(ESBL), carbapenemase and mobilised colistin resistance-1 (mcr-1)) is
assessed in cohort participants during an asymptomatic period.
Conclusions The NNSID is a useful and stable surveillance system
and health system component which is well accepted by stakeholders.
Surveillance data from the NNSID suggest increasing trends for Campy-
lobacter and EHEC and decreasing trends for Salmonella and hepatitis
A. Our complementary research studies come to the same conclusion
even though trends might appear more pronounced (EHEC) or atten-
uated (Salmonella) in the notification system than the true incidence
due to changes in diagnostic procedures. Hence, from what we know
we cannot fully explain the increase of Campylobacter and EHEC seen
in the notification system. Therefore, an increase in disease incidence
or an outbreak must be considered from an epidemiological perspective.
Furthermore, underestimation is probably substantial. Cases seen in the
NNSID are more likely to be severe, have co-morbidities or present with
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well-known risk factors. Assessing all factors contributing to underes-
timation on a regular basis is hardly possible. Instead, complementary
research such as the proposed BUGS study are needed.
The information on disease trends and individual cases obtained through
the NNSID should be restricted to the minimum (with high data qual-
ity) rather than expanded to keep the system as simple and responsive
as possible, providing reliable information. This enables the system to
stay alert to and be prepared for a rapid response in the event of chan-
ging case numbers. Maintaining systems like Sentinella and fostering
strategic research partnerships for action is important to be able to re-
act immediately once an outbreak or a change in disease epidemiology is
suspected. Pathways to provide good evidence for public health policy
and distribute information to stakeholders should be established.
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iii Zusammenfassung
Hintergrund Infektionskrankheiten verursachen weltweit eine be-
trächtliche Krankheitsbürde. Um Änderungen in der Häufigkeit von be-
kannten sowie neuen Infektionskrankheiten festzustellen und Ausbrüche
einzudämmen, werden verschiedene Überwachungssysteme eingesetzt.
Passive Überwachungssysteme sind am weitesten verbreitet. Diese passi-
ven Überwachungssysteme messen nicht die effektive Krankheitshäufig-
keit – die Inzidenz in der Bevölkerung, sondern vielmehr die “Inzidenz der
gemeldeten Fälle”. So zeigen beispielsweise Personen, die mit durch Le-
bensmittel übertragenen Krankheitserregern infiziert sind, nicht immer
Symptome – sie sind asymptomatische Träger. Symptomatische Perso-
nen wiederum – die Erkrankung äussert sich dabei meistens in Form
einer akuten Gastroenteritis – melden sich nicht immer beim Arzt. Wird
ein Arzt aufgesucht, wird die Ursache der Erkrankung zudem nur bei
einem Bruchteil der Patienten mittels weiterführender Labor-Untersu-
chungen abgeklärt. Und letztlich führt ein positiver Laborbefund einer
meldepflichtigen Krankheit nicht immer zu einer Meldung an das Über-
wachungssystem. Die Dunkelziffer, d.h. wie viele Fälle entlang dieser
sogenannten Krankheitspyramide – auf dem Weg von der Infektion bis
zur Erfassung der Krankheitsepisode im Meldesystem – verloren gehen,
hängt sehr vom Pathogen und vom jeweiligen Gesundheitssystem ab.
Die Schweiz betreibt zwei Systeme zur Früherkennung und Überwa-
chung von Infektionskrankheiten: das obligatorische Meldesystem für
Infektionskrankheiten und das “Swiss Sentinel Surveillance Network”,
kurz Sentinella. Das obligatorische Meldesystem für Infektionskrankhei-
ten stützt sich auf das Epidemiengesetz und ist das einzige obligatorische
Überwachungssystem für Infektionskrankheiten der Schweiz, welches die
gesamte Bevölkerung abdeckt und das alle Ärzte und diagnostischen La-
boratorien zur Meldung verpflichtet. Das Epidemiengesetz regelt, welche
Beobachtungen zu melden und welche Meldefristen dabei einzuhalten
sind. Sentinella ist ein Netzwerk, in dem eine Gruppe aus freiwillig teil-
nehmenden Ärztinnen und Ärzten Konsultationen zu bestimmten The-
men meldet und somit eine Charakterisierung des Krankheitsgeschehens
auf Ebene der Grundversorgung erlaubt.
Im Jahr 2010 verursachten 31 von Lebensmitteln ausgehende Gefähr-
dungen für die Gesundheit weltweit 33 Millionen sogenannte ‘Disability
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Adjusted Life Years (DALYs)’ und rund 600 Millionen Erkrankungen.
Die Inzidenz akuter Gastroenteritis wurde in europäischen Ländern auf
0.3–1.5 Krankheitsepisoden pro Person und Jahr geschätzt. Sowohl in
der Europäischen Union (EU) als auch in der Schweiz ist Campylobacter
spp. der häufigste, meldepflichtige, bakterielle Erreger, der durch Lebens-
mittel übertragen werden kann. Die Fallzahlen nahmen dabei im letzten
Jahrzehnt stetig zu. Im Gegensatz dazu nahmen die Fallzahlen von Sal-
monella spp. in der EU und der Schweiz ab. Die Anzahl Meldungen von
enterohämorrhagischen Escherichia coli (EHEC)-Infektionen war in der
EU grösstenteils konstant, während sie in der Schweiz zunahm. Zurzeit
verfügbare Informationen zu lebensmittelbedingten Infektionskrankhei-
ten beschränken sich in der Schweiz mehrheitlich auf Informationen aus
dem obligatorischen Meldesystem. Die Dunkelziffer der Erkrankungen,
die durch zahlreiche Faktoren beeinflusst wird, ist unbekannt. Eine Aus-
sage, inwiefern die Melderaten die wahre Inzidenz der Erkrankungen in
der Allgemeinbevölkerung widerspiegeln, ist daher nicht möglich.
Ziele Im Rahmen dieser Dissertation soll ein besseres Verständnis
der Krankheitspyramide am Beispiel von lebensmittelbedingten Infektio-
nen erarbeitet werden. Die Erkenntnisse sollen dazu beitragen, die Über-
wachung und Kontrolle von Infektionskrankheiten in der Schweiz zu ver-
bessern. Zu diesem Zweck wird die Häufigkeit von Fällen lebensmittelbe-
dingter Erkrankungen oder akuter Gastroenteritiden auf verschiedenen
Stufen der Krankheitspyramide untersucht. Es werden Trends beschrie-
ben und Faktoren identifiziert, welche schlussendlich zur Meldung eines
Krankheitsfalles führen. Die daraus gewonnenen Erkenntnisse helfen die
Früherkennung und Kontrolle von Infektionskrankheiten zu verbessern.
Methodik Diese Forschungsarbeit besteht aus mehreren Projekten,
welche sich unterschiedlichen Stufen der Krankheitspyramide, von der
Spitze bis zur Basis, widmen. In einem ersten Schritt wurden Meldeda-
ten zu Campylobacter , Salmonella und Hepatitis A untersucht, um deren
Entwicklung seit 1988 zu beschreiben. Die Entwicklung des Anteils posi-
tiver Testresultate unter allen durchgeführten Tests wurde analysiert, da
die Anzahl durchgeführter Tests einen grossen Einfluss auf die Anzahl
identifizierter Fälle haben kann. Diese sogenannte “Positivitätsrate” von
Campylobacter , Salmonella und EHEC wurde über einen Zeitraum von
jeweils 10 Jahren untersucht. Mitarbeitende aus Diagnostiklaboratori-
en wurden zu ihrem Vorgehen bei der Stuhlproben-Diagnostik befragt,
insbesondere im Hinblick auf die Diagnostik von EHEC. Des Weiteren
wurde eine qualitative Studie durchgeführt, um das Vorgehen der Ärzte
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bei der Anamnese (und der damit verbundenen Diagnostik) und Behand-
lung von akuten Gastroenteritiden (mit Fokus auf Campylobacteriose)
in der Schweiz zu verstehen. Diese Erkenntnisse wurden im Anschluss
durch eine Studie im Sentinella-Meldesystem ergänzt, in der die Anzahl
Patienten untersucht wurde, welche aufgrund von akuter Gastroente-
ritis einen Hausarzt aufsuchen. Dazu haben Ärztinnen und Ärzte alle
Erstkonsultationen aufgrund einer akuten Gastroenteritis gemeldet. Die
Meldungen beinhalteten Informationen zur Hospitalisierung, Stuhldia-
gnostik, Behandlung und Arbeitsunfähigkeit des jeweiligen Patienten.
Gesundheitskosten, die durch akute Gastroenteritis und Campylobacte-
riose in der Schweiz entstehen, wurden basierend auf Resultaten aus den
vorangegangenen Studien, Expertenmeinungen und öffentlich verfügba-
ren Daten geschätzt und erstmals publiziert. Es wurden dafür vier Pa-
tientenmodelle definiert, für welche jeweils deren Häufigkeit und die in-
dividuellen Behandlungskosten geschätzt wurden. Mittels Hochrechnung
wurden so die direkten Gesundheitskosten, die durch akute Gastroente-
ritis und Campylobacteriose entstehen, quantifiziert. Basierend auf den
Ergebnissen der oben genannten Studien wurde schliesslich deutlich, wie
wichtig es ist, die Basis der Krankheitspyramide für akute Gastroen-
teritiden zu verstehen. Deshalb wurde ein Studienprotokoll entwickelt,
um die Krankheitshäufigkeit (Inzidenz) von akuter Gastroenteritis auf
Populationsebene zu untersuchen sowie deren Ätiologie abzuklären.
Resultate Die Anzahl Fallmeldungen von Campylobacter hat zwi-
schen 1988 und 2013 zugenommen während diejenige von Salmonella
zurückgegangen ist. Die höchste Anzahl Campylobacter-Fälle wurde im
Jahr 2012 mit 8’480 Krankheitsfällen registriert. Mit 7’806 Fällen wur-
den die höchsten Fallzahlen für Salmonella im Jahr 1992 beobachtet.
Während diese beiden Pathogene über die Jahre hinweg gegenläufige
Trends aufweisen, zeigen sie eine ähnliche Saisonalität mit hohen Fall-
zahlen während der Sommermonate. Zusätzlich wird bei Campylobacter
ein kurzer, aber prägnanter Anstieg jeweils um Weihnachten und Neu-
jahr beobachtet. Campylobacter-Positivitätsraten nahmen zwischen 2003
und 2012 zu, während sie bei Salmonella abnahmen. Die Anzahl durch-
geführter Tests stieg für beide Pathogene im Verlauf der Jahre an.
Hepatitis A-Fallmeldungen waren in der Schweiz zwischen 1988 und 2016
rückläufig, ähnlich wie die Salmonellen-Fallzahlen. Der stärkste Rück-
gang zeigte sich in den frühen 1990er-Jahren, noch bevor die aktive Im-
munisierung im Jahr 1992 eingeführt wurde. Gleichzeitig veränderten
sich die gemeldeten Risikoexpositionen für Hepatitis A im Verlauf der
Zeit: zu Beginn des untersuchten Zeitraums wurde intravenöser Drogen-
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konsum am häufigsten genannt während in der jüngeren Vergangenheit
der Konsum von kontaminierten Speisen und Getränken als mögliche
Infektionsquelle dominierte. In diesen 29 Jahren wurden die Meldefor-
mulare und deren Inhalt vielfach überarbeitet.
Experten aus Diagnostik-Laboratorien sind sich einig, dass der beobach-
tete Anstieg von EHEC-Meldungen durch die Einführung von sogenann-
ten “Multiplex PCR-Panels” für gastrointestinale Erreger begründet ist.
Bei diesen Panels ist ein Test auf EHEC mit eingeschlossen, während
die traditionelle Diagnostik mittels Stuhlkultur meist nur Campylobac-
ter spp., Salmonella spp. und Shigella spp. berücksichtigte. Neben einem
Anstieg der Anzahl durchgeführter Tests stieg jedoch auch die Positivi-
tätsrate von EHEC zwischen 2007 und 2016.
Eine vorläufige Analyse der Anzahl durchgeführter Tests, die seit der
Einführung des neuen Epidemiengesetzes im Jahr 2016 gemeldet werden
muss, zeigt diverse Probleme in Bezug auf die Datenqualität auf. Die
Datenqualität steht mit der komplexen und heterogenen “Labor-Land-
schaft” in der Schweiz in einem klaren Zusammenhang.
Die Behandlung von Patienten mit akuter Gastroenteritis durch Schwei-
zer Hausärzte ist vielfältig. Dennoch konnten vier Behandlungsstrategien
identifiziert werden. Die Mehrheit der Patienten wird mit einem “wait
& see”-Ansatz behandelt (frei übersetzt: “Abwarten und Tee trinken”).
Dieser Ansatz stützt sich auf das Wissen, dass eine akute Gastroenteri-
tis normalerweise selbst-limitierend verläuft. Zwei der vier Behandlungs-
strategien schliessen eine mikrobielle Untersuchung (Stuhltest) mit ein;
mit Beginn einer antibiotischen Behandlung bevor oder nachdem die
Resultate der Stuhluntersuchung vorliegen. Schweizer Hausärzte sehen
sowohl die akute Gastroenteritis als auch die Campylobacteriose als Er-
krankungen von geringer Bedeutung im Praxisalltag. Sie räumen jedoch
ein, dass sie für den individuellen Patienten unangenehm und beein-
trächtigend sein können. Die Überwachung von akuter Gastroenteritis
im Rahmen von Sentinella zeigte, dass 8.5% der Patienten mit aku-
ter Gastroenteritis ein Antibiotikum verschrieben erhielten, bei 12.3%
eine Stuhluntersuchung veranlasst wurde und 86.3% der Berufstätigen
nicht arbeiten gehen konnten. Eine Hochrechnung der Fallzahlen ergab,
dass akute Gastroenteritis im Jahr 2014 zu 2’146 Erstkonsultationen pro
100’000 Einwohner in der medizinischen Grundversorgung geführt hat.
Im Jahr 2012 führten akute Gastroenteritis und Campylobacteriose in
der Schweiz zu geschätzten direkten Gesundheitskosten in Höhe von
e29–45 Millionen (36–54 Millionen Schweizer Franken). Davon fielen
e8.3 Millionen durch die 8’480 laborbestätigten Campylobacteriose-Fälle
an, die im obligatorischen Meldesystem registriert wurden. Schätzungen
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ergaben, dass 233’000–629’000 Patienten einen Arzt aufsuchten, ohne
dass bei diesen eine Stuhluntersuchung durchgeführt wurde. Dies führ-
te zu Gesundheitskosten von e9.0–24.2 Millionen. Arbeitsausfälle und
andere Kosten, die mit akuter Gastroenteritis und Campylobacteriose
in Zusammenhang stehen, wurden in dieser Studie nicht berücksichtigt.
Diese sozioökonomische Bürde soll aber in einer nächsten Studie zur
Krankheitslast von Gastroenteritiden in der Schweiz genauer untersucht
werden. Diese sogenannte BUGS-Studie (“Burden of gastroenteritis in
Switzerland”) soll die “wahre” Inzidenz, die Krankheitslast, die Ätio-
logie und die sozioökonomischen Auswirkungen von akuter Gastroente-
ritis in der Schweiz näher erforschen, um die “volle” Krankheitsbürde
auf Populationsebene sowie die Dunkelziffer – die Krankheitsfälle, die
dem Meldesystem verborgen bleiben – aufzuzeigen. Bei dieser geplanten
Studie handelt es sich um eine prospektive Kohortenstudie, bei der die
Studienteilnehmerinnen und -teilnehmer aus der Allgemeinbevölkerung
während eines Jahres wöchentlich befragt werden. Des Weiteren wird die
Häufigkeit von vier pathogenen Bakterien (Campylobacter , Salmonella,
Shigella und EHEC) und von Bakterien, die gegen bestimmte Antibioti-
ka resistent sind (Fluorchinolon-Resistenz, ESBL, Carbapenemase und
mcr-1-Resistenz), unter den Studienteilnehmerinnen und -teilnehmern
während einer asymptomatischen Periode erhoben.
Schlussfolgerungen Das schweizerische obligatorische Meldesystem
für Infektionskrankheiten ist ein nützliches, von den Akteuren des Ge-
sundheitswesens gut akzeptiertes und stabiles Überwachungssystem. Da-
ten aus dem obligatorischen Meldesystem deuten auf einen steigenden
Trend von Campylobacter und EHEC und auf einen abnehmenden Trend
von Salmonella und Hepatitis A hin. Unsere ergänzende Forschungsar-
beit kam zum gleichen Schluss, auch wenn die Trends im obligatorischen
Meldesystem stärker (EHEC) bzw. schwächer (Salmonella) erscheinen
könnten als die “wahren” Inzidenzen – dies aufgrund von Änderungen in
der Diagnostik. Die verfügbaren Erkenntnisse können den im Meldesys-
tem beobachteten Anstieg nicht vollumfänglich erklären. Eine Verände-
rung der Inzidenz – der Krankheitshäufigkeit in der Bevölkerung – oder
auch eine Ausbruchssituation muss daher aus epidemiologischer Sicht in
Betracht gezogen werden. Dies auch in Anbetracht der Tatsache, dass die
Dunkelziffer beträchtlich sein dürfte. Die im obligatorischen Meldesys-
tem erfassten Krankheitsfälle zeichnen sich durch einen schweren Verlauf
aus, sind häufiger mit Co-Morbiditäten verbunden oder weisen bekann-
te Risikofaktoren auf. Bedingt durch die Vielzahl an Faktoren, die zur
Dunkelziffer beitragen, ist deren routinemässige Erhebung kaum mög-
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lich. Deshalb ist ergänzende Forschung wie die geplante BUGS-Studie
nötig.
Die Informationen, die im obligatorischen Meldesystem gesammelt wer-
den, sollten auf das nötige Minimum und auf Daten beschränkt wer-
den, die über längere Zeit verlässlich erhoben werden können; dies, um
das System so einfach und anpassungsfähig wie möglich zu halten. Ein
derartiges System erlaubt eine schnelle Reaktion auf sich verändernde
Fallzahlen. Systeme wie Sentinella und strategische Forschungspartner-
schaften aufrecht zu erhalten bzw. zu fördern ist wichtig, um sofort auf
vermutete Ausbrüche und epidemiologische Veränderungen reagieren zu
können. Es sollten Strategien erarbeitet werden, wie solide Evidenz für
die Gesundheitspolitik generiert und wie Informationen an die relevanten
Akteure weitervermittelt werden können.
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iv Abbreviations
AG Acute gastroenteritis
AGI Acute gastrointestinal illness
BUGS Burden of gastroenteritis in Switzerland
CDC Centers for Disease Control and Prevention
CI Confidence interval
CJD Creutzfeldt-Jakob disease
CRP C-reactive protein
DALY Disability Adjusted Life Year
EAEC Enteroaggregative Escherichia coli
ECDC European Centre for Disease Prevention and Control
EEA European Economic Area
EHEC Enterohaemorrhagic Escherichia coli
EIEC Enteroinvasive Escherichia coli
EKNZ Ethikkommission Nordwest- und Zentralschweiz (Ethics Com-
mittee northwest/central Switzerland)
EPEC Enteropathogenic Escherichia coli
ESBL Extended-spectrum β-lactamase
ETEC Enterotoxigenic Escherichia coli
EU European Union
FDHA Federal Department of Home Affairs
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Abbreviations
FERG Foodborne Disease Burden Epidemiology Reference Group
FOPH Federal Office of Public Health
FSO Federal Statistical Office
FSVO Federal Food Safety and Veterinary Office
GBS Guillain-Barré syndrome
GI Gastrointestinal
GP General practitioner
HA Hepatitis A
HAV Hepatitis A virus
HBV Hepatitis B virus
HCV Hepatitis C virus
HEV Hepatitis E virus
HIV Human immunodeficiency virus
HUS Haemolytic-uraemic syndrome
IBD Inflammatory bowel disease
IBS Irritable bowel syndrome
ICD-10 International Statistical Classification of Diseases and Related
Health Problems 10th Revision
IDU Injecting drug user
IHR International Health Regulations
IID Infectious intestinal disease
ILI Influenza-like illness
IQR Interquartile range
mcr-1 Mobilised colistin resistance-1
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Abbreviations
MSM Men who have sex with men
NENT National Reference Centre for Enteropathogenic Bacteria and
Listeria
NGS Next-generation sequencing
NNSID National Notification System for Infectious Diseases
NUTS Nomenclature of Units for Territorial Statistics
OR Odds ratio
PCR Polymerase chain reaction
PPC Physician-patient-contact
PPHS PhD Program Health Sciences
PPI Proton pump inhibitor
PPV Positive predictive value
ReA Reactive arthritis
RKI Robert Koch Institute
SARS Severe acute respiratory syndrome
Sentinella Swiss Sentinel Surveillance Network
SPSU Swiss Pediatric Surveillance Unit
StAR Strategy on Antibiotic Resistance Switzerland
STEC Shiga toxin-producing Escherichia coli
Swiss TPH Swiss Tropical and Public Health Institute
TESSy The European Surveillance System
UK United Kingdom
USA United States of America
VFR [Traveller] visiting friends and relatives
VTEC verotoxin-producing Escherichia coli
WHO World Health Organization
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v Glossary
Acute gastrointestinal illness An illness with gastrointestinal signs and
symptoms. In contrast to “acute gastroenteritis”, an episode of
AGI does not have to fulfil a strict case definition but is rather
defined by the individual experiencing the illness.
Acute gastroenteritis “An individual with ≥3 loose stools, or any
vomiting, in 24h, but excluding those (a) with cancer of the bowel,
irritable bowel syndrome, Crohn’s disease, ulcerative colitis, cystic
fibriosis, coeliac disease, or another chronic illness with symptoms
of diarrhoea or vomiting, or (b) who report their symptoms were
due to drugs, alcohol, or pregnancy.” [Majowicz et al., 2008]. Note,
however, that Majowicz et al. proposed this definition for “gast-
roenteritis” instead of “acute gastroenteritis”.
Epidemic intelligence “All activities related to the early identification
of potential health hazards that may represent a risk to health, and
their verification, assessment and investigation so that appropriate
public health control measures can be recommended. The scope of
epidemic intelligence includes risk monitoring and risk assessment
and does not include risk management” [Paquet et al., 2006]
Foodborne disease “Any disease of an infectious or toxic nature caused
by the consumption of food.” [World Health Organization, 2008]
Foodborne intoxication “Illness caused by ingestion of toxins produced
in food by bacteria as a naturally occurring by-product of their
metabolic processes.” [World Health Organization, 2008]. A subset
of foodborne diseases.
Illness “[. . . ] a subjective or psychological state of the person who feels
aware of not being well; the experience of a person with a disease; a
social construct fashioned out of transactions between healers and
patients in the context of their common culture.” [Porta, 2014]
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Laboratory-based surveillance “A form of [. . . ] surveillance of cases
that have been confirmed by a laboratory test. The laborator-
ies that perform the testing report the results to the surveillance
system, as well as informing the clinicians who requested the tests.”
[World Health Organization, 2017]
Notification rate The number of newly notified cases per X (usually
100’000) population under surveillance in a given time period.
Could be considered the “incidence rate of notified cases”.
One Health “Any added value in terms of human and animal health, fin-
ancial savings or social and environmental benefits from closer co-
operation of professionals in the health, animal and environmental
sectors at all levels of organisation” [Zinsstag et al., 2012]
Passive surveillance “Regular reporting of disease data by all institu-
tions that see patients (or test specimens) and are part of a report-
ing network [. . . ]. There is no active search for cases. It involves
passive notification by surveillance sites and reports are generated
and sent by local staff.” [World Health Organization, 2018]
Physician-patient-contact Each consultation in the practice and each
domiciliary visit, independent of whether or not the consultation/
visit takes place in the framework of the usual consultation hour or
outside consultation hour or during emergency service. This term
and definition is used by the Swiss Sentinel Surveillance Network
(Sentinella).
Sentinel surveillance “Surveillance based on selected population
samples chosen to represent the relevant experience of particular
groups. [. . . ] In sentinel surveillance, standard case definitions and
protocols must be used to ensure validity of comparisons across
time and sites despite lack of statistically valid sampling. [. . . ] ”
[Porta, 2014]
Surveillance “1. Systematic and continuous collection, analysis, and
interpretation of data, closely integrated with the timely and co-
herent dissemination of the results and assessment to those who
have the right to know so that action can be taken. It is an essen-
tial feature of epidemiological and public health practice. The final
phase in the surveillance chain is the application of information to
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health promotion and to disease prevention and control. A sur-
veillance system includes a functional capacity for data collection,
analysis, and dissemination linked to public health programs [. . . ];
2. Continuous analysis, interpretation, and feedback of system-
atically collected data, generally using methods distinguished by
their practicality, uniformity, and rapidity rather than by accuracy
or completeness. [. . . ]” [Porta, 2014]
Syndrome “A complex of signs and symptoms that tend to occur to-
gether, often characterizing a disease.” [Porta, 2014]
Under-ascertainment “[. . . ] the number of infections occurring in indi-
viduals that do not attend healthcare services for every case that
attends. There is a symptomatic fraction of all under-ascertained
cases that do not attend healthcare due to mild symptoms and/or
the knowledge that the illness is self-limiting or for some other
reasons, and an asymptomatic fraction that do not seek health-
care as they are not aware of their infection status due to lack of
symptoms [1].” [Gibbons et al., 2014]
1. European Centre for Disease Prevention and Control (ECDC): Report:
Surveillance and Prevention of Hepatitis B and C in Europe. Stockholm,
Sweden: ECDC; 2010
Under-diagnosis Refers to “[. . . ] the cases attending healthcare but
whose infection or pathogen is not diagnosed or misdiagnosed [1,
2]”. [Gibbons et al., 2014]
1. Hardnett FP, Hoekstra RM, Kennedy M, Charles L, Angulo FJ, for the
Emerging Infections Program FoodNet Working Group: Epidemiologic is-
sues in study design and data analysis related to FoodNet activities. Clin
Infect Dis 2004, 38(Supplement 3):S121–S126
2. MacDougall L, Majowicz S, Dore K, Flint J, Thomas K, Kovacs S, Sockett
P: Under-reporting of infectious gastrointestinal illness in British Columbia,
Canada: who is counted in provincial communicable disease statistics? Epi-
demiol Infect 2008, 136(02):248–256
Underestimation “[. . . ] the many ways in which surveillance systems fail
or are unable to reflect all infections in a given population. [. . . ] UE
[underestimation] can be split into two distinct levels [. . . ]; under-
ascertainment [. . . ] of infections occurring at the community-level
and underreporting [. . . ] of infections occurring at the healthcare-
level.” [Gibbons et al., 2014]
Under-notification Refers to “[. . . ] the failure to report (using correct
International Classification of Diseases (ICD) codes [1, 2]) all pos-
itive diagnoses through the notification system [3, 4].” [Gibbons
et al., 2014]
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1. Khosravi A, Rao C, Naghavi M, Taylor R, Jafari N, Lopez AD: Impact
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Part I
INTRODUCTION,
OBJECTIVES AND
METHODOLOGY

1 Introduction
1.1 Surveillance of infectious diseases – the
‘burden of illness pyramid’
Infectious diseases are of concern worldwide: globally, 230 million all–age
Disability Adjusted Life Years (DALYs) were caused by “diarrhoea, lower
respiratory, and other common infectious diseases” in 2016, according to
the Global Burden of Diseases Study [GBD 2016 DALYs and HALE
Collaborators, 2017]. Thereof, 74.4 million DALYs (95% confidence in-
terval (CI): 63.4–93.4) were attributable to “diarrhoeal diseases”, or 10.6
million (95% CI: 6.0–17.3) to “intestinal infectious diseases”. Globally,
“diarrhoeal diseases” are still ranked fifth in terms of leading causes of
total DALYs in 2016 even though the number of DALYs due to com-
municable diseases decreased while the number of DALYs due to non-
communicable diseases increased [GBD 2016 DALYs and HALE Collab-
orators, 2017].
Surveillance* is defined by Porta as the “1. Systematic and continuous
collection, analysis, and interpretation of data, closely integrated with
the timely and coherent dissemination of the results and assessment to
those who have the right to know so that action can be taken. It is
an essential feature of epidemiological and public health practice. The
final phase in the surveillance chain is the application of information
to health promotion and to disease prevention and control. A surveil-
lance system includes a functional capacity for data collection, analysis,
and dissemination linked to public health programs [. . . ]; 2. Continuous
analysis, interpretation, and feedback of systematically collected data,
generally using methods distinguished by their practicality, uniformity,
and rapidity rather than by accuracy or completeness. [. . . ]” [Porta,
2014]. Surveillance of infectious diseases is, therefore, key for prevention
and control. The disease surveillance and notification required accord-
ing to the International Health Regulations (IHR) could be considered
to constitute the most comprehensive surveillance system for infectious
diseases worldwide considering that 196 countries (including all World
Health Organization (WHO) member states) are committed to these reg-
ulations. However, only “events which may constitute a public health
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emergency of international concern within its [the State Party’s] ter-
ritory in accordance with the decision instrument [provided in Annex
2 of the IHR] [. . . ]” should be notified to WHO. Such events include,
but are not limited to, a case of smallpox, poliomyelitis due to wild-
type poliovirus, human influenza caused by a new subtype, severe acute
respiratory syndrome (SARS), and “any event of potential international
public health concern, including those of unknown causes or sources
[. . . ]”. However, at national or regional level, also other infectious dis-
eases or “events” are of concern apart from those potentially representing
an international emergency. Therefore, many countries have set up their
own infectious disease surveillance system(s). Such surveillance systems
can be national, regional or based on sentinel sites; include physicians,
hospitals and/or laboratories; and reporting can be compulsory or vol-
untary. Passive surveillance* systems have in common that they hardly
‘measure’ disease incidence of the general population. Depending on
their set-up, they are subject to different degrees of underestimation*.
Therefore, the incidence estimated through surveillance systems does
not reflect the incidence of disease (or infection) in the population. To
account for this, the term notification rate* is used for the remainder of
this thesis when referring to the ‘incidence of notified cases’.
The metaphor of a pyramid is frequently used to illustrate underes-
timation of surveillance systems, especially in the field of foodborne
or gastrointestinal (GI) diseases. The different levels of the pyramid,
referred to as the “burden of illness pyramid” [Allos et al., 2004], the
“disease pyramid” [Lake et al., 2010], the “morbidity surveillance pyr-
amid” [Gibbons et al., 2014], the “surveillance pyramid” [Haagsma et al.,
2013; O’Brien et al., 2010], the “reporting pyramid” [Lake et al., 2010;
O’Brien et al., 2010; Wheeler et al., 1999], or the “under-reporting pyr-
amid” [MacDougall et al., 2008], depict the various steps involved leading
to a case being notified (Figure 1.1). The lowest level of the pyramid
reflects the population exposed to a pathogen or the population devel-
oping symptoms, depending on the author, while the top level of the
pyramid represents the notified cases.
Individuals infected with a foodborne pathogen who either do not de-
velop symptoms and hence, are not aware of their disease or individuals
not seeking medical attention (due to mild symptoms or because they
are aware of the self-limiting nature of their disease) are referred to as
under-ascertained cases [Gibbons et al., 2014]. Individuals not reques-
ted to submit a stool sample among those consulting a physician and
individuals whose stool sample is tested for the “wrong” pathogens are
summarised as under-diagnosed cases [Gibbons et al., 2014]. Finally,
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Figure 1.1: The burden of illness pyramid for foodborne pathogens.
UE: underestimation, UA: under-ascertainment, UR: underreporting, UD: under-diagnosis, UN: under-notification. Adap-
ted from Allos et al. [2004]; Gibbons et al. [2014]; MacDougall et al. [2008]
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the term of under-notification* is used to refer to cases whose pathogen
is identified by the laboratory but not reported to national surveillance.
Under-diagnosis* and under-notification are summarised as underreport-
ing*; underestimation is composed of under-ascertainment* and under-
reporting.
1.2 History of infectious disease surveillance in
Switzerland
Already the first federal constitution of Switzerland from 1848 contained
an article on infectious diseases:
“Art. 59. Die Bundesbehörden
sind befugt, bei gemeingefährli-
Art. 59. The federal authorit-
ies are entitled to issue decrees for
chen Seuchen gesundheitspolizeili- the sanitary police in case of epi-
che Verfügungen zu erlassen.” [Ver- demic plagues constituting a public
fassungen der Schweiz. Bundesver- danger.
fassung der Schweizerischen Eid-
genossenschaft vom 12. September
1848, n.d.]
With the complete revision of the federal constitution, entering into
force in 1874, the corresponding article was rephrased. However, the law
still stipulated a reactive rather than a proactive role of the authorities
by defining competencies only in case of epidemics (as opposed to pre-
ventive measures).
“Art. 69. Dem Bunde steht Art. 69. The federal authorit-
die Gesetzgebung über die gegen ies are responsible to issue decrees
gemeingefährliche Epidemien und for the sanitary police against epi-
Viehseuchen zu treffenden gesund- demics and epizootic diseases con-
heitspolizeilichen Verfügungen zu” stituting a public danger.
[Verfassungen der Schweiz. Bun-
desverfassung der Schweizerischen
Eidgenossenschaft vom 29. Mai
1874, n.d.]
On 31st January 1882, the Swiss Federal Council issued the first Epi-
demics Act which was, however, overruled by the popular vote in July
1882 [Bundesblatt, 1882, 1886a]. Finally, in 1886, the first Epidemics
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Act was established in Switzerland and entered into force on 1st Janu-
ary 1887 [Bundesblatt, 1886b]. It targeted “epidemics constituting a
public danger” (“gemeingefährliche Epidemien”), namely pox, cholera,
epidemic typhus and plague [Bundesblatt, 1886b]. Already this first
version of the Epidemics Act stipulated that each case of the afore-
mentioned diseases had to be notified to the local authorities. The draft
version from 1882 allowed for an extension of the law to also include “epi-
demics constituting a public danger temporarily” such as scarlet fever,
diphtheria, typhoid fever, dysentery and childbed fever [Bundesblatt,
1882], an earlier version (from 1879) additionally mentioned measles
[Bundesblatt, 1911]. This part was, however, discussed controversially
and, hence, was not included in the final version [Bundesblatt, 1886a].
In 1887 and 1894, respectively, the Federal Council specified that no-
tification should occur within 12 (cholera) or 24 hours (pox, epidemic
typhus and plague), and that reports should include the name and age
of the patient, the illness onset and severity, the date of notification,
and information about mode of transmission and measures implemented
[Bundesblatt, 1887, 1894].
Meanwhile, a division for health (“Schweizerisches Gesundheitsamt”;
Swiss Health Authority) was founded in 1893 with three employees, sub-
ordinate to the Federal Department of Home Affairs (FDHA) [Bundes-
blatt, 1893a,b]. The main responsibilities of the Swiss Health Authority,
today’s Federal Office of Public Health (FOPH), were to coordinate the
federal diplomas for physicians, veterinarians and pharmacists, and to
control epidemics and food safety [Bundesamt für Gesundheit, 1993].
Concerns were raised that the federal authorities should contribute to
the control of diseases other than the four “epidemic diseases constitut-
ing a public danger” soon after the implementation of the first Epidemics
Act [Bundesblatt, 1911]. Additionally, it was suggested to replace the
term “epidemics constituting a public danger” (“gemeingefährliche Epi-
demien”) for two reasons: first, the term “constituting a public danger”
is too vague and second, the federal authorities should also be entitled
to intervene in case of severe endemic diseases and/or in single cases of
epidemic diseases (preventing an epidemic) and hence, the term “epi-
demic” was considered inappropriate. Therefore, revision of article 69
of the federal constitution from 1874 was suggested to:
“Der Bund ist befugt, gegen The federal authorities are en-
übertragbare, stark verbreitete oder titled to issue decrees for the san-
bösartige Krankheiten von Men- itary police against communicable,
schen und Tieren auf dem Wege widespread or virulent diseases of
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der Gesetzgebung gesundheitspo- humans and animals by means of
lizeiliche Verfügungen zu treffen.” legislation.
[Bundesblatt, 1911]
This revision (with slightly different wording) was approved by a pop-
ular vote in 1913 [Bundesblatt, 1913]. It provided a basis for revising
the Epidemics Act from 1886. Considering that total revision of laws is
time-consuming, the Federal Assembly decided on a partial revision of
the Epidemics Act in 1921 (based on a communication from the Federal
Council from 1920) [Bundesblatt, 1920, 1921]. Among others, Art. 1
(defining the four “epidemic diseases constituting a public danger”) was
complemented by:
“Der Bundesrat ist indessen er- The Federal Council is author-
mächtigt, die Bestimmungen die- ised to apply the terms of this law
ses Gesetzes auch auf andere be- also for other especially dangerous
sonders gefährliche übertragbare communicable diseases.
Krankheiten anzuwenden.”
The original “Federal Act concerning measures against epidemics con-
stituting a public danger” from 2nd July 1886 was finally replaced by
the “Federal Act on combating communicable human diseases” from
18th December 1970 (entering into force on 1st July 1974) [Bundesblatt,
1970b]. Main drivers for this revision were the increasing (awareness of
the) importance of viral infections, the change in international traffic
(increasing numbers as well as rapidly decreasing duration of a journey),
and the outbreak of typhoid fever in Zermatt (Valais, Switzerland) in
1963 with around 400 persons infected [Bundesblatt, 1970a]. Based on
this revised Epidemics Act, the Confederation and all cantons were em-
powered and obliged to implement measures for combating communic-
able human diseases [Bundesblatt, 1970b]. It defined the obligation for
physicians and hospitals to report cases and suspected cases of certain
diseases, and persons shedding pathogens to the cantonal authorities
who then had to forward the report to the Federal Health Authority.
Similarly, it newly obliged diagnostic laboratories to report certain mi-
crobiological or serological findings to the cantonal authorities and the
Federal Health Authority. The Federal Health Authority, on the other
hand, was responsible for publishing weekly, monthly and yearly statist-
ics based on the aforementioned notifications.
The Epidemics Act of 1970 further defined that cantons were respons-
ible for the implementation of measures to control communicable diseases
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[Bundesblatt, 1970b]. The Federal Council could, however, mandate the
implementation of measures for the whole or parts of the country in case
of extraordinary circumstances.
Finally, on 1st January 2016 a newly revised Epidemics Act, the “Fed-
eral Act on combating communicable human diseases (Epidemics Act)”
of 28th September 2012, entered into force [Die Bundesversammlung der
Schweizerischen Eidgenossenschaft, 2012a].
This revised Epidemics Act includes a more refined specification of roles
and processes for preparedness and response to crisis situations and lays
a basis for establishing national goals and strategies in the context of
communicable diseases, strengthening the leading role of the FOPH,
representing the federal authorities [Bundesamt für Gesundheit, 2016].
Additionally, adaptations to new, contemporary challenges such as in-
creased mobility and migration, climate change and newly emerging dis-
eases have been made. One of the main triggers for the revision of the
Epidemics Act of 1970 was the SARS epidemic of 2003 which showed
that coordination between federal and cantonal authorities could be im-
proved.
In conclusion, the inception of the Epidemics Act in Switzerland as well
as the two revisions thereof seem mostly triggered by national public
health threats in the form of major outbreaks or newly emerging dis-
eases.
1.3 Infectious disease surveillance systems in
Switzerland
There are currently four systems for surveillance and early detection
in place in Switzerland: a notification system for surveillance of clinical
and laboratory findings – the National Notification System for Infectious
Diseases (NNSID); a system for surveillance of frequent, communicable
diseases – the Swiss Sentinel Surveillance Network (Sentinella); a sys-
tem to survey rare communicable diseases in hospitalised children – the
Swiss Pediatric Surveillance Unit (SPSU); and a system for surveillance
of therapy-associated infections and resistances of pathogens. Those four
systems are all based on the Epidemics Act and its related ordinances
[Der Schweizerische Bundesrat, 2015b; Die Bundesversammlung der Sch-
weizerischen Eidgenossenschaft, 2012b]. The purpose and set-up of the
two first-mentioned systems is explained in more detail in the following
sections.
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1.3.1 The National Notification System for Infectious
Diseases
The National Notification System for Infectious Diseases (NNSID) is a
mandatory surveillance system for infectious diseases in Switzerland. Its
legal basis is the current Epidemics Act and more specifically the “Or-
dinance on the control of human communicable diseases” of 25th April
2015 and the “DHA Ordinance on the reporting of observations on hu-
man communicable diseases” of 1st December 2015 [Das Eidgenössische
Departement des Innern, 2015a; Der Schweizerische Bundesrat, 2015b;
Die Bundesversammlung der Schweizerischen Eidgenossenschaft, 2012b].
In general terms, the Epidemics Act stipulates that it is compulsory to
report observations on communicable diseases: a) which can cause epi-
demics; b) which can have serious consequences; c) which are novel or un-
expected; or d) whose surveillance has been internationally agreed. The
ordinances explicitly list which clinical and laboratory findings have to
be reported, by whom and to whom they have to be reported, as well as
within which time limit notification has to occur. Notifiable observations
and the content thereof are reviewed for their necessity and purpose as
required but at least once a year by the FOPH in collaboration with the
cantonal physicians. Currently (as per January 2018), the DHA Ordin-
ance lists 55 notifiable observations. A list of all notifiable observations
is provided in appendix A, table A.1. As soon as the criterion for noti-
fication is fulfilled, observations have to be reported within 2 hours, 24
hours or 1 week.
The process of notification
Physicians, hospitals and other public or private institutions in the
healthcare sector have to report observations on communicable diseases
to the cantonal health authorities of the patient’s canton of residence
and, for selected observations, additionally to the FOPH [Das Eidgenöss-
ische Departement des Innern, 2015a; Der Schweizerische Bundesrat,
2015b]. If the patient’s canton of residence is not known, the cantonal
authorities of the canton in which the observation was made has to be
notified. Diagnostic laboratories have to report laboratory findings on
communicable diseases both to the cantonal health authorities and to
the FOPH. Additionally, cantonal health authorities have to report all
observations which could point towards a threat for public health to the
FOPH. Similarly, commanders of vessels and airplanes have to report
observations indicative of a threat for public health to the operators of
harbours and airports.
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Cantonal physicians have to check completeness of notifications sent to
the cantonal health authorities and request additional information or
notifications, if necessary [Der Schweizerische Bundesrat, 2015b]. Fur-
thermore, cantonal physicians forward notifications to the FOPH within
the time frame for notification of the concerning observation and inform
cantonal chemists, cantonal veterinarians, cantonal pharmacists and/or
other cantonal authorities (including cantonal physicians of other can-
tons) as needed.
Finally, at the FOPH, data from notification forms is manually entered
into an electronic database since 1988. The process of disease notific-
ation for clinical and laboratory findings is illustrated in appendix B
(Figures B.1 and B.2).
The processing of notifications
Cantonal physicians are obliged to conduct epidemiological invest-
igations in their cantons based on notifications, as appropriate [Der
Schweizerische Bundesrat, 2015b]. The cantonal authorities may oblige
a person who could be infected and/or infectious to undergo medical
examination and treatment, or to isolate this person (quarantine) [Die
Bundesversammlung der Schweizerischen Eidgenossenschaft, 2012b].
The FOPH is available for consultation and support. The FOPH co-
ordinates epidemiological investigations in case several cantons and/or
international authorities or organisations are involved. Additionally, the
FOPH itself can initiate epidemiological investigations.
Furthermore, the FOPH has the responsibility to analyse the no-
tifications and to provide anonymised statistics and reports for
the general public regularly [Der Schweizerische Bundesrat, 2015b].
Weekly reports on case numbers can be found on the webpage of the
FOPH (https://www.bag.admin.ch/bag/de/home/zahlen-und-st
atistiken/zahlen-zu-infektionskrankheiten/meldepflichtige-
infektionskrankheiten---woechentliche-fallzahlen.html1)
and in the “BAG Bulletin” (also available electronically, see
https://www.bag.admin.ch/bag/de/home/das-bag/publikatio
nen/periodika/bag-bulletin.html1). Additionally, analyses of
surveillance data are published regularly in the “BAG Bulletin”.
1last accessed: 24 September 2018
11
1 Introduction
1.3.2 The Swiss Sentinel Surveillance Network
The Swiss Sentinel Surveillance Network (Sentinella) is a voluntary sen-
tinel surveillance* system established in 1986 [Bundesamt für Gesund-
heit, 2018b]. It allows surveying frequent non-notifiable diseases and
pathogens and other public health issues as well as researching primary
care. Its purpose is to provide important insight into the incidence of
contemporary diseases and public health issues in the Swiss population
and to highlight the importance of primary care medicine. Sentinella
is managed by a steering committee consisting of representatives of the
participating physicians, of the division of Communicable Diseases at
the FOPH, and of academic primary care institutes (of Lausanne, Bern,
Basel, Zurich and Geneva) [Sentinella, 2018a]. The network is divided
into six regions (“Sentinella-regions”); each region having its representat-
ive in the steering committee. The administration of Sentinella is at the
FOPH. They are responsible for data entry apart from completing other
administrative tasks (e.g. organising meetings of the steering committee
and managing the database of participating physicians). Finally, physi-
cians working as general practitioners (GPs), internists or paediatricians
in a (single or group) private practice are constituting the network (re-
ferred to as “Sentinella-physicians” in this thesis).
The steering committee decides which topics are surveyed (usually for
at least one year). Between 8 and 14 topics per year were subject to
surveillance [Sentinella, 2018b]. Three thereof were included since the
implementation of Sentinella in 1986: influenza-like illness (ILI), death
due to influenza, and mumps.
In contrast to the NNSID, in Sentinella also non-communicable dis-
eases or observations can be surveyed. Other differences are that re-
ports within Sentinella are anonymous (with respect to the patient; the
physician can be identified on the notification form) and that Sentinella-
physicians are financially compensated for their work. The network is
financed by the FOPH.
In Sentinella, physicians also report the number of consultations per day
(the so-called “physician-patient-contact (PPC)*” which is defined as
“each consultation in the practice and each domiciliary visit, independ-
ent of whether or not the consultation/visit takes place in the framework
of the usual consultation hour or outside consultation hour or during
emergency service”). This allows calculating the incidence per 1’000
consultations and the consultation frequency per 100’000 population.
The standard procedure for extrapolation used by Sentinella has been
described by Altpeter et al. [2013].
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In conclusion, Sentinella provides a platform to investigate a broad range
of public health issues at primary care level in Switzerland which may be
important but do not qualify for compulsory surveillance in the frame-
work of the NNSID. The topics surveyed within Sentinella are set by
a steering committee and hence, do not need to fulfil the same strict
“requirements” as those surveyed within the NNSID (i.e. potential to
cause epidemics, have serious consequences, be novel or unexpected, or
be of international importance).
1.4 Foodborne diseases and acute
gastroenteritis
1.4.1 The difference between foodborne disease and
acute gastroenteritis
Foodborne diseases* are defined as “Any disease of an infectious or toxic
nature caused by the consumption of food.” [World Health Organiza-
tion, 2008]. Hence, foodborne diseases include bacterial diseases such
as campylobacteriosis, salmonellosis, and listeriosis; viral diseases such
as hepatitis A and norovirus; parasitic diseases such as cryptosporidi-
osis, giardiasis and trichinellosis, but also foodborne intoxications* due
to enterotoxins of Bacillus cereus, aflatoxins, or toxin of Clostridium
botulinum. Many foodborne diseases cause GI signs and symptoms;
however, they can also manifest differently, for example with neurolo-
gical symptoms (e.g. botulism).
Illnesses* due to GI signs and symptoms (such as diarrhoea, vomiting,
nausea, abdominal pain) are often called “diarrhoeal diseases”, “acute
diarrhoea”, “gastroenteritis”, and “acute gastroenteritis”. Such illnesses
are frequently caused by infectious agents but can also be due to non-in-
fectious conditions (e.g. appendicitis, inflammatory bowel disease (IBD),
adverse effects of drugs, pregnancy, cancer) [Frese et al., 2011; Manat-
sathit et al., 2002; Pfeiffer et al., 2012]. Diarrhoea can further be classi-
fied as “acute” (lasting ≤14 days), “persistent” (lasting >14 days, or >14
and ≤29 days), or “chronic” (lasting >30 days) [DuPont, 2014; Guerrant
et al., 2001; Riddle et al., 2016]; and “watery” or “bloody” (in the lat-
ter case often referred to as “inflammatory diarrhoea” or “dysentery”)
[Guerrant et al., 2001; Manatsathit et al., 2002].
This variety of terms used – sometimes with clear definitions, sometimes
used interchangeably – for syndromes* associated with GI signs and
symptoms and foodborne diseases makes it difficult to compare estim-
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ates of the disease incidence and burden from different studies. Using
the “correct” terms is further complicated by the fact that not all food-
borne diseases result in acute gastroenteritis (AG)*; and conversely, not
every person experiencing AG suffers from a foodborne disease.
1.4.2 The burden of foodborne diseases
In 2010, 600 million cases of illness were caused by 31 foodborne hazards,
according to estimates of the Foodborne Disease Burden Epidemiology
Reference Group (FERG) established by WHO [Havelaar et al., 2015].
An estimated 33 million DALYs were attributable to those 600 million
cases of foodborne illnesses including sequelae [Havelaar et al., 2015].
For these calculations, the viral, bacterial and protozoal hazards were
classified as “diarrhoeal disease” or “invasive disease” according to their
main manifestation; additionally, all hazards were classified as either
“entirely foodborne” or “partly foodborne” (Table 1.1; [Havelaar et al.,
2015]. It is apparent that none of the pathogens classified as “diarrhoeal
disease” (of viral, bacterial and protozoal origin) is entirely foodborne.
In contrast, many helminths and chemicals or toxins are considered to
be exclusively transmitted through food.
The burden of foodborne disease is not evenly distributed across the
world: it was estimated that the 31 foodborne hazards considered
by the FERG were causing the least DALYs per 100’000 popula-
tion (35 DALYs/100’000; 95% uncertainty interval: 23–49) in the
“AMR A” region2 and the most DALYs in the “AFR D” region3 (1’276
DALYs/100’000; 95% uncertainty interval: 459–2’263) [Havelaar et al.,
2015]. The largest burden occurs in children under 5 years of age.
Other estimates of the FERG suggest that 22 diseases (viruses, bacteria
and protozoa; 4 of which are distinct manifestations of Salmonella en-
terica) lead to 2 billion illnesses in 2010 worldwide of which 582 million
were of foodborne origin [Kirk et al., 2015]. Campylobacter spp. and
norovirus were the bacterial and viral pathogens causing most illnesses
of foodborne origin. Furthermore, it was estimated that the 22 diseases
caused 1.1 million deaths in 2010, 32% of which (350’686) were of food-
borne origin [Kirk et al., 2015]. The highest number of foodborne deaths
2Countries included in “AMR A” region are: Canada, Cuba, United States of Amer-
ica
3Countries included in “AFR D” region are: Algeria, Angola, Benin, Burkina Faso,
Cameroon, Cape Verde, Chad, Comoros, Equatorial Guinea, Gabon, Gambia,
Ghana, Guinea, Guinea-Bissau, Liberia, Madagascar, Mali, Mauritania, Mauri-
tius, Niger, Nigeria, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone,
Togo
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Table 1.1: Predominant disease manifestation and estimated proportion of foodborne transmission for the “EUR A”
regiona (including Switzerland) of 31 hazards commonly associated with foodborne illness according to Hald et al. [2016];
Havelaar et al. [2015]
Predominantly causing Entirely foodborne Partly foodborne (estimated %
foodborne in “EUR A” regiona)
Viruses Acute diarrhoeal disease Norovirus (26%)
Invasive infectious disease Hepatitis A virus (42%)
Bacteria Acute diarrhoeal disease Campylobacter spp. (76%)
Enteropathogenic E. coli (64%)
Enterotoxigenic E. coli (42%)
Shiga toxin-producing E. coli (60%)
Non-typhoidal Salmonella entericab (76%)
Shigella spp. (7%)
Vibrio cholerae (31%)
Invasive infectious disease Listeria monocytogenes Brucella spp. (66%)
Mycobacterium bovis Salmonella Paratyphi A (n.a.c)
Salmonella Typhi (10%)
Protozoa Acute diarrhoeal disease Cryptosporidium spp. (10%)
Entamoeba histolytica (33%)
Giardia spp. (11%)
Invasive infectious disease Toxoplasma gondii (61%)
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Table 1.1: (continued)
Predominantly causing Entirely foodborne Partly foodborne (estimated %
foodborne in “EUR A”a region)
Helminths Clonorchis sinensis Ascaris spp. (85%)
Fasciola spp. Echinococcus granulosus (21%)
Intestinal flukesd Echinococcus multilocularis (52%)
Opisthorchis spp.
Paragonimus spp.
Taenia solium
Trichinella spp.
Chemicals
and toxins
Aflatoxin
Cassava cyanide
Dioxins
a “EUR A” region includes: Andorra, Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Finland, France,
Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San
Marino, Slovenia, Spain, Sweden, Switzerland, United Kingdom
b Diarrhoeal and invasive disease
c n.a. = not available
d Includes selected species of the families Echinostomatidae, Fasciolidae, Gymnophallidae, Heterophyidae, Nano-
phyetidae, Neodiplostomidae, and Plagiorchiidae (depending on data availability)
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was attributed to Salmonella enterica Typhi, followed by enteropatho-
genic Escherichia coli (EPEC) and norovirus.
In Europe, Campylobacter is the most frequently reported bacterial,
foodborne pathogen since 2005 [European Food Safety Authority and
European Centre for Disease Prevention and Control, 2017]. The num-
ber of reported confirmed cases was 246’307 in 2016, corresponding to
a notification rate of 66.3/100’000 population (based on reports from
27 European Union (EU) member states) [European Food Safety Au-
thority and European Centre for Disease Prevention and Control, 2017].
Sixteen member states also provided information on the outcome for
178’726 cases. They reported a total of 62 deaths attributable to cam-
pylobacteriosis corresponding to a case fatality rate of 0.03%. However,
all these figures are subject to underestimation. The “true” incidence of
campylobacteriosis in the EU was estimated at 9.2 million cases in 2009
– a year in which 198’252 confirmed cases were reported [Havelaar et al.,
2013].
Foodborne disease can also lead to sequelae apart from causing acute
illnesses and deaths. Infection with Campylobacter can lead, for ex-
ample, to reactive arthritis (ReA), Guillain-Barré syndrome (GBS), hae-
molytic-uraemic syndrome (HUS), IBD, and irritable bowel syndrome
(IBS) [Keithlin et al., 2014; Mahon and Patrick, 2015; O’Brien, 2017].
Enterohaemorrhagic Escherichia coli (EHEC) infection has mostly been
associated with HUS, but also thrombotic thrombocytopenic purpura
and ReA have been described [Dundas and Todd, 2000; Keithlin et al.,
2014]. The best described complications of enteric Salmonella infections
are ReA and IBS [Keithlin et al., 2015].
1.4.3 The burden of acute gastroenteritis
The Global Burden of Disease Study provided estimates for “diarrhoeal
diseases” but not for “acute gastroenteritis” [GBD Diarrhoeal Diseases
Collaborators, 2017]. In 2015, “diarrhoeal diseases” were estimated to
result in a global burden of 71.6 million DALYs (74.4 million in 2016
[GBD 2016 DALYs and HALE Collaborators, 2017]) and 1.3 million
deaths (corresponding to 17.8 deaths per 100’000 population) due to
2.4 billion episodes. The burden of diarrhoeal diseases was estimated at
80’000 episodes, 1’787 DALYs, and 135 deaths (1.6/100’000) for Switzer-
land [GBD Diarrhoeal Diseases Collaborators, 2017]. Population-based
studies investigating the incidence or burden of disease of AG are lacking
for Switzerland. However, results of several studies conducted in high-
income countries indicate that AG is more frequent than suggested by
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the aforementioned Global Burden of Disease Study. For example, a
modelling study revealed that, in Australia, there were 16 million cases
of “all-cause infectious AG” in 2010, corresponding to around 0.76 epis-
odes per person-year [Gibney et al., 2014]. Around 0.33 cases of AG per
person-year were found in a retrospective cross-sectional telephone sur-
vey in France in 2009/2010 [Van Cauteren et al., 2012]. A retrospective
telephone survey on “intestinal infectious disease” in the UK found 0.53
and 1.53 cases per person-year, depending on the recall period [Viviani
et al., 2016]. In the Netherlands, 0.96 episodes of “infectious intestinal
disease” were reported per person-year [Doorduyn et al., 2012]. Sim-
ilarly, the incidence of “acute gastrointestinal illness” was estimated at
0.95 episodes per person-year in Germany [Wilking et al., 2013]. Assum-
ing similar incidence rates for Switzerland of 0.3–1.5 disease episodes per
person-year (with a population size of 8.4 million [Bundesamt für Stat-
istik, 2017a]) would result in around 2.5–12.6 million episodes annually.
As mentioned above, differences in reported disease incidence cannot
only be due to actual differences between countries but could also result
from different case definitions and study designs used. To overcome this
limitation, Majowicz et al. [2008] proposed a standard case definition for
AG which is generally used in this thesis: “An individual with ≥3 loose
stools, or any vomiting, in 24h, but excluding those (a) with cancer of
the bowel, irritable bowel syndrome, Crohn’s disease, ulcerative colitis,
cystic fibriosis, coeliac disease, or another chronic illness with symptoms
of diarrhoea or vomiting, or (b) who report their symptoms were due to
drugs, alcohol, or pregnancy.” [Majowicz et al., 2008]. Note, however,
that Majowicz et al. proposed this definition for “gastroenteritis” instead
of “acute gastroenteritis”. Still, it has to be noted that this standard case
definition is not universally applied and hence, might not always have
been used, especially when referring to other literature.
Generally, AG is self-limiting. Therapy should focus on fluid replace-
ment; however in patients with febrile or dysenteric diarrhoea, patients
with co-morbidities, and/or in laboratory-confirmed cases of bacterial in-
fection antimicrobial therapy should be considered [DuPont, 2014; Guer-
rant et al., 2001; Schweiger et al., 2005b].
1.4.4 Foodborne disease or acute gastroenteritis: what
is and what should be measured
Laboratory-based surveillance* systems measure the (laboratory-con-
firmed) incidence of selected pathogens. This incidence will neither re-
flect the incidence of foodborne disease nor the incidence of AG due to
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this pathogen except if the pathogen is entirely foodborne and/or its
only manifestation is AG.
Surveillance systems focussing on clinical features of a disease rather
than laboratory results could more precisely measure AG. However, this
approach would also include cases which are not caused by infectious
agents and hence, which require a different approach to control and pre-
vention.
Finally, whether or not a certain pathogen was transmitted via food or
through another route of transmission can hardly be determined without
detailed investigation. Such detailed investigation could involve identi-
fication and molecular characterisation of the pathogen both, in foodstuff
and in human samples.
What should be measured largely depends on the purpose of the investig-
ation or the perspective to look at. For characterising the burden of dis-
ease in a population, looking at signs and symptoms (hence, AG) rather
than the aetiology seems appropriate. However, usefulness of these data
is probably limited for defining interventions. Hence, if targeted inter-
ventions are the ultimate goal, investigating transmission routes and the
frequency of foodborne disease is probably more appropriate.
In summary, most studies and surveillance systems investigate or meas-
ure a part or a combination of foodborne disease and AG. Surveillance
systems such as the NNSID could be best described as measuring the
“incidence of laboratory-confirmed infections caused by pathogens com-
monly transmitted through food” (apart from many other diseases and
pathogens neither associated with foodborne disease nor AG).
1.5 Foodborne disease surveillance in
Switzerland
In Switzerland, the following diseases commonly transmitted through
food are currently notifiable (as per January 2018): Botulism, brucel-
losis, campylobacteriosis, cholera, infection with EHEC, hepatitis A, hep-
atitis E, listeriosis, salmonellosis, shigellosis, trichinellosis, and typhoid
fever. Table 1.2 shows the notification criteria for reports on clinical find-
ings (completed by physicians) and on laboratory findings (completed
by laboratories) and the time frame for reporting for the aforementioned
pathogens. The time frame for reporting most foodborne pathogens has
been shortened to 24 hours with the implementation of the new Epidem-
ics Act. For campylobacteriosis, salmonellosis and shigellosis no clinical
reports are required; hence, nothing is known about disease manifesta-
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Table 1.2: Notifiable pathogens and diseases commonly transmitted through food in Switzerland: notification criteria,
process and time frame as per January 2018 [Das Eidgenössische Departement des Innern, 2015a]
Physician Laboratory
Disease/pathogen Notification criterion Time
frame
To whom Notification criterion Time frame
Botulism /
Clostridium
botulinum
Clinical suspicion
AND administration
of antitoxin (not to
notify: wound and
infant botulism)
2 hours,
by phone
CPa and
FOPH
Positive finding
Negative finding (not
to notify: wound and
infant botulism)
2 hours, by
phone
Brucellosis / Brucella
spp.
Positive laboratory
finding
1 week CPa Positive finding 1 week
Campylobacteriosis /
Campylobacter spp.
Positive finding
Negative findingb
Pos: 24 hours
Neg: 1 week
Cholera / Vibrio
cholerae
Positive laboratory
finding
24 hours CPa Positive finding 24 hours
Infection with
EHEC / EHEC
Positive laboratory
finding
24 hours CPa Positive finding
Negative findingb
Pos: 24 hours
Neg: 1 week
Hepatitis A /
Hepatitis A virus
Positive laboratory
finding
24 hours CPa Positive finding (not
to notify:
investigation of
immune status)
Negative findingb
Pos: 24 hours
Neg: 1 week
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Table 1.2: (continued)
Physician Laboratory
Disease/pathogen Notification criterion Time
frame
To whom Notification criterion Time frame
Hepatitis Ec /
Hepatitis E virusc
Positive laboratory
finding (PCR)
24 hours CPa Positive finding (PCR
only)
Negative findingb
Pos: 24 hours
Neg: 1 week
Listeriosis / Listeria
monocytogenes
Positive laboratory
finding
24 hours CPa Positive finding
Negative findingb
Pos: 24 hours
Neg: 1 week
Salmonellosis /
Salmonella spp.
Positive finding
Negative findingb
Pos: 24 hours
Neg: 1 week
Shigellosis / Shigella
spp.
Positive finding
Negative findingb
Pos: 24 hours
Neg: 1 week
Trichinellosis /
Trichinella spiralis
Positive laboratory
finding
1 week CPa Positive finding 1 week
Typhoid
fever / Salmonella
Typhi/Paratyphi
Positive laboratory
finding
24 hours CPa Positive finding
Negative findingb
Pos: 24 hours
Neg: 1 week
a CP = cantonal physician
b Only upon request of the FOPH for epidemiological investigations; since 2018
c Notifiable since 2018
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Table 1.3: Case numbers and notification rates of notifiable pathogens com-
monly transmitted through food in Switzerland, 2017.
Source: [Bundesamt für Gesundheit, 2018c]
Pathogen Case
numbers
Notification
rate (cases/
100’000 pop-
ulation)
Botulism / Clostridium botulinum 2 0.02
Brucellosis / Brucella spp. 10 0.12
Campylobacteriosis / Campylobacter
spp.
6’828 80.73
Cholera / Vibrio cholerae 0 0
Infection with EHEC / EHEC 698 8.25
Hepatitis A / Hepatitis A virus 114 1.35
Listeriosis / Listeria monocytogenes 45 0.53
Salmonellosis / Salmonella spp. 1’832 21.66
Shigellosis / Shigella spp. 142 1.68
Trichinellosis / Trichinella spiralis 1 0.01
Typhoid fever / Salmonella
Typhi/Paratyphi
22 0.26
tion from surveillance data.
Additionally, in 2016, it was introduced that for Campylobacter and Sal-
monella (and selected other non-foodborne pathogens) the total number
of tests conducted by month and test method and, thereof, the num-
ber of positive results has to be reported once a year. Before this date,
no information on the testing volume was available for foodborne infec-
tions. Testing volume was only notifiable for human immunodeficiency
virus (HIV), influenza and Legionella [Das Eidgenössische Departement
des Innern, 1999]. Since 2018, the ordinance furthermore stipulates that
for selected pathogens (among them are almost all foodborne patho-
gens) negative findings are notifiable for epidemiological investigations
upon request of the FOPH [Das Eidgenössische Departement des Innern,
2015a].
Reports on clinical findings usually include the patient’s name and ad-
dress or the patient’s initials and place of residence, date of birth, sex,
profession, diagnosis and disease manifestation, information on exposure
and risk factors.
Reports on laboratory findings include also the name and address or the
initials and place of residence, date of birth and sex of the patient; and
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the test result with its interpretation, the sample material, and the dia-
gnostic method used. Additionally, the species, subspecies, serotype or
type of toxin (if applicable) have to be reported by laboratories.
Campylobacter spp. is the most frequently reported foodborne pathogen
in Switzerland, followed by Salmonella spp. and EHEC (Table 1.3). This
is in line with surveillance data from the EU [European Food Safety Au-
thority and European Centre for Disease Prevention and Control, 2017].
However, in the EU, EHEC is relegated to the fourth place by yersiniosis,
the latter not being notifiable in Switzerland.
1.6 The epidemiology of selected foodborne
pathogens in Switzerland and in the
European Union
Campylobacter notifications have been increasing between 2005 and 2012
by about 50% in Switzerland and stabilised at high levels since then
[Baumgartner et al., 2012; Bundesamt für Lebensmittelsicherheit und
Veterinärwesen and Bundesamt für Gesundheit, 2017]. EHEC case num-
bers are increasing considerably since 2014 [Bundesamt für Lebensmit-
telsicherheit und Veterinärwesen and Bundesamt für Gesundheit, 2017].
With almost 700 cases, case numbers in 2017 were the highest ever re-
gistered since the beginning of EHEC-reporting in 1999 [Bundesamt für
Gesundheit, 2018c; Bundesamt für Lebensmittelsicherheit und Veter-
inärwesen and Bundesamt für Gesundheit, 2017]. In contrast, Salmon-
ella notifications were highest in 1992 with around 7’900 cases and de-
creased continuously thereafter [Schmid and Baumgartner, 2013]. Since
2009, case numbers stabilised at 1’000–1’500 cases per year [Bundesamt
für Lebensmittelsicherheit und Veterinärwesen and Bundesamt für Ge-
sundheit, 2017].
Similarly, in the EU, Campylobacter and Salmonella showed an increas-
ing and decreasing trend between 2008 and 2016, respectively, which
was, however, not statistically significant for the period between 2012
and 2016 [European Food Safety Authority and European Centre for
Disease Prevention and Control, 2017]. Reasons for the increase in cam-
pylobacteriosis cases in the EU are manifold: apart from changes in
disease epidemiology, some countries have improved their reporting sys-
tem or changed diagnostic methods leading to an increase in notified
cases [European Food Safety Authority and European Centre for Dis-
ease Prevention and Control, 2017]. In a modelling study, Havelaar
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et al. [2013] estimated the true incidence of campylobacteriosis and sal-
monellosis for all EU member states (27 at that time). They came up
with factors of underestimation4 for campylobacteriosis ranging from 0.4
(Finland & Sweden) to 39’400 (Bulgaria) and for salmonellosis ranging
from 0.4 (Finland) to 2’080 (Portugal). Additionally, they modelled also
the numbers for Switzerland and suggested that reported cases underes-
timate the true incidence by a factor of 3.3 for campylobacteriosis and
7.1 for salmonellosis. However, there are no other research studies avail-
able to support these modelling results for Switzerland. In France, the
factor of underestimation was found at 115 (campylobacteriosis) and 20
(salmonellosis) [Van Cauteren et al., 2015a]. Two studies in England /
the United Kingdom (UK) revealed multiplication factors of 7.6 and 9.3
for campylobacteriosis, and 3.2 and 4.7 for salmonellosis [Tam et al.,
2012; Wheeler et al., 1999].
For EHEC, the epidemiological situation looks different in the EU com-
pared to Switzerland: there was only a slight increase noted in the EU
between 2015 and 2016 [European Food Safety Authority and European
Centre for Disease Prevention and Control, 2017]. However, case num-
bers in the 2012–2016 period are reported to be at higher levels after
a large outbreak in 2011 compared to the period before the outbreak
[European Food Safety Authority and European Centre for Disease Pre-
vention and Control, 2017]. The outbreak in Germany in 2011 most
likely raised the awareness for EHEC among Swiss physicians, leading
to slightly higher case numbers also in Switzerland [Bundesamt für Ge-
sundheit and Nationales Referenzzentrum für enteropathogene Bakterien
und Listerien, 2015]. For EHEC, the multiplication factor was estimated
at 7.4 in the UK [Tam et al., 2012].
Hepatitis A, the only viral foodborne disease in the Swiss notification
system, showed a decreasing trend from 1988 with a notification rate of
10/100’000 population to 2002 (1.9/100’000) [Bundesamt für Gesund-
heit et al., 2007]. Case numbers remained at a low level until 2016
[Bundesamt für Gesundheit, 2018c]. In early 2017, an increase in cases
was noted which may be linked to a European-wide outbreak among
men who have sex with men (MSM) [Bundesamt für Gesundheit, 2017b;
European Centre for Disease Prevention and Control, 2017]. Underes-
timation is also an issue in hepatitis A surveillance: in the United States
of America (USA) it was estimated that 2 infections occur in the pop-
4Havelaar et al. [2013] refers to “underreporting”, not “underestimation”. However,
what they compared is the number of reported cases and the “true incidence”
which reflects underestimation according to the definition used in this thesis (see
chapter v “Glossary”)
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ulation for every case reported to national surveillance [Klevens et al.,
2014]. Furthermore, a systematic review and meta-analysis looking at
underreporting of hepatitis A in non-endemic countries revealed that 4
to 97% of hepatitis A cases were reported to public health [Savage et al.,
2016].
In conclusion, the huge range of underestimation factors between coun-
tries shows that reported case numbers should be compared across coun-
tries with caution and that multiplication factors are not interchangeable
between countries or health systems not allowing comparing national
disease burdens. Similarly, multiplication factors are pathogen-specific.
Therefore, exploring the level of underestimation is key in order to un-
derstand how surveillance data relate to the incidence in the population.
Furthermore, underestimation involves many steps which can change
over time; hence, the validity of estimated multiplication factors should
be assessed regularly.
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2 Rationale, aim and objectives
2.1 Rationale to study the ‘burden of illness
pyramid’
In Switzerland, notifiable foodborne diseases show both, increasing and
decreasing trends in the surveillance data of the NNSID. However, it
is largely unknown how these trends observed in national surveillance
relate to trends in disease incidence. A variety of factors contributes
to the underestimation of the burden of notifiable diseases which de-
pend on characteristics of the pathogen and the health system, both
influencing patients’ health seeking, physicians’ case management and
laboratories’ testing practices. These steps leading from infection to na-
tional disease registration, represented in the burden of illness pyramid,
are neither fully understood nor quantified for Switzerland. Underestim-
ation is highly country- and pathogen-specific. Furthermore, the level of
underestimation can change over time. Therefore, estimates of underes-
timation from other countries can only give limited insight into possible
multiplication factors for Switzerland.
Knowing the burden of disease at population level is important for pri-
ority setting of interventions. However, this burden cannot be quantified
in the absence of knowing levels of and factors contributing to under-
estimation of surveillance data, or of data of population-based studies.
Under the assumption that underestimation does not change over time,
surveillance data could still be used to assess trends in disease incidence.
However, this assumption is daring given the sheer number of factors
contributing to underestimation. Hence, decisions based on currently
available surveillance data are subject to questionable assumptions.
In summary, understanding the different levels of the burden of illness
pyramid and the determinants for advancing from one level to the next
is key for correctly interpreting data from the NNSID and for evidence-
based decision-making.
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2.2 Aim and objectives
The aim of this PhD thesis is to contribute to a better understanding of
the burden of illness pyramid for foodborne infections in Switzerland and
to apply this knowledge to improve Swiss infectious disease surveillance
and control. This will be achieved by characterising data and disease
in the surveillance system, researching physicians’ and patients’ beha-
viour, determining validity of routine health data bases and assessing
the social and economic impacts of foodborne infections. Furthermore,
the proportion of individuals advancing from one level to the next in the
burden of illness pyramid will be quantified.
Objective 1: To investigate the frequency of cases of foodborne infec-
tions as reported to the NNSID and thus, as seen in the
top levels of the burden of illness pyramid
a) To describe trends in notification data of foodborne
pathogens
b) To calculate positivity rates of foodborne pathogen
testing in Switzerland
Objective 2: To investigate the frequency and burden of disease of
acute gastroenteritis (AG) at the primary care level in
Switzerland
a) To assess trends in the frequency of stool testing for
foodborne pathogens
b) To understand and quantitatively characterise physi-
cians’ stool testing practices for patients with AG
c) To describe the physicians’ perception of AG and food-
borne diseases
d) To estimate direct healthcare costs of AG at primary
care level in Switzerland
Objective 3: To propose a concept to investigate acute gastrointestinal
illness (AGI) at population level in Switzerland
a) To develop a study protocol for a population-based
study on the frequency, burden of disease, aetiology
and socio-economic impact of AGI in the Swiss popu-
lation
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The research presented in this PhD thesis is part of a broader research
portfolio consisting of several projects and culminating in multiple PhD
theses on Swiss health system’s research of food- and water-borne in-
fectious diseases. This PhD thesis is the second in the series. The first
volume on “Infectious disease surveillance in Switzerland” is entitled
“Epidemiology of campylobacteriosis and acute gastroenteritis from a
human and health system’s perspective in Switzerland” [Bless, 2018].
The research portfolio started by exploring the epidemiology of campylo-
bacteriosis in Switzerland. In this context the importance and lack of
understanding of the burden of illness pyramid was noted. Consequently,
the scope was broadened to include foodborne diseases in general and
strengthened its focus on understanding and quantifying the different
levels of the burden of illness pyramid. Furthermore, this research port-
folio aims at understanding the validity of data from Swiss infectious
disease surveillance and generating a basis for improving national sur-
veillance.
3.1 Overview of research approaches and study
designs
The research approach applied for each study is summarised in this sec-
tion. Figure 3.1 provides an overview of each study undertaken for this
thesis studying the various levels of the burden of illness pyramid.
3.1.1 Analysing notification data on Campylobacter ,
Salmonella, and hepatitis A
These studies contribute to objective 1a of this thesis.
Notification data of different foodborne pathogens have been analysed in
the framework of this thesis to understand the tip of the burden of illness
pyramid. For this, data from the NNSID were requested from the FOPH
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Figure 3.1: Overview of PhD research framework to better understand the burden of illness pyramid for foodborne
infections in Switzerland
AG: acute gastroenteritis; EHEC: enterohaemorrhagic E. coli; GP: general practitioner
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for Campylobacter and Salmonella (both for the years 1988–2013) and
for hepatitis A (years 1988–2016).
Campylobacter and Salmonella notification data included only inform-
ation from reports on laboratory findings. Trends in case numbers and
characteristics (age, sex) were analysed and compared for the two patho-
gens in the light of similar transmission patterns and different public
awareness.
For hepatitis A, laboratory reports are complemented by reports on clin-
ical findings providing more detailed information on patient character-
istics such as risk factors and suspected exposure sources. Hepatitis A
notification data was not only analysed for trends due to changing dis-
ease epidemiology and patient characteristics or interventions, but also
for trends due to changes in the surveillance system (e.g. changes in
notification forms).
Detailed descriptions of the methods applied for these research compon-
ents are provided in chapter 4 (Schmutz et al. [2016]) and chapter 5
(Schmutz et al. [2018]).
3.1.2 Studying trends in laboratory positivity rates of
Campylobacter , Salmonella, and EHEC
These studies contribute to objective 1b and objective 2a of this
thesis.
The number of tests conducted by diagnostic laboratories is notifiable
for selected foodborne pathogens only since the introduction of the new
Epidemics Act in 2016. Testing per se is a pre-requisite for isolating a
pathogen, and hence, the number of tests conducted is strongly influen-
cing the number of case notifications. Therefore, diagnostic laboratories
were asked to provide information on all tests conducted for Campy-
lobacter spp., Salmonella spp. and EHEC over a 10-year period. This
data was used to calculate positivity rates, defined as the proportion of
positive test results out of all tests conducted for a certain pathogen.
Time trends in positivity rates were evaluated together with time trends
observed in the NNSID to better understand how notification data trans-
late to the incidence of the disease at population level.
Laboratories reporting highest case numbers for the respective patho-
gens were selected. Additional laboratories were selected, if necessary,
to include all language regions of Switzerland and to represent both hos-
pital and private-sector laboratories.
For Campylobacter and Salmonella, 11 diagnostic laboratories were se-
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lected and asked to provide data for the years 2003–2012. Requested
information included case-based data on the patient tested (sex, age,
canton of residence, personal identification number assigned by laborat-
ory) and test characteristics (pathogen tested, test result, date of test,
test method applied).
For EHEC, the selection included 11 diagnostic laboratories as well. The
laboratories were asked for the same information as for Campylobacter
and Salmonella for the years 2007–2016.
Detailed descriptions of the methods applied for these research compon-
ents are provided in chapter 6 (Bless et al. [2017]) and chapter 8.
3.1.3 Understanding laboratory practices and its
influence on notification data: the example of
EHEC
This study contributes to objective 1a and objective 2a of this thesis.
Usually, stool samples are used for laboratory diagnostics in case of AG, if
laboratory diagnostics are considered at all. Physicians as well as labor-
atory experts influence the selection of pathogens for which the stool
sample is tested. Stakeholders from diagnostic laboratories were con-
sulted to understand current practice in laboratory diagnosis of EHEC
in Switzerland as well as recent changes therein, potentially influencing
surveillance data. Experts working at the laboratories selected for the
positivity study on EHEC (see subsection 3.1.2 and chapter 8) were
asked to participate. This sampling allowed obtaining background in-
formation for interpretation of findings from the positivity study apart
from providing important insight into current laboratory practices.
A detailed description of the methods applied for this research compon-
ent is provided in chapter 7.
3.1.4 Understanding physicians’ approaches towards
acute gastroenteritis case management – a
qualitative approach
This study contributes to objective 2b, objective 2c and objective 2d
of this thesis.
Swiss GPs in charge of treating campylobacteriosis patients of a case-
control study [Bless et al., 2014] were invited to participate in this qual-
itative study. GPs were interviewed to get insight into their approaches
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to managing patients presenting with AG in general and campylobac-
teriosis in particular. Understanding case management, and the GPs’
decision-making process for or against stool diagnostics in particular, is
important for understanding the burden of illness pyramid.
Interviews were additionally used to assess the GPs’ perception of the
FOPH.
A detailed description of the methods applied for this research com-
ponent is provided in Bless et al. [2016]. A summary of this article
including further analyses and additional results on the GPs perception
of their role, of the Swiss health system and of the FOPH is provided in
chapter 10.
3.1.5 Understanding physicians’ approaches towards
acute gastroenteritis case management – a
quantitative study
This study contributes to objective 2b, objective 2c and objective 2d
of this thesis.
In 2014, a study on the frequency of consultations due to AG at the pri-
mary care level in Switzerland was conducted within Sentinella. All first
consultations due to AG were reported by Sentinella-physicians for a full
calendar year. Date of birth, sex, hospitalisation status and whether or
not the GP requested a stool sample was recorded for all cases. For a sub-
sample of patients, physicians reported additional information including
signs and symptoms, medication, absence from work and exposure to se-
lected risk factors. Results from the preceding qualitative study among
Swiss GPs (see chapter 10 and Bless et al. [2016]) were considered when
developing the questionnaire for this study. Apart from providing estim-
ates on the frequency of consultations due to AG at the primary care
level, this study provided quantitative insights into GPs’ approaches to
diagnosis and treatment of AG in Swiss primary care.
A detailed description of the methods applied for this research compon-
ent is provided in chapter 11 [Schmutz et al., 2017a].
3.1.6 Studying healthcare costs of acute gastroenteritis
and campylobacteriosis
This study contributes to objective 2d of this thesis.
This study aimed at estimating healthcare costs of campylobacteriosis in
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Switzerland. Given the difficulty to clearly separate campylobacteriosis
from AG (without known aetiology), estimates for both conditions were
made. Different patient management models were developed based on
expert opinions and results from our previous research to account for the
heterogeneity in disease presentation and patient characteristics influen-
cing case management. Healthcare costs for consultations, laboratory
diagnostics, medication and hospitalisation associated with each patient
management model were extracted from official tariff lists. Estimates of
the frequency of each model were used to extrapolate individual costs to
overall healthcare costs for Switzerland. Estimates were based on costs
and case numbers for the year 2012 as this was the year with most avail-
able information (health and cost statistics).
A detailed description of the methods applied for this research compon-
ent is provided in chapter 12 [Schmutz et al., 2017b].
3.1.7 Studying the incidence, burden of disease, socio-
economic impact and aetiology of acute
gastroenteritis
This study proposal contributes to objective 3a of this thesis.
To understand the lowest levels of the burden of illness pyramid, a pop-
ulation-based study is required. Considering the various studies conduc-
ted as part of volume I on “Infectious disease surveillance in Switzerland”
[Bless, 2018] and our current understanding of food- and water-borne dis-
ease surveillance in Switzerland, a one-year, prospective cohort study is
proposed to assess the incidence, burden of disease, socio-economic im-
pact and aetiology of AG in Switzerland. Given our previous research
on surveillance data, its generation and limitations, and the awareness of
this data situation on the side of the FOPH and the Federal Food Safety
and Veterinary Office (FSVO) allowed us to propose such a cohort study
to the federal authorities.
A cohort of 3’000 participants, recruited from a random sample of the
general population in Switzerland, is followed-up weekly during a one-
year period (52 weeks). Occurrence of GI signs and symptoms as well as
exposure to transient risk factors are assessed through weekly question-
naires, available electronically and on paper. After reporting an episode
of acute gastrointestinal illness (AGI)*, participants receive an addi-
tional questionnaire to assess the perceived illness experience, patients’
help seeking behaviour and socio-economic consequences of the disease
episode (including inability to work). Furthermore, stool samples from a
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subsample of symptomatic and asymptomatic participants are obtained
to investigate the aetiology of AGI (symptomatic participants) and the
prevalence of bacteria harbouring selected antibiotic resistances and of
selected bacterial GI pathogens in asymptomatic participants.
As part of this PhD thesis, a detailed proposal for the cohort study was
developed and funding was obtained. Operational planning and execu-
tion of the study will be conducted in the framework of two upcoming
PhD theses.
A detailed description of the proposed cohort study is provided in
chapter 13.
3.2 Ethical considerations
Studies involving personal health-related data or human biological ma-
terial are subject to the Federal Act on Research involving Human Be-
ings (Human Research Act, HRA; SR 810.30) and require ethical clear-
ance except if the data or material is fully anonymised [Die Bundesvers-
ammlung der Schweizerischen Eidgenossenschaft, 2011]. Studies conduc-
ted or data collected in pursuance of the Epidemics Act are exempted
from ethical clearance.
Data from the NNSID was collected under the Epidemics Act and was
anonymised. Therefore, the analyses of notification data of Campylob-
acter , Salmonella and hepatitis A (chapters 4 and 5) did not require
ethical clearance. Similarly, data collection for the study in Sentinella
(chapter 11) was conducted through the FOPH in pursuance of the Epi-
demics Act.
For the positivity studies on Campylobacter and Salmonella (chapter 6),
ethical clearance was obtained from the Ethikkommission Nordwest-und
Zentralschweiz (EKNZ) (ethics committee northwest/central Switzer-
land) to work with “already existing, health-related data without in-
dividual consent and information” (reference number: EKNZ:2014–164)
while the positivity study on EHEC (chapter 8) was mandated by the
FOPH and conducted under the Epidemics Act (decree issued by the
FOPH).
The stakeholder consultation for understanding laboratory practices of
EHEC diagnostics (chapter 7) did neither involve personal health-related
data nor biological material and hence, this research was not subject to
the Human Research Act.
Similarly, the qualitative study among Swiss GPs (chapter 10) involved
their professional experience and opinion rather than personal health-
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related information. Furthermore, this project was part of an outbreak
investigation [Bless et al., 2014] conducted under the Epidemics Act.
The project estimating healthcare costs of AG and campylobacteriosis
(chapter 12) relied on publicly available or aggregated data from previous
research and official statistics. Experts were asked about their profes-
sional opinion, not about personal- or patient-related information. This
part of the project did, hence, not require ethical clearance. However,
ethical approval was obtained for using pseudonymised patient invoices
to cross-validate cost estimates (reference number: EKNZ:2014–159).
Finally, the cohort study on AG (chapter 13) will require ethical clear-
ance. Submission to the respective ethical committee(s) will occur as
soon as the detailed planning of the study is completed and all docu-
ments (e.g. questionnaires) are prepared.
Research presented in this thesis was conducted in agreement with the
Declaration of Helsinki [World Medical Association, 2013] as well as the
Essentials of Good Epidemiological Practice [Altpeter et al., 2005].
3.3 Collaborations
The main external partners for the research presented in this thesis were
the FOPH and the FSVO.
The surveillance systems maintained by the FOPH generate data only
at the upper level(s) of the burden of illness pyramid. However, the
FOPH is well aware of this limitation and has a vested interest in (a)
understanding lower parts of the pyramid and (b) generating knowledge
to potentially improve current infectious disease surveillance systems.
Several projects which are part of this thesis relied on and profited from
this openness and interest of the Swiss public health authorities. This
PhD research is part of a longstanding research partnership with the
FOPH through several mandated research works in foodborne infectious
diseases. Specifically, the FOPH provided data for the analyses of trends
in Campylobacter , Salmonella and hepatitis A (chapters 4 and 5), facil-
itated the initial contact with the diagnostic laboratories involved in the
positivity studies (chapters 6 and 8), organised joint visits of laborat-
ory experts (chapter 7), and was instrumental in and funded large parts
of these research endeavours. Furthermore, the administrative lead and
data management of Sentinella is with the FOPH. This enabled us to get
access to the data generated through this system (chapter 11). Finally,
the FOPH is supporting the upcoming cohort study (chapter 13) both
conceptually and financially together with the FSVO.
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The FSVO is interested in our research as many GI diseases are zoonoses
and/or concern food safety. The two federal offices maintain a close dia-
logue within this thematic field which is fostered by our research outputs.
For example, media communications in response to our research was har-
monised between the FOPH and the FSVO as well as between the federal
offices and the Swiss Tropical and Public Health Institute (Swiss TPH).
Several diagnostic laboratories from all over Switzerland were involved in
our research by providing data for the positivity studies and important
background information for interpretation of surveillance and laboratory
data (chapters 6 and 8).
We collaborated with medical anthropologists from Partners for Applied
Social Sciences (PASS) Suisse and with the Centre for Primary Health
Care from the University of Basel to investigate the GPs’ management
and understanding of AG and campylobacteriosis (chapter 10). The lat-
ter also supported us in developing the questionnaire for the Sentinella
study (chapter 11).
Collaboration with the Institute of Pharmaceutical Medicine of the Uni-
versity of Basel and internal collaboration with the Medical Services and
Diagnostics department at Swiss TPH was sought for the estimation of
healthcare costs of AG and campylobacteriosis (chapter 12).
The cohort study on AG in Switzerland (chapter 13) will involve several
partners. Apart from the federal offices, collaboration with the National
Reference Centre for Enteropathogenic Bacteria and Listeria (NENT),
the German National reference laboratory for Clostridium difficile and
with the “labormedizinisches zentrum Dr Risch” (a Swiss private-sector
diagnostic laboratory) was initiated. Future internal and external collab-
orators will involve, among others, social scientists and health economists
to develop the tools for assessing the social and economic burden and
medical personnel to follow-up on patient histories and medical records.
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Abstract
Clinical isolates of Campylobacter spp. and Salmonella spp. are notifi-
able in Switzerland. In 1995, Campylobacter replaced Salmonella as the
most frequently reported food-borne pathogen. We analysed notification
data (1988–2013) for these two bacterial, gastrointestinal pathogens of
public health importance in Switzerland. Notification rates were cal-
culated using data for the average resident population. Between 1988
and 2013, notified campylobacteriosis cases doubled from 3’127 to 7’499,
while Salmonella case notifications decreased, from 4’291 to 1’267. Case
notifications for both pathogens peaked during summer months. Cam-
pylobacter infections showed a distinct winter peak, particularly in the
2011/12, 2012/13 and 2013/14 winter seasons. Campylobacter case no-
tifications showed more frequent infection in males than females in all
but 20–24 year-olds. Among reported cases, patients’ average age in-
creased for campylobacteriosis but not for salmonellosis. The inverse
trends observed in case notifications for the two pathogens indicate an
increase in campylobacteriosis cases. It appears unlikely that changes
in patients’ health-seeking or physicians’ testing behaviour would affect
Campylobacter and Salmonella case notifications differently. The im-
plementation of legal microbiological criteria for foodstuff was likely an
effective means of controlling human salmonellosis. Such criteria should
be decreed for Campylobacter , creating incentives for producers to lower
Campylobacter prevalence in poultry.
Introduction
Campylobacter spp. and Salmonella spp. are the most frequently re-
ported zoonotic infections in Switzerland. The Federal Office of Public
Health (FOPH) monitors communicable diseases in Switzerland. The
National Notification System for Infectious Diseases (NNSID) is an in-
tegral part of ensuring compliance with this obligation and was imple-
mented nationwide, in a standardised way, in 1987. The regulation on
communicable disease notifications determines which diseases have to
be reported, by whom and in what timeframe [1]. Among food-borne
pathogens, Campylobacter spp., Salmonella spp., Listeria spp., entero-
haemorrhagic Escherichia coli, Salmonella spp., and hepatitis A virus
are notifiable. Laboratories must report isolates of Campylobacter and
Salmonella within one week of discovery. For patients with suspected
bacterial diarrhoea, basic stool culture including Campylobacter spp.,
Salmonella spp. and Shigella spp. is the routine method of laboratory
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diagnosis [2].
In humans, campylobacteriosis is most frequently caused by Campylob-
acter jejuni and C. coli [3]. Signs and symptoms include watery or
bloody diarrhoea, fever, abdominal cramps, vomiting and malaise and
usually occur after an incubation period of 2–5 days [4]. The disease
usually resolves without antibiotic treatment within one week. A recent
study on determinants of the disease in Switzerland showed that labor-
atory-confirmed campylobacteriosis can lead to severe illness in patients
[5]. Complications such as Guillain-Barré syndrome can follow Campy-
lobacter infections, although this is rare [4, 6]. Fatal cases are possible,
but the reported case fatality rate of 0.1% is small and four times lower
than the fatality rate for salmonellosis [7].
There are more than 2’600 serovars of Salmonella, of which S. enter-
ica subspecies enterica serovars Enteritidis (S. Enteritidis) and Typh-
imurium (S. Typhimurium) are the most frequently reported [8]. Signs
and symptoms of salmonellosis are similar to those of campylobacteriosis
but the incubation period is shorter at 6–72 hours (usually 12–36 hours)
[9]. In a group of volunteers, the minimal infectious dose was found
to be at least 200 times higher for Salmonella than for Campylobacter
(105–109 vs. 500 organisms) [10]. However, Salmonella outbreaks have
been reported where fewer than 100 organisms had caused disease [11].
In Switzerland, Campylobacter replaced Salmonella as the most frequent
food-borne pathogen isolated from clinical specimens in 1995 [12]. In
Europe, predominance of Campylobacter has been reported from 2005
onwards [13]. Campylobacter notifications were stable in European
Union (EU) countries between 2009 and 2013 while Salmonella notific-
ations declined. Nonetheless, reported food-borne outbreaks were more
often caused by Salmonella spp. than by Campylobacter spp. (1’168 vs.
414 in 2013).
The aim of this study is to describe the epidemiological patterns and
trends of Campylobacter and Salmonella case notifications in Switzer-
land and to identify factors leading to the inverse trends observed from
the NNSID.
Methods
Medical diagnostic laboratories in Switzerland are obliged by law to re-
port positive Campylobacter and Salmonella test results to the FOPH
and to the cantonal chief medical officer in the patient’s canton of resid-
ence within one week of discovery [1]. Reports must include information
44
Published article
on laboratory diagnosis (test result, interpretation, type of sample, de-
tection method and date), patient data (sex, date of birth and place of
residence) and physician- and diagnosing laboratory-related data (name,
phone and fax number, and address). The FOPH enters the informa-
tion into the NNSID database. If the patient’s canton of residence is
unknown, the canton of the reporting laboratory is entered.
The present study used Campylobacter and enteric Salmonella case no-
tification data from the present NNSID’s first full year of data collec-
tion (1988) until the end of 2013. Data on patients residing outside of
Switzerland were excluded. If residency was not specified, the record was
kept in the analysis. Notification rates, defined as the number of cases
per 100’000 resident population, were calculated. The term ‘notification
rate’ was used instead of ‘incidence rate’ to be consistent with other
authors [13] and because the numbers calculated should not be equated
with a true population incidence. To calculate notification rates, data
on the average permanent resident population, obtained from the Fed-
eral Statistical Office’s STATTAB database, were used [14]. Data was
analysed and graphically represented using the statistical software Stata
(Version 13.0).
Results
Campylobacteriosis trends
A 2.5-fold increase in the number of reported campylobacteriosis cases,
from 3’127 cases in 1988 to 7’499 cases in 2013, was observed (Figure 4.1).
Case numbers increased steadily from 1988 to 2000, until they reached
7’000. Thereafter, Campylobacter case notifications dropped and lev-
elled off at 5’000 cases annually and then rose steadily again from 2007,
exceeding the peak level reached in 2000. The highest number of cases
reported to date was 8’480 cases in 2012. In each year since 1988, a
peak was observed during the summer months (June–August) (Figures
4.2 and 4.3).
A second, much shorter peak was noted in December and January in
all years. This winter peak has been especially pronounced in the past
few years. While the highest weekly case numbers during the summer
and winter peaks were comparable in 2009 and 2010, weekly case num-
bers were much higher during the winter peaks of 2011/12, 2012/13 and
2013/14 compared with the preceding summer peaks (Figure 4.3).
The increase in Campylobacter case notification rates differed by age
(Figure 4.4). Among younger age groups, the increase in notification
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Figure 4.1: Number of Campylobacter and Salmonella case notifications and notification rates registered at the Federal
Office of Public Health, Switzerland, 1988–2013
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Figure 4.2: Monthly number of notified campylobacteriosis and salmonellosis cases, Switzerland, 1988–2013
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Figure 4.3: Weekly number of notified campylobacteriosis and salmonellosis cases, Switzerland, 2009–2013
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Figure 4.4: Trends in Campylobacter notification rates between age groups and sexes, Switzerland, 1988–2013
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Table 4.1: Comparison of notification rates for Campylobacter and Salmon-
ella among different age groups, Switzerland, 1988 and 2013
Campylobacter Salmonella
Age Notification rate % Notification rate %
group 1988 2013 increase 1988 2013 increase
<5 105.3 102.3 -3% 216.1 51.5 -76%
5–9 49.9 62.9 +26% 85.1 23.4 -73%
10–14 29.7 58.1 +96% 59.1 15.1 -74%
15–19 54.7 108.1 +98% 63.4 18.1 -71%
20–24 97.4 160.7 +65% 68.1 25.3 -63%
25–44 49.2 91.2 +85% 51.6 10.6 -79%
45–64 24.4 78.3 +221% 41.1 10.9 -73%
65–84 19.2 100.1 +421% 38.6 15.1 -61%
85+ 11.7 92.2 +688% 62.7 9.3 -85%
rates over the years was less pronounced than among older age groups.
In children younger than five years old, the notification rates decreased
from 105.3 to 102.3 cases per 100’000 population between 1988 and 2013
(-3%) (Table 4.1).
This decrease was statistically significant (permutation test for trend,
p=0.03). There was no statistically significant (decreasing or increas-
ing) trend in the 5–9 year-olds; in all older age groups, the increasing
trend was statistically significant (permutation test for trend, p=0.01
for 20–24 year-olds, p<0.01 for all other age groups). Among those aged
85 years and older, the notification rate increased more than seven-fold,
from 11.7 to 92.2 cases per 100’000 population during the same time
period. The median age of campylobacteriosis patients increased from
25 years (interquartile range, IQR: 17–38) in 1988 to 39 years (IQR: 23–
59) in 2013. In all but the 20–24 year-old age group, notification rates
were higher for males than for females (Figure 4.4). Males accounted for
53.4–57.5% of total case notifications each year.
Campylobacter diagnostics identified C. jejuni or C. coli in the majority
of clinical samples (88.5–96.8% every year; data not shown). For most of
the remaining cases, the species was not identified or not reported. Re-
ported sample material came from stool (98.8%), blood or serum (0.4%),
and other or unspecified materials (0.8%). The majority of cases were
tested using culture-based methods directly or confirmatively after PCR
(>97%).
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Figure 4.5: Trends in Salmonella notification rates between age groups and sexes, Switzerland 1988–2013
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Salmonellosis trends
Salmonellosis cases reported to the FOPH increased from 4’291 cases in
1988 to 7’806 cases in 1992 (Figure 4.1). Since 1992, Salmonella case
notifications steadily decreased until reaching 1’267 cases in 2013. The
highest number of Salmonella case notifications each year was registered
in late summer (July–October), indicating a seasonal pattern (Figures
4.2 and 4.3).
Time trends did not differ between sex and age groups (Table 4.1, figure
4.5).
Each year, 49.6–56.2% of reported cases occurred in males. The me-
dian age of salmonellosis patients increased from 25 years (IQR: 7–44)
in 1988 to 29 years (IQR: 11–56) in 2013. In terms of notification rates,
the highest absolute reduction occurred in the youngest age group (un-
der five years, figure 4.5). The reduction was, however, similar for all age
groups when looking at percentage decrease (Table 4.1). The decreasing
trend for all age groups from 1988 to 2013 was statistically significant
(permutation test for trend, p<0.01 for all age groups).
The two most frequently reported serovars were S. Enteritidis (54.0%)
and S. Typhimurium (13.7%). Other reported S. enterica serovars in-
cluded Virchow, Infantis and the monophasic Typhimurium 4,12:i:- (only
differentiated in the notification system since 2010).
Discussion
In Switzerland, there has been a marked increase in Campylobacter case
notifications since 1988, when surveillance began, while case numbers
have decreased for salmonellosis. The number of Campylobacter infec-
tions nowadays is similar to levels of Salmonella 20 years ago. Salmonel-
losis has reduced considerably since then, due to control programmes
targeting poultry production. Campylobacteriosis has also increased
throughout the EU, though the numbers seem to have stabilised between
2009 and 2013; for salmonellosis, a decreasing trend continues [13]. Time
trends for Campylobacter in Switzerland differ between age groups, even
when looking at age-group-specific notification rates and adjusting for
demographic changes in the population.
True increase in campylobacteriosis frequency
One study from the Netherlands showed that stool-testing frequency
increased between 1998 and 2008, which might help to explain the in-
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crease in campylobacteriosis cases [15]. Along these lines, the decrease
in salmonellosis cases would be even larger in the absence of intensified
testing.
It is difficult to interpret the changes in the number of positive test res-
ults without knowing more about changes in the number of individuals
seeking medical consultations, in the proportion of patients being pre-
scribed stool testing and in the total number of tests performed (positive
and negative) in Switzerland. Different factors can influence notification
data such as changes in risk factors, in patients’ health-seeking beha-
viour, in physician testing practices, in human susceptibility, or in the
virulence or pathogenicity of Campylobacter spp. and Salmonella spp.
When a patient presents with acute gastroenteritis necessitating further
laboratory testing, Swiss physicians most commonly request basic stool
bacteriology, which includes testing for Campylobacter , Salmonella and
Shigella (data not shown). Therefore, a change in testing frequency
without a change in disease epidemiology would most likely lead to a
similar change in both Campylobacter and Salmonella case notifications.
Some improvements in stool culture methodology have been made in
the past 25 years; however, changes cannot explain the inverse trends
observed (personal communication, Roger Stephan, 30 July 2015). Fur-
thermore, negative test results are not notifiable and, hence, the total
number of tests (denominator) is unknown. Knowing the denominator
would help to confirm or reject the hypothesis that a change in testing
frequency does not explain the increase in Campylobacter case notifica-
tions and would allow for a better interpretation of the trends observed
in the NNSID. Though stool culture methods did not change signific-
antly, the physicians’ awareness towards campylobacteriosis is likely to
have increased. It is not known to what extent this might have influ-
enced notification data. Changes in patients’ health-seeking behaviour
are unlikely to influence Campylobacter and Salmonella case notifica-
tions in different ways. Consequently, we assume that the decrease in
Salmonella case notifications and the increase in Campylobacter case no-
tifications represent real epidemiological trends.
The revised Swiss Epidemics Act effective since January 2016, and its
allocated ordinances obligates diagnostic laboratories to report annually
the total number of positive and negative Campylobacter and Salmonella
tests performed [16]. This innovation will allow basic routine analysis of
trends in testing frequency and positivity rates in the future.
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The influence of sex and age on food-borne disease
notifications
Salmonella case notifications do not differ between sexes, even when
stratified by age groups. In contrast, Campylobacter case notifications
reveal higher notification rates among males in all age groups, except
for those in the 20–24 year-old group. Interestingly, studies from Ger-
many and England and Wales also show that females in their twenties
are more frequently affected by campylobacteriosis than males, while
male cases dominate in all other age groups [17, 18]. Schielke et al. [17]
suggested that women in this age group are more frequently involved
in childcare activities, which might lead to increased human-to-human
transmission. They also suggest that women in this age group are more
often exposed to potentially contaminated chicken because they prepare
and eat chicken more frequently than men of the same age. They may
also be in closer contact with pets, which often harbour the same strains
as their owners [19]. Different help-seeking behaviour of patients in this
age group or different testing practices of physicians could also explain
variations. Moreover, it seems likely that genetic or hormonal factors
lead to differences by sex, as notification rates in males and females dif-
fer already in the youngest age group (under five years) (Figure 4.4) [20].
We assume that in the youngest age group, health-seeking behaviour and
eating habits are not yet dependent on sex and are rather driven by par-
ents or other persons engaged in childcare.
Available information from England and Wales also shows that adults,
including the elderly, increasingly test positive for Campylobacter [18].
It has been suggested that the increasing use of proton pump inhibitors
(PPIs) might explain a part of this phenomenon, especially among the
elderly. Several studies have found that the use of PPIs is a risk factor
for infection with Campylobacter and other enteric pathogens [21]. How-
ever, one study revealed that patients prescribed PPIs were already at
increased risk of gastrointestinal infection, even before prescription of
these drugs [22]. In any case, conditions leading to PPI use or prescrip-
tion are likely associated with acute infectious gastroenteritis. Why the
aforementioned risk factor would only influence the frequency of Cam-
pylobacter but not Salmonella case notifications remains unknown. One
possible explanation is that the infective dose of Campylobacter is gen-
erally lower than that of enteric Salmonellae. A recent study of poultry
consumers’ behaviour, risk perception and knowledge related to cam-
pylobacteriosis and domestic food safety showed that unsafe cooks were
more likely to be male and of younger age [23]. Even though this finding
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is consistent with high Campylobacter notification rates observed among
young adults, it does not explain the increasing rates among the elderly.
Food safety regulations
Campylobacter and Salmonella infections are assumed to be mainly food-
borne. Genotyping and epidemiological studies in Switzerland have
shown that chicken meat is the most likely source of infection in the
majority of human campylobacteriosis cases [5, 24-26]. In concert with
these findings, a recent time-series analysis showed a significant associ-
ation between Campylobacter prevalence in broiler chickens and human
illness [27]. In Switzerland, poultry consumption has increased in the
past 25 years. While the average per capita consumption was 7.8kg in
1988, it was 11.4kg in 2013 [28, 29].
Eggs and egg-containing products were shown to be risk factors for sal-
monellosis in Switzerland in 1993 [30]. The legislating authorities ad-
dressed the risk of these food-borne pathogens by setting and enforcing
microbiological criteria.
As early as 1969, an official method to detect enteritic Salmonella in
foods was published in the Swiss Food Manual [31]. Also, guidance
levels for Salmonella in different food categories were given.
In 1981, legal microbiological criteria for foods were decreed for the first
time in a Federal Ordinance [32]. Criteria for Salmonella were as follows.
For baby foods and diet products: not detectable (nd) in 50g; drinking
water: nd in 5l; other products: nd in 20g. For ‘other products’, au-
thorities could refrain from measures if the product in question had to
undergo treatment (e.g. cooking) prior to consumption. In 1995, after a
revision of the ordinance, criteria for Salmonella were set at as follows.
For baby foods: nd in 50g; drinking water: nd in 5l; ready-to-eat foods:
nd in 25 g; and spices: nd in 25g [33]. In 2005, Swiss food legislation
adopted the European Union’s microbiological criteria for Salmonella in
food [34].
Salmonella limits for some categories of raw meat were issued as the
national law adapted to EU hygiene regulations in 2006 [35]. To combat
the epidemic with S. Enteritidis in eggs, mandatory screening of layer
hens and measures to eradicate positive flocks were decreed by the Or-
dinance for the Control and Eradication of Epizoonotic Diseases as early
as 1993 [36]. Apart from a ban on battery-caged chicken rearing (in
effect since 1992 [37]), no further measures (such as vaccinations of layer
hens against S. Enteritidis) are implemented in Switzerland.
As early as 1987, a limit for Campylobacter was decreed in the Ordinance
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on Hygiene, which was ‘not detectable in 10g of ready-to-eat foods’ (later,
not detectable in 25g) after enrichment. This microbiological criterion
was abrogated in 2006. To address the risk of Campylobacter in con-
nection with poultry liver, since 2014 the Ordinance has stipulated that
poultry liver must be sold frozen if it cannot be shown that the product
comes from a Campylobacter-free flock [35]. Furthermore, a process hy-
giene criterion to minimise Campylobacter in poultry slaughterhouses
is underway and should enter into force in 2016. However, criteria for
Campylobacter on raw poultry meat are not currently being considered.
Relevant epidemiological studies in Switzerland
In 2013, 37.7% (169/448) of broiler flocks and 65% (226/348) of rectum-
anal swab samples taken from pigs at slaughter tested positive for Cam-
pylobacter [38]. In the same year, only 1% of 3’636 samples of fresh
poultry meat, poultry meat preparations and poultry meat products at
different stages of processing tested positive for Salmonella. Twenty-
three years prior, Salmonella contamination levels in Switzerland were
much higher. In a 1990 study, 19.2% of chicken neck skin lobs and
47.7% of broiler flocks were found to be Salmonella-positive [39]. As a
consequence, Salmonella control measures as described above were im-
plemented in the 1990s and led to a significant reduction in the number
of human cases reported.
In Switzerland, salmonellosis and campylobacteriosis case curves crossed
in 1995; in Austria, it was in 2006 [40]. The reason for this striking differ-
ence might be that Switzerland addressed the epidemic of S. Enteritidis
in eggs at a very early stage.
The reduction of domestic salmonellosis cases resulted in a higher prom-
inence of travel-associated transmission risks in relative terms, which was
shown by Schmid and Baumgartner: the (relative) proportion of travel-
associated S. Enteritidis cases increased substantially from 20% in 1993
to 45% in 2011/12 [41]. Two case-control studies on campylobacterio-
sis [5, 26] and a case-control study on salmonellosis [30] conducted in
Switzerland identified travel abroad as a risk factor for the diseases.
However, this finding has to be interpreted with care, as patients with
travel history are more likely to be tested (data not shown) and all stud-
ies recruited laboratory-confirmed cases.
The observed winter peak in Campylobacter infections can be attributed
partly to the traditional consumption of meat fondue over Christmas
and New Year [5]. However, it is not known why this winter peak has
been more pronounced in the past few years. Given the increasing per
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capita consumption of poultry meat [28, 29], one could hypothesise that
poultry has become more popular in meat fondues.
Outbreaks due to Campylobacter or Salmonella also occurred in Switzer-
land. However, the number of foodborne outbreaks decreased signific-
antly between 1993 and 2010, mainly due to the reduction of salmonel-
losis [12]. The number of registered Salmonella outbreaks dropped from
27 in 1993 to one in 2010 while the number of Campylobacter outbreaks
varied between none and five throughout this time period. In relation to
the number of cases, Salmonella is causing more outbreaks than Cam-
pylobacter both in Europe and in Switzerland.
Public awareness and knowledge about the diseases
Public awareness and people’s knowledge of Campylobacter and Salmon-
ella in Switzerland are as different as the trends observed in the two
pathogens in the NNSID. In 2011, a consumer survey showed that 76%
of participants were ‘very concerned’ or ‘somewhat concerned’ about Sal-
monella in foods [42]. Only 1% of respondents stated that they had not
heard of the Salmonella bacterium. In contrast, only 33% were ‘very con-
cerned’ or ‘somewhat concerned’ about Campylobacter and more than
half (52%) had not heard of the pathogen. Unpublished data from a
recent case-control study in Switzerland [5] confirm those figures: 55%
of people infected with campylobacteriosis (cases) and 68% of healthy
people (population-based controls) had never heard of Campylobacter ,
while only 2% of cases and 3% of controls had never heard of Salmonella.
The lack of knowledge about safe food handling and avoidance of cross-
contamination, and low personal risk perception are the main reasons
for unsafe food handling [23, 43]. The high prevalence of Campylobac-
ter in chicken products, the low infective dose of Campylobacter and
the increasing consumption of chicken meat combined with the appar-
ent lack of knowledge about the Campylobacter-pathogen are all factors
facilitating infection.
Conclusions
Campylobacter spp. infections are a serious and increasing public health
concern in Switzerland. For Salmonella spp. infections, an epidemiolo-
gical turnaround has been achieved through concerted efforts and legal
regulations of the poultry- and food-production industries, but little has
been done to date to prevent Campylobacter infections on a large scale.
Food safety interventions before the sale of poultry meat are urgently
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required to reduce Campylobacter contamination frequencies. Since the
number of control options is limited, the hygienic treatment of chicken
carcasses with chemicals, for example peracetic acid, should not be ex-
cluded from discussion [44]. However, the population’s limited awareness
of Campylobacter must also be addressed. It seems reasonable to believe
that the same type of behaviour changes that reduced Salmonella in-
fections can be applied to prevent Campylobacter infections and that
caution can be extended from eggs to raw poultry meat, cutting boards
and knives.
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Abstract
Background: Hepatitis A (HA) incidence declined in most European
countries in the past decades. We analysed HA notification data for
Switzerland of 29 years looking for disease- and notification system-re-
lated factors possibly contributing to observed trends.
Method: Notification data were descriptively analysed using five time in-
tervals (1988–1993, 1994–1999, 2000–2005, 2006–2011, 2012–2016); and
notification rates were calculated.
Results: From 1988 to 2016, the HA notification rate decreased from
9.5 to 0.5 per 100’000 population in Switzerland. Median age and the
proportion of hospitalised cases increased over time. In the 1988–1993-
time period, intravenous drug use was the most frequently mentioned
risk exposure while consumption of contaminated food/beverages was
most frequently mentioned in the 2012–2016-time period.
Conclusions: Notification data does not allow reliably identifying current
risk groups (e.g. travellers) due to low case numbers, limited availabil-
ity and reliability of information. It is important to document changes
in the surveillance system for later analyses and interpretation of long-
term trends. Population susceptibility likely increases underlining the
importance of continued and continuous surveillance and prevention ef-
forts despite decreasing case numbers. Operational research is recom-
mended to further investigate observed trends of HA and to enhance the
abilities for decision making from Swiss HA surveillance data.
Introduction
In most European countries, incidence and endemicity of hepatitis A
virus (HAV) infection are classified as low or very low1 [2-5]. However,
this does not mean that the disease can be ignored. It rather implies
that the characteristics of HAV infections differ from those countries
with high or intermediate HAV endemicity features.
HAV infection is usually asymptomatic or mild in young children [6].
HAV infection is more often symptomatic with increasing age, and may
present with fever, malaise, anorexia, nausea, abdominal discomfort,
diarrhoea, vomiting, fatigue and jaundice after an incubation period
of 15–50 days [1,6]. Signs and symptoms of acute hepatitis A (HA)
1Levels of endemicity have been defined by WHO on the basis of seroprevalence
as follows: “high (≥90% by age 10 years); intermediate (≥50% by age 15 years,
with<90% by age 10 years); low (≥50% by age 30 years, with<50% by age 15);
and very low (<50% by age 30 years)” [1].
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are indistinguishable from acute hepatitis B (HBV) and C virus (HCV)
infections [6]. However, in contrast to HBV and HCV, HAV does not
lead to chronic infection even though relapse of symptoms and fulminant
hepatitis can occur [6].
Safe and effective vaccines against HAV exist. HAV vaccination rather
than passive immunisation is recommended for pre- and post-exposure
prophylaxis and can be considered to contain outbreaks [1]. In areas
of high endemicity, most people get infected at very young age. Hence,
asymptomatic infection is likely and the burden of disease of HA is low
in these countries. With decreasing level of endemicity, average age at
infection and disease severity increase. Therefore, it is assumed that
countries with intermediate endemicity levels benefit the most from uni-
versal vaccination against HAV [1]. The World Health Organization
(WHO) recommends large-scale vaccination in areas with intermediate
HAV endemicity and targeted vaccination of people at high risk in areas
of low and very low endemicity [1].
HAV is transmitted via the faecal-oral route from person-to-person or
through contaminated food and water [6]. Young children are an import-
ant reservoir and source of transmission considering that the majority of
young children infected with HAV are asymptomatic [6,7]. Infectivity of
HA is highest during the second half of the incubation period up until a
few days after onset of jaundice [6]. Most people are no longer infectious
one week after onset of jaundice [6]. High-risk groups for HAV infection
include unimmunised travellers to areas of high endemicity, men who
have sex with men (MSM), and injecting drug users (IDUs) [1].
Case fatality of HA ranges from 0.1 to 0.3%, but increases strongly with
age with rates of sometimes >10% observed in hospitalised adults ≥40
year old or older age groups [6,8,9]. Globally, 14’900 deaths were attrib-
utable to HAV infection in 2013 compared to 22’600 in 1990 [10].
In 2016, WHO published a guide for viral hepatitis surveillance [11]. One
of the three mentioned purposes of viral hepatitis surveillance is relevant
for HA: “detect outbreaks, monitor trends in incidence and identify risk
factors for new, incident infections”. Syndromic surveillance is recom-
mended to detect outbreaks while enhanced case reporting is recommen-
ded to “describe trends in type-specific acute hepatitis and identify risk
factors”. Case definitions suggested by WHO and case definitions used
by the European Centre for Disease Prevention and Control (ECDC)
and by the Federal Office of Public Health (FOPH) for Switzerland are
presented in table 5.1. In Switzerland, there is currently no syndromic
surveillance for hepatitis but reporting of laboratory-confirmed cases of
hepatitis A (and B and C; and hepatitis E as per 01.01.2018) is mandat-
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Table 5.1: World Health Organization (WHO), European Centre for Disease Prevention and Control (ECDC) and Federal
Office of Public Health (FOPH) case definitions for hepatitis A surveillance
Acute hepatitis / hepatitis A case definition according to WHO [11]
Presumptive
case / case
definition for
syndromic
surveillance (“acute
hepatitis”):
Any person meeting the
• Clinical criteria
Confirmed case
(type-specific
surveillance;
hepatitis A):
Any person meeting the
• Clinical criteria AND
• biomarker or epidemiological criteria
Clinical
criteria:
“Discrete onset of an acute illness with signs/symptoms of (i) acute viral
illness (e.g. fever, malaise, fatigue) and (ii) liver damage, which can be
clinical (e.g. anorexia, nausea, jaundice, dark urine, right upper quadrant
tenderness), and/or biochemical (alanine aminotransferase [ALT] levels more
than 10 times the upper limit of normal.a” [11]
a Ten times the upper limit of normal (400 IU/L) is the threshold used by
the State and Territorial Epidemiologists (CSTE). Countries may also select
lower thresholds that could be more sensitive or higher thresholds that could
be more specific
Biomarker
criteria:
IgM anti-HAV positive
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Table 5.1: (continued)
Epidemiological
criteria:
Epidemiological linkb with a confirmed case [11]
b Contact with a confirmed case-patient during the referent exposure period
or context of an etiologically confirmed outbreak
Hepatitis A case definition according to ECDC [70]
Confirmed case Any person meeting the
• Clinical criteria AND
• Laboratory criteria
Probable case Any person meeting the
• Clinical criteria AND
• Epidemiological criteria
Clinical
criteria:
“Any person with a discrete onset of symptoms (e.g. fatigue, abdominal
pain, loss of appetite, intermittent nausea and vomiting) AND at least one
of the following three: fever, jaundice, elevated serum aminotransferase
levels” [70]
Laboratory
criteria:
“At least one of the following three: detection of hepatitis A virus nucleic
acid in serum or stool, hepatitis A virus specific antibody response,
detection of hepatitis A virus antigen in stool” [70]
Epidemiological
criteria:
“At least one of the following four: human to human transmission, exposure
to a common source, exposure to contaminated food/drinking water,
environmental exposure” [70]
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Table 5.1: (continued)
Hepatitis A case definition according to FOPH
Confirmed case Any person meeting the
• Laboratory criteria AND
• Clinical criteria or epidemiological link
In absence of information on laboratory criteria:
• Both clinical criteria (icterus and increased transaminase) present AND contact with
laboratory-confirmed case
Probable case Any person meeting the
• Clinical criteria but without any information on laboratory criteria (with indication
of name of laboratory and/or reason for testing on clinical notification form)
Possible case Any person meeting the
• Laboratory criteria but without any information on clinical and epidemiological
criteria OR
• Clinical criteria but without any information on laboratory criteria (without indica-
tion of name of laboratory and/or reason for testing on clinical notification form)
No case
• Neither laboratory nor clinical criteria met OR
• Laboratory criteria met, but neither clinical criteria met nor epidemiological link
present (but information from clinical notification form is available)
• Neither laboratory criteria met nor epidemiological link present (independent of pres-
ence or absence of clinical criteria)
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Table 5.1: (continued)
Laboratory
criteria:
anti-HAV IgM positive
Clinical
criteria:
Icterus and/or increased transaminase
Epidemiological
link:
Stay in an endemic region (high or moderate risk according to WHO, p. 95
[71]) or contact to a laboratory-confirmed case
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ory [12].
HAV seroprevalence and incidence vary substantially across countries
of the European Union (EU) and the European Economic Area (EEA),
but decreased in all countries between 1975 and 2014 [2,5]. However, the
notification rate of HAV, 3.0 cases per 100’000 population in 2014, has
been slightly increasing again since 2011 [13]. There is a high variability
across EU/EEA countries also in terms of notification rates: Iceland re-
ported zero cases per 100’000 population, while Romania reported 33.3
cases per 100’000 population in 2014. In Switzerland, the notification
rate decreased from 10/100’000 population in 1988 to 2.6/100’000 pop-
ulation in 2004 [14].
Most EU/EEA countries recommend vaccination against HAV for se-
lected risk groups while only few recommend universal vaccination (in-
cluded in national immunisation programme: Greece; universal child-
hood vaccination for parts of the country: Italy, Spain; recommended,
but not included in national immunisation schedule: Bulgaria, Cyprus,
Czech Republic, Estonia) [2]. In Switzerland, the first HAV vaccine was
available in 1992 [15]. Before, only passive immunisation was available
for travellers at risk [15]. Risk groups, for which vaccination against
HAV is recommended, are presented in table 5.2. The costs of HAV vac-
cination have been covered by the compulsory health insurance for risk
groups since 2008 except for travel-related and occupational indications
[17]. For the latter, the employer usually covers the costs for vaccina-
tion.
This study describes the notification data of HA for Switzerland. It
identifies factors potentially contributing to observed trends, including
changes in the notification system. We investigated the epidemiology of
HA in Switzerland in relation to the current Swiss vaccination recom-
mendations and trends observed in other European countries.
Material and methods
The National Notification System for Infectious Diseases
HA has been a notifiable disease in Switzerland since 1984 [14]. Man-
datory notification of HA includes a “report on laboratory findings” and
a “report on clinical findings”. Current reporting forms can be accessed
at www.bag.admin.ch/infreporting (available in German, French and
Italian).
Reports on laboratory findings are completed by those responsible at the
diagnosing laboratory, upon confirmation of a HAV infection. Reports
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Table 5.2: Overview of Swiss recommendations for vaccination against hepatitis A virus (HAV)
1992 2005 2007 Summary of current (2007)
vaccination
recommendations as
published in yearly
vaccination schedule (2017)
Source: [15] Source: [16] Source: [14] Source: [17]
Primary prevention
Non-immune travellers to
countries with high risk of
HAV infection (mainly “third
world countries” and selected
countries in Eastern Europe)
[travellers]a Travellers to countries with
medium or high endemicity
(according to www.who.int/ith
or www.safetravel.ch).
In case of adoption of a child
from a country of high
endemicity, all family members
(not only those travelling)
should be vaccinated.
Travellers to countries with
medium and high endemicity
Illegal drug users Drug users People injecting drugs People injecting drugs
Partly recommended: Children
>12 months of age visiting
relatives in “third world
countries” or in Eastern
Europe and attending day care
in Switzerland
Children from countries of
medium and high endemicity
living in Switzerland and
temporarily returning to their
country of origin
Children from countries of
medium and high endemicity
living in Switzerland and
temporarily returning to their
country of origin
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Table 5.2: (continued)
1992 2005 2007 Summary of current (2007)
vaccination
recommendations as
published in yearly
vaccination schedule (2017)
Partly recommended: Selected
staff of day care facilities and
children hospitals
Partly recommended: Persons
in close occupational contact
with refugees, asylum seekers
or drug users
Persons in close occupational
contact to people injecting
drugs (including prison staff);
and to persons from countries
of medium and high endemicity
(asylum seekers, refugees)
Persons in close occupational
contact to drug users; and to
persons from countries of high
endemicity
Persons with
chronic
hepatopathies
Persons with chronic liver
disease (Hepatitis B, C or
other chronic hepatopathies,
especially candidates of liver
transplantation
Persons with chronic liver
disease
Persons in close
contact to
people with
HAV infection
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Table 5.2: (continued)
1992 2005 2007 Summary of current (2007)
vaccination
recommendations as
published in yearly
vaccination schedule (2017)
Staff of
microbiological
laboratories
Laboratory personnel working
with HAV or with primates
infected with HAV, or
investigating stool samples
Laboratory personnel working
with HAV
Men who have
sex with men
(MSM)
Men who have sex with men
(MSM) (outside of stable
relationship)
Men who have sex with men
(MSM)
Drainers and employees of
sewage plants
Drainers and employees of
sewage plants
Secondary prevention
After close contact with a
person with acute hepatitis A,
or after exposure to a potential
source within 7 days after
exposure (or after development
of symptoms of the primary
case)
Within 7 days after exposure
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Table 5.2: (continued)
1992 2005 2007 Summary of current (2007)
vaccination
recommendations as
published in yearly
vaccination schedule (2017)
Staff and persons in
institutions, in which there was
a case of HAV (e.g. day-care
centres, home for persons with
disabilities, retirement homes,
casern), and their families, if
appropriate
In case of an epidemic (social
environment of cases)
a Travel-related vaccination recommendations / indications were not considered in this document
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are sent within 24 h to the FOPH and to the cantonal physician of the
patient’s canton of residence. The current laboratory notification form
includes date of diagnosis, type of sample, laboratory method, patient’s
name, address, date of birth, and sex.
Physicians are to complete the “report on clinical findings” upon receipt
of a positive laboratory result for HAV, and send it to the cantonal
physician of the patient’s canton of residence, within 24 h. The cantonal
physician forwards this information to the FOPH and takes appropriate
disease control and prevention measures, if indicated. The FOPH takes
on and/or coordinates prevention and control measures if several can-
tons and/or other countries are involved, or if requested by the cantonal
physician. The notification form on clinical findings contains information
on the patient (name, date of birth, sex, address, nationality), and the
course of disease (date of disease onset and diagnosis, signs and symp-
toms, reason for laboratory testing, hospitalisation, sequelae, death).
The patient’s vaccination status and exposure within 2 months before
disease onset are also recorded. Information from both notification forms
(laboratory and clinical findings) is then entered into an electronic data-
base at the FOPH. Reports on the same patient are linked, whenever
possible.
Data sources and analysis
Surveillance data on HA was extracted from the National Notification
System for Infectious Diseases’ (NNSID) database for the years 1988–
2016 (data as of 12 April 2017). Data before 1988 were not available.
Cases residing outside Switzerland and the Principality of Liechtenstein,
and cases finally classified as “no case” (see table 5.1 for case classifica-
tion) were excluded.
Data were analysed descriptively in terms of case numbers and case
characteristics (incl. possible transmission routes). For description of
case characteristics, notification years were grouped into four 6-year and
one 5-year-period. Notification rates, defined as the number of notified
cases per 100’000 resident population, were calculated using population
statistics from the Federal Statistical Office (FSO). Population statistics
were not yet available for 2016 at the time of data extraction; there-
fore, we used 2015 population statistics to calculate notification rates
for 2016. We compared the number of hospitalised cases and deaths as
reported on notification forms with the number of hospitalisations and
deaths due to the International Statistical Classification of Diseases and
Related Health Problems 10th Revision (ICD-10) codes B15.0 (“hepatitis
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A with hepatic coma”) or B15.9 (“hepatitis A without hepatic coma”)
according to official hospital and mortality statistics (data obtained from
the FSO). Main and secondary diagnoses/deaths were considered for ex-
traction of hospitalisations/deaths due to ICD-10 codes B15.0 and B15.9
from hospital and mortality statistics, respectively. Data were analysed
using the statistical software Stata (Version 13.1 [18]).
Notification data were collected under the Swiss Epidemics Act and
hence, no ethical approval was required.
Results
Trends in hepatitis A case numbers and demographic
characteristics
The notification rate of HA decreased from 9.5/100’000 population (628
cases) in 1988 to 0.5/100’000 population (43 cases) in 2016 in Switzer-
land (Figure 5.1). The highest notification rate was observed in 1990
(14.2/100’000).
Median age of cases increased from 25 years (1988–1993) to 43 years
(2012–2016). In the most recent years, no age group predominated while
in the early 1990s there was a clear predominance of young adults for
both sexes (highest notification rate in 15–24 year age group, followed
by 25–44 year age group; figure 5.2). In the two youngest and in the
oldest age groups (0–4, 5–14 and 65+ age groups) there was no clear
sex-pattern observed. In the 15–24, 25–44 and 45–65 year age groups,
males had a higher notification rate. However, this male predominance
decreased over the years. In 2015 and 2016, the overall female notifica-
tion rate was even slightly higher than the male notification rate.
The proportion of cases of Swiss or Liechtensteiner nationality decreased
during the observation period: 83.9% were Swiss/Liechtensteiner (ex-
cluding those with nationality not specified) during the 1988–1993-
period, while in the 2012–2016-period 70.1% were reported to be Swiss/
Liechtensteiner (Table 5.3). A similar trend was observed in the propor-
tion of Swiss among the permanent resident population of Switzerland:
in the 1988–1993-period, between 81.7 and 84.6% were of Swiss national-
ity while in the 2012–2015-period (2016 data not yet available) between
75.6 and 77.0% were Swiss [19].
In all notification periods, between 2.4 and 4.9% of cases were reported to
be vaccinated against HAV. For 45 of 285 cases with reported vaccination
prior to HA infection, at least the year of the first and/or last vaccination
was reported. Of those, 3 were reported to be vaccinated before 1992,
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Figure 5.1: Trend in number of reported hepatitis A cases and notification rate from 1988–2016 with major “events” (e.g.
concerning vaccination) labelled, Switzerland.
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Figure 5.2: Male and female hepatitis A notification rate by age group and
year, 1988–2016, Switzerland.
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Table 5.3: Characteristics of notified hepatitis A cases, 1988–2016, Switzerland
All cases
1988–1993 1994–1999 2000–2005 2006–2011 2012–2016 1988–2016
% (N) % (N) % (N) % (N) % (N) % (N)
Total cases (4’328) (2’334) (1’105) (626) (262) (8’655)
Possible case - (0) - (0) - (0) 7.0 (44) 8.4 (22) 0.8 (66)
Probable case 0.3 (14) 1.1 (25) 0.2 (2) 4.5 (28) 4.2 (11) 0.9 (80)
Confirmed case 0.6 (27) 11.0 (256) 89.8 (992) 78.4 (491) 87.4 (229) 23.1 (1’995)
Case not classified 99.1 (4’287) 88.0 (2’053) 10.0 (111) 10.1 (63) - (0) 75.3 (6’514)
Sex
Male 64.2 (2’779) 60.5 (1’412) 60.1 (664) 56.1 (351) 51.7 (136) 61.7 (5’342)
Female 34.5 (1’494) 38.9 (908) 39.4 (435) 43.6 (273) 48.3 (126) 37.4 (3’237)
Not specified 1.3 (55) 0.6 (14) 0.5 (6) 0.3 (2) - (0) 0.9 (77)
Age group, years
<5 2.4 (103) 5.1 (120) 5.6 (62) 3.2 (20) 1.5 (4) 3.6 (309)
5–14 7.6 (330) 19.8 (462) 23.1 (255) 12.8 (80) 9.2 (24) 13.3 (1’151)
15–24 35.1 (1’517) 16.4 (382) 12.3 (136) 11.2 (70) 15.6 (41) 24.8 (2’146)
25–44 40.4 (1’750) 39.1 (912) 33.6 (371) 32.9 (206) 25.6 (67) 38.2 (3’306)
45–64 10.2 (441) 15.2 (355) 18.8 (208) 28.4 (178) 30.9 (81) 14.6 (1’263)
>64 2.7 (116) 4.2 (99) 6.6 (73) 11.5 (72) 17.2 (45) 4.7 (405)
Not specified 1.6 (71) 0.2 (4) - (0) - (0) - (0) 0.9 (75)
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Table 5.3: (continued)
All cases
1988–1993 1994–1999 2000–2005 2006–2011 2012–2016 1988–2016
% (N) % (N) % (N) % (N) % (N) % (N)
Total cases with
notification on
clinical findings
80.9 (3’503) 89.5 (2’088) 93.0 (1’028) 91.4 (572) 93.9 (246) 85.9 (7’437)
Nationality
Swiss/
Liechtensteiner
70.2 (2’458) 62.2 (1’299) 63.4 (652) 62.6 (358) 60.2 (148) 66.1 (4’915)
Foreign 13.5 (472) 21.1 (441) 22.4 (230) 21.2 (121) 25.6 (63) 17.8 (1’327)
Not specified 16.4 (573) 16.7 (348) 14.2 (146) 16.3 (93) 14.2 (35) 16.1 (1’195)
Reported location
of exposure
Switzerland <0.1 (1) 3.2 (66) 33.4 (343) 27.3 (156) 25.6 (63) 8.5 (629)
Switzerland and
abroad
- (0) <0.1 (1) 1.7 (17) 4.7 (27) 2.4 (6) 0.7 (51)
Abroada 39.3 (1’375) 46.5 (971) 42.2 (434) 51.9 (297) 55.7 (137) 43.2 (3’214)
Europeb 38.3 (527) 49.0 (476) 38.6 (174) 34.9 (113) 25.2 (36) 40.6 (1’326)
Africab 24.0 (330) 17.6 (171) 22.0 (99) 34.0 (110) 37.1 (53) 23.4 (763)
Americab 18.0 (247) 17.4 (169) 18.8 (85) 11.1 (36) 17.5 (25) 17.2 (562)
Asiab 17.3 (238) 12.7 (123) 14.4 (65) 16.0 (52) 19.6 (28) 15.5 (506)
Australiab 0.4 (6) 1.2 (12) 0.7 (3) 0.3 (1) 1.4 (2) 0.7 (24)
Not specifiedb 3.6 (49) 3.3 (32) 6.4 (29) 4.9 (16) 0.7 (1) 3.9 (127)
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Table 5.3: (continued)
All cases
1988–1993 1994–1999 2000–2005 2006–2011 2012–2016 1988–2016
% (N) % (N) % (N) % (N) % (N) % (N)
Unknown or not
specified
60.7 (2’127) 50.3 (1’050) 22.8 (234) 16.1 (92) 16.3 (40) 47.6 (3’543)
Reported
exposure riska
Food/beverages 2.2 (76) 8.7 (181) 22.0 (226) 25.3 (145) 28.5 (70) 9.4 (698)
Contact with
infected person
18.2 (639) 21.6 (451) 17.6 (181) 11.2 (64) 12.6 (31) 18.4 (1’366)
Sexual contact
with infected
person
3.5 (124) 5.5 (115) 2.9 (30) 4.0 (23) 4.1 (10) 4.1 (302)
Intravenous drug
user
33.4 (1’171) 10.0 (208) 1.7 (17) 0.3 (2) - (0) 18.8 (1’398)
Other 3.3 (117) 5.0 (105) 2.8 (29) 3.7 (21) 3.7 (9) 3.8 (281)
Unknown or not
specified
50.5 (1’768) 57.3 (1’197) 56.0 (576) 58.9 (337) 58.9 (145) 54.1 (4’023)
Immunisation
status
Vaccinatedc 4.5 (158) 3.1 (64) 2.4 (25) 4.5 (26) 4.9 (12) 3.8 (285)
Vaccinated with 1
dosed
0.6 (1) 6.3 (4) 48.0 (12) 57.7 (15) 66.7 (8) 14.0 (40)
Vaccinated with
≥2 dosesd
- (0) - (0) 16.0 (4) 30.8 (8) 8.3 (1) 4.6 (13)
84
P
ublished
article
Table 5.3: (continued)
All cases
1988–1993 1994–1999 2000–2005 2006–2011 2012–2016 1988–2016
% (N) % (N) % (N) % (N) % (N) % (N)
Not specifiedd 99.4 (157) 93.8 (60) 36.0 (9) 11.5 (3) 25.0 (3) 81.4 (232)
Not vaccinated or
not specified
95.5 (3’345) 96.9 (2’024) 97.6 (1’003) 95.5 (546) 95.1 (234) 96.2 (7’152)
Manifestationa
Jaundice 74.1 (2’596) 75.9 (1’585) 76.7 (788) 70.1 (401) 65.0 (160) 74.4 (5’530)
Transaminase
increased ≥2.5fold
70.1 (2’457) 57.1 (1’192) 76.8 (790) 83.4 (477) 86.6 (213) 69.0 (5’129)
Other - (0) 0.4 (10) 4.7 (52) 19.2 (120) 39.3 (103) 3.8 (285)
None 1.2 (41) 1.6 (33) 3.0 (31) 1.6 (9) 1.2 (3) 1.6 (117)
Unknown or not
specified
12.9 (451) 9.5 (199) 5.3 (54) 2.8 (16) 2.8 (7) 9.8 (727)
Hospitalisation
Yes 21.4 (750) 20.0 (418) 24.8 (255) 30.6 (175) 44.7 (110) 23.0 (1’708)
Due to hepatitis
Ae
- (0) - (0) 0.4 (1) 56.6 (99) 63.6 (70) 10.0 (170)
Other reasone - (0) - (0) - (0) 21.1 (37) 18.2 (20) 3.3 (57)
Due to hepatitis A
and other reasone
- (0) - (0) - (0) - (0) 0.9 (1) 0.1 (1)
Unknown or not
specifiede
100 (750) 100 (418) 99.6 (254) 22.3 (39) 17.3 (19) 86.7 (1’480)
No or not specified 78.6 (2’753) 80.0 (1’670) 75.2 (773) 69.4 (397) 55.3 (136) 77.0 (5’729)
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Table 5.3: (continued)
All cases
1988–1993 1994–1999 2000–2005 2006–2011 2012–2016 1988–2016
% (N) % (N) % (N) % (N) % (N) % (N)
Complications
Yes - (0) - (0) - (0) 3.7 (21) 4.5 (11) 0.4 (32)
No or not specified 100 (3’503) 100 (2’088) 100 (1’028) 96.3 (551) 95.5 (235) 99.6 (7’405)
Death
Yes 0.5 (19) 0.4 (8) 0.1 (1) 0.9 (5) 1.2 (3) 0.5 (36)
Due to hepatitis Af 15.8 (3) 12.5 (1) - (0) - (0) - (0) 11.1 (4)
Other reasonf 10.5 (2) 50.0 (4) 100 (1) 100 (5) 100 (3) 41.7 (15)
Unknown or not
specifiedf
73.7 (14) 37.5 (3) - (0) - (0) - (0) 47.2 (17)
No or not specified 99.5 (3’484) 99.6 (2’080) 99.9 (1’027) 99.1 (567) 98.8 (243) 99.5 (7’401)
a Multiple answers possible
b % among cases with exposure “Switzerland and abroad” or “abroad”
c Occasionally reported for cases already before 1992 when hepatitis A virus (HAV) vaccination was introduced. It
cannot be determined whether these cases received passive immunisation against HAV (which was available already
before 1992) or whether the information on the notification form was incorrect. It is suspected that physicians may not
be able to easily differentiate active from passive immunisation based on information from vaccination cards and – in
the absence of vaccination cards – patients may confuse HAV and hepatitis B virus vaccination
d % among all vaccinated cases
e % among hospitalised cases
f % among deceased cases
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13 received vaccination ≤14 days before disease onset and 7 received
vaccination between 14 and 28 days before disease onset. For one case,
the date of last vaccination was after disease onset. However, it was
reported that this case received 3 doses of HA vaccine, the first one in
the year prior to disease onset in mid-January. For the remaining 21
cases, disease onset was reported between 31 days and 14 years after
their last (or only) vaccination.
Clinical characteristics
Jaundice was reported for 65.0–76.7% and increased transaminases for
57.1–86.6% of cases over all notification periods (Table 5.3). Other re-
ported signs and symptoms included fever, gastrointestinal symptoms
(nausea, vomiting, abdominal pain, diarrhoea), reduced general state,
weakness, myalgia, arthralgia, dark urine and pale stools. Fever, listed
on the notification form since 2015, was specified for 39.3% of cases since
2015 but only for 2.9% of cases between 1999 and 2014 (no option to list
“other symptoms” before 1999).
The proportion of hospitalised cases increased from 21.4% in 1988–1993
to 44.7% in 2012–2016 (Table 5.3, figure 5.3a). The number of cases
with hospitalisation indicated as “yes” on the report on clinical findings
is much lower than the number of hospitalisations due to ICD-10 codes
B15.0 and B15.9 according to Swiss hospital statistics from 1998 to 2015
(the years for which hospital statistics were available; figure 5.3b). How-
ever, when considering only main diagnoses (as opposed to main and
secondary diagnoses), numbers from the two statistics are comparable.
The reason for hospitalisation (due to HA and/or for other reason) has
been included in the reporting form since 2006. In three quarters of
cases (171/228) with this information available, HA was indicated as
the reason for hospitalisation (including one case hospitalised due to HA
and another reason).
Complications, recorded since 2006, were reported for 3.9% (32/818)
of cases and included coagulopathy, acute or imminent liver failure,
cholecystitis, and general malaise.
Official mortality statistics, coded according to ICD-10, were available
for 1995–2014. During this time period, 46 HA-related deaths were re-
corded (ICD-10 codes B15.0 and B15.9 as main or secondary cause).
In the notification data, only 14 deaths among HA cases were captured
during this time period (36 deaths from 1988–2016).
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Reported location of exposure and exposure risks
Exposure abroad (or both, in Switzerland and abroad) increased from
39.3% in 1988–1993 to 58.1% in 2012–2016 while the proportion of “un-
known or not specified” location of exposure decreased (Table 5.3).
European followed by African countries were most frequently mentioned
as countries of exposure in the past. In the most recent years, exposure
in African countries was more frequently reported (Table 5.3). The pro-
portion of cases exposed in the Americas, Asia and Australia remained
stable over the entire time period. Italy, Turkey and Germany were
the three most frequently mentioned European countries between 2012
and 2016 while from 1988–1993 Italy, Spain and former Yugoslavia were
lead exposure countries. Morocco, Tunisia, Egypt and Kenya were most
frequently mentioned African countries from 1988–1993 and Morocco,
Egypt, Togo, Ethiopia and Cap Verde from 2012–2016.
For the majority of cases (50.5%–58.9% for all notification periods), the
source of exposure was reported to be unknown or was not specified.
Intravenous drug use was the most frequently reported exposure risk in
the 1988–1993 notification period while this exposure risk was not men-
tioned in the 2012–2016 period (Table 5.3). In contrast, the proportion
of cases for which contaminated food or beverages was indicated as ex-
posure risk increased over the years (2.2% of cases in 1988–1993; 28.5%
of cases in 2012–2016). The mentioning of “contact with an infected
person” as exposure risk decreased over the observation period (18.2%
in 1988–1993; 12.6% in 2012–2016) while “sexual contact with an infec-
ted person” remained stable at around 4%. Exposure risks mentioned in
the “other” category included occupational exposures, exposure to blood
or blood products (including transfusions), or (previous and/or current)
residency abroad.
Discussion
Our analysis of Swiss hepatitis A notification data from 1988–2016 re-
vealed temporal trends in case numbers and case characteristics which
may be caused by changes in disease epidemiology but also are likely to
reflect changes in disease reporting and notification.
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Figure 5.3: (a) Proportion of hospitalised hepatitis A cases according to
notification data (bars, left axis) and number of notified cases (line, right
axis), and (b) hospitalisations due to hepatitis A according to notification
forms (solid black line) and hospital statistics (bars; data for 1998–2015 only),
1988–2016, Switzerland.
Source of hospital statistics: Federal Statistical Office, Neuchâtel, Switzerland.
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No unexpected risk group for HAV infection according to
Swiss notification data
Recently published analyses of HA notification data in Switzerland in-
cluded data until 2004 apart from a recent article of the FOPH reporting
on an increase in case numbers in early 2017 [14,20,21]. All analyses ex-
cept of the latter documented decreasing trends regarding HA notifica-
tion rates that continue into contemporary times. Today, the notification
rate in Switzerland is comparable for all age groups and for males and
females, though fluctuating quite substantially in the setting of low case
numbers. In contrast, the notification rate of 2014 in 30 EU/EEA coun-
tries was still highest for the 5–14 year age group, followed by the 0–4
and the 15–24 year age groups, and slightly higher in males compared
to females [13].
The strongest decline in HAV notifications started in 1990, even before
the introduction of HAV vaccination in Switzerland (Figure 5.1). How-
ever, passive immunisation was already available since the early 1980ies
[22]. Additionally, campaigns among IDUs could have contributed to
the observed decline: The most frequently mentioned risk exposure in
the early 1990s, intravenous/injecting drug use, has infrequently been
reported in the last 10 years. It has been hypothesised that transmis-
sion of HA among IDUs could occur through sharing equipment or due
to contaminated drugs or generally poor hygienic conditions [23,24]. De-
creasing case numbers were also observed for hepatitis B together with
a strong decline in IDU as reported risk exposure [25]. The decreasing
case numbers were attributed to preventive measures introduced to con-
trol human immunodeficiency virus (HIV). The HIV/AIDS epidemic in
the late 1980s and peak levels of drug consumption in the early 1990s
resulted in the establishment of needle exchange facilities providing a
“safe” environment for drug consumption [26]. A study among persons
entering heroin-assisted treatment found that the proportion of HAV-
infected persons decreased from 2003 to 2013 while the proportion of
people vaccinated against HAV increased [27]. Nevertheless, the preval-
ence of HA is still higher in persons entering heroin-assisted treatment
in Switzerland than among the general population [27]. Reports on IDU
as a risk exposure among notified cases of HA from other countries are
scarce. In Eastern Sydney, Australia, one third of notified cases was
associated with IDU between September 1994 and June 1995 while this
proportion dropped to 9% between July 1995 and December 1996 [28].
In New South Wales, Australia, recreational drug use decreased among
reported HA cases between 2000 and 2009 [29]. In contrast, in Italy,
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the frequency of IDUs among cases of viral hepatitis (slightly more than
half of which were HA cases) remained at constant but low levels (<5%)
between 1991 and 2006 [30]. Similarly, IDU was a reported risk factor
for 2% of HA cases in 1994–1995 as well as in 2006–2007 in Arizona,
United States [31].
HA vaccination failure and clinical cases of HA among vaccinated in-
dividuals reported in the literature are very rare [32-42]. Nevertheless,
3.8% of notified cases (285/7437) were reported to be vaccinated against
HAV in Switzerland between 1988 and 2016. There are several explan-
ations for this notably high proportion: (i) “vaccinated” cases might in-
clude persons having received passive immunisation (see also footnote in
table 5.2) which has only a short-term protective effect [1,43]; (ii) vaccin-
ation may have occurred only shortly before travel or in the framework of
post-exposure prophylaxis – potentially too late to prevent disease onset
(even though the notification form asked for vaccination status prior to
infection); and (iii) HAV vaccination may be confused with other vac-
cinations, e.g. HBV vaccination, especially if information provided by
physicians is obtained from patients rather than from vaccination cards
(as it has been shown that travellers could frequently not recall their
vaccination history [44]). Nevertheless, vaccination failure cannot be
ruled out, especially in immunocompromised patients. A recent study
among Swedish travellers under immunosuppressive medication due to
reactive arthritis has shown that similar protection after two months can
be achieved by administering a 3-dose regimen (1 + 1 + 1 or 2 + 1) at
0, (1) and 6 months compared to a 2-dose regimen at 0 and 6 months
among healthy individuals [45].
The decline in the HA incidence led to an increase in the population
susceptible to HAV in the EU/EEA which was not compensated by in-
creased vaccination rates, as highlighted by Gossner et al. [3]. This is
assumed to be the case also in Switzerland in the absence of universal
vaccination recommendation. However, data on population susceptibil-
ity are not available. Vaccination coverage was assessed in Switzerland
for 2-, 8- and 16-year old children and adolescents and was 4% [95% con-
fidence interval (CI): 3.2–4.6], 11% [95% CI: 9.5–11.7], and 28% [95% CI:
24.8–30.6] for two doses, and slightly higher for one dose, in 2014–16 [46].
Between 2002 and 2012, 53.1% of travellers seeking pre-travel health ad-
vice in one Swiss travel clinic received HAV vaccination (in part com-
bined with HBV vaccination) [47]. On the other hand, a survey among
travellers to tropical and subtropical countries at a Swiss airport in 2002
revealed that only 26% of travellers were protected against HAV and an
additional 12% were potentially protected [48]. It has to be considered
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that surveys conducted at the airport might be biased (over-representing
frequent travellers, and considering only one mode of transport) as high-
lighted by Pedersini et al. (2016) [44]. They showed that the frequency
of international travel and endemicity at destination are both associated
with HA vaccination among travellers in five European countries. In
2014, 62.6% of MSM reported to be vaccinated against HAV in a Swiss
online survey among MSM [49]. Further insights into vaccination rates
and knowledge about HA among Swiss MSM are expected once the data
from the European MSM Internet Survey (EMIS-2017) becomes avail-
able [50].
Recently, HAV outbreaks among MSM have been reported in several
European countries [51] including England [52], the Netherlands [53] and
Germany [54]. Our analysis did not suggest any similar outbreak among
MSM in Switzerland: in 2016 sexual contact with an infected person
was specified as a risk exposure only for one case and the male-to-female
ratio did not change compared to 2015. However, case notifications for
HAV more than doubled in the first 22 weeks of 2017 compared to the
same time period in 2016 (41 vs. 17 cases) [21]. A link to the European
outbreaks among MSM seems likely considering that the increase in case
numbers mainly affects males.
“Exposure abroad” was indicated for more than half of recently notified
cases, suggesting that travelling is still a main risk factor for acquir-
ing HA. Previous analyses of Swiss HAV notification data identified risk
groups or different exposure patterns among subgroups of notified cases
(e.g. among cases below 20 years of age, those with Swiss nationality
tended to be exposed in Switzerland while those with foreign nationality
tended to be exposed abroad [14]). We did not conduct such subgroup
analyses considering the low case numbers in recent years.
Relative increase in hospitalisations
Data on hospitalisations revealed two interesting trends: (i) the propor-
tion of hospitalised patients increased among reported cases, and (ii)
hospital statistics suggest substantial underreporting of hospitalisations
due to HA in the NNSID. An increasing proportion of hospitalisations
has also been reported in the United States [55]. Ly and Klevens hypo-
thesised that this observation is explained by a shift of the susceptible
population towards older adults together with the fact that HA leads
to more severe disease with increasing patient age. This is likely also
the case for Switzerland: while the median age of reported cases was 26
and 25 years in non-hospitalised (incl. hospitalisation status not spe-
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cified) and hospitalised patients, respectively, in 1988–1993, median age
for those two groups increased to 36.5 and 47 years in 2012–2016. An al-
ternative explanation links the decreasing frequency of HAV infection in
Switzerland (or at least the decreasing notification rate) to physicians’
decreasing awareness for the disease, especially in patients with mild
manifestations.
The number of hospitalisations according to hospital statistics is com-
parable with the number of hospitalised cases according to notification
data when considering the main diagnosis in hospital statistics. When
also considering secondary diagnoses, hospital statistics suggest more
than double the number of HA cases compared to notification data (Fig-
ure 5.3b). It should be considered that re-admission of the same patient
is counted as a new case in Swiss hospital statistics except if readmission
occurs within 18 days and in the same hospital (personal communication,
FSO, 11 July 2017). Still, we believe that the striking difference between
hospital statistics and notification data is not fully explained by re-ad-
missions alone. We also speculate that the observed difference, apart
from under-notification, could arrive from GPs completing notification
forms before the patient is hospitalised. If the hospital physician then
does not complete another notification form (assuming or knowing that
the case was already reported by the GP), the patient’s hospitalisation
is not captured by the NNSID. The same probably applies to mortality
data.
System changes influence trends in notification data
The notification form is provided by and submitted to the FOPH. The
notification form was changed several times between 1988 and 2016, as
were case definitions, classifications and data entry procedures. All these
changes are difficult to document post-hoc for the purpose of this study
and to separate from each other; they make interpretation of long-term
trends difficult. In the following we discuss such issues using examples
from Swiss HA notification given that these experiences likely also apply
for other diseases and surveillance systems.
Introducing a new variable on the notification form is a change which
is relatively easy to track as it leads to a rather abrupt change in the
data. The location of exposure to HAV could be recorded as “abroad”
before 1999 and as “abroad” and/or “in Switzerland” thereafter. In the
notification data, this is reflected in a sudden increase in the proportion
of cases exposed in Switzerland and a parallel drop in the “unknown or
not specified” category.
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Similarly, the “reason for hospitalisation” and “complications” were in-
cluded on the form probably only since 2006 (notification forms for 2002–
2005 were not available to check). Such changes can potentially be no-
ticed even if old notification forms are not available, but their impact is
difficult to quantify. In contrast, more subtle changes, e.g. in wording
can also influence answers given, but might not be easily recognisable
in the absence of actual notification forms or stringent documentation
of changes on the reporting forms. For example, main features of HA
(increased transaminases and jaundice), were recorded from 1988 until
2016. Nevertheless, changes occurred repeatedly: from 1988–1990, they
were listed under the heading “clinic”. From 1991–1998, they were lis-
ted under the heading “reason for laboratory test” while since 1999 they
are part of the section on “manifestation”. Also, in 1999 the wording
changed from “increased transaminases” to “transaminase(s) ≥2.5× ↑”.
While asking for symptoms under the headings “clinic” and “manifest-
ation” are likely to result in the same responses, the heading “reason
for laboratory test” might not: a symptom might be present but not be
considered the reason for laboratory testing and hence, not checked on
the form.
Another, potentially important, change: up until 1998, all cases of viral
hepatitis were captured using the same notification form entitled “Viral
hepatitis”. Only since 1999, separate notification forms exist for hep-
atitis A, B, and C (other types of viral hepatitis are not reportable as
per 2017). At the same time, the notification form was revised substan-
tially. Revisions of notification forms are complex processes involving a
number of people and perspectives; we exemplify the Swiss experience:
the expert analysing the notification data for a given disease tries to get
the most relevant information needed for appropriate interpretation of
the epidemiology. Managers of the overall notification system (including
data entry and management), and hence, with a view on all notifiable
diseases, try to avoid long notification forms, frequent changes and het-
erogeneous forms – e.g. once asking for nationality, once for country of
origin, and once for country of birth. Furthermore, information should
not be too difficult to obtain/know by laboratory personnel or physi-
cians (those requested to complete the forms), otherwise compliance will
be low. Finally, the legal department will critically review the forms
aiming at reducing the personal information obtained to the essentials
for fulfilling the mandate of the FOPH for early detection, monitoring,
prevention and containment of communicable diseases.
In summary, changes in notification forms and procedures may be needed
at times, but should be kept to a minimum in order to allow analysis
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and interpretation of long-term trends. This in turn is only possible if
changes made are meticulously documented.
System-inherent limitations
Patients’ information is provided by physicians in charge of HA patients.
However, it is not known how complete and systematically they assess
e.g. exposure history. Assessing exposure risks in a systematic fashion
is likely not a priority of physicians given that the source of infection
does not matter for treatment. This is reflected in the high proportion
of cases (>50%) for which exposure risk is indicated as “unknown” or
not specified at all. We hypothesise that “traditional” (well-known) risk
factors are often overestimated compared to less known risk exposures
in surveillance systems. This could also be a reason for the observed in-
crease in “contaminated food and/or water” mentioned as risk exposure:
in the absence of “specific” risk factors such as IDU and travel, phys-
icians may be choice-biased being tempted to indicate “contaminated
food and/or water” instead of ticking “unknown” or not indicating any
risk factor(s).
Probably almost every person has consumed a food item which could
have been contaminated with HAV during the relevant time window of
15–50 days before symptom onset. At the same time, reports of food-
borne outbreaks of HA – recently frequently associated with fresh and
frozen berries and fruits [56-61] – could also have increased awareness
that HAV can be transmitted through contaminated food. The rather
long incubation period, together with a wide range, and more or less
non-specific or ubiquitous risk exposures could also explain the high
proportion of unknown or unspecified exposure risks. Suspected sources
of infection are usually not followed-up, unless there is evidence of an
outbreak. Therefore, location of exposure remains speculative as long as
no mandated research studies are conducted.
Furthermore, the surveillance system is likely to capture mainly severe
and/or “typical” cases as these are most likely to undergo laboratory
testing. Gastroenteritis patients reporting recent travel were found to
have a 3.6 times increased odds for stool testing compared to patients
not reporting travel in the 7 days preceding symptom onset [62]. Simil-
arly, we suspect that travel-related HA cases (or patients with a history
of recent travel) are more likely to be captured by the NNSID. This may
not compromise validity of the surveillance system, but should be born
in mind when interpreting surveillance data.
In contrast, we have anecdotal evidence from notification forms that
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physicians suspect transmission from a (symptomatic or asymptomatic)
contact person who had been travelling recently, but the patient him" /
herself (the suspected secondary case) stayed in Switzerland. These HA
cases would no longer be considered an imported/travel-related case as
the reported patient did not travel and was indeed exposed in Switzer-
land. Hence, the distinction between imported and autochthonous cases
might be flawed.
Similarly, the importance of migrants and travellers visiting friends and
relatives (VFR) is difficult to evaluate: on the one hand, those born in
high-endemicity countries could already be immune and hence, increase
population seroprevalence in Switzerland. On the other hand, young
children having visited their home country (or the home country of their
parents) could be asymptomatically infected and spread the disease once
back in Switzerland. Generally it is known that VFR are at increased
risk of infectious diseases during travel [63-65], they are less likely to
seek pre-travel health advice [65-67] and are less adherent to pre-travel
health advice [68,69].
Furthermore, it is not known how often contact persons of HA cases are
tested and how this may influence notification data. Testing may be
considered unnecessary for both, secondary cases showing clear and typ-
ical signs and symptoms, and (potential) secondary cases not showing
any signs and symptoms of HAV infection.
Conclusions
Hepatitis A incidence is declining globally including in Switzerland, apart
from outbreaks (such as the recent European outbreak among MSM).
Case numbers have been low in recent years. However, considering that
the population is becoming increasingly susceptible to HAV infection
and hence, the probability of outbreaks is increasing, it is important to
strengthen surveillance and prevention efforts as shown by the recent
outbreak among MSM in Europe.
Current Swiss notification data on HAV do not allow reliably identifying
existing (IDU, MSM, travellers) and potential new risk groups as in-
formation on exposure to HAV available to and provided by physicians
is limited and case numbers are low. Patient information on exposure is
often poorly filled in on the notification forms. Thus, changes in NNSID
data or outbreaks need to be followed up with indepth investigations to
understand contemporary transmission patterns.
Thorough understanding of physicians’ approaches to diagnose a patient
with HAV infection, changes in notification forms, case definition, case
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classification, and data entry is required for correct interpretation of no-
tification data. Additionally, research studies are needed to complement
information from routine surveillance to answer specific questions such as
estimating levels of under-ascertainment, under-diagnosis and under-no-
tification, or evaluating best practices to collect data on exposure. Such
complementary information is especially important for interpretation of
long-term trends of hepatitis A in particular and of highly dynamic dis-
eases and surveillance systems in general.
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Summary
BACKGROUND: Campylobacteriosis and salmonellosis are important
foodborne diseases in Europe, including in Switzerland. In 2014, noti-
fication rates for Switzerland were 92.9 per 100’000 population for cam-
pylobacteriosis and 15.2 per 100’000 population for salmonellosis. These
notification rates originate from laboratory-based surveillance whereby
positive test results are reported to the National Notification System for
Infectious Diseases. Consequently, notification rates do not directly cor-
respond to the disease burden among the population as the number of
positive tests depends on patients’ healthcare-seeking behaviour, stool
sampling rates and other factors.
METHODS: We assessed laboratory positivity rates (proportion of pos-
itive tests among all tests performed) of diagnostic tests for Campylobac-
ter and Salmonella from five private laboratories in Switzerland between
2003 and 2012. We analysed demographic characteristics, temporal and
spatial distribution of test numbers and positivity rates. Predictors for
a positive test and disease seasonality were assessed with logistic regres-
sion analyses.
RESULTS: A total of 135’122 (13’095 positive) Campylobacter tests and
136’997 (2’832 positive) Salmonella tests were obtained with positive
tests corresponding to 20.4% and 17.2% of notified campylobacteriosis
and salmonellosis cases, respectively. The number of tests conducted
annually increased for both pathogens by 51% from 2003 to 2012. An-
nual positivity rates of Campylobacter increased from 7.6 to 11.1% and
rates of Salmonella decreased from 2.7 to 1.5%. The largest increases in
annual Campylobacter positivity rates were observed for patients older
than 85 years (+193.7%), followed by children aged 5–9 years (+131.9%).
Positivity rates and test numbers for both diseases by month or calen-
dar week showed a distinct seasonality, with peak rates for Salmonella
occurring in autumn and for Campylobacter in summer and at the turn
of the year. These findings were independent of patients’ age and sex.
CONCLUSIONS: Both positivity rates and notification rates showed in-
creasing trends for Campylobacter and decreasing trends for Salmonella,
suggesting that these trends reflect changes in disease epidemiology at
population level. The continuous assessment of positivity rates remains
important to appropriately interpret changes observed in the notification
system especially considering the increasing use of multiplex polymerase
chain reaction test panels where multiple pathogens are tested simultan-
eously.
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Introduction
Human campylobacteriosis and salmonellosis are the most frequently re-
ported foodborne bacterial infections in Europe. In 2014, notification
rates in the European Union (EU) were 71.0 cases per 100’000 popula-
tion (corresponding to approximately 236’900 cases) for campylobacteri-
osis and 23.4 cases per 100’000 population (approximately 88’700 cases)
for salmonellosis [1]. In the same year, in Switzerland, the notification
rate for Campylobacter infections was 92.9 cases per 100’000 popula-
tion (approximately 7’600 cases) and 15.2 cases per 100’000 population
(approximately 1’200 cases) for Salmonella infections [1]. During the
mid-1990s, the annual number of notified human Campylobacter infec-
tions surpassed that of Salmonella infections in Switzerland [2]. This was
owing to a reduction of human salmonellosis following the introduction
of control measures in the egg and poultry industry, such as mandatory
screening of layer hens, in the early 1990s [2]. So far, similar control
measures for Campylobacter are lacking and campylobacteriosis is cur-
rently the most frequently notified foodborne disease in Switzerland [2].
In Switzerland, notifiable diseases are monitored by the Federal Office
of Public Health (FOPH) through the National Notification System for
Infectious Diseases (NNSID) [3, 4]. Laboratory-based surveillance of
Campylobacter and Salmonella infections, as defined by the Epidemics
Act of 1970 and its related ordinances, captured only those cases that
tested positive [5-7]. Since the implementation of the new Epidemics
Act at the beginning of 2016, the total number of tests conducted for
these two pathogens, including the number of positive results, must be
reported annually as aggregated numbers, stratified by month and test
method [4, 8]. Hence, denominator data to help draw inferences from
surveillance data about the epidemiological situation in the community
have not been collected so far. The number of stool tests performed
depends on the healthcare-seeking behaviour of patients with diarrhoea
and the stool sampling rate of treating physicians [9-11]. As not all in-
dividuals affected by acute gastroenteritis seek medical care or have a
stool sample examined for enteric pathogens, there are likely to be many
undetected (at community level) and unreported (at healthcare level)
campylobacteriosis and salmonellosis cases [12, 13]. Hence, changes in
notification rates do not necessarily reflect an epidemiological trend, but
could be attributable to changes in healthcare-seeking behaviour or stool
sampling rates. A more informed interpretation of surveillance data is
made possible by calculating positivity rates (proportion of positive tests
among all tests performed). Because positivity rate calculations also
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consider denominator data, they adjust for the number of tests [14, 15].
We analysed laboratory data for stool tests performed for Campylobac-
ter spp. and Salmonella spp. by Swiss diagnostic laboratories over a
10-year period to better interpret the trends of campylobacteriosis and
salmonellosis case notifications seen in the NNSID.
Materials and methods
Selection of diagnostic laboratories
The study aimed to include private diagnostic laboratories from all
geographical and linguistic regions of Switzerland to reach an optimal
representation of the campylobacteriosis cases reported to the NNSID
between 2003 and 2012. Eleven private diagnostic laboratories, each re-
porting more than 1’000 campylobacteriosis cases during that decade,
were contacted and invited to provide data for the study. The case-
based laboratory data requested comprised patients’ demographic char-
acteristics (sex, age, canton of residence, personal identification code
assigned by laboratory) and test characteristics (pathogen tested, test
result, date of test, test method) on all Campylobacter and Salmonella
tests performed between 2003 and 2012.
Analysis of positivity rates
Datasets from individual laboratories were transformed uniformly,
merged and analysed with STATATM Version 13.1 (Stata Corporation;
College Station, TX, USA). Firstly, double entries, repeated tests and
tests for patients without Swiss residency were excluded. The following
rules – based on disease durations and durations of organism excretion
[16] – were applied to identify and exclude repeated tests: (i) control or
follow-up tests, irrespective of result, following a positive result within
42 days for both, Campylobacter and Salmonella; (ii) negative tests fol-
lowing a negative result within 10 days (Campylobacter) or 21 days (Sal-
monella); and (iii) negative tests followed by a positive result within 10
days (Campylobacter) or 21 days (Salmonella). The patient population
was characterised by sex, age, diagnostic laboratory, test year and res-
idence by greater region (corresponding to the Nomenclature of Units
for Territorial Statistics (NUTS) 2 level [17]). Age groups for statist-
ical analyses were predefined. Residence by greater region was based
on the patients’ canton of residence (NUTS 3 level). Descriptive ana-
lysis of positivity rates – defined as positive tests divided by total tests
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performed – and exploratory logistic regression analyses of predictors
for and seasonality of positive tests were performed. Characteristics of
laboratory-confirmed cases of campylobacteriosis and salmonellosis were
additionally compared with national surveillance data. Time trends of
annual positivity rates were investigated using stratification and direct
standardisation for age groups and sex. Thus, the population of indi-
viduals tested from 2003 to 2012 was used as the reference population.
The seasonality of monthly and weekly positivity rates was assessed by
calculating positivity rates from laboratory data from the whole obser-
vation period pooled by month or calendar week.
Univariable and multivariable regression models
In a first step, univariable logistic regression analyses were performed to
estimate the effect of sex, age group, laboratory, residence by greater re-
gion, test week, test month and test year on the test result. Afterwards,
a multivariable logistic regression model estimated the unconfounded ef-
fects of sex, age groups, laboratories, residence by greater region and test
year on the test result. The effect of seasonal within-year variations on
test outcome were investigated with a second multivariable logistic re-
gression model including test month and adjustments for sex, age groups,
laboratories, residence by greater region and test year. For this model,
the test month with a positivity rate closest to the mean positivity rate
of all test months was used as a baseline and test year was introduced
as a random effect. The significance of variables in the multivariable
models was assessed by likelihood ratio tests and the category of each
variable with the most observations (except for test month) was used
as a baseline to make the model more robust. Patients with missing
information on the canton of residence were assigned the greater region
of their corresponding laboratory.
Ethics statement
The study was approved by the local ethical committee “Ethikkommis-
sion Nordwest- und Zentralschweiz” [Ethical committee of Northwestern
and Central Switzerland] (No.: EKNZ:2014–164).
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Results
Exclusion of test results and representativeness
Eight laboratories agreed to participate in the study and five of them
provided complete data for Campylobacter and Salmonella tests per-
formed as requested. The eight laboratories conducted a total of 196’307
Campylobacter tests (17’694 positive) and 199’062 Salmonella tests
(4’163 positive) between 2003 and 2012. Excluding data from the three
laboratories with incomplete data led to the exclusion of 43’530 (3’345
positive) Campylobacter tests and 45’114 (640 positive) Salmonella tests.
Among the remaining laboratories (A to E), removal of double entries,
repeated tests and tests of non-Swiss residents led to the exclusion of
a further 17’211 (1’245 positive) Campylobacter tests and 16’499 (689
positive) Salmonella tests. Additionally, we excluded 444 (9 positive)
Campylobacter tests and 452 (2 positive) Salmonella tests because of
missing information on sex and/or age. In the detailed analysis, 135’122
(13’095 positive) Campylobacter tests and 136’997 (2’832 positive) Sal-
monella tests were included. Culture-based test methods accounted for
98.7% of all Campylobacter and Salmonella tests conducted, and poly-
merase chain reaction (PCR) tests accounted for 1.3%. Positive tests
included in the analysis corresponded to 20.4% and 17.2% of campylo-
bacteriosis and salmonellosis cases, respectively, registered in the NNSID
between 2003 and 2012 (Tables 6.1 and 6.2).
Characteristics of the patient population and overview of
tests performed
The annual number of tests performed increased by 51.1% from 2003 to
2012 (11’674 to 17’641 tests) for Campylobacter and by 50.7% (11’842 to
17’842 tests) for Salmonella (Figure 6.1). For both diseases, annual test
numbers decreased by at least 6% for the age groups <5 years and 5–9
years, and increased by at least 31% in the older age groups. The median
age of patients tested for Campylobacter was 42 years (range: <1–108
years) and 41 years (range: <1–108 years) for Salmonella. Patients’
age differed significantly between laboratories and test years for both
pathogens (Kruskal-Wallis test: p<0.01 for all four tests). Slightly more
tests were conducted among females than among males for Campylobac-
ter (54.8%) and for Salmonella (54.3%). The sex ratio differed between
laboratories and test years for both pathogens (chi-square test: p<0.01
for all four tests). The patients’ residence by greater region was asso-
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Table 6.1: Comparison of campylobacteriosis cases from laboratory data with cases registered in the National Notification
System for Infectious Diseases by test year, Switzerland, 2003–2012
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Proportion of NNSID cases reported
by study laboratories in %
16.7 16.7 17.6 20.4 21.8 21.1 21.4 21.0 21.1 23.0
Proportion of NNSID cases by
greater region reported by study
laboratories in %
Lake Geneva 1.5 2.5 2.0 3.5 3.0 3.0 4.0 4.0 3.5 4.0
Espace Mittelland 17.0 17.0 18.5 26.0 27.0 27.0 28.5 29.0 28.0 28.5
Northwestern Switzerland 26.0 22.5 23.0 25.0 27.5 26.0 27.0 25.0 27.0 33.0
Zurich 24.0 27.0 28.0 29.0 29.5 29.0 23.0 28.0 25.0 26.5
Eastern Switzerland 15.0 18.0 18.0 16.5 18.5 20.5 22.0 19.5 23.0 24.0
Central Switzerland 8.0 7.5 8.5 6.5 7.0 6.5 6.0 7.0 6.5 8.0
Ticino 45.5 47.0 44.0 63.0 69.5 54.5 60.0 52.5 57.0 58.0
Proportion of males in %
Laboratories 56.6 55.4 53.5 57.7 55.2 53.7 55.8 53.0 54.6 54.9
NNSID 55.4 54.8 54.8 55.0 53.5 53.5 53.6 53.8 53.7 54.0
Median age in years
Laboratories 34 34 34 35 35 36 37 37 39 36
NNSID 32 33 34 34 35 35 35 37 36 36
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Table 6.2: Comparison of salmonellosis cases from laboratory data with cases registered in the National Notification
System for Infectious Diseases by test year, Switzerland, 2003–2012
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Proportion of NNSID cases reported
by study laboratories in %
15.6 15.9 15.7 16.7 17.7 16.4 17.4 19.0 21.0 19.8
Proportion of NNSID cases by
greater region reported by study
laboratories in %
Lake Geneva 0.5 2.5 2.0 3.0 4.5 4.0 2.0 1.0 3.0 1.0
Espace Mittelland 14.5 18.0 14.0 19.0 19.5 19.0 18.5 20.5 28.5 21.0
Northwestern Switzerland 20.0 21.0 21.0 24.0 22.5 17.5 23.0 23.0 19.0 29.5
Zurich 19.0 17.5 18.0 22.0 23.5 21.5 23.0 25.0 14.0 24.5
Eastern Switzerland 9.5 11.0 16.5 12.5 14.5 14.0 17.0 23.0 19.5 18.5
Central Switzerland 6.0 6.5 3.5 7.5 3.5 4.5 4.5 12.0 3.0 10.5
Ticino 49.5 51.0 43.5 48.5 46.0 49.5 45.0 47.0 72.5 48.5
Proportion of males in %
Laboratories 53.2 53.4 56.0 58.8 57.1 55.0 57.9 52.3 49.6 52.2
NNSID 52.1 49.6 53.1 56.2 54.3 51.4 53.0 52.4 51.2 52.5
Median age in years
Laboratories 18 23 23 25 30 28 29 25 24 25
NNSID 25 25 26 25 27 28 27 27 28 26
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ciated with the geographical location of the laboratory that performed
the test.
Annual positivity rates overall and by laboratory
Annual Campylobacter positivity rates standardised for age and sex in-
creased by 46.1% from 2003 (7.6%) to 2012 (11.1%) (Figure 6.2). Annual
standardised Salmonella positivity rates showed an inverse trend and
decreased by 44.4% from 2003 (2.7%) to 2012 (1.5%). Campylobacter
positivity rates stratified by laboratory (and standardised for age and
sex) showed similar annual trends (Supplementary figure S1). The an-
nual positivity rates of laboratory C were remarkably lower throughout
the investigated period compared with other laboratories. Laboratory-
specific Campylobacter positivity rates ranged from 3.8 to 9.4% in 2003
and continuously increased to 7.0–13.2% in 2012. For Salmonella, annual
positivity rates by laboratory differed only slightly between laboratories;
the highest rates were observed for laboratory C, with two distinct peaks
in 2007 and 2011. Overall, a decreasing trend was observed; positivity
rates dropped from 2.1–3.8% in 2003 to 1.2–2.7% in 2012.
Annual positivity rates by sex and age groups
The annual Campylobacter positivity rates for males and females in-
creased by 43.6% (from 9.4 to 13.5%) and by 45.2% (from 6.2 to 9.0%),
respectively, from 2003 to 2012. In the same decade, annual Campylobac-
ter positivity rates by age group increased for all age groups. The largest
increase was observed for the age group ≥85 years (193.7%) followed by
the 5–9-year-olds (131.9%). Compared with 2003, annual Campylobacter
positivity rates of sex-specific age groups were higher in 2012, except for
females in the age group 10–14 years (Figure 6.3a). Annual Campylobac-
ter positivity rates were generally higher for males than for females over
the entire observation period. For males and females in the age groups
<5 years, 5–9 years and ≥85 years, similar annual Campylobacter posit-
ivity rates were observed at the beginning of the decade but rates were
later slightly higher for males in the age group ≥85 years and for females
in the age groups <5 years and 5–9 years.
Annual Salmonella positivity rates decreased from 3.3% to 1.6% (-51.5%)
for males and from 2.5% to 1.2% (-52.0%) for females between 2003 and
2012. Annual positivity rates decreased for all age groups between 2003
and 2012 except for the age group 20–24 years, for which the rate re-
mained rather stable. The largest relative decrease of positivity rates
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Figure 6.1: Number of stool tests for Campylobacter (a) and Salmonella (b)
by sex in five diagnostic laboratories, Switzerland, 2003–2012.
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Figure 6.2: National Notification System for Infectious Diseases (NNSID) notification rates and positivity rates (stand-
ardised for age and sex) of Campylobacter and Salmonella, Switzerland, 2003–2012. NNSID data provided by the Federal
Office of Public Health, Bern, Switzerland
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was observed for the age groups 10–14 years and ≥85 years, where rates
decreased from 10.5 to 3.7% (-64.8%) and from 0.8 to 0.2% (-75.0%),
respectively. Sex-specific Salmonella positivity rates were similar or
slightly higher for males compared to females in all age groups although
for some age groups, positivity rates varied strongly between years (Fig-
ure 6.3b).
Seasonal trends in stool sampling and positivity rates
The number of tests performed for Campylobacter and Salmonella star-
ted to increase in spring (Figure 6.4 panels a and c, figure 6.5 panels a
and c). Test numbers peaked in late August (calendar week 34) after a
brief and strong temporary decline at the beginning of the month (cal-
endar week 31). Afterwards, the number of tests decreased until the end
of the year. Monthly test numbers were lowest in February for Cam-
pylobacter and Salmonella, even though calendar week 1 was the week
with the fewest tests performed.
After a continuous increase during spring, monthly Campylobacter posit-
ivity rates peaked during summer months, with the highest monthly rate
occurring in July (13.8%) (Figure 6.4 panels b and d). Likewise, monthly
Salmonella positivity rates started increasing during the spring. They
peaked twice, first in late summer (August) and then in the autumn,
with the highest rate occurring in October (3.1%) (Figure 6.5 panels b
and d). The highest weekly positivity rate for Campylobacter (17.3%)
was in calendar week 1 (January), whereas the peak of weekly Salmonella
positivity rates (3.5%) was in calendar week 43 (October). The lowest
monthly positivity rates for Campylobacter and Salmonella were in Feb-
ruary (5.3%) and March (1.1%), respectively. The seasonal trends of
Campylobacter and Salmonella positivity rates were also observable for
sex- and age-specific positivity rates although less pronounced in certain
groups.
Regression analyses
In the univariable regression analyses, sex, age, laboratory, residence by
greater region, test week, test month and test year all had a significant
effect on the test result for both diseases. The multivariable regression
analysis of predictors for a positive Campylobacter test showed higher
odds of a positive test for males than for females (odds ratio [OR] 1.53,
95% confidence interval [CI] 1.47–1.59) (Supplementary table S1, ap-
pendix 1). Patients in the age groups 15–19 years and 20–24 years had
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Figure 6.3: Annual positivity rates of Campylobacter (a) and Salmonella (b)
by age group and sex, Switzerland, 2003–2012
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Figure 6.4: Seasonality of Campylobacter tests and positivity rates (pooled over study period) per month and calendar
week, Switzerland, 2003–2012.
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Figure 6.5: Seasonality of Salmonella tests and positivity rates (pooled over study period) per month and calendar week,
Switzerland, 2003–2012.
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higher odds for a positive test outcome compared with the age group
25–44 years, whereas patients of other age groups had reduced odds.
The patients’ place of residence by greater region had similar odds for a
positive test, except for patients from the Ticino region (OR 0.44, 95%
CI 0.38–0.52). From 2003 to 2008, the odds increased continuously and
decreased slightly between 2009 and 2011 compared with 2012.
The regression model for seasonal within-year variations showed that the
odds for a positive Campylobacter test was highest in July (OR 1.52,
95% CI 1.40–1.65) and lowest in February (OR 0.55, 95% CI 0.49–0.61)
compared with May, which had a positivity rate closest to the monthly
average (Supplementary table S2). Significantly higher odds were also
observed for June (OR 1.38, 95% CI 1.26–1.50) and August (OR 1.24,
95% CI 1.14–1.35) compared with May.
In the multivariable regression model for Salmonella, males had higher
odds (OR 1.30, 95% CI 1.21–1.40) of a positive test than females (Sup-
plementary table S3). The odds of a positive test outcome increased
threefold for the age groups <5 years, 5–9 years and 10–14 years com-
pared with the age group 25–44 years. Greater region was no longer
significantly associated with the outcome in the multivariable regression
model. The odds of a positive test outcome steadily decreased during the
study period compared with 2012. In the second multivariable model for
seasonality, the highest odds of a positive Salmonella test were observed
in October (OR 1.61, 95% CI 1.36–1.90) and August (OR 1.44, 95%
CI 1.23–1.70) compared with November (Supplementary table S4). The
lowest odds (compared with November) were observed in March (OR
0.55, 95% C: 0.44–0.68) and February (OR 0.57, 95% CI 0.46–0.72).
Discussion
Annual Campylobacter positivity rates standardised for age and sex in-
creased from 2003 to 2012, whereas standardised Salmonella positivity
rates decreased. During the same time period, campylobacteriosis no-
tification rates increased from 72.7 to 105.5 notifications per 100’000
population, whereas salmonellosis notification rates decreased from 29.8
to 15.4 per 100’000 population. Campylobacter positivity rates were
generally higher for males than females in all age groups. Monthly and
weekly Campylobacter positivity rates showed a distinct seasonality, with
a peak during the summer months and again at the beginning of the year,
which was independent of sex and age group. Salmonella positivity rates
showed a similar seasonality, but peaked in autumn. Annual Salmonella
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positivity rates were similar or slightly higher for males than for females,
with the highest rates observed in the younger age groups, <5, 5–9 and
10–14 years. The observed seasonality and annual trends of positivity
rates for both pathogens are congruent with reports from other countries
[14, 18].
Annual positivity rates in relation to NNSID notification
rates
Annual positivity rates of Campylobacter and Salmonella standardised
for age and sex and annual NNSID notification rates showed similar
trends. Multiple testing, data duplication or simultaneous testing of
several pathogens could potentially affect both numerator and denom-
inator data in different ways. However, similar trends were observed
for the standardised annual positivity rates presented here and for the
crude, non-standardised positivity rates calculated from raw data from
all eight laboratories included in the study (Supplementary figure S2,
appendix 1).
The stool test data analysed for this study originated mainly from
culture-based test methods, which used to be the standard diagnostic
method for detecting Campylobacter and Salmonella. Campylobacter ,
Salmonella and Shigella are often tested simultaneously [19]. In terms
of relative frequency, more positive Salmonella tests (18.9%) than posit-
ive Campylobacter tests (8.4%) were excluded, whereas the proportion of
excluded duplicate and repeated tests was similar for negative Campylob-
acter and Salmonella tests (11.2 vs. 10.2%). The proportion of negative
Salmonella tests excluded dropped only slightly from 10.2 to 9.4% when
the same time span used for excluding negative Campylobacter tests was
applied. Hence, only laboratory-confirmed campylobacteriosis and sal-
monellosis patients differ with regard to repeated testing. In summary,
reducing the number of tests per patient and disease episode to one test
result is crucial for an accurate calculation of positivity rates whereas
the temporal trend of positivity rates is not considerably affected.
The relative increase in standardised annual Campylobacter positivity
rates (+46.1%) and the relative decrease in standardised annual Sal-
monella positivity rates between 2003 and 2012 (-44.4%) are close to
the increase in notification rates of Campylobacter (+45.0%) and the
decrease in notification rates of Salmonella (-48.4%). During the same
time period, the number of tests performed for Campylobacter and Sal-
monella increased by around 51%. The proportion of cases diagnosed
by participating laboratories among NNSID case notifications increased
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by 37.7% for campylobacteriosis and by 26.9% for salmonellosis over the
study period.
The observed increase of test numbers in our study was partially due to
a single laboratory (laboratory A), where the number of tests increased
3.5 times for Campylobacter and 3.8 times for Salmonella between 2003
and 2012. This laboratory was founded a few years before the study
period. For the remaining laboratories (B, C, D, E), a smaller increase
of 32.0% for Campylobacter tests and of 29.0% for Salmonella tests was
observed. An increase in testing frequency has also been observed in
other European countries [14, 20], except in the Netherlands, where
testing frequency remained rather stable [21]. Testing frequencies are
largely influenced by physicians’ stool sampling behaviour and patients’
healthcare-seeking behaviour [14, 22-25]. It is also possible that labor-
atories in the study increased their market shares.
The increase of Campylobacter notification rates is probably due to a
combination of increasing test numbers and an upward epidemiological
trend in the population, as suggested by the increase in positivity rates.
The decrease of Salmonella notification rates presumably reflects an epi-
demiological trend in the population, as the notification rate decreased
at the same time that testing frequency increased. The increase of cam-
pylobacteriosis cases in the population, together with the co-testing of
Salmonella and Campylobacter , is probably responsible for the increase
of Salmonella test numbers.
In summary, notification rates are influenced by both epidemiological
trends in the population and test numbers. More infections in the pop-
ulation will lead to higher notification rates and fewer infections will
lead to lower notification rates. On the other hand, increasing test num-
bers can lead to the detection of more cases in the population, i.e., higher
notification rates without necessarily reflecting an increase in disease fre-
quency. Consequently, an observed increase in notification rates does not
necessarily represent an actual increase of disease frequency in the popu-
lation. A change in test numbers can be due to a number of factors such
as changes in the prevalence of risk factors leading to testing, altered
healthcare-seeking behaviour, and changes in physicians’ testing prac-
tices, human susceptibility, and pathogenicity. Assessing the interplay
of notification rates and test numbers by positivity rates provides more
insights into the epidemiological situation in the population than one of
these measures alone. Nevertheless, understanding underlying reasons
for changes in one of these measures requires further investigation.
125
6 Positivity rates from foodborne pathogen testing, 2003–2012
Positivity rates in relation to age and sex
A remarkable increase in Campylobacter positivity rates was observed for
the age groups 5–9 years and ≥85 years (+131.9% and +193.7%). Test
numbers for the age group 5–9 years decreased during the observation
period (-6.1%), and they more than doubled for the age group ≥85 years
(+131.5%). During the same time period, notification rates for the ≥85
years age group increased by 94.9% (47.2–92.0 per 100’000 population)
and for the 5–9 years age group by 30.7% (55.3–72.3 per 100’000 popu-
lation) [2]. It was found that adults and the elderly suffered increasingly
more frequently from campylobacteriosis; this could be related to the
frequent use of proton pump inhibitors and comorbidities in these age
groups [2, 26, 27]. Others have also observed increasing test numbers
among the elderly and related it to changes (increases) in healthcare-
seeking and physicians’ testing behaviour [14, 18, 24]. Additionally, the
Swiss population aged ≥85 years increased by 29% from 2003 to 2012,
which probably also contributed to the observed increase in test numbers
[28].
Salmonella notification rates and annual sex-specific positivity rates
showed similar decreasing trends. The strongest decreases in age-spe-
cific annual Salmonella positivity rates were observed for the age groups
10–14 years and ≥85 years (-64.8% and -75.0%, respectively). At the
same time, notification rates dropped by 55.4% (39.2–17.5 per 100’000
population) for the 10–14 year age group and by 55.6% (23.9–10.6 per
100’000 population) for the ≥85 years group. It appears, therefore, that
these decreases are true epidemiological trends. Age-specific Salmonella
positivity rates tended to be slightly higher for males but did not re-
markably differ between sexes. Similar observations have been made for
corresponding NNSID data [2].
The increasing trend in Campylobacter positivity rates was similar for
males and females. Also, male and female notification rates to the
NNSID likewise increased during this time [2]. Both positivity rates
and notification rates for Campylobacter were higher among males than
among females in nearly all age groups. Higher positivity rates for males
have also been observed by others [18]. Higher stool sampling rates have
been reported for male patients in Canada [18] and for female patients
in Wales [14]. Sex-specific differences in healthcare seeking or in risk
exposures could account for this observation.
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Seasonality of positivity rates and notification rates
Monthly and weekly Campylobacter and Salmonella positivity rates
showed seasonal trends corresponding to the NNSID notification rates,
which peaked during the summer months and, for Campylobacter , also
at the beginning of the year [2]. Summer peaks of Campylobacter and
Salmonella positivity rates have also been described previously [18].
Monthly and weekly test numbers also peak in summer. The seasonal
variation of test numbers could indicate seasonality of acute gastroen-
teritis, a temporal variation in the medical care-seeking behaviour of
affected individuals and in the proportion of patients being tested. For
instance, returning travellers are more likely to undergo stool diagnostics
[24, 25, 29], leading to increased test numbers during the public school
holiday season in the summer. The combination of high test numbers
and high positivity rates in summer and autumn generates the observed
peak in case numbers in the NNSID [2].
Peaks of Campylobacter and Salmonella notification rates during sum-
mer months are observed in most European countries [1, 2, 27, 30, 31].
The prevalence of Campylobacter in broiler flocks and the contamin-
ation of chicken meat with Campylobacter at retail are higher during
summer months than during the rest of the year [31-34]. This probably
explains the observed seasonality as poultry meat from broilers is the
main source of Campylobacter infections in Switzerland [35-37]. How-
ever, it seems that the summer peak is not caused by a single common
source of infection and is more likely driven by multiple sources of animal
and environmental exposures and climatic conditions [27, 31, 38, 39]. An
additional reason for the summer peak in Switzerland and parts of the
EU could be related to the culture of barbequing during summer, which
provides multiple occasions for disease transmission through undercook-
ing of and cross-contamination by poultry and red meat [40-43]. Travel
abroad is a known risk factor for contracting campylobacteriosis [42-45]
– also in Switzerland [46, 47] – and a large proportion of notified Sal-
monella infections in Switzerland is travel-related [48]. Hence, travelling
probably contributes to the observed seasonality of campylobacteriosis
and salmonellosis test numbers and case notifications in Switzerland.
The highest weekly positivity rate for Campylobacter was found in calen-
dar week 1 when test numbers were lowest. Notification rates of campylo-
bacteriosis in Switzerland show a strong annual increase over Christmas
and New Year (“winter peak”). A similar peak in notification data at
the beginning of January has also been observed in Germany [30] and
in the Campylobacter surveillance data of The European Surveillance
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System [1]. In Switzerland, the major driver for the winter peak is fre-
quent consumption of meat fondue at festive occasions around this time,
especially if it includes chicken meat [47]. The low test numbers over the
festive season in December and January are probably related to a dif-
ferent healthcare-seeking behaviour and restricted access to healthcare
services during the holiday period. Therefore, the winter peak in Cam-
pylobacter notification rates is probably attenuated and does not reveal
the full magnitude of the problem.
Strengths and limitations
In Switzerland, private diagnostic laboratories operate on a regional or
national level and predominantly serve the practices of general practi-
tioners and medical specialists. The study did not consider hospital-
based laboratories as their patient profile generally differs from the pa-
tient profile in private practices at the primary care level. Hospitalised
patients are likely to be more severely affected by acute gastroenter-
itis and to undergo more extensive diagnostic testing. Hence, their pre-
test probability for a positive Campylobacter or Salmonella test result is
different from that of patients consulting at primary care practices [18].
The catchment population of the participating laboratories is not known.
Therefore, it was not possible to describe the catchment population, ad-
just for potential changes therein or to estimate any population-based
indicators like stool sampling rates. Similarly, we could not assess how
well the data of the five participating laboratories represent the whole
tested population in Switzerland, given the latter is not known. We could
only assess the representativeness of the patient population by compar-
ing “our” positively tested patients with all notified cases (and hence,
supposedly, all positively tested patients in Switzerland; table 6.1 and
table 6.2). From this comparison we conclude that estimated positivity
rates are likely to represent accurately the epidemiological trends and
situation in Switzerland as median age and the sex-ratio of cases iden-
tified in participating laboratories and in cases from the NNSID were
comparable.
Conclusions
The study results support the assertion that the increase in notification
rates of campylobacteriosis and the decrease in notification rates of sal-
monellosis are epidemiological trends in the population. These trends
cannot be solely explained by changing test numbers. Still, we believe
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it is important to continuously assess test numbers or positivity rates to
note changes in stool testing frequency that could lead to changes in case
numbers seen in the notification system. This becomes especially im-
portant in the light of the increasing use of multiplex PCR panels where
multiple pathogens are tested simultaneously and, hence, test numbers
can change substantially [49]. The annual collection of test numbers of
selected notifiable diseases as stipulated under the newly enforced Swiss
Epidemics Act will allow for continuous assessment of positivity rates in
the future.
Supplementary data
For supplementary data accompanying this paper visit https://doi.or
g/10.4414/smw.2017.14569.
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7 Enterohaemorrhagic E. coli (EHEC)
in Switzerland: epidemic pattern due
to changing laboratory methods?!
Parts of this chapter are extracted/adapted from an unpublished report
prepared for the FOPH:
Schmutz C, Mäusezahl D. Abklärung der steigenden EHEC-
Meldezahlen bei den Laboratorien. Report of laboratory visits.
27 Oct 2016; Basel: Swiss Tropical and Public Health Institute.
7.1 Introduction
The Federal Office of Public Health (FOPH) noticed a strong increase in
enterohaemorrhagic Escherichia coli (EHEC) case notifications in 2015
without obvious geographical clusters (Figure 7.1) [Bundesamt für Ge-
sundheit and Nationales Referenzzentrum für enteropathogene Bakterien
und Listerien, 2015]. It was suspected that new laboratory techniques,
namely multiplex polymerase chain reaction (PCR) panels, could have
contributed to this increase. Such panels allow testing a sample for mul-
tiple pathogens in one single run. Different multiplex PCR panels for
gastrointestinal (GI) pathogens are commercially available, among those
the BD MAXTM Enteric Bacterial Panel [Becton, Dickinson and Com-
pany, 2016], the xTAG R© Gastrointestinal Pathogen Panel (GPP) [Lu-
minex, 2012], and the FilmArray R© Gastrointestinal (GI) Panel [BioFire
Diagnostics, 2016]. An overview of pathogens included in those three
panels is provided in table 7.1.
Traditionally, routine testing of stool samples for bacterial pathogens
included only Campylobacter spp., Salmonella spp. and Shigella spp.
[Schweiger et al., 2005a], using culture-based techniques. It is conceiv-
able that EHEC – which is included in all three of the above-mentioned
panels – is tested more frequently if traditional stool culture is replaced
by multiplex PCR. However, it was not known if this was indeed the
case. Therefore, the FOPH initiated several studies to investigate if the
increase seen in EHEC notification data is due to an underlying out-
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Figure 7.1: Annual number of probable and confirmed enterohaemorrhagic Escherichia coli (EHEC) cases reported to the
Federal Office of Public Health between 1999 and 2016 (* Data as per 20 July 2016). Cases residing outside Switzerland
were excluded
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Table 7.1: Overview of pathogens included in four commercially available multiplex PCR panels for gastrointestinal
pathogens
BD MAXTM Enteric
Bacterial Panel
xTAGR© Gastrointestinal
Pathogen Panel (GPP)
FilmArrayR© Gastrointestinal (GI)
Panel
Bacteria Campylobacter spp. (jejuni
and coli)
Campylobacter Campylobacter
(C. jejuni/C. coli/C. upsaliensis)
Salmonella spp. Salmonella Salmonella
Shigella spp./EIEC Shigella Shigella/EIEC
Shiga toxin-producing
organisms (STEC, Shigella
dysenteriae)
Shiga-like Toxin producing E.
coli (STEC) stx1/stx2
Shiga-like toxin producing E. coli
(STEC) stx1/stx2
Escherichia coli O157 E. coli O157
Clostridium difficile toxin
A/B
Clostridium difficile (toxin A/B)
ETEC LT/ST ETEC lt/st
Vibrio (V. parahaemolyticus/
V. vulnificus/V. cholerae)
Vibrio cholerae Vibrio cholerae
Yersinia enterocolitica Yersinia enterocolitica
Plesiomonas shigelloides
EAEC
EPEC
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Table 7.1: (continued)
BD MAXTM Enteric
Bacterial Panel
xTAGR© Gastrointestinal
Pathogen Panel (GPP)
FilmArrayR© Gastrointestinal (GI)
Panel
Viruses Adenovirus 40/41 Adenovirus F 40/41
Norovirus GI/GII Norovirus GI/GII
Rotavirus A Rotavirus A
Astrovirus
Sapovirus (Genogroups I, II, IV, and V)
Parasites Cryptosporidium Cryptosporidium
Entamoeba histolytica Entamoeba histolytica
Giardia Giardia lamblia
Cyclospora cayetanensis
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break situation or whether it reflects a change in laboratory methods.
One of these studies aimed to get a better understanding of the current
diagnostic algorithms and methods used by Swiss diagnostic laboratories
and of their reporting procedures. Therefore, visits to Swiss diagnostic
laboratories reporting many EHEC cases were scheduled with the ob-
jectives to:
• assess the laboratory techniques currently used by Swiss diagnostic
laboratories to test for EHEC with special emphasis on the import-
ance of multiplex PCR panels
• network to personalise the institution “FOPH” and to foster the re-
lationship between the FOPH and the laboratories
• enhance the mutual understanding of the Swiss notification system
and associated challenges
• prepare for a subsequent study, a so-called “positivity study”, by
explaining its aims and objectives, its significance, and the data re-
quirements, and enquiring about data availability and willingness to
participate
7.2 Methods
The 10 laboratories reporting most EHEC cases in 2015 were selected.
Two of those 10 laboratories were closely collaborating; the same person
was responsible for EHEC testing in those two laboratories. There-
fore, an additional laboratory was selected. Furthermore, the sample of
10 laboratories included only one hospital laboratory. Hence, a second
hospital laboratory was selected to increase the variety of possible ap-
proaches to EHEC diagnostics.
The visit was kept as informal as possible in order to establish (in parts
for the first time) a personal relationship with laboratory staff. The
laboratory staff should not feel controlled or intimidated despite being
visited by an authority. In contrary, the visit was supposed to facilitate
interaction and enhance mutual understanding of everyday activities and
challenges. Therefore, the term “conversation” is used instead of “inter-
view” for the remainder of this chapter. Nevertheless, conversations were
prepared similar to preparing interviews for a qualitative research study.
A question guide with leading questions was developed jointly between
the Swiss Tropical and Public Health Institute (Swiss TPH) and the
FOPH to help structure the conversation. The FOPH sent letters ex-
plaining the current epidemic increase of EHEC in Switzerland and the
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need to understand underlying reasons to the selected laboratories. Af-
terwards, FOPH staff contacted the laboratories by phone and fixed an
appointment with the person responsible for microbiology and/or EHEC
diagnostics, if they agreed to participate. One or two employees of the
FOPH and one Swiss TPH staff (two in one case) attended the conver-
sations. The employee of the FOPH lead the conversation; Swiss TPH
staff was responsible for note taking and for explaining the planned pos-
itivity study. Conversations were not recorded as this would defy the
intended informal character.
7.3 Results
All 11 laboratories were visited between 08 June and 13 July 2016. Four
laboratories were in the French-speaking part of Switzerland with con-
versations conducted in French while seven were in the German-speaking
part of Switzerland with conversations in German.
7.3.1 Use and characteristics of multiplex PCR panels
Laboratory experts unanimously agreed that the increasing use of mul-
tiplex PCR panels is responsible for the increase in EHEC case num-
bers seen in the National Notification System for Infectious Diseases
(NNSID). Some spontaneously noted “Wer sucht, der findet” (“seek and
you shall find”). All except two laboratories had at least one multiplex
PCR system in use for GI pathogens at the time of the visit. One of the
two laboratories not currently using a multiplex PCR panel, however,
evaluated different panels in 2013/14. The majority of laboratories vis-
ited uses GI multiplex PCR panels since 2014 or 2015.
The number of EHEC notifications by participating laboratory and the
time of introduction of the multiplex PCR panel is displayed in figure 7.2.
In some laboratories, routine testing of stool samples has been changed
from using traditional culture-based techniques to using the “small” mul-
tiplex PCR panel (BD MAXTM Enteric Bacterial Panel). Hence, in these
laboratories, all stool samples which were previously tested for Campy-
lobacter spp., Salmonella spp. and Shigella spp. are now (additionally)
tested for EHEC.
Laboratory experts stated that multiplex PCR panels give more fre-
quently positive results than culture-based methods. Their estimates on
what proportion of additional cases is identified with PCR compared to
culture differed: for Campylobacter estimates ranged from “20% more”
to “40% more” with multiplex PCR than with culture. Others stated
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Figure 7.2: Number of enterohaemorrhagic Escherichia coli (EHEC) noti-
fications registered at the Federal Office of Public Health (FOPH) per year
between 2006 and 2016 (data as per 20 July 2016) and time point of introduc-
tion of multiplex PCR panels, among laboratories visited by the FOPH and
the Swiss Tropical and Public Health Institute in June/July 2016
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that “5–10%” or “up to 40%” of PCR-positive results cannot be con-
firmed by culture.
Opinions differed also when asked if a positive PCR result for EHEC
is considered clinically relevant or rather an accidental finding. Even
though most laboratory experts consider EHEC an accidental finding –
physicians hardly ask specifically for EHEC testing – some seemed more
confident in relying on multiplex PCR panel results than others. Some
laboratory experts assess the clinical relevance together with the phys-
ician, on a case-by-case level. An expert mentioned that BD MAXTM
Enteric Bacterial Panel only detects vtx1 and vtx2 (cytotoxins expressed
by EHEC) but that the clinical relevance also depends on other pathogen
characteristics. Similarly, it was mentioned that all serotypes (harbour-
ing at least one of the cytotoxins) are detected by the test and reported
to the FOPH but one single serotype (O157) is responsible for 80% of
cases of haemolytic-uraemic syndrome (HUS).
On the other hand, it is assumed that patients are sick (do show signs
and symptoms) when stool samples are sent in for diagnostics. Hence, if
a pathogen is detected this is considered the likely cause. In this context,
interpretation of multiple positive PCR results was discussed. Again, ex-
pert opinions differed. Some stated that multiple infections are rarely
found in patients without travel history; hence, in cases without travel
history, the identified pathogen is considered causing the symptoms. In
contrast, in patients with travel history, multiple positive findings are
more frequent. In those cases it is difficult to evaluate which of the or-
ganisms is causing disease. One respondent stated that identifying 2–3
pathogens is plausible in a returning traveller depending on the travel
destination. He also referred to the manual of the testing kit stating that
results have to be questioned or re-checked only in case of 4 or more pos-
itive test results. Other experts seemed more sceptical towards multiple
positive results. It has to be noted, however, that some experts may have
referred to the “small” panel (BDMAXTM Enteric Bacterial Panel) while
others may have thought of the “large” panel (FilmArray R© Gastrointest-
inal (GI) Panel) when talking about multiple infections. Furthermore,
the “large” panel might more frequently be used in returning travellers
than in persons without travel history (see also next section).
7.3.2 Diagnostic algorithm in case of diarrhoea
Laboratory experts were also asked about the diagnostic procedures that
are applied in case of receiving a stool sample from a patient with
diarrhoea. Responses to this question were heterogeneous: in some
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laboratories the pathogens tested for and the diagnostic methods applied
are exclusively defined by the ordering physician; others apply their own
diagnostic algorithms. For example, several experts mentioned that they
would test using BD MAXTM Enteric Bacterial Panel if “general bacteri-
ology” was requested for a patient without travel history and they would
use the FilmArray R© Gastrointestinal (GI) Panel in a patient with travel
history. Others use a “single PCR” if only one pathogen is requested
by the physician but a multiplex PCR panel if testing for two or more
pathogens is requested. Such decisions can also be based on economic
reasons (cost- and time-effectiveness).
Many laboratories confirmed relying on PCR in the first instance for
stool diagnostics but most still conduct a culture-based confirmation
test in case a PCR-test generated a positive result. Reasons mentioned
for using culture-based diagnostics after PCR-positive results were: for
knowing the antibiotic resistance profile, for obtaining the isolate, for
typing, for billing purposes, and for distinguishing species which are not
distinguished by PCR (e.g. Arcobacter spp. from Campylobacter spp.
or Shigella spp. from enteroinvasive Escherichia coli (EIEC)).
7.4 Discussion
7.4.1 “Seek and you shall find (EHEC)”
The conversations with the laboratory experts revealed that the labor-
atories in Switzerland operate independently and apply heterogeneous
algorithms for stool diagnostic testing. However, one issue was undis-
puted among the experts: the increase in EHEC notifications is due
to the change from conventional stool culture to multiplex PCR pan-
els. Looking at the date of implementation of the multiplex PCR panels
as reported by laboratory representatives and the number of reported
EHEC cases by laboratory supports this finding (Figure 7.2). Apart
from confirming the switch from culture-based to multiplex PCR meth-
ods, laboratory representatives also highlighted that testing specifically
for EHEC is rarely asked for by physicians.
The potentially large impact of laboratory practices was already de-
scribed by a Swiss diagnostic laboratory for Aeromonas spp.: They ex-
cluded Aeromonas spp. from routine testing (“basic stool culture”) due
to a change in the official tariff structure in 2006 [Tritten et al., 2014].
After that change, this pathogen was rarely isolated until its reintroduc-
tion in routine testing in this laboratory in 2011. This change was not
noted by the FOPH as it did not concern a notifiable disease/pathogen.
143
7 EHEC: epidemic pattern due to laboratory methods?!
However, it shows the importance of understanding laboratory practices
for interpreting laboratory data including notifications.
7.4.2 Implications of laboratory practices for surveillance
and outbreak detection
Interestingly, the number of confirmed EHEC cases remained rather
stable in the European Union (EU) between 2012 and 2015 with a slight
increase in 2016 [European Food Safety Authority and European Centre
for Disease Prevention and Control, 2017]. In 2016, the notification rate
in the EU was 1.82 confirmed cases per 100’000 population. For com-
parison, the Swiss notification rate was at 5.5 per 100’000 population
which is the highest notification rate since 1999, the year in which EHEC
became notifiable [Bundesamt für Lebensmittelsicherheit und Veterinär-
wesen and Bundesamt für Gesundheit, 2017; European Food Safety Au-
thority and European Centre for Disease Prevention and Control, 2017].
It has to be noted, however, that the notification rate in the EU differed
quite substantially by country with two countries (Ireland and Sweden)
reporting higher rates than Switzerland [European Food Safety Author-
ity and European Centre for Disease Prevention and Control, 2017].
Even though the “EU summary report on zoonoses, zoonotic agents
and food-borne outbreaks 2016” [European Food Safety Authority and
European Centre for Disease Prevention and Control, 2017] mentions
that “diagnosis by direct detection of the toxin or toxin genes by PCR
without strain isolation is increasing”, it also states that diagnosis is
“generally performed by culture from stool samples and indirect dia-
gnosis by detection of antibodies [. . . ]”. Hence, the fact that EHEC
notifications are not (yet) increasing in the EU could be linked to differ-
ences in laboratory techniques.
In the US, testing of all stool samples from patients with acute, com-
munity-acquired diarrhoea for EHEC was recommended already in 2009,
before PCR methods were widely used for EHEC diagnosis and before
multiplex PCR panels were available [Gould et al., 2009]. Nevertheless,
also in the US an increase in EHEC infections was noticed in 2016 com-
pared to 2013–2015 both in culture-confirmed and ‘culture-independent
diagnostic test positive-only’ cases [Marder et al., 2017].
In Switzerland, the number of HUS cases among notified EHEC cases
remained stable in absolute terms despite the strong increase in the num-
ber of EHEC cases, hence, reflecting a relative decrease [Bundesamt für
Lebensmittelsicherheit und Veterinärwesen and Bundesamt für Gesund-
heit, 2017]. This observation additionally supports the hypothesis of
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Figure 7.3: Number of hospitalisations due to enterohaemorrhagic Escherichia coli (ICD-10 code A04.3) and haemolytic-
uraemic syndrome (ICD-10 code D59.3) according to Swiss hospital statistics, 1999–2016.
* Data from 2015 were not available online. Source: Bundesamt für Statistik [n.d.]
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increased testing rather than dealing with an outbreak: with the new
methods, also patients in which there was no direct suspicion of EHEC
are tested. Those patients are unlikely to show severe symptoms or even
serious complications of this disease.
Considering that laboratory results are available faster with PCR than
with culture, one could argue that notification forms are completed at an
earlier time point during the course of disease by physicians. This could
result in a lower proportion of sequelae reported given that HUS usually
occurs 5–13 days after onset of diarrhoea [Karch et al., 2005]. However,
HUS cases (whether or not caused by EHEC) are also not increasing
according to Swiss hospital statistics (Figure 7.3).
Finally, in other countries, several EHEC outbreaks have been detected
by an increase in HUS cases in the first instance [Germinario et al., 2016;
Vygen-Bonnet et al., 2017; Werber et al., 2008]. In summary, there is
no evidence of an EHEC outbreak in Switzerland despite increasing case
numbers.
7.4.3 Importance of good relations among national
surveillance actors
The visits of health authority personnel also aimed at enhancing the
relationship between diagnostic laboratories and the FOPH. Different
statements and observations suggest that this was both necessary and
successful to foster a sense of community. The rather formal reception
of the FOPH and Swiss TPH employees in some laboratories showed
the partly existing reserved attitude towards the FOPH. It was men-
tioned repeatedly that getting into contact with the FOPH by phone or
identifying the person in charge at the FOPH for questions (e.g. con-
cerning notification forms) was always difficult. It is also perceived that
the obligation to report creates a lot of work at the laboratories with
no “return” (i.e. feedback). Similarly, it was stated that “knowing the
faces behind” (from this visit) tremendously facilitates future contacts
and interactions.
On the web page of the German Robert Koch Institute (RKI),
for example, each department and unit is presented, naming the
leader and the substitute and providing contact details (e.g. Surveil-
lance unit: https://www.rki.de/EN/Content/Institute/Departme
ntsUnits/InfDiseaseEpidem/Div32/div32_node.html [accessed: 27
July 2018]). Providing such information also on the web page of the
FOPH could be appreciated by the laboratories and facilitate closer con-
tact given the results of the laboratory visits. Furthermore, the RKI
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publishes an annual report with data analyses of all notifiable observa-
tions1. Developing something similar for Switzerland could address the
perceived lack of feedback on notifications by laboratory staff. The im-
portance of close collaboration and communication among stakeholders
in the framework of disease surveillance has also been stressed, especially
in the context of outbreak investigations [Henao et al., 2015; Knoblauch
et al., 2015; Schjørring et al., 2017]. Therefore, those laboratory visits
initiated by the FOPH were important. The positive effects resulting
from the visits should be maintained and strengthened, e.g. by repeat-
ing those visits regularly, inviting laboratories for a return visit at the
FOPH, or organising regular (e.g. annual) meetings between all stake-
holders involved in the NNSID (laboratory experts, physicians, cantonal
and national public health authorities). Furthermore, laboratory experts
mentioned that actively informing their clients (i.e. physicians) about
new technologies and changes in their laboratory practices is key and
can prevent fears and a negative attitude towards those changes. This
common practice of actively informing clients, partners or collaborators
about changes in a personal manner, e.g. by letters instead of through
official communication channels only (e.g. BAG Bulletin) should be ad-
opted by the FOPH.
7.5 Conclusions
The example of EHEC suggests that changes in diagnostic methods must
not only be considered for long-term trends but can also be a reason for
rather rapid changes in case numbers. Such factors should be considered
before or in parallel to initiating outbreak investigations.
Apart from being an important resource for interpretation of notifica-
tion data, talking to the experts from diagnostic laboratories also proved
important to enhance mutual trust and understanding. It is important
for institutions such as the FOPH to “step out of anonymity”. Good
networks with experts “in the field” could even prevent unnecessary out-
break investigations if they can provide convincing arguments for changes
in case numbers which are not linked to disease incidence.
1Available online at https://www.rki.de/DE/Content/Infekt/Jahrbuch/jahrbuch_
node.html (accessed: 27 July 2018)
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Abstract
Laboratory-confirmed cases of enterohaemorrhagic Escherichia coli
(EHEC) are notifiable to the National Notification System for Infec-
tious Diseases in Switzerland since 1999. Since 2015 a large increase
in case numbers has been observed. Around the same time, syndromic
multiplex PCR started to replace other diagnostic methods in standard
laboratory practice for gastrointestinal pathogen testing in Swiss dia-
gnostic laboratories, suggesting that the increase in notified cases is due
to a change in test practices and numbers.
We analysed laboratory data from 11 laboratories across Switzerland
from 2007 to 2016 to calculate the positivity – i.e. the rate of the num-
ber of positive test results for EHEC divided by the total number of tests
performed.
The age- and sex-standardised positivity of EHEC testing increased from
0.8% in 2007 to 1.7% in 2016. This increasing positivity suggests that
the increase in case notifications cannot uniquely be attributed to an
increase in test numbers alone.
Therefore, we find no evidence to exclude a real epidemiological trend
for the observed raise in EHEC-related disease frequency. The apparent
epidemic seems restricted to Switzerland as notification data of other
European countries do not show comparably strong increasing trends.
Introduction
Enterohaemorrhagic Escherichia coli (EHEC) is a subtype of E. coli
characterized by the potential of causing human illness, belonging to the
group of Shiga toxin-producing Escherichia coli (STEC). EHEC infec-
tion is sometimes asymptomatic and generally self-limiting but it can also
lead to severe gastroenteritis with haemorrhagic diarrhoea, and poten-
tial subsequent life-threatening conditions, such as haemolytic-uraemic
syndrome (HUS) [1, 2].
EHEC transmission can occur through consumption of contaminated
food and drinks or by direct contact with infected individuals or animal
shedders [1, 3-5]. EHEC is endemic in Europe and Switzerland. Cases
appear sporadically or as clusters in outbreaks. A large outbreak oc-
curred in 2011 in Germany and was attributed to contaminated sprouts
[6]. Smaller outbreaks were reported from, e.g. Italy in 2013 due to
contaminated milk and Romania in 2016 due to fresh cheese [7].
It is estimated that STEC leads to 2.8 million of illness cases annually,
including over 3’800 cases of HUS [8]. However, those estimates may be
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conservative.
In Switzerland, the Federal Office of Public Health (FOPH) refers to this
group of notifiable pathogens as “Escherichia coli, enterohämorrhagische
(EHEC, VTEC or STEC)” [9]. The Swiss National Notification System
for Infectious Diseases (NNSID), managed by the FOPH, gathers all no-
tifications on laboratory-confirmed EHEC infections since 1999. Case
numbers were stable until 2010, with only a few laboratories reporting
EHEC in Switzerland. A slight rise in cases was observed in 2011 after
intensified testing following the outbreak in Germany and numbers of
EHEC notifications strongly increase since 2015 [10]. It is hypothesised
that this recent increase in case notifications is due to the introduction
of multiplex polymerase chain reaction (PCR) panels for the analysis of
stool samples. Gastrointestinal multiplex PCR panels are able to detect
multiple gastrointestinal pathogens in one single test [10, 11]. Tradition-
ally, routine testing of stool samples for bacterial pathogens involved
only Campylobacter spp., Salmonella spp. and Shigella spp. using cul-
ture-based techniques. With multiplex PCR panels, stool samples can
be tested for up to 22 pathogens including EHEC in one single run.
Previously, EHEC was rarely tested and only on demand by the physician
alerted by clinical signs. The increase in testing rate for EHEC, likely
occurring when PCR panels are introduced, could lead to identification
and notification of cases that were simply not discovered beforehand
[10].
This study aims to assess the development of the EHEC positivity in
the Swiss population between 2007 and 2016 and to give more insight
into the epidemiology and notification numbers of EHEC infections in
Switzerland in recent years.
Methods
Individual-based testing data were requested from 11 Swiss diagnostic
laboratories. Laboratories were selected based on providing most EHEC
notifications in 2015, to include all regions of Switzerland and to include
both, hospital and private diagnostic laboratories.
Data collected comprised all tests performed for EHEC between January
2007 and December 2016, including positive and negative test outcomes.
Information requested included date of test, test result, test method, pa-
tient identification number, and patients’ date of birth, sex and canton
of residence.
Test records indicating patients’ residence outside Switzerland and those
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without a (conclusive) test result were omitted. Duplicate entries,
defined as identical values for all variables, and “repeated tests” were
excluded from the analyses. Repeated tests were defined as more than
one test performed for the same patient during a single disease episode.
The analysis was planned a priori and was performed using STATA 14
(StataCorp., USA).
We use the term positivity as the rate of number of positive tests in
relation to the total number of tests performed for EHEC [12, 13]. The
positivity was calculated for different demographic groups, test meth-
ods, spatial (based on the patients’ canton of residence) and temporal
(annual and seasonal) trends. The main outcome, the annual positivity,
was age- and sex-adjusted using direct standardisation with the sample
population (2007–2016) as reference population.
Univariable logistic regression was used to test the association between
test result and test year, season, time trend, sex, age group, laboratory,
test method and greater region. Season was modelled using a sine and
cosine function with an annual period. The time trend was a continuous
variable combining test month and test year. The greater regions cor-
respond to the Nomenclature of Units for Territorial Statistics (NUTS)-
2-level. Categories with most observations were chosen as reference cat-
egories, except for the seasonality (first month of the year).
A multivariable mixed effect logistic regression model was defined a pri-
ori, independent of the outcome of the univariable regressions. The
model’s explanatory variables included sex, age group, seasonality, time
trend, greater region and diagnostic test method. The model included
an interaction term for sex and age group. The variable “laboratory”
was included as a random effect to account for clustering. The clustering
effect of the same patient (same identification number) was omitted.
Finally, the multivariable model was compared to a reduced model
without adjustment for test method in order to validate the results and
ensure the consistency of the time trend, independently from the dia-
gnostic method.
Based on multivariable regression results, predicted probabilities for a
positive test result were computed and plotted for direct visualisation
and comparison of categories and models.
Ethical statement
This study was funded by the Swiss FOPH. The authors declare that
they have no conflict of interest. The study was conducted under the
Epidemics Act (SR 818.101). The data, provided by laboratories, were
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anonymised for the analysis. Other data (e.g. notification data, popula-
tion statistics) is publicly available from the FOPH or the Swiss Federal
Statistical Office.
Results
Data received
The participating 11 laboratories provided in total 91’685 records of
EHEC tests (thereof 1’366 positives). Only five laboratories provided
data for the entire study period (2007–2016, N=61’916). Three of the
remainder six laboratories did not perform EHEC tests for the entire
study period, two laboratories could not extract all data requested due
to changes in the information technology and data storage system; one
laboratory did not specify a reason for missing years of data.
Following our exclusion criteria, 1’407 records (22 positives) were ex-
cluded. After initial cleaning of the dataset, further 71 observations (3
positives) with either missing sex or age were excluded. Finally, 1’110
duplicated entries (31 positives) and 3’054 repeated tests (96 positives)
were excluded. In total, 6.2% (N=5’642) of the original dataset were
excluded. The final dataset comprised 86’043 observations (1’149 posit-
ives).
Figure 8.1 shows the number of EHEC cases in the NNSID, and in our
dataset as obtained by the laboratories. Data from the NNSID show
that the laboratories selected for this study reported 61.9% of all cases
registered in the NNSID between 2007 and 2016 (range 39.4% in 2011
to 73.2% in 2009).
Characteristics of the patient population
The proportion of males to females tested remained constant between
2007 and 2016 with 44.3% males and 55.7% females across all study
years. The median age of the tested population increased from 30 years
to 44 years old (Kruskal-Wallis test: p<0.01). Median age of patients
differed significantly between laboratories (median by laboratory ranging
from 27–55, overall median: 40 years old) and greater regions (median
by greater region ranging from 37–44) (Kruskal-Wallis test: p<0.01).
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Figure 8.1: Number of enterohaemorrhagic Escherichia coli (EHEC) notifications of 11 Swiss diagnostic laboratories as
reported in the National Notification System for Infectious Diseases (NNSID), the number of positive tests of the laboratories
in their own datasets, and the total number of EHEC notifications reported in the NNSID per year, 2007–2016, Switzerland
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(a) Data of 11 Swiss diagnostic laboratories
Figure 8.2: Total number of enterohaemorrhagic Escherichia coli tests performed by test method and number of positive
tests for the entire study period (2007–2016)
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(b) By laboratory
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Laboratories, diagnostic methods and greater regions
The variables “laboratory”, “greater region” and “diagnostic test used”
strongly correlated (Fisher’s exact test: p<0.01 for all three tests).
The diagnostic methods performed included multiplex PCR (66.5%,
N=57’168), antigen test (26.3%, N=22’588), PCR (7.3%, N= 6’247)
and culture-based diagnostics (<0.1%, N=24). Multiplex PCR panels
able to detect different pathogens were distinguished from PCR panels
targeting EHEC/E. coli only (thereafter referred to as “single PCR”).
Multiplex PCR panels used were mainly BD MAXTM (Extended) En-
teric Bacterial Panel (52%), Luminex xTAG R© Gastrointestinal Patho-
gen Panel (36%), BioFire FilmArrayTM Gastrointestinal Panel (5.9%),
and Seegene (not specified whether AllplexTM Gastrointestinal Panel or
Seeplex R© Diarrhea ACE Detection, 4.6%).
The number of tests performed using the antigen test, single PCR or
culture remained stable between 2007 and 2016, while the number of
multiplex PCR panels performed increased by 42% (Figure 8.2a). The
five laboratories providing data for the entire study period were using
single PCR or antigen tests before the introduction of multiplex PCR
(Figure 8.2b). Only one of these five laboratories kept using primarily
antigen tests for the entire study period.
From the six laboratories that could not provide data for the entire study
period, three started to perform EHEC testing only between 2014 and
2015, once multiplex PCR panels were available.
Positivity
The number of tests for EHEC increased sevenfold from 2007 to 2016
(3’711 to 26’639) while the number of positive test results increased 13-
fold in the same time period (33 to 440). The age- and sex-standardised
positivity of EHEC testing increased from 0.8% in 2007 to 1.7% in 2016
(Figure 8.3).
Positivity increased for all age categories. The positivity calculated over
the entire study period is highest for children 1–4 years old (2.2%) and
increased from 1.4% in 2007 to 2.9% in 2016. The largest relative in-
crease was seen in the elderly aged “80+”, from zero (no positive case in
2007) to 1.8%.
The overall positivity is similar for men (1.4%) and women (1.3%) and
increased from 0.7% and 1.1% to 1.7% and 1.6%, respectively.
The positivity and trend in positivity differed across laboratories (Figure
8.4). The overall positivity ranged from 0.6% to 5.8%. Three laborator-
ies showed a large fluctuation in the annual positivity, due to the small
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Figure 8.3: Age- and sex-standardised positivity of enterohaemorrhagic E. coli testing, Switzerland, 2007–2016
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number of tests performed. The largest relative increase in positivity
was 2.8-fold from 2% to 5.7%. After 2014 the positivity of most labor-
atories stabilised, though at different levels.
The positivity further differed by test method. The positivity of culture-
based tests was not calculated due to (i) the small number of observa-
tions and (ii) the exclusion process for “repeated tests”. Most culture-
based tests performed were confirmation tests; therefore, they were of-
ten classified as “repeated tests” and excluded. The positivity across all
test years was highest for tests using single PCR (2.4%) and lowest for
the antigen test (0.6%), positivity of multiplex PCR panels was at 1.5%.
The positivity of multiplex PCR increased from 1.1% in 2014 to 1.7%
in 2016. In contrast, the positivity for single PCR and antigen tests
started to decrease in 2013 and 2014 respectively, just after peaking at
4.3% (PCR; 2013) and 1.4% (antigen test; 2014).
Determinants of a positive diagnostic test result
The univariable regressions showed a marginal but significant trend for
the time trend variable (Odds ratio [OR] 1.003, p<0.01) as shown in
Table 8.1. Almost all test years, except 2013 showed decreased odds for
a positive test outcome compared to the reference year 2016. All calendar
months except July have smaller odds for a positive test outcome than
the reference month of August.
The age groups “1–4” and “5–9” years old were almost twice as likely to
have a positive test outcome (OR 1.88, p<0.01 and OR 1.80, p<0.01)
than the reference category of “20–39” years old. No difference was seen
between sexes.
Compared to multiplex PCR panels, the use of the antigen test had a
63% lower probability to generate a positive test outcome, while the use
of single PCR showed 56% higher chance for a positive test outcome.
The odds of culture-based tests could not be evaluated due to the small
sample size.
The ORs and significance levels from the fully-adjusted multivariable
model varied only marginally from the univariable models and do not
alter the interpretation, therefore, they will not be detailed, but are
presented in Table 8.1.
Predicted probabilities based on the multivariable model showed an in-
creasing time trend for all test methods and regions.
Comparison of the fully adjusted model to a model excluding the adjust-
ment for test method showed increasing predicted probabilities for both
models, but with a lower slope for the fully adjusted model (Figure 8.5).
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(a) Data of nine Swiss diagnostic laboratories, scale y-axis: 0–10%
(b) Data of two laboratories, using a different scale for the y-axis: 0–50%
Figure 8.4: Enterohaemorrhagic E. coli positivity by Swiss laboratory for
the entire study period (2007–2016)
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Table 8.1: Odds ratios for a positive test result for enterohaemorrhagic Escherichia coli of the uni- and multivariable
logistic regression models, 2007–2016, Switzerland
N OR 95% CI aORa 95% CI
Age group (year)
Under 1 2’915 0.97 (0.67–1.40) 1.28 (0.72–2.28)
1–4 8’855 1.88 *** (1.56–2.27) 3.38 *** (2.56–4.45)
5–9 2’593 1.80 *** (1.34–2.43) 1.66 * (1.07–2.58)
10–19 5’898 1.03 (0.79–1.35) 1.03 (0.71–1.49)
20–39 21’971 1 1
40–59 19’404 1.00 (0.84–1.20) 1.03 (0.81–1.31)
60–79 17’685 1.10 (0.92–1.32) 1.05 (0.82–1.34)
Over 79 6’722 1.14 (0.89–1.45) 1.11 (0.81–1.52)
Sex
Male 38’209 1.03 (0.91–1.16) 0.93 (0.72–1.20)
Female 47’834 1 1
Male, age group (year)
Under 1 1’582 1.14 (0.52–2.47)
1–4 4’962 0.92 (0.62–1.36)
5–9 1’325 1.23 (0.67–2.27)
10–19 2’827 1.14 (0.66–1.95)
20–39 9’080 1
40–59 8’833 1.02 (0.70–1.47)
60–79 7’408 1.27 (0.88–1.84)
Over 79 2’192 1.17 (0.69–1.95)
Greater region
Lake Geneva region 15’526 0.79 ** (0.66–0.93) 1.20 (0.89–1.60)
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Table 8.1: (continued)
N OR 95% CI aORa 95% CI
‘Espace Mittelland’ 20’000 1 1
Northwestern Switzerland 15’273 0.39 *** (0.32–0.49) 0.69 ** (0.53–0.89)
Zurich 14’439 0.79 ** (0.66–0.94) 0.75 * (0.58–0.98)
Eastern Switzerland 6’474 0.70 ** (0.55–0.90) 0.88 (0.67–1.16)
Central Switzerland 10’015 0.90 (0.74–1.09) 0.92 (0.70–1.21)
Ticino 1’008 0.74 (0.43–1.30) 1.30 (0.73–2.32)
Test method
Multiplex PCR 57’168 1 1
Antigentest 22’588 0.37 *** (0.31–0.45) 0.34 *** (0.26–0.44)
PCR 6’247 1.56 *** (1.31–1.86) 2.31 *** (1.55–3.45)
Culture 24 - -
Time trend 86’043 1.00 *** (1.00–1.01) 1.00 * (1.00–1.01)
Test month
January 6’040 0.50 *** (0.37–0.68)
February 5’529 0.59 ** (0.44–0.80)
March 6’137 0.58 *** (0.43–0.77)
April 5’872 0.76 * (0.58–0.99)
May 6’357 0.69 ** (0.53–0.90)
June 7’084 0.77 * (0.60–0.99)
July 7’321 1.08 (0.86–1.35)
August 9’154 1
September 8’919 0.68 ** (0.54–0.87)
October 8’098 0.78 * (0.61–0.99)
November 8’000 0.71 ** (0.55–0.91)
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Table 8.1: (continued)
N OR 95% CI aORa 95% CI
December 7’532 0.62 *** (0.47–0.81)
Seasonality
sin(d ∗ 2 ∗ pi/T ) 0.84 *** (0.77–0.91) 0.89 *** (0.82–0.98)
cos(d ∗ 2 ∗ pi/T ) 0.83 *** (0.76–0.90) 0.81 * (0.75–0.89)
Test year
2007 3’711 0.53 ** (0.37–0.76)
2008 3’978 0.47 *** (0.32–0.67)
2009 3’421 0.54 (0.38–0.79)
2010 2’536 0.35 *** (0.21–0.59)
2011 3’393 0.67 * (0.48–0.94)
2012 4’483 0.63 ** (0.47–0.85)
2013 6’152 0.82 (0.65–1.04)
2014 10’246 0.74 ** (0.61–0.90)
2015 21’484 0.85 * (0.74–0.99)
2016 26’639 1
Laboratory
A 8’712 2.98 *** (2.44–3.64)
B 8’861 3.15 *** (2.59–3.83)
C 5’102 2.09 *** (1.60–2.75)
D 7’181 2.13 *** (1.68–2.70)
E 2’197 2.84 *** (2.02–4.00)
F 2’904 4.80 *** (3.75–6.16)
G 9’852 2.86 *** (2.36–3.48)
H 38’796 1
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Table 8.1: (continued)
N OR 95% CI aORa 95% CI
I 121 9.66 *** (4.46–20.95)
J 1’438 6.14 *** (4.55–8.28)
K 879 8.09 *** (5.81–11.27)
N, number of observations; OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio
a Adjusted for sex, age group, method, temporal trend, seasonality (refer to supplementary material for details). Inter-
action between age and sex. Random effect of laboratory
* p<0.05; ** p<0.01; *** p<0.001
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Figure 8.5: Predicted probability for a positive test outcome of an enterohaemorrhagic E. coli infection for the full
multivariable model and a model without adjustment for methods across 10 years (in months) of the study period, 2007–
2016, Switzerland
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Discussion
We investigated the apparent epidemic increase of EHEC infections as
seen in the rise of case notifications in the NNSID. We calculated the
positivity as the rate of all positive diagnostic EHEC tests to the total
number of EHEC tests performed. The number of positive tests in our
sample of 11 laboratories comprised 61.3% of all notified cases between
2007 and 2016. The positivity gradually increased since 2007.
The impact of diagnostic tests on EHEC surveillance
The increase in positivity coincides with the introduction of multiplex
PCR panels as a new diagnostic method for EHEC detection in Switzer-
land. The impact of changes in diagnostic approaches on public health
surveillance has been highlighted before, especially in relation to the
switch from culture-dependent to culture-independent diagnostics for
foodborne diseases [14, 15]. Such diagnostic changes are especially im-
portant for EHEC, as the case definitions for EHEC in the European
Union (EU) and in Switzerland are not limited to culture-confirmed
cases, but include the detection of the Stx1 or Stx2 antigen or their
respective genes [16]. Increases in EHEC notifications in Ireland are
explained by the shift from culture-dependent to culture-independent
diagnostic methods; the latter showing higher sensitivity and ability to
detect non-O157 EHEC [17, 18].
The 11 Swiss diagnostic laboratories in the study switched to culture-
independent methods for EHEC detection before 2007. Our data showed
that the laboratories were using multiplex PCR panels (BD MAX,
BioFire, Luminex) since 2007, but their introduction to routine dia-
gnostics and subsequent replacement of other standard diagnostic meth-
ods only happened between 2011 and 2015. These panels comprise the
largest proportion of all diagnostic tests performed for EHEC in Switzer-
land ever since.
Implications of using multiplex PCR panels for EHEC
diagnosis
The introduction of multiplex PCR panels for gastrointestinal pathogens
is the next paradigm shift in diagnostics for foodborne diseases after the
switch to culture-independent tests.
Our data shows that EHEC test numbers increased considerably since
the introduction of multiplex PCR panels. The increase in test volume
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reflects a larger proportion of the population being screened for EHEC
resulting in more positives notified to the NNSID [10]. The availability
and use of gastrointestinal multiplex PCR panels has a large impact on
testing behaviour. Previously, a test for EHEC was likely ordered by the
treating physician if the patient was a paediatric case and/or reported
a bloody stool and/or history of travel, due to higher probabilities to
develop severe complications such as HUS [19-21]. The increased and
wider-spread use of multiplex PCR panels leads to a larger screening
of the population in two ways: (i) the suspicion of other gastrointest-
inal pathogens, such as Campylobacter spp., now also leads to an EHEC
test, if the laboratory uses such multiplex PCR panels for the standard
detection of Campylobacter ; (ii) the physician orders a gastrointestinal
panel directly when the patient presents with diarrhoea (i.e. syndromic
testing). We assumed that the introduction of multiplex PCR for stool
testing, and hence, co-testing for EHEC lacking this pre-selection, would
result in a decreased positivity due to a lower pre-test probability for a
positive test outcome. Surprisingly, this decrease is not reflected in our
data. Instead, the increase in EHEC cases is disproportionally higher
compared to the increase in test volume, resulting in the observed in-
crease of positivity.
Part of the increased testing could also be due to a change in physicians’
testing behaviour following the raising public awareness for EHEC in-
fections. However, laboratory experts reported that tests for EHEC are
rarely ordered by the treating physician which suggests little change
in physicians’ testing behaviour [22]. It seems, therefore, that positive
test results for EHEC tend to be largely accidental and their clinical
relevance for the individual patient is questionable. Hence, the inter-
pretation of these findings remains complex for the physicians and has
implications on public health surveillance. Questions concerning the ap-
propriate treatment (no antibiotics, no antidiarrhoeal medicines for ac-
tual EHEC infections [23]) and respective reporting to the patient and
the NNSID still need to be addressed.
Using multiplex PCR increases the number of cases found due to the
higher sensitivity of (multiplex) PCR compared to other conventional
diagnostic methods, and the increased probability to detect co-infections
[24-27]. A study among staff members of meat-processing companies in
Switzerland found that 3.5% were asymptomatic carriers of verotoxin-
producing Escherichia coli (VTEC) [28]. Using multiplex PCR, such
carriers could now be detected as having co-infections, whilst another
gastrointestinal pathogen is causing the symptoms. While it is clear
that changes in the diagnostic landscape can influence surveillance data
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and trend monitoring, we believe this explains only part of the increase
in EHEC case notifications in Switzerland.
Indications for a real increase in EHEC incidence independent of the
diagnostic test method are threefold: First, our logistic regressions and
predicted probabilities for a positive EHEC test outcome showed an
increasing trend between 2007 and 2016 even after adjusting for the dia-
gnostic method applied. Second, the predicted probabilities for a positive
EHEC test show an upward trend for all methods (multiplex PCR, single
PCR, culture-based and antigen test) during the study period. Third,
two of the laboratories, which introduced multiplex PCR panels late or
not at all, also showed an increase in positivity.
Therefore, we cannot rule out a real epidemiological increase in incidence
of EHEC infections among the Swiss population.
Rising incidence of EHEC cases
To interpret a potential EHEC epidemic merits to also consider the epi-
demiological situation of HUS in Switzerland, as EHEC infections are
the main cause to develop HUS. In Switzerland, reported HUS cases re-
mained stable over the past years [10]. Thus, the increase in EHEC case
notifications observed in the NNSID might represent mainly mild cases
and/or to some extent “asymptomatic” co-infections with another infec-
tious agent of higher pathogenicity causing the symptoms. We have no
data on co-infections available to assess their relative contribution to the
increase in EHEC case notifications. Though, STEC patients associated
with a recent outbreak in Finland were classified as rather mild cases
[29]. Furthermore, the authors reported that testing for STEC increased
in Finland as well due to PCR screening of gastroenteritis patients.
The change in disease severity could further be explained with changes
in the distribution of serogroups found among cases: the proportion of
non-O157 EHEC associated with human disease increased in Switzer-
land, other European countries and the USA [30-32]. O157 EHEC cases
are mostly associated with the development of severe disease (HUS) al-
though the importance of non-O157 infections as a cause for HUS is be-
ing increasingly recognised [33-35]. Age and sex distributions of EHEC
patients in Switzerland remained stable during the observation period
2007–2016. We, therefore, argue that risk groups for EHEC infections
remained unchanged and are not the cause for an increase in incidence.
In an international context, the USA also reported an increased incid-
ence of STEC cases in 2017 compared to 2014–2016, though not to the
extent as Switzerland [31]. The USA also noted a stable incidence of
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HUS in children in 2016 compared to 2013–2015, likely related to a de-
crease of O157 cases.
No other European country reported an increase in EHEC notification
numbers to the extent observed in Switzerland (8-fold increase in cases
between 2012 and 2016), except Romania, which had the highest relat-
ive increase between 2012 and 2016 (1 to 29 cases), associated with an
outbreak in 2016 [32]. However, European countries’ notification rates
are as high as in Switzerland. In Finland, the increase in reported cases
between 2012 and 2016 was 4-fold [32].
Limitations
We selected our sample of laboratories, among other criteria, based on
their contribution to the latest notifications. This choice favoured labor-
atories which had switched to multiplex PCR and, therefore, may not
represent the whole laboratory landscape in Switzerland.
We noted that in recent years NNSID case numbers and the number of
positive test results recorded in the laboratories’ individual datasets did
not match. Positive cases were either underreported to the NNSID, or
the NNSID excluded certain reports from their official statistics, or the
number of positive test results in our sample was overestimated, e.g. due
to an insufficient exclusion of repeated tests.
The correlation of “laboratory”, “region” and “diagnostic method”
hampered the evaluation of spatial trends. Inferences on specific greater
regions in Switzerland largely depended on the laboratories chosen in our
sample, e.g. the number of tests in each region per 100’000 population
either relate to true differences in testing frequencies between regions or
to under- or over-representation in our sample.
Conclusion
Since 2015 the notification numbers for enterohaemorrhagic Escherichia
coli (EHEC) markedly increased in Switzerland. However, meaningful
interpretation of such surveillance data is only possible if every aspect
of the disease trajectory from changes in awareness (among physicians
and patients) and testing behaviour to the choice of diagnostic method
are taken into consideration.
Due to previously infrequent, but targeted testing for EHEC and the lack
of culture-based test confirmation, EHEC surveillance has been heavily
impacted by recent changes in diagnostic methods. The switch from tar-
geted EHEC testing to co-testing of virtually all stool samples submitted
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for “basic stool bacteriology” using multiplex PCR panels has notably
increased the test volume for EHEC. This development led to a larger
number of EHEC detection partly explaining the observed increase in
notification numbers. However, the rise in EHEC cases is disproportion-
ally high compared to the increase in test volume, resulting in a clearly
increasing positivity for EHEC tests since 2007.
Hence, our study findings suggest that there is a real increase and epi-
demiological trend in EHEC infection incidence in Switzerland. The
recently observed changes in the frequency of different serogroups and
the stability of HUS cases suggests that the trend observed for EHEC is
mostly attributable to rather mild cases.
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9.1 Summary
9.1 Summary
Infectious disease surveillance systems are often based on reporting of
laboratory-confirmed cases. Apart from changes in actual disease incid-
ence, there are various factors which can influence the number of cases
reported such as changes in diagnostic methods. Reporting the number
of tests conducted and calculating the proportion of positive results is
seen as a solution to overcome parts of these limitations associated with
surveillance data.
Since 2016, laboratories in Switzerland are obliged to report annually
the number of tests performed per month for selected notifiable diseases
to the Federal Office of Public Health (FOPH). Results from prelimin-
ary analyses of these surveillance data are presented in this article with
special emphasis on data usefulness and validity. Furthermore, the con-
clusiveness of positivity studies in general is discussed.
It is difficult to assess data validity of reports on testing frequency for
several reasons: (i) multiple testing of the same patient during one dis-
ease episode is likely to occur but cannot be quantified, (ii) positivity
rates heavily depend on individual laboratories’ practices which are not
known by the FOPH, and (iii) the “laboratory landscape” in Switzerland
is highly complex and dynamic, making it difficult to compare reports
from case-based reporting and from aggregated reporting of test and case
numbers.
Calculation of positivity rates can complement surveillance data and
help interpreting trends. However, it does still not allow to conclude
on population incidence. The current way of collecting information on
the frequency of testing in Switzerland requires individual data handling
and follow-up with the diagnostic laboratories. Therefore, better ways
of collecting valid information on testing frequency should be identified.
9.2 Introduction
Surveillance systems for infectious diseases mostly rely on reports from
health professionals. In Switzerland, the Epidemics Act and its related
ordinances define which observations are to be reported by physicians
and by personnel of diagnostic laboratories [Das Eidgenössische De-
partement des Innern, 2015a; Der Schweizerische Bundesrat, 2015b; Die
Bundesversammlung der Schweizerischen Eidgenossenschaft, 2012b]. It
additionally defines the process and time limits for reporting and the in-
formation to be reported. Many observations are notifiable upon labor-
atory confirmation. Hence, the frequency of testing can heavily influence
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the case numbers seen in the surveillance system, as noted by others as
well [Gibney et al., 2017; Janiec et al., 2012; Kløvstad and Aavitsland,
2015; Lambert et al., 2010; Van Cauteren et al., 2015b]. Negative test
results usually do not need to be reported. Making negative test results
notifiable and calculating test positivity rates (the proportion of positive
test results out of all tests performed) have been suggested to overcome
this limitation [Janiec et al., 2012; Kløvstad and Aavitsland, 2015; Lam-
bert et al., 2010]. However, this will still not allow concluding on popula-
tion incidence as several factors have an influence on the number of tests
conducted. The physicians’ awareness for a disease, for example, can im-
pact on testing frequency. Screening-like testing practices of physicians
can strongly increase test frequency, especially if disease episodes can be
mild or even asymptomatic (e.g. Chlamydia trachomatis; [Kløvstad and
Aavitsland, 2015; Schmutz et al., 2013]). On the side of the laborat-
ory, changing practices of co-testing of different pathogens (e.g. routine
parallel testing of enterohaemorrhagic Escherichia coli (EHEC) when
Campylobacter spp., Salmonella spp. and Shigella spp. are requested)
can result in changes in test numbers (chapters 7 and 8).
We previously conducted different studies looking at trends in positiv-
ity rates for selected notifiable diseases in Switzerland to better under-
stand reporting trends observed in the National Notification System for
Infectious Diseases (NNSID) (Bless et al. [2017]; Schmutz et al. [2013];
chapter 8). We found increasing positivity rates for EHEC between 2007
and 2016 (chapter 8), increasing positivity rates for Campylobacter spp.
and decreasing positivity rates for Salmonella spp. between 2003 and
2012 [Bless et al., 2017] and stable positivity rates for Chlamydia tracho-
matis in one canton of Switzerland (Basel-Stadt) between 2002 and 2010
[Schmutz et al., 2013]. Currently, we are investigating positivity rates for
Legionella spp. All aforementioned notifiable diseases showed increasing
trends in the NNSID for the time period positivity was looked at, except
for Salmonella.
With the implementation of the revised Epidemics Act in Switzerland
in January 2016, information on the number of tests performed has to
be reported annually for a number of notifiable diseases, additional to
the individual case reports by diagnostic laboratories. These laborat-
ory statistics have to be supplied for Campylobacter , carbapenemase-
producing Enterobacteriaceae, Chlamydia trachomatis, Francisella tular-
ensis, hepatitis C virus (HCV) (since January 2018), hepatitis E virus
(HEV) (since January 2018), human immunodeficiency virus (HIV), Le-
gionella spp., Neisseria gonorrhoeae, Salmonella spp. and Zika virus
(since March 2016) [Das Eidgenössische Departement des Innern, 2015a].
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Before 2016, the number of tests performed had only to be reported for
HIV, influenza and Legionella.
The purpose of this article is twofold: first, a preliminary analysis of the
data from the first two years of reporting of laboratory statistics (since
the implementation of the new Epidemics Act) is conducted with special
emphasis on the data’s usefulness and validity. Second, the relevance and
significance of positivity studies to interpret surveillance data in general
is discussed. Hence, this chapter is a reflection on whether positivity
rates and related denominator data are indeed the solution to overcome
limitations with surveillance data for interpretation of trends.
9.3 Methods
Data on the “statistic of reports on laboratory findings” were sent by
diagnostic laboratories in Switzerland to the Federal Office of Public
Health (FOPH) according to Swiss law. Data were entered into an elec-
tronic database at the FOPH. Data from laboratory statistics on all
notifiable diseases were extracted for the years 2016 and 2017. For most
pathogens (all except Francisella tularensis and HIV), the number of
tests, and thereof the number of positive results, stratified by diagnostic
method and calendar month had to be reported. The official reporting
form is available at www.bag.admin.ch/infreporting and in appendix
D of this thesis.
Data analysis was exploratory, focussing on data quality and validity.
Case-based notification data for 2016 and 2017 were extracted for cer-
tain diseases to compare case numbers from individual reports with the
reported number of positive results from laboratory statistics.
For the present article, data on Campylobacter was analysed exemplary
for others. Data from laboratory statistics (“statistic of reports on labor-
atory findings”) were extracted as of 3rd August 2018; case-based noti-
fications as of 21st June 2018.
9.4 Results and discussion
For the year 2016, 52 laboratories reported a total number of tests per-
formed for Campylobacter spp. of 110’971; thereof, 9’119 with a positive
result. For the year 2017, 54 laboratories reported test numbers stating
that 105’348 tests for Campylobacter spp. were performed with a total
of 8’868 positive results. These numbers correspond to an overall crude
positivity rate of 8.2% and 8.4% in 2016 and 2017, respectively. Re-
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Table 9.1: Number of positive tests for Campylobacter spp. according to individual “reports on laboratory findings”
and according to “statistic of reports on laboratory findings” and total number of tests performed for Campylobacter spp.
according to “statistic of reports on laboratory findings” as reported to the Federal Office of Public Health, 2016–2017,
Switzerland
Year Method Number of positive tests Number of tests Positivity rate
from case
notifica-
tions
from laborat-
ory statistics
from laboratory
statistics
(in %)
2016 Detection of antigen 0 3 112 2.68
2016 Detection of antigen (IgG) 0 6 261 2.30
2016 Detection of antigen (IgM) 0 4 261 1.53
2016 Detection of nucleic acid 719 2’299 26’459 8.69
2016 Culture/isolation 8’902 6’807 83’878 8.12
2016 Unknown/not specified 18 0 0
2016 Total 9’639 9’119 110’971 8.22
2017 Detection of antigen (IgG) 0 4 273 1.47
2017 Detection of antigen (IgM) 0 2 253 0.79
2017 Detection of nucleic acid 902 2’957 37’560 7.87
2017 Culture/isolation 8’211 5’905 67’262 8.78
2017 Microscopy 5 0 0
2017 Unknown/not specified 47 0 0
2017 Total 9’165 8’868 105’348 8.42
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9.4 Results and discussion
ported test numbers stratified by test method are summarised in table
9.1.
9.4.1 Multiple tests and reports per disease episode
As far as possible, the FOPH merges multiple reports (on clinical or
laboratory findings) received for the same individual on one disease epis-
ode into one record for analysis and reporting of surveillance data. Fur-
thermore, reports from individuals living abroad and from cases not ful-
filling the case definition are excluded. This procedure of data cleaning
was omitted in the present analysis given that laboratories are unlikely to
follow the same procedure when reporting the summary statistics for the
number of tests and the number of positive tests performed during one
year. Hence, case numbers from individual case notifications as reported
here must not be compared with case numbers reported in previously
published analyses of surveillance data.
There are several reasons why multiple notifications are sent to the
FOPH for one disease episode: (i) Multiple samples were sent to and
have been tested by the laboratory. This can include multiple samples of
the same type (e.g. 2–3 stool samples to increase sensitivity, recommen-
ded especially for parasites; or to control disease evolution [e.g. antibody
response] or treatment outcome), and multiple samples of different spe-
cimen types (e.g. urine and sputum to test for Legionella); (ii) Multiple
tests were conducted on one sample by the laboratory (either reques-
ted by the physician or based on the laboratories’ routine procedures),
for example to confirm a positive result (e.g. stool culture after positive
result from polymerase chain reaction (PCR)) or to obtain additional in-
formation (e.g. antibiotic resistance profile; serotyping); (iii) Additional
information (related to the test and/or the patient) became available
to the laboratory which was forwarded to the FOPH. The two first-
mentioned reasons for multiple notifications could also be reflected in
laboratory statistics. However, how multiple tests for the same disease
episode are reported by the diagnostic laboratories, hence, how they are
reflected in test and case numbers, is unknown to the FOPH (except if
spontaneously noted under “remarks” on the notification form) and is
likely heterogeneous. Therefore, comparison of case numbers from indi-
vidual notifications (report on clinical findings and/or laboratory find-
ings) and reports on laboratory statistics (report on “statistic of reports
on laboratory findings”) is hampered and must be interpreted with cau-
tion.
Similarly, laboratory practices of confirmatory testing (e.g. confirming
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every Campylobacter-positive result from multiplex PCR testing using
culture-based methods) can have a large impact on test numbers and
on the number of positive findings depending on how this is reported
by laboratories – both, in individual case notifications and in reports
on laboratory statistics. For example, some laboratories may report the
individual case only after culture-confirmation while others are report-
ing PCR-positive findings already (potentially sending a second report
after culture-confirmation). Remarks provided on laboratory statist-
ics reporting forms indicate that some laboratories counted tests from
culture-confirmation after PCR-testing twice (in test numbers for both
diagnostic methods) while others counted them only once (often unclear
in which category).
These laboratory practices of confirmatory testing (also referred to as
“reflex testing”), together with the different handling of such multiple
tests for one disease episode by the FOPH and the laboratories may
explain that substantially more positive tests using culture-based meth-
ods were reported according to individual case notifications compared
to laboratory statistics while the contrary is the case for detection of
nucleic acid (i.e. PCR) (Table 9.1).
9.4.2 Data validity and positivity rates
One option to evaluate validity of the data reported on “statistic of re-
ports on laboratory findings” reporting forms is to compare the number
of positive tests with the number of positive tests reported according to
case-based notifications. This option and its associated challenges were
already discussed above. Another way to look at data validity is to cal-
culate positivity rates, defined as the proportion of positive tests out of
all tests performed. While positivity rates are likely to differ between
diagnostic methods applied, they are expected to be similar across labor-
atories. Furthermore, variability of positivity rates should decline with
increasing test numbers for statistical reasons. Hence, when plotting
positivity rates by test numbers, observations should show the pattern
of a funnel. Figure 9.1 shows the positivity rates for Campylobacter by
laboratory, test method and year. Observations from PCR-diagnostics
(“detection of nucleic acid”) and culture-based methods follow the ex-
pected funnel pattern. Interestingly, however, some observations from
culture-based methods form a second “cloud”, characterised by low test
numbers and high positivity rates. It seems likely that these obser-
vations represent laboratories applying culture-based methods only for
confirmation of PCR-positive results given the diagnostic procedures re-
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Figure 9.1: Positivity rate and total number of tests per year by test method for Campylobacter spp., according to reports
on laboratory statistics, 2016–2017, Switzerland
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ported by laboratory experts (chapter 7) and what was discussed above
on confirmatory “reflex” testing. This would explain the low test num-
bers combined with high positivity rates.
It is possible that a laboratory conducts only one culture-based test in a
given month. In this case, the positivity rate will either be 0 or 100%. If
a laboratory reports that 7 out of 7 culture-based tests were positive in a
given month, this seems already less likely (but still possible). However,
it could be suspected that the number of negative tests instead of the
number of positive tests is reported together with the total number of
tests. Hence, very high positivity rates could also point at erroneous
data. On the other hand, both, very high and very low positivity rates
are reasonable given common testing procedures (high: confirmatory
testing; low: screening) and hence, plausibility (internal validity) of val-
ues reported on laboratory statistics forms can hardly be assessed. One
laboratory (“lab B”) reported having performed 30 culture-based tests in
May 2017, thereof 29 with a positive result (Table 9.2). These numbers
seem unlikely if regarded separately. However, 25 “reports on labor-
atory findings” from a culture-based test were received from the same
laboratory in this month. Hence, the 29 positive test results reported as
summary statistic are plausible again and suggest that this laboratory
applies culture-based methods for confirmation of positive test results
obtained through another diagnostic method (likely PCR). Yet, lab B
reported only one test for detection of nucleic acid (and 20 tests each for
detection of IgG and IgM antibodies) in the same month.
However, the 7 out of 7 positive results reported by “lab A” in August
2016 are indeed explained by confirmatory testing, as indicated by a re-
mark on the notification form: Lab A indicated performing PCR since
May 2016 and applying culture-based methods for “screening/control”.
Furthermore, this laboratory reported having conducted 162 tests for
detection of nucleic acid (e.g. PCR) in August 2016 of which 14 were
positive.
In summary, it seems impossible to evaluate internal validity of the
data reported on “statistic of reports on laboratory findings” notific-
ation forms in the absence of detailed information from the laboratory
on diagnostic procedures.
9.4.3 Swiss “laboratory landscape”: Complex and
dynamic
There are laboratories operating on a national level in Switzerland with
different branches throughout the country. For some companies, those
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Table 9.2: Selected records of “statistic of reports on laboratory findings” on Campylobacter spp. to illustrate difficulty
in evaluating plausibility of data comparing the number of positive results with the total number of tests reported from
laboratory statistics and with the number of cases reported by the corresponding laboratory in the framework of individual
case reporting, 2016–2017, Switzerland
Year Month Laboratory Method Number
of positive
tests
Number of
total tests
Positivity
(in %)
Number of re-
ports on labor-
atory findings
2016 June lab A Detection of nucleic acid 12 172 7.0 0
2016 June lab A Culture/isolation 1 1 100 12
2016 July lab A Detection of nucleic acid 12 142 8.5 0
2016 July lab A Culture/isolation 3 3 100 14
2016 August lab A Detection of nucleic acid 14 162 8.6 2
2016 August lab A Culture/isolation 7 7 100 10
2017 April lab B Detection of nucleic acid 0 3 0 0
2017 April lab B Culture/isolation 19 21 90.5 19
2017 April lab B IgG antibody response 0 26 0 0
2017 April lab B IgM antibody response 0 26 0 0
2017 May lab B Detection of nucleic acid 1 1 100 0
2017 May lab B Culture/isolation 29 30 96.7 25
2017 May lab B IgG antibody response 0 20 0 0
2017 May lab B IgM antibody response 0 20 0 0
2017 June lab B Detection of nucleic acid 0 3 0 0
2017 June lab B Culture/isolation 52 55 94.5 43
2017 June lab B IgG antibody response 1 28 3.6 0
2017 June lab B IgM antibody response 0 28 0 0
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sites are autonomous and can almost be seen as separate enterprises
while other companies have central headquarters. Furthermore, there
are (mostly regionally operating) independent laboratories which form
a corporate group. Reporting can be organised at the local sites or
managed by headquarters. It is difficult to merge individual case re-
ports (from “reports on laboratory findings”, reported on a daily basis)
with summary statistics (from reports on “statistic of reports on laborat-
ory findings”, reported annually) given this heterogeneity and frequent
changes in the “laboratory landscape” of Switzerland with rearrange-
ments of such groups, company mergers, and discontinuation and start-
up of businesses.
For example, labs “C” and “D” belong to “lab group 1”. In 2016, no
individual-based “reports on laboratory findings” from “lab D” are re-
gistered in the NNSID except for two cases in December while from “lab
C” only individual-based reports are available but no report on “statistic
of reports on laboratory findings”(Table 9.3). FromMarch 2017 onwards,
no reports at all from “lab C” were received. Instead, “lab D” reported
individual-based laboratory findings but no laboratory statistics. Both,
labs C and D are based in the canton of Ticino. It seems possible that
lab C discontinued its business or rather joined “lab group 1”, changed
its name and moved to another place. However, this is purely speculat-
ive.
In conclusion, thorough understanding of the structure and operating
procedures of the diagnostic laboratories in Switzerland is needed in or-
der to correctly enter and merge notification data.
9.4.4 Comparable positivity rates from other studies
A previously conducted positivity study in Switzerland reported (age-
and sex-standardised) positivity rates for Campylobacter increasing from
7.6% in 2003 to 11.1% in 2012 [Bless et al., 2017]. This study collected
test-based data from selected diagnostic laboratories directly. The find-
ings from the current study suggest that the positivity rate decreased
again. It has to be noted, however, that Bless et al. [2017] reported
slightly lower rates for crude data compared to age- and sex-adjusted
rates. Additionally, Bless et al. [2017] analysed data from a sample of five
diagnostic laboratories which were selected based on the number of noti-
fications received by the FOPH. This sampling procedure could have fa-
voured laboratories with high positivity rates. Our preliminary analysis
of summary statistics included data from all laboratories in Switzerland
complying with their obligation to report. Furthermore, multiplex PCR
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Table 9.3: Selected records of “statistic of reports on laboratory findings” on Campylobacter spp. to illustrate difficulty
in merging records with case-based “reports on laboratory findings” by laboratory, 2016–2017, Switzerland
Year Month Laboratory
group
Laboratory Method Number
of positive
tests
Number of
total tests
Number of
reports on
laboratory
findings
2016 October lab group 1 lab C Culture/isolation 8
2016 October lab group 1 lab D Detection of nucleic acid 0 41
2016 October lab group 1 lab D Culture/isolation 8 85
2016 November lab group 1 lab C Culture/isolation 10
2016 November lab group 1 lab D Detection of nucleic acid 1 39
2016 November lab group 1 lab D Culture/isolation 8 63
2016 December lab group 1 lab C Detection of nucleic acid 1
2016 December lab group 1 lab C Culture/isolation 4
2016 December lab group 1 lab D Detection of nucleic acid 2 44
2016 December lab group 1 lab D Culture/isolation 3 151 2
2017 January lab group 1 lab C Culture/isolation 4
2017 January lab group 1 lab D Culture/isolation 1
2017 February lab group 1 lab C Culture/isolation 3
2017 February lab group 1 lab D Culture/isolation 3
2017 March lab group 1 lab D Culture/isolation 2
2017 April lab group 1 lab D Detection of nucleic acid 1
2017 April lab group 1 lab D Culture/isolation 5
2017 April lab group 1 lab D Unknown/not specified 1
Note: There were other laboratories belonging to lab group 1 reporting Campylobacter .
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panels for routine testing of stool samples for gastrointestinal pathogens
were introduced in several diagnostic laboratories in Switzerland between
2012 and 2016 and are likely to affect positivity rates (chapters 7 and
8).
A study conducted in Wales, United Kingdom (UK), reported a declin-
ing trend in the proportion of positive stool samples for Campylobacter
from 8.9% in 1998 to 7.5% in 2008 for samples obtained by general prac-
titioners [Janiec et al., 2012]. At the same time, the stool sampling rates
have increased by 40%. The Welsh positivity rates are within the same
range as those found in Switzerland. The advantage of the Welsh system
is that they profit from a national database which is fed by all diagnostic
laboratories. Janiec et al. [2012] stated that “all laboratories in Wales
follow a standard operating procedure for investigation of stool samples
for bacterial pathogens” and that “there was no change in testing pro-
cedures throughout the study period”. This is in strong contrast to the
Swiss situation where the majority of diagnostic laboratories are private
businesses and act independently.
In Norway, mandatory case-based surveillance data for Chlamydia
trachomatis are supplemented by voluntary reporting of aggregated test-
ing numbers stratified by age group and sex by diagnostic laboratories
[Kløvstad and Aavitsland, 2015]. In contrast to Switzerland, Norwe-
gian laboratories are requested to report “cases” rather than “laborat-
ory tests”. Chlamydia cases are defined as “a person with one or more
positive laboratory tests for Chlamydia trachomatis in a urinary sample
or a sample from anus, cervix, urethra, or vagina within a period of 60
days” [Kløvstad and Aavitsland, 2015]. Hence, the Norwegian system
tries to overcome the problem of repeated testing in the same individual
at the reporting level rather than at the level of analysis. Collecting
testing numbers stratified by age group and sex allows identifying which
population group is tested most frequently (e.g. to adapt campaigns pro-
moting testing) and which population group yields the highest positivity
rate, either due to most targeted testing or due to highest incidence.
Lambert et al. [2010] proposed to introduce mandatory reporting of
laboratory tests with a negative result for influenza complementing re-
ports on positive laboratory findings which are notifiable since 2001 in
Australia. They suggest collecting the same information for positive and
negative findings, thus, reporting of case-based data. Acknowledging
that also positivity rates may be biased, e.g. due to co-testing of speci-
mens for other pathogens, Lambert et al. [2010] argue that calculating
the proportion of positive test results would still allow a better assess-
ment of spatial and temporal trends in surveillance data.
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9.4.5 Positivity rates do not suffice
Even though denominator data such as test numbers are factors to be
considered when interpreting surveillance data, they are not a general
solution to overcome limitations associated with case reports of labor-
atory-confirmed infections: it is still impossible to infer population in-
cidence from case notifications if testing frequency is the only additional
information obtained. There are too many factors which affect trends in
test numbers upwards or downwards – exemplified in the following for an
upward trend: (a) a “true” change in disease incidence, leading to more
people falling ill, seeking help and being tested, (b) a change in disease
severity (due to a change in pathogenicity or in human susceptibility),
leading to more people seeking help and/or more people being tested, (c)
a change in patients’ help seeking behaviour, leading to more consulta-
tions and more people being tested, (d) a change in physicians’ “criteria
for testing” (e.g. based on symptoms or based on presence of selected
risk factors) leading to a higher proportion of individuals being tested
among those consulting a physician, (e) a change in the prevalence of risk
factors “qualifying” for testing, (f) a change in laboratory diagnostics,
e.g. from single pathogen testing to using a panel, hence samples are
also tested for this pathogen if another pathogen included in this panel
was requested by the physician, and (g) a change in one of the above-
mentioned factors for a pathogen which is usually tested in parallel (e.g.
with similar signs and symptoms and/or reasons for testing).
It is unlikely that only one of the above-mentioned factors changes con-
siderably while all others remain constant, and there are about the same
number of reasons explaining a change in positive test results. Con-
sequently, trends in positivity rates can arise from a number of combin-
ations of changes in testing frequency and case numbers and hence, an
upward, downward or stable trend in positivity cannot be stringently
assigned to an upward, downward or stable trend in disease incidence.
Still, certain combinations of increasing and decreasing test numbers and
positive results are more likely to result from an increase (or decrease)
in disease incidence than others. For example, if both, the number of
tests and the positivity rate increase (i.e. the number of positive results
increases more strongly than the number of tests performed), it is very
unlikely that the disease frequency in the population actually decreases.
This situation was found for EHEC in Switzerland (chapter 8). Hence,
looking at test numbers and positivity rates does provide additional in-
formation and can help interpreting trends in surveillance data.
Another important aspect to be considered for interpretation of posit-
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ivity rates is the pathogen and its characteristic: for instance, an in-
crease in test numbers for Chlamydia trachomatis is much more likely
to result from a change in testing behaviour (e.g. screening additional
risk groups) than an increase in test numbers for Neisseria meningitidis.
For the latter, a change in the number of patients presenting with the
respective symptoms seems more likely considering severity of invasive
meningococcal disease.
9.5 Conclusions: Pros and cons of collecting
information on test numbers
An analysis of test and case numbers in parallel (hence, positivity rates)
can neither confirm nor disprove what is seen in the surveillance sys-
tem of positive case notifications. However, both measures can either
lead to the same or to different conclusions. It is reassuring that trends
are interpreted correctly if conclusions drawn from looking at positivity
rates are the same as those drawn from looking at notification data of
laboratory-confirmed cases alone.
However, collecting information on test numbers is not straightforward.
The first two years of reporting “laboratory statistics” (reporting of test
numbers and positive results thereof, reported annually as aggregated
numbers) have demonstrated that validity of data cannot be assessed
easily and that follow-ups with laboratories for collecting a lot of addi-
tional information would be required to understand and clean the data.
In summary, assessing test numbers (either as aggregated numbers or
case-based) in a notification system can help to identify (major) changes
in testing frequency. Researching reasons for observed changes can then
be initiated in a timely fashion. However, further research is required
to identify appropriate ways of collecting such information on test num-
bers on a routine basis given the highly dynamic sector of diagnostic
laboratories and the heterogeneity in laboratory practices observed in
Switzerland. It is questionable if the collection of denominator data in
its current form is worth the effort of data acquisition and analysis.
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Part III
ACUTE GASTROENTERITIS:
PHYSICIANS’ CASE
MANAGEMENT AND
PATIENTS’ HEALTH SEEKING
AND ITS INFLUENCE ON
SURVEILLANCE DATA

10 General practitioners’ viewpoint on
acute gastroenteritis,
campylobacteriosis and Swiss
primary care
The first section of this chapter (section 10.1) provides a summary (incl.
excerpts) of the published article “Acute gastroenteritis and campylo-
bacteriosis in Swiss primary care: the viewpoint of general practition-
ers” [Bless et al., 2016]. The article discusses how general practitioners
(GPs) in Switzerland perceive and manage patients consulting with acute
gastroenteritis (AG)* and campylobacteriosis. Understanding this case
management is an important step in reconstructing the burden of illness
pyramid. Further results that were obtained during the interviews with
those GPs are presented in the second section (section 10.2). Those
findings concern the GPs’ perception of their role in the Swiss health
system, their perception of the FOPH, the surveillance system, and the
Swiss health system in general.
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10.1 Summary of “Acute Gastroenteritis and
campylobacteriosis in Swiss primary care:
the viewpoint of general practitioners”
Philipp J. Bless1, 2, Joan Muela Ribera3, Claudia Schmutz1, 2,
Andreas Zeller4, Daniel Mäusezahl1, 2
1 Swiss Tropical and Public Health Institute, Basel, Switzerland
2 University of Basel, Basel, Switzerland
3 Partners for Applied Social Sciences (PASS) Suisse, Neuchâtel,
Switzerland
4 Centre for Primary Health Care, University of Basel, Basel, Switzer-
land
The full text of this article was published in:
PLoS ONE (2016), 11(9):e0161650.
doi: 10.1371/journal.pone.0161650
This is an open access article distributed under the terms of the Creative Com-
mons Attribution License, which permits unrestricted use, distribution, and re-
production in any medium, provided the original author and source are credited.
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Introduction
Infectious acute gastroenteritis (AG)* is caused by a wide range of
gastrointestinal pathogens. Public health is concerned particularly with
food- and waterborne pathogens which can cause disease outbreaks. In
the Swiss National Notification System for Infectious Diseases (NNSID)
a range of food- and waterborne pathogens are monitored. Notifications
of campylobacteriosis – the most frequently reported foodborne pathogen
in Switzerland – increased, reaching almost 8’500 cases in 2012. Increas-
ing trends of Campylobacter have also been observed in the European
Union (EU).
Information in the NNSID about cases of notifiable AG is restricted to
laboratory-confirmed cases and information from diagnostic laboratories
for many foodborne pathogens. There is insufficient information avail-
able on the burden of disease and the clinical presentation of infectious
AG at primary care and at population level.
The aims of this qualitative study among Swiss general practitioners
(GPs) were to investigate the case management of AG and campylobac-
teriosis patients, to assess the influence of patients’ health care seeking
behaviour and of GPs’ clinical decision making on surveillance data and
to collect estimates on the incidence of AG and campylobacteriosis at
the primary care level.
Materials and methods
Face-to-face interviews were conducted based on a semi-structured ques-
tionnaire. The first part of the questionnaire covered GPs’ perception
of AG and campylobacteriosis including the perceived magnitude of the
burden, the public health relevance, clinical presentation, and perceived
patients’ health care seeking behaviour, risk behaviours and risk groups.
The second part of the questionnaire targeted case management focus-
sing on diagnostic practices and treatment approaches and reasons for re-
lated decisions. The questionnaire was re-structured and adapted based
on one key informant interview and five test interviews (four in German,
one in French).
Interviews were conducted by three female social scientists and one
male epidemiologist who were trained by a senior medical anthropologist
in qualitative interviewing techniques. One-hundred-forty-six German-
speaking and 29 French-speaking GPs who had managed campylobac-
teriosis patients in a previous case-control study and six purposely re-
cruited French-speaking GPs were invited for study participation with
an information letter sent by postal mail. During a follow-up contact
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by telephone, GPs were asked for verbal informed consent. Interviews
were conducted with consenting GPs usually in his or her own practice,
lasted for 20–40 minutes and were tape recorded.
Interviews were transcribed immediately after conduct and analysed
while data collection was ongoing. The question guide was refined and
emerging themes were included in subsequent interviews. Codes for data
analysis were continuously developed and assigned to GPs’ narratives by
a senior medical anthropologist using Weft-QDA software. Data ana-
lysis followed the principles of inductive content analysis as required by
Grounded Theory.
The study was part of a project mandated by the Swiss Government
studying the epidemic increase of human campylobacteriosis and was
performed under the Swiss Epidemics Act. Therefore, no ethical ap-
proval was sought. The interviews focused solely on GPs’ professional
views, not on any personal aspects or data of individual patients. Parti-
cipants did not receive any financial compensation for their participation.
Results
In total, 51 German-speaking and 18 French-speaking GPs participated
in the study. Their median professional experience was 23 years (range:
3–39 years). GPs considered AG to be of little relevance both, for the
patient and for public health in Switzerland. They stated that AG is im-
portant in travel medicine but uncommon in daily practice. GPs stated
that campylobacteriosis patients occur in waves throughout the year,
with peaks during summer linked to barbecuing and in winter linked to
the consumption of meat fondue. GPs acknowledged that campylobac-
teriosis can be painful and disturbing even though it is a self-limiting
and easy-to-treat disease. The type of work and social factors influence
the duration of absence from work even though the patient’s general
condition is the main criterion. Sick leave lasts usually for several days
to more than one week.
Perceived disease severity, past experiences, health insurance and the
need for a medical certificate influence whether the physician is consul-
ted immediately (within hours) or after some time (days) after onset of
symptoms of AG. Telephone consultations with the practice nurse and/or
the physician are common. Depending on the GP’s preference, the pa-
tient is either advised to schedule a follow-up consultation by phone or
at the practice, or to call again in case the symptoms do not improve.
The first consultation of a patient with AG usually includes anamnesis,
clinical examination and point-of-care diagnostics (e.g. C-reactive pro-
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tein (CRP) level). Diagnostics based on faecal specimens depend on a
number of factors such as the patients’ symptoms, general condition,
disease duration, inflammatory signs, and exposure history. It includes
mainly stool cultures for Campylobacter spp., Salmonella spp. and Shi-
gella spp.
Symptomatic treatment with anti-motility drugs, oral (for simple cases)
or intravenous (for severe cases) rehydration is very common. Antibiotic
therapy is considered useful, but prescribed cautiously as AG is usually
self-limiting and GPs are aware of the occurrence of antibiotic resistance.
Reasons favouring antibiotic therapy are comparable to those for stool
diagnostics. Additionally, stool diagnostic results can influence antibi-
otic therapy.
Four distinct approaches to case management were apparent: “wait &
see” including recommendations for diet, rehydration and symptomatic
treatment, is mostly applied when the episode is recent and mild. “Treat
& see” is based on the pragmatic reasoning that for antibiotic therapy
(“treat”), there is no need to know the exact cause – if there is evidence
for bacterial infection (e.g. elevated CRP). The third approach starts
with obtaining a stool specimen (“test”) but initiating empirical antibi-
otic therapy before knowing the test result. This “treat & test” strategy
allows adapting treatment once diagnostic results are available. Finally,
by applying “test & see”, physicians try to avoid unnecessary antibi-
otic treatment. Antibiotics are only prescribed if bacterial pathogens
are identified and symptoms persist. Most physicians appeared to follow
various approaches depending on the respective situation. Hospitalisa-
tion and referral to specialists are rather uncommon.
Discussion
GPs perceptions of the epidemiology of campylobacteriosis in terms of
seasonality (summer and winter peak), trends over the last 20 years (in-
creasing trend; nowadays more frequent than salmonellosis) and age of
patients affected (all age groups, but disproportionately frequent among
young adults) is in line with what is seen in the NNSID. GPs are aware
that their case management, apart from the patients’ healthcare seeking
behaviour, leads to underestimation of campylobacteriosis in the NNSID.
The wide range of physicians’ self-estimated frequency of requesting stool
samples is also observed among GPs within and between other countries.
Financial factors (e.g. costs for diagnostics and health insurance deduct-
ible) and the duration until results are available also affect the decision to
perform stool diagnostics apart from factors consistent with published
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literature on the clinical management of AG. Considering the lack of
curative treatment for viral causes of AG, physicians make use of CRP
levels to distinguish bacterial from viral AG. An increased CRP level fa-
vours bacterial AG and hence, the likelihood that the physician decides
to perform stool diagnostics. Patients with travel history and severely
affected patients are likely over-represented in the NNSID considering
GPs’ diagnostic behaviour.
Swiss GPs mainly follow the “wait & see” approach for patients con-
sulting with AG. Due to the perceived long duration until culture-based
stool diagnostic results are available, GPs favour “treat & see” and “treat
& test” over “test & see”. Ciprofloxacin (a fluoroquinolone) is frequently
used for empirical antibiotic treatment of AG even though around 50%
of Campylobacter spp. show resistance to fluoroquinolones.
Conclusions
Triage steps, reasons for and frequency of stool diagnostics need to be
considered when interpreting NNSID data. Cases reported to the NNSID
are more likely to be severe or to have travelled abroad compared to un-
der-ascertained cases. Current developments in laboratory methods from
culture-based stool diagnostics to multiplex polymerase chain reaction
(PCR) panels could change physicians’ case management approaches
and hence, the proportion and selection of cases seen in the NNSID.
Knowledge of physicians’ case management and laboratory practices is,
therefore, important for public health authorities to accurately interpret
NNSID data.
10.2 Additional analysis & results: The general
practitioners’ role in the Swiss health
system
10.2.1 GPs’ knowledge on campylobacteriosis
GPs were not systematically asked about their knowledge on Campylob-
acter spp. and campylobacteriosis. However, several statements during
the interviews pointed at their perception of incubation period, risk
factors and clinical manifestation of the disease (the latter has already
been discussed in the published article; section 10.1 and Bless et al.
[2016]). While many facts mentioned were in agreement with published
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literature, some statements pointed at uncommon, if not wrong, percep-
tions of incubation period or risk exposures, or lack of knowledge.
The incubation period for Campylobacter is said to be 2–5 days, some-
times 1–10 days [Mahon and Patrick, 2015]. But:
“[Vermutete Fälle von Campylo-
bacteriose] Der anamnestische
“[For suspected campylobacteri-
osis] the anamnestic indicator is
Hinweis ist da der plötzliche Aus- the sudden onset. Approximately
bruch. Ungefähr 12 Stunden nach 12 hours after a meal. This is
einer Mahlzeit. Das ist verdäch- suspicious. Especially, if also
tig. Vor allem, wenn auch andere others show the same symptoms.”
die gleichen Symptome aufwei-
sen.” (MZ11)
The most common risk factors for campylobacteriosis are: international
travel, consumption of undercooked chicken, environmental exposure
and direct contact with farm animals [Kaakoush et al., 2015]. In terms
of contaminated food, poultry products (mostly chicken, but also tur-
key and duck), unpasteurized milk, and water are common. Also other
meat – beef, veal and pork – can harbour Campylobacter . Even though
chicken are frequently infected with Campylobacter , eggs are generally
not considered a risk factor for human infection [Fonseca et al., 2014;
Kaakoush et al., 2015]. Apart from raw milk, other milk products were
not found to be contaminated with Campylobacter [Modi et al., 2015].
“Bei Campylobacter ist es na- “For Campylobacter it is the
türlich klassisch, dass es über classic that it is transmitted
Nahrungsmittel aufgenommen through food. So, the typical way
wird. Also der klassische Weg ist is through eggs which are contam-
über Eier, die befallen sind. Ti- inated. Tiramisù as an example.
ramisù zum Beispiel. Oder Pou- Or chicken meat.”
letfleisch.” (MZ04)
“Campylobacter ist oft im Pou- “Campylobacter is often found
let, also. . . Hühnerfleisch und in poultry, so. . . chicken meat
auch Eier sind häufig kontami- and also eggs are contaminated
niert. . . Das wissen die Leute frequently. . . This is often not
häufig nicht.” (PH04) known by people.”
[Über Nahrungsanamnese] [Talking about food anamnesis]
“Häufig beim Campylobacter ist “Often with Campylobacter is
Poulet. . . das Poulet, Glace auch chicken. . . the chicken, ice cream
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noch relativ viel, und Softeis. . . ” quite frequently too, and soft ice
(PH21) cream. . . ”
Interviewer : “Et quels sont les Interviewer: “And what are
facteurs de risque pour une in- risk factors for campylobacteri-
fection au campylobacter ? Est-ce osis? Is there anything common
qu’il y a quelque chose en com- among these patients which would
mun chez ces patients qui expli- explain this. . . ?”
querait. . . ?”
Physician : “J’arrive pas à Physician: “I cannot tell. Since
dire. Comme on en voit tellement you see this so infrequently. I
peu. Je sais pas.” (SFY09) don’t know.”
Interviewer : “Et dans leur Interviewer: “And concerning
[patients avec Campylobacter] ali- their [campylobacteriosis patients]
mentation, vous remarquez quelque nutrition, do you notice some-
chose qui pourrait provoquer l’in- thing which could cause the in-
fection ?” fection?”
Physician : “Non. C’est vrai Physician: “No. It is true that
qu’on leur demande toujours aussi one always asks if they ate some-
s’ils ont mangé quelque chose de thing special which did not appear
particulier qui leur paraissait pas fresh, but this exposure is not al-
frais, mais on ne trouve pas tou- ways established.”
jours.”
Interviewer : “Une hypothèse Interviewer: “One hypothesis
c’est que ça vienne de la viande is that it is from undercooked
de poulet mal cuite.” chicken meat.”
Physician : “Le campylobac- Physician: “Campylobacter? I
ter ? Moi j’avais la notion pour personally knew this for Salmon-
les salmonelles mais pas pour le ella but not for Campylobacter,
campylobacter, pour le poulet pas the chicken not cooked. . . ”
cuit. . . ” (SFY12)
Interviewer : “Et les risque. . . Interviewer: “And the risks. . .
ma question c’était plutôt, d’où my question was rather related to
vient ce Campylobacter, est-ce the source of Campylobacter, is
qu’il y a un comportement. . . ?” there a behaviour. . . ?”
Physician : “Oui, alors. C’est Physician: “Well, yes. It is
vraiment l’ignorance totale, d’où really total ignorance from where
viennent ces bactéries. Est-ce que these bacteria originate. Do
les gens consomment beaucoup people consume a lot of uncooked
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de légumes pas cuits, donc des vegetables, like salads, which they
salades, qu’ils ne les lavent pas, don’t wash, that they. . . that they
qu’ils ne. . . qu’ils ne lavent pas don’t wash their fruit before eat-
leurs fruits avant de les manger. ing. Sometimes, one simply does
Parfois on a même pas le temps not have the time to make a huge
de faire une immense enquête.” enquiry.”
(SFY07)
Campylobacter is not considered to strongly proliferate in foods [Burgess
et al., 2016].
“Man könnte mit einfachen “With very simple hygiene in-
Hygienemassnahmen, wie [zum terventions Campylobacter could
Beispiel] das Fleisch nicht lan- be reduced, [for example] if it was
ge herumliegen zu lassen, Cam- not lying around for a long time.”
pylobacter deutlich reduzieren.”
(MZ24)
10.2.2 GPs’ perspective on stool testing
Physicians usually order “packages” and follow laboratory recommend-
ations of the laboratory they work with. GPs focus on the patient when
deciding for or against conducting stool diagnostics as expressed by one
respondent:
“Sagen wir, wir machen die
Stuhlprobe und haben jetzt den
“Let’s say we do a stool cul-
ture and we identify the pathogen
Erreger und es heilt ohnehin in and the illness recedes in five, six,
fünf, sechs, sieben Tagen spontan seven days spontaneously any-
aus. Was bringt uns das? Ausser, way. What does this help? Ex-
dass man jetzt vielleicht wichtige cept that maybe we collected im-
epidemiologische Daten gesam- portant epidemiological data. But
melt hat. Aber für den Patien- this doesn’t help the patient much
ten bringt das alles letztlich nicht ultimately. It is of little advant-
viel. Zu wissen, welcher Erreger age to the patient to know which
im Stuhl ist oder welchen man pathogen is in the stool or which
in Ägypten aufgeschnappt hat, [pathogen] he caught in Egypt.”
bringt dem Patienten ja relativ
wenig.” (MZ18)
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The GPs’ approach seems pragmatic and based on experience:
Interviewer: “Welche Rolle Interviewer: “What role does
spielt die Erfahrung? Wenn ein experience play? When a patient
Patient in Ihr Behandlungszim- comes to the practice, can you
mer kommt, können Sie da schon already pre-assess him or her?
auf den ersten Blick etwas über I refer to this famous medical
ihn sagen? Ich meine diesen be- vision [visual and/or general im-
rühmten medizinischen Blick, ob pression and feeling] whether or
jemand krank ist oder nicht.” not someone is ill.”
Arzt: “Ja. Das sieht man schon Physician: “Yes, you can no-
gut. Also, die Unterscheidung, ob tice this quite well, so the differ-
jemand einen infektiösen Durch- entiation whether somebody has
fall oder eher einen Reizdarm infectious diarrhoea or rather an
hat sieht man schon eher. Aber irritable colon. This you can see
man muss gewisse Sachen ein- quite well. But one must exclude
fach ausschliessen. Man muss si- certain conditions. One does cer-
cher nicht bei jedem eine Stuhl- tainly not need to do stool bacteri-
bakteriologie machen.” (MZ21) ology with every diarrhoea case.”
Factors related to the patients’ expectations and the physician’s assur-
ance can also influence decisions on stool testing, apart from medical
signs and symptoms, patients’ general condition, risk exposure, risk of
transmission, and assuring accurate treatment:
Arzt: “In der heutigen Zeit. . . Physician: “Nowadays people
die Leute erwarten dies bis zu ei- expect it to a certain degree that
nem gewissen Grad, dass man ob- one documents it objectively with
jektiv mit Laboruntersuchungen laboratory investigations.”
dokumentiert, oder?”
Interviewer: “Und nicht nur Interviewer: “And not only
aufgrund der Untersuchung und based on the examination and
Ihrer Erfahrung. . . ” your experience.”
Arzt: “Richtig.” (PH08) Physician: “Exactly.”
“[. . . ] pour avoir quand même “[. . . ] for still having certainty
une certitude de ce que je fais, of what I do, you see. After all,
vous voyez ? Après, si ça tourne if it turns worse, one will say
mal, on me dira vous n’avez fait you did not even perform an ana-
aucune analyse.” (SFY07) lysis.”
Furthermore, also costs can play a role even though many physicians
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stated that their decisions are not influenced by economic considerations.
Interviewer: “Oder gibt es auch Interviewer: “Or are there eco-
ökonomische Faktoren, welche nomic factors as well which influ-
die Testentscheidung beeinflus- ence the decision to do a test?”
sen?”
Arzt: “Also die Ökonomie spielt Physician: “Well, the economy
in diesem Sinne eine Rolle, in- plays a role in a sense that one
dem man sagt, eine banale Durch- says that banal diarrhoea does
fallerkrankung erfordert keine not require specific diagnosis. It
spezielle Diagnostik. Es wird sym- is treated symptomatically and
ptomatisch behandelt und sollte should be over within 3 to 4 days,
innerhalb von 3 bis 4 Tagen wie- self-limiting disease, self-purific-
der vorbei sein, selbstlimitierende ation of the body.”
Erkrankung, Selbstreinigung des
Körpers.”
[. . . ] [. . . ]
Interviewer: “Spielt auch die Interviewer: “Do considera-
Krankenkasse eine Rolle? Des tions regarding the patient’s health
Patienten?” insurance play a role, too?”
Arzt: “In diesem Falle jetzt In this case not. I really
nicht. Da habe ich mir jetzt wirk- have never thought about this
lich noch nie Gedanken darüber and thought: ‘Wait, one mo-
gemacht und gedacht: ‘Halt, Mo- ment, with this insurance I can-
ment, bei dieser Krankenkasse not do a diagnostic test.’ What
kann ich jetzt keine Diagnostik really counts is the clinic [clinical
betreiben.’ Sondern da geht es ef- symptoms].”
fektiv nach der Klinik.” (PH02)
“Pour la raison pour laquelle “For the reason why I do only
je fais peu de cultures, c’est pour few cultures, it’s because of the
les coûts. Ça coûte très cher une costs. Stool culture is very ex-
culture de selles. Quand on a un pensive. If a patient with a high
patient qui a une franchise éle- deductible – no, let’s put it this
vée – non, disons, alors, s’il y way, when it is a low deductible
une franchise basse c’est pas juste it is not just for the insurance –
pour l’assurance – mais pour un but for a patient if a diarrhoea
patient si une diarrhée par té- [is managed] by telephone it costs
léphone ça lui fait 20 francs, him 20 francs, for a diarrhoea
une diarrhée au cabinet avec une in the practice with stool culture
culture de selles on est pratique- costs reach basically 200 francs! I
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ment à 200 francs ! Je trouve que think that this represents enorm-
ça représente des coûts énormes ous costs for the patient and for
pour le patient et le système de the health system. And if in both
santé. Et si dans les deux cas il cases he [the patient] is better
va mieux en 3 jours, je trouve after 3 days, I think it makes no
que ça n’a pas de sens de faire sense to spend a lot of money on
des grosses dépenses de santé.” health.”
(SF17)
Finally, also the (long) duration until results are available is likely to in-
fluence testing behaviour, although few physicians explicitly mentioned
that it prevents them from testing:
“Und wir machen Stuhlkultu- “We do stool cultures rather
ren eher sparsam. Stuhlkulturen sparingly. Stool cultures do not
bringen uns überhaupt nichts. Bis come with any benefit: until we
wir das Resultat haben ist der have the result the patient is
Patient entweder wieder gesund either healthy again or. . . one
oder. . . man kann ja nicht war- cannot wait to give antibiotics
ten mit den Antibiotika, bis man until one finally has the result
endlich das Resultat hat [. . . ]” [. . . ]”
(PH12)
10.2.3 The GPs’ perception of their role
Swiss GPs emphasise that their approach is patient-centred or even situ-
ation-centred and they deal with “the patient in his or her individual
context”. They also highlight the long-term relationship which is based
on mutual confidence and trust. This confidence is considered essential
and represents a key motivation and appreciation for working in primary
health care as opposed to working in a hospital.
In line with their patient-centred approach, GPs’ decisions for or against
stool testing largely depend on the expected impact of the results on
subsequent case management. Considerations on public health stay in
the background:
“Plus on en [culture de selles]
fait, plus on va en trouver, mais
“The more [stool cultures] you
do, the more you will find, but
est-ce que ça va changer grand would this change a lot? The idea
chose ? L’idée c’est quand même is still that it changes the atti-
que ça change l’attitude, si un tude, if a test does not change
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test ne change pas l’attitude, c’est the attitude, it is useless. Then,
inutile. Après on dit considéra- people argue for reasons of public
tion de santé publique, c’est pour health, and that GPs have to con-
ça que vous êtes là, mais ça, si tribute to public health. If testing
on nous prouve que c’est utile en widely/screening is proven bene-
terme de santé publique de dé- ficial for public health, we can do
pister toul le monde, on peut le it. Yet, it would still cost a lot.
faire, mais c’est vrai que ça a un And will it change something?”
coût, et est-ce que ça va changer
quelque chose ?” (SFY05)
The physician working as a GP requires psychosocial skills. Further-
more, he develops the “medical vision” (assessment of the patient based
on general impression and intuition) which helps to follow his or her
pragmatic and experience- or intuition-based approach.
Arzt: “Ich sage immer, dass Physician: “I always say that
wir in der Hausarztpraxis keine in general practice, we do not do
‘evidence-based Medizin’ machen, evidence-based medicine, but an
sondern eine ‘intuition-based Me- intuition-based medicine.”
dizin’ ”
[. . . ] [. . . ]
Interviewer: “Sie haben vorhin Interviewer: “Before you said
etwas sehr Interessantes gesagt, something very interesting, espe-
vor allem aus der sozialwissen- cially from a social science per-
schaftlichen Perspektive. Sie ha- spective. You said, that there is
ben gesagt, dass es so ein Gefühl this special feeling when diagnos-
gibt bei der Diagnose. . . Können ing. . . Can you describe this in
Sie dieses genauer beschreiben?” more detail?”
Arzt: “Also, Sie merken ein- Physician: “Well, you just no-
fach, ob jemand krank ist oder tice whether someone is ill or
nicht. . . ” not. . . ”
Interviewer: “Der medizinische Interviewer: “The medical vis-
Blick?” ion?”
Arzt: “Das ist der medizinische Physician: “That is the med-
Blick und das ist die Erfahrung, ical vision and that is the experi-
oder? Das ist die Erfahrung! Und ence, no? That is the experience!
diese muss man sich erwerben.” And this you have to acquire.”
(MZ20)
“Vous savez, chaque praticien “You know, each practitioner
fait son. . . son travail de façon does his. . . his work in a per-
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personnelle,. . . en quelque sorte.” sonal fashion,. . . to a certain de-
(SFY07) gree.”
Arzt: “Es ist sehr viel Soft- Physician: “There is a lot of
Wissen dabei, also Soft. . . Ge- soft-knowledge involved, soft. . .
fühlsentscheidungen. Manchmal in the sense of intuition. Some-
weiss man selbst gar nicht, warum times we don’t even know ourselves
man so entscheidet. Durch die why we decided this way. Based
jahrelange Erfahrung, hat man on years of experience we some-
manchmal die Nase dafür.” times have the flair for it.”
(PH12)
“Vous savez, c’est toujours dif- “You know, it is always diffi-
ficile en médicine d’être absolu- cult to be absolutely systematic in
ment systématique, c’est une im- medicine, it is also an impres-
pression aussi.” (SFY11) sion.”
This dependence on intangible knowledge, soft skills and intuition could
explain why some GPs feel that their discipline is neglected by colleagues
of other disciplines, and politics:
“[. . . ] dass die Hausarztmedi- “[. . . ] that primary care medi-
zin, ähnlich wie in Deutschland, cine, similar to Germany, does
nicht die Wertschätzung geniesst, not get the recognition it mer-
die sie eigentlich haben sollte. its. That specialists are unduly
Dass man einfach auch von der advantaged in terms of payment,
Bezahlung, den Tax-Punkten her tax points. That is just like in
die Spezialisten eigentlich über Germany. The specialist then
Gebühr bevorteilt. Das ist genau earns the double or triple, but
wie in Deutschland. Der Spezia- works the same time. I don’t
list verdient dann das doppelte want to deny this – also he is
und dreifache und arbeitet die working a lot – but we do so
gleiche Zeit. Ich will ihm das too! You cannot be surprised,
auch nicht in Abrede stellen – after all, that fewer and fewer
auch der arbeitet viel – wie wir people choose primary care medi-
nun halt eben auch! Man darf cine. At some point this jeopard-
sich dann nicht wundern, dass ises the broad health care, if we
dann immer weniger Leute die [GPs] once do not exist anymore.
Hausarztmedizin ergreifen. Man I don’t know if the political level is
gefährdet damit irgendwann mal aware of this. Because basically it
diese breite Gesundheitsversor- is always difficult. . . A politician
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gung, wenn es uns dann mal nicht closes a cantonal hospital which
mehr gibt. Ich weiss nicht, ob das is public – in Germany too, a uni-
in der politischen Ebene so klar versity hospital that is closed –
angekommen ist. Weil im Grunde that is less favourable for a politi-
ist das natürlich immer schwieri- cian than if three, four practices
ger. . . sie schliessen als Politiker are closing. This will get lost in
ein Kantonsspital, was staatlich the ambient noise. By way of ex-
ist – auch in Deutschland, ein ample, if there are 15 or 13 or
Unispital, das geschlossen wird 12 general practitioners in Vec-
– das ist natürlich für sie als hta or Weinfelden. . . might not
Politiker ungünstiger, als wenn be of interest to the politician.
drei, vier Arztpraxen zu machen. But if there is a hospital in this
Das geht so im Grundrauschen place or not. . . this is something
unter. Ob es da in Vechta oder which is also noted by public me-
in Weinfelden, exemplarisch ge- dia and could also go at the ex-
sehen, 15 oder 13 oder 12 Hau- pense of the politician’s re-elec-
särzte hat. . . interessiert ja den tion. So basically, one should get
Politiker vielleicht nicht. Aber away from this specialist-thinking
ob es ein Spital hat in dem Ort and see the health care system as
oder nicht. . . das ist schon wie- a pyramid which needs primary
der etwas, was dann in der Pres- health care [. . . ]”
se auftaucht und vielleicht auch
den Politiker die Wiederwahl kos-
tet. Also im Grunde müsste man
eigentlich eher von diesem Spe-
zialisten-Gedanken weg kommen
und das Gesundheitssystem eher
wie eine Pyramide verstehen wo
es eine Grundversorgung braucht
[. . . ]” (MZ18)
10.2.4 The GPs’ view of the Federal Office of Public
Health
Physicians were also asked about their perception of the Federal Of-
fice of Public Health (FOPH) apart from their approaches to diagnosis
and treatment of AG and campylobacteriosis. This question about the
FOPH was phrased very broadly, hence, not referring to a specific task
or field of responsibility or action of the FOPH such as health insurance,
health policy, consumer protection or public health.
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Opinions about the FOPH differed among GPs. Given that the question
about the FOPH was phrased very broadly, the GPs’ perception was
largely dependent on the division or task of the FOPH the physician
was referring to. Own past experiences with the federal authority were
influencing factors. Also personal preferences and expectations about in-
formation sources (e.g. on guidelines) influenced the GPs’ opinion about
the federal office. Statements about the political aspects of the FOPH’s
work (e.g. tariff structure or lack of support in strengthening family
medicine) and on personnel dealing with “administrative tasks” (e.g.
permission to work as a GP in a private practice) were rather negative
while the scientific collaborators and the parts on infectious diseases,
disease surveillance and vaccination recommendations (including travel
medicine) tended to be perceived positively.
Several GPs thought that the FOPH was not important or “far away” –
sometimes in a negative, but often in a neutral sense. They felt that the
federal authority was too distal from primary health care implementa-
tion to understand “real”, everyday issues. Furthermore, GPs have no
interaction with the FOPH during their daily work and, thus, are not
aware of the tasks and responsibilities of the FOPH.
Expectations on part of the GPs towards the FOPH are high during in-
ternational emergencies (e.g. severe acute respiratory syndrome (SARS),
H5N1 [bird flu] epidemic, H1N1 [swine flu] pandemic). In these situ-
ations, physicians expect to get advice and support from the FOPH. At
the same time, they claim that the FOPH overreacted with regard to its
response to epidemic and pandemic threats in the past. Consequently,
they claim the population was scared and contacted the physician who
then had to deal with the anxiety of his patients.
In terms of information provided by the FOPH on a regular basis, many
GPs considered the vaccination regimen as very useful, especially in the
context of travel medicine. The weekly journal of the FOPH, the “BAG
Bulletin”, was appreciated very much by some physicians while others
thought it did not provide useful information. Some GPs claimed to
read it every week while others were not sure if it still exists as they
stopped receiving the printed version of the “blue booklet”. Physicians
frequently mentioned Swiss medical journals (mostly sent to them for
free), continuous education and quality circles as useful sources to keep
up-to-date.
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10.2.5 GPs and the FOPH: Lack of mutual
understanding
The qualitative study among Swiss GPs provided important insights
into the case management of AG and campylobacteriosis in Switzerland.
Additionally, the study allowed exploring the GPs’ perception of and
expectations towards the FOPH. Ideally, the findings of this latter part
should be complemented by looking at the perception of and expectations
towards primary care from the FOPH’s perspective. However, already
the unilateral point of view indicates that there is a need for improving
mutual understanding of tasks, responsibilities and challenges. Similar
to laboratory experts claiming that the FOPH staff is “difficult to con-
tact” (chapter 7), GPs feel that the FOPH is “distant”. This perception
of distance could result from lack of interaction between the two actors
(FOPH and GPs) of the Swiss health system but also from their different
perspectives (individual-based vs. population-based). The FOPH could
probably improve its reputation among physicians by informing phys-
icians more directly and proactively about its work and openly name
associated challenges, e.g. showing the need to and interest in under-
standing the current practice in diagnosis and treatment of infectious
diseases. Given information sources used by Swiss GPs according to the
study, the FOPH could use local medical journals as a communication
channel. Medical societies, events for continuous education and local
quality circles could be targeted for more personal contact platforms.
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Abstract
Purpose Acute gastroenteritis (AG) leads to considerable burden of
disease, health care costs and socio-economic impact worldwide. We
assessed the frequency of medical consultations and work absenteeism
due to AG at primary care level, and physicians’ case management
using the Swiss Sentinel Surveillance Network “Sentinella”.
Methods During the 1-year, longitudinal study in 2014, 172 physicians
participating in “Sentinella” reported consultations due to AG including
information on clinical presentation, stool diagnostics, treatment, and
work absenteeism.
Results An incidence of 2’146 first consultations due to AG at primary
care level per 100’000 inhabitants in Switzerland was calculated for
2014 based on reported 3.9 thousand cases. Physicians classified
patients’ general condition at first consultation with a median score
of 7 (1=poor, 10=good). The majority (92%) of patients received
dietary recommendations and/or medical prescriptions; antibiotics were
prescribed in 8.5%. Stool testing was initiated in 12.3% of cases; more
frequently in patients reporting recent travel. Among employees (15–64
years), 86.3% were on sick leave. Median duration of sick leave was 4
days.
Conclusions The burden of AG in primary care is high and com-
parable with that of influenza-like illness (ILI) in Switzerland. Work
absenteeism is substantial, leading to considerable socio-economic
impact. Mandatory infectious disease surveillance underestimates the
burden of AG considering that stool testing is not conducted routinely.
While a national strategy to reduce the burden of ILI exists, similar
comprehensive prevention efforts should be considered for AG.
Background
Acute gastroenteritis (AG)* is a common disease in humans worldwide.
Case definition varies between studies and countries but mostly includes
signs and symptoms of diarrhoea, vomiting, nausea, abdominal cramps
or pain, fever, and blood or mucus in the stool [1-5]. AG can be
caused by a wide variety of pathogens ranging from viruses and bac-
teria to protozoa and other parasites [5]. A study in Austria identified
norovirus, Clostridium difficile and rotavirus as the most frequent aeti-
ological agents in patients consulting general practitioners (GPs) due to
AG [4]. Norovirus, rotavirus, sapovirus and Campylobacter spp. were
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the most common organisms among cases of infectious intestinal disease
(IID) presenting to the GP in the UK [6].
Bacterial pathogens causing AG which have to be reported to the Na-
tional Notification System for Infectious Diseases (NNSID) include pos-
itive laboratory tests for Campylobacter spp., Salmonella spp., and Shi-
gella spp. as well as clinical and laboratory reports of positively tested
patients with Listeria monocytogenes and enterohaemorrhagic Escheri-
chia coli (EHEC). None of the above-mentioned viral causes of AG are
notifiable in Switzerland [7]. As a result, the NNSID underestimates the
true burden of AG because of non-notifiable pathogens causing AG. Ad-
ditionally, not every patient suffering from AG presents to a physician
(under-ascertainment) and, the physician does not always initiate stool
diagnosis to investigate the aetiology of the illness (under-reporting) [8,
9]. Hence, what is seen in the Swiss mandatory notification system rep-
resents only an incomplete picture of the burden of disease due to AG.
The determinants of under-ascertainment or under-reporting have been
described for several countries but not for Switzerland: In the UK, it is
estimated that every case of IID reported to national surveillance repres-
ents 9.5 cases presenting to a GP or 147 cases in the community [6]. In
the Netherlands, 8% of patients with an IID visited a physician [10]. Van
Cauteren et al. [11] estimated that of 115 community cases of campylo-
bacteriosis and 20 community cases of salmonellosis one case is reported
to the surveillance system in France. However, it has to be noted that
the French surveillance systems are voluntary for these two pathogens.
Swiss routine surveillance data suggest an increasing frequency of cam-
pylobacteriosis and a decreasing frequency of salmonellosis [12]. More
than half of campylobacteriosis patients in a case-control study ap-
proached a physician within 3 days after onset of symptoms and 14.5%
were hospitalised [13]. A subsequent qualitative survey among primary
care physicians described case management approaches including treat-
ment strategies and stool diagnostic testing behaviours from the physi-
cians’ perspective for patients with AG [8]. Four main approaches were
identified of which only two – the “test & wait” and the “test & treat”
approaches – include stool specimen testing and, hence, would result in
case registration in the mandatory disease surveillance system in case of
a positive test outcome. Healthcare costs for AG in Switzerland were
estimated at e29–45 million annually [14].
In Switzerland, we lack data on under-ascertainment and under-report-
ing. Under-ascertainment refers to people not seeking healthcare and,
hence, not being captured by the surveillance system as defined by Gib-
bons et al. [9]. Under-reporting is defined as people seeking healthcare
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but not being reported because of under-diagnosis – not diagnosing or
misdiagnosing the infection or pathogen – or under-notification – failure
to report positive diagnoses [9].
This study within the Swiss Sentinel Surveillance Network, Sentinella,
aimed at understanding the lower levels of the burden of illness pyramid
and addressing the incidence of AG in a broader context. Specifically,
the study aimed at understanding determinants of under-diagnosis by
(1) estimating the incidence and burden of AG seen at the primary care
level, (2) describing the physicians’ case management (diagnostics, treat-
ment) of AG patients and (3) estimating the work loss due to AG of cases
presenting to a physician.
Methods
A 1-year, longitudinal study in Sentinella, during the year 2014, was
conducted asking physicians to report cases of AG on a weekly basis
(later referred to as data from the “weekly questionnaire”). A question-
naire about disease characteristics, stool testing, and treating strategies
was completed for a subset of cases (later referred to as “supplementary
questionnaire”).
Study setting
Sentinella is a voluntary surveillance system and research network of pri-
mary care physicians existing since 1986 which is operated and funded
by the Federal Office of Public Health (FOPH). Physicians are organ-
ised in six geographical regions, each having its representative within
the Sentinella steering committee. The steering committee, consisting
of physicians and researchers of academic primary care institutes, meets
regularly to set the research priorities and to decide on submitted pro-
jects. Our study was accepted to run in 2014.
During the Sentinella-year 2014, 172 physicians (47% general practi-
tioners, 37% internists and 16% paediatricians; thereafter referred to as
“Sentinella-physicians”) covering entire Switzerland were active in the
network. In Switzerland, 6’930 physicians were practising in the ambu-
latory sector with the main specialty “general internal medicine” (sum-
marising general practitioners and internists) or “paediatrics” in 2014
according to the Swiss medical association FMH [15]. Among these, 86%
were practicing in general internal medicine and 14% in paediatrics.
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Case definition
A case of AG was defined as (a) a patient consulting a Sentinella-phys-
ician for the first time during the illness episode and suffering from
diarrhoea (at least 3 watery or pasty stools daily; for at least 24h but
14 days the longest) likely due to an infectious cause or (b) a patient
consulting a Sentinella-physician for the first time during the illness epis-
ode with vomiting and abdominal cramps without significant diarrhoea,
likely due to an infectious cause. Patients were excluded if diarrhoea
was due to a known gastrointestinal disease (e.g. Crohn’s disease, ul-
cerative colitis, coeliac disease), medication intake (e.g. antibiotics) or
food intolerance. Also patients with persistent diarrhoea (>14 days), or
if vomiting was due to pregnancy, were excluded.
Data collection
Sentinella-physicians reported basic data on patients suffering from AG
on a weekly questionnaire, and more detailed data for a subsample of
patients through a supplementary questionnaire which were available
in German and French. German versions of the weekly (part on AG
only) and supplementary questionnaires are available online (see elec-
tronic supplementary material 1). The questionnaires were piloted with
10 general practitioners.
The weekly questionnaire included information on sex, date of birth,
stool testing and hospitalisation of all AG patients (see case definition)
seen in the corresponding week. The supplementary questionnaire con-
tained additional questions on employment status, dates of symptom
onset and consultation(s), signs and symptoms until first consultation,
general condition, antibiotic and symptomatic treatment, stool testing,
sick leave, hospitalisation, sequelae, and selected risk exposures in the 7
days preceding symptom onset.
Weekly questionnaires were available on paper and electronically accord-
ing to the Sentinella standard procedure (method chosen by physician).
More than half of the Sentinella-physicians reported electronically, all
others reported on paper. Supplementary questionnaires were available
on paper only. While weekly paper questionnaires were sent to the FOPH
once a week by postal mail according to routine procedures, Sentinella-
physicians were asked to send the supplementary questionnaire as soon
as they considered the corresponding case as “completed”. Weekly elec-
tronic questionnaires were entered directly into the Sentinella-database
by the Sentinella-physician.
Information available on Sentinella-physicians included the physicians’
218
Published article
specialty and location of practice. Sentinella-physicians additionally re-
ported the total number of daily physician-patient-contacts (PPCs) on
the weekly questionnaire. A PPC is defined as each consultation inde-
pendent of place (in practice or as domiciliary visit) and time (during or
off consultation-hour or on emergency service) and serves as denominator
for calculating disease incidence rates.
Subsample for supplementary questionnaire
We expected that each Sentinella-physician would report around two
AG cases per week based on the pilot testing and discussions with phys-
icians. Assuming that 150 physicians report during 48 weeks, 14’400
cases were expected during the 1-year-study period. To reduce the an-
ticipated work load for Sentinella-physicians but still reaching an ap-
propriate sample size allowing for estimates with acceptable precision,
we decided to apply the supplementary questionnaire to a subsample of
cases. The targeted subsample size was set at 4’800 cases (one-third of all
cases). A sampling scheme was defined whereby every Sentinella-physi-
cian had to complete supplementary questionnaires during four consec-
utive weeks four times a year (=16 weeks per physician per year). We
randomly assigned each Sentinella-physician a sampling pattern with
sampling periods distributed equally over the year, hence not allowing
for two consecutive sampling periods.
Case numbers in the first half of the study period were lower than ex-
pected necessitating the sampling scheme to change to full sampling.
Starting from week 25 (starting on 14.06.2014), supplementary ques-
tionnaires had to be completed for every AG patient until the end of the
study.
Data entry and analysis
Weekly questionnaires on paper forms and all supplementary question-
naires were entered into the electronic Sentinella database at the FOPH.
Ten percent of supplementary questionnaires was randomly selected for
double entry to assess data quality. Double entries of questionnaires
were compared and discrepancies were eliminated by re-checking against
the original paper forms.
Cases of Sentinella-physicians who reported PPC for less than 75% of
the weeks during the study period, i.e. <39 of 52 weeks were excluded
from data analysis. This rule and cutoff value for regularly reporting
physicians are standard for analyses of Sentinella data. Additionally,
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cases not fulfilling the case definition or cases where the Sentinella-phys-
ician spontaneously indicated a final diagnosis not in agreement with
infectious AG were excluded from the analysis of supplementary ques-
tionnaire data.
Data of weekly questionnaires were analysed descriptively. We calcu-
lated the average number of cases per Sentinella-physician and week and
the number of initial consultations due to AG per 1’000 PPCs per week.
Additionally, we estimated the incidence and total number of first con-
sultations due to AG at the primary care level for 2014 in Switzerland by
the standard extrapolation of the Sentinella system which is described
elsewhere [16].
Due to the mid-study change in the sampling scheme of supplement-
ary questionnaires, analyses of the supplementary questionnaire data
were weighted according to the sampling probability: information from
the supplementary questionnaire of cases reported during the first half
of the study period was analysed using a sampling weight of 3.25 (as
each physician was required to submit a supplementary questionnaire
for each case seen during 16 of 52 weeks; 1/(16/52) = 3.25) while in-
formation reported during the second half had a sampling weight of 1
(supplementary questionnaire required for every case). Point-estimates
including 95% confidence interval (CI) and interquartile ranges (IQR) for
medians are reported for weighted analyses. Data from supplementary
questionnaires were analysed descriptively and differences were assessed
for significance by weighted, univariable logistic regression. For all ana-
lyses involving employment status, only patients aged 15–64 years were
considered. Data were analysed and represented graphically using Stata
13.1 (StataCorp.). Maps were created using ArcGIS 10.2.1 for desktop
(Environmental Systems Research Institute, Inc., Esri).
Results
Physician and patient characteristics
In total, 3’867 cases of AG were reported on weekly questionnaires by
172 participating Sentinella-physicians. After exclusion of cases repor-
ted by not regularly reporting Sentinella-physicians (130 cases) and for
other reasons (3 cases), 3’734 cases were used for analyses of weekly ques-
tionnaires. 2’200 cases were retained for the analyses of supplementary
questionnaires. The detailed inclusion process is described in figure 11.1.
Out of 172 physicians registered in the Sentinella system in 2014, 154
of the regularly reporting physicians reported at least one case of AG
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Table 11.1: Basic characteristics of acute gastroenteritis cases reported on
the weekly and supplementary questionnaires by physicians from the Swiss
Sentinel Surveillance Network in 2014
Weekly
form
Supplementary questionnaire
Cases included in
analysis (N )
3’734 2’200
Proportion of male
cases, % (95% CI)
50.2 50.6 (48.0–53.3)
Median age, years
(IQR)
21 (5–41) 22 (6.0 [95% CI 2.6–9.4]–43.0
[95% CI 38.1–47.9])
Physicians’ area of
specialisation
General medicine, %
(95% CI)
35.3 37.5 (29.9–45.8)
Internal medicine, %
(95% CI)
26.7 27.6 (21.1–35.4)
Paediatrics, % (95%
CI)
38.0 34.9 (25.7–45.3)
Stool testing initiated,
% (95% CI)
10.9 12.3 (10.1–14.8)
Hospitalised, % (95%
CI)
2.0 2.7 (1.9–3.7)
on the weekly questionnaire. Over the whole study period, individual
physicians reported up to 400 cases (median 17, IQR 7–29). A total of
144 physicians submitted at least one supplementary questionnaire of a
case fulfilling the case definition (Figure 11.1). The subsample of cases
with supplementary questionnaires was comparable to cases reported on
weekly forms in terms of basic patient characteristics (Table 11.1).
Median age of AG cases was 21 years (IQR 5–41 years). Children, ad-
olescents and young adults (age groups <1, 1–4, 5–9, 10–14, 15–19 and
20–29 years) were overrepresented among AG cases consulting a physi-
cian compared to the frequency of those age groups in the general Swiss
population for both genders (Figure 11.2). In the age group of 10–14
year olds, males were more frequent than females. In adults, female
cases aged 20–29 years were most frequently reported while in males the
30–44 year age group predominated.
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Figure 11.1: Study profile of notified cases and reporting physicians. Acute
gastroenteritis study, Swiss Sentinel Surveillance Network, 2014.
AG acute gastroenteritis, PPC physician-patient contact
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Figure 11.2: Age distribution by sex among acute gastroenteritis cases repor-
ted by Sentinella-physicians on weekly and/or supplementary questionnaires.
Swiss Sentinel Surveillance Network, 2014; age distribution of Swiss population
(official numbers [17]) added for comparison
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Burden of AG at primary care level
Each week, 15–139 cases (median 69, IQR 54–80) were reported (Fig-
ure 11.3). Case numbers were highest during the first weeks of the year
(maximum in week 4) and decreased thereafter. A median rate of 5.4
first consultations due to AG per 1’000 PPCs per week (IQR 4.6–6.7)
was observed. The notifications correspond to 2’146 first consultations
due to AG at primary care level per 100’000 inhabitants or 174’610 first
consultations due to AG in Switzerland in 2014 using the standard ex-
trapolation method of the FOPH for Sentinella data. Incidence (of first
consultations) by Sentinella-region is displayed in figure 11.4.
Health care seeking and clinical presentation
The median time from symptom onset to first consultation was 2 days
(95% CI 2.0–2.0, IQR 1.0 [95% CI 1.0–1.0]–3.0 [95% CI 2.4–3.6]). The
majority of patients (87.9% [95% CI 85.6–89.9]) suffered from diarrhoea
(Table 11.2). Loss of appetite was reported for 63.5% (95% CI 58.4–
68.4), abdominal pain or cramps for 61.1% (95% CI 57.0–65.1), nausea
for 60.4% (95% CI 56.6–64.1) and vomiting for 57.5% (95% CI 54.3–
60.7) of patients. Less frequently reported signs and symptoms included
flatulence, fever, dehydration and headache.
The majority of patients consulted the Sentinella-physician only once
(79.6%, 95% CI 76.5–82.4) (Table 11.2). The median general condition
of cases as reported by Sentinella-physicians at the time of first con-
sultation was 7 (95% CI 6.5–7.5, IQR 5.0 [95% CI 4.5–5.5]–9.0 [95% CI
8.5–9.5]) on a rating scale from 1 (poor) to 10 (good). Overall, 86.3%
(95% CI 83.1–89.0) of employed patients were unable to work. The odds
for a good general condition (7 or above) was lower for employed patients
compared to unemployed patients although not significantly (odds ratio
[OR] 0.76, 95% CI 0.52–1.11, p=0.159). The median duration of sick
leave was 4 days (95% CI 3.8–4.2, IQR 3.0 [95% CI 3.0–3.0]–5.0 [95%
CI 4.5–5.5]). For all except seven cases, the duration of sick leave was
below 15 days.
The hospitalisation rate was 2.7% (95% CI 1.9–3.7). The highest hos-
pitalisation rate was observed for the >74 year age group (11.5%, 95%
CI 6.4–19.9) whereas for the remaining age groups the rates were below
4%. For 2.0% (95% CI 1.4–2.9) of patients, Sentinella-physicians repor-
ted sequelae, like dehydration, diverticulitis, or colitis. No deaths due to
AG were reported.
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Figure 11.3: Acute gastroenteritis cases reported by physicians from the
Swiss Sentinel Surveillance Network in 2014 (28.12.2013–26.12.2014): weekly
case numbers (bars) and number of initial AG consultations per 1’000 physi-
cian-patient contacts (PPCs, “consultations”) per week (line).
Vertical, dashed line: date of change of sampling scheme (from subsample of
cases with supplementary questionnaires to supplementary questionnaire for
every reported case)
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Figure 11.4: Calculated incidence of first consultations due to acute gast-
roenteritis at primary care level in Switzerland by Sentinella-region, based on
standard extrapolation. Swiss Sentinel Surveillance Network, 2014.
Note: an outlier (one physician reporting 400 cases) was excluded from this
extrapolation by region.
Source of map shapefile: Swiss Federal Office of Topography
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Stool diagnostics and results
Sentinella-physicians reported the initiation of stool specimen testing in
12.3% (95% CI 10.1–14.8); in 11.6% (95% CI 9.5–14.1) of cases they in-
dicated that the sample was actually sent off (Table 11.3). The odds for
stool testing did not differ between sexes ([female vs. male]: OR 1.13,
95% CI 0.84–1.50, p=0.423) but differed by age group (p<0.001): The
proportion of stool testing was generally higher among older age groups.
Paediatricians initiated stool testing less frequently (OR 0.32, 95% CI
0.18–0.55, p<0.001) than general practitioners. The odds of initiating
stool testing did not differ significantly for internists compared to gen-
eral practitioners (OR 1.13, 95% CI 0.71–1.78, p=0.610).
Even though the questionnaire explicitly asked for the main reason for
initiating stool testing, multiple answers were given for 31.0% (95% CI
24.9–37.8) of cases. The three most frequent reasons mentioned were
protracted course of disease (29.4%, 95% CI 21.9–38.2), poor general
condition (11.5%, 95% CI 6.9–18.4) and due to a specific symptom (9.5%,
95% CI 4.6–18.6) when excluding those with multiple answers. When
considering also multiple answers, staying abroad before symptom onset
was the third most frequent reason (data not shown).
Travelling within the 7 days preceding symptom onset was reported
for 9.0% (95% CI 7.4–10.8) of cases. Patients with recent travel his-
tory were significantly more likely to undergo stool testing than patients
not reporting any recent travels (OR 3.60, 95% CI 2.47–5.33, p<0.001).
Among patients with recent travel history, 30.0% (95% CI 22.7–38.6)
were tested while for patients without travel to a foreign country in the
7 days preceding the symptom onset this proportion was 10.6% (95% CI
8.6–13.0). “Staying abroad” was indicated as the main reason for testing
for 40.8% (95% CI 24.4–59.6) of patients with a travel history. Protrac-
ted course of disease was the second most often mentioned reason for
stool testing among patients with travel history abroad (17.4%, 95% CI
7.2–36.2).
A positive test result was reported for more than one-third (35.9%, 95%
CI 29.2–43.2) of tested patients while for the remaining 64.1% (95% CI
56.8–70.8) of patients test results were negative or not specified. The
most frequently identified pathogen was Campylobacter spp. (50.8%,
95% CI 39.2–62.3) followed by norovirus (10.9%, 95% CI 5.0–21.9), and
Blastocystis spp. (9.6%, 95% CI 4.0–21.1) (Table 11.3). Other patho-
gens identified included rotavirus, Clostridium spp., Entamoeba spp.,
pathogenic E. coli, Candida spp., Salmonella spp., Giardia spp., mi-
crosporidia, adenovirus, Aeromonas spp. and hepatitis E virus. Two
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Table 11.2: Characteristics of cases with acute gastroenteritis at first con-
sultation and number of consultations as reported by primary care physicians
from the Swiss Sentinel Surveillance Network, 2014
Number of
cases [n]
Percent [%] (95%
confidence interval)
Signs and symptoms until first consultationa (N=2’200)
Diarrhoea 1’940 87.9 (85.6–89.9)
Diarrhoea with blood and/or
mucus
249 10.8 (8.5–13.7)
Loss of appetite 1’345 63.5 (58.4–68.4)
Abdominal pain/cramps 1’329 61.1 (57.0–65.1)
Nausea 1’296 60.4 (56.6–64.1)
Vomiting 1’227 57.5 (54.3–60.7)
Flatulence 896 40.6 (35.6–45.7)
Fever 530 25.0 (22.3–27.9)
Dehydration 183 8.5 (6.6–11.0)
Headache 68 3.2 (2.1–4.8)
General condition at first consultation (according to physicians’
impression) (N=2’115)
Poor: 1 1 0.09 (0.01–0.6)
2 28 1.1 (0.7–1.9)
3 95 4.6 (3.3–6.4)
4 177 8.4 (6.2–11.4)
5 237 10.7 (7.9–14.4)
6 228 10.1 (8.3–12.3)
7 318 15.8 (13.6–18.2)
8 476 23.9 (20.6–27.5)
9 356 16.5 (13.5–20.1)
Good: 10 199 8.7 (6.3–12.0)
Number of consultations (N=2’200)
1 1’742 79.6 (76.5–82.4)
2 365 16.4 (14.0–19.2)
3 75 3.2 (2.4–4.2)
4 18 0.8 (0.4–1.5)
a Multiple answers possible
pathogens were identified in 11.5% (95% CI 5.4–22.9) of the 98 cases
with a positive stool test result.
228
Published article
Table 11.3: Frequency of and reasons for prescription of stool diagnostics
among acute gastroenteritis patients consulting primary care physicians from
the Swiss Sentinel Surveillance Network, 2014
Number of
cases [n]
Percent [%] (95%
confidence interval)
Stool test initiated (N=2’176) 286 12.3 (10.1–14.8)
Stool test performed
(N=2’176)
272 11.6 (9.5–14.1)
Main reason for stool testing (N=197)
Protracted course of disease 62 29.4 (21.9–38.2)
Poor general condition 23 11.5 (6.9–18.4)
Specific symptom 19 9.5 (4.6–18.6)
Stay abroad before symptom
onset
18 7.8 (4.5–13.1)
Comorbidity 10 5.3 (2.5–10.7)
Outbreak investigation 8 5.3 (1.6–16.4)
Occupation 10 3.8 (1.8–8.1)
Resident/patient institution 2 2.0 (0.5–8.0)
Age 2 1.3 (0.3–6.2)
Contact to animals 1 1.0 (0.1–6.8)
Contact to ill persons 1 0.3 (0.04–2.3)
Other reasons (e.g. elevated
CRP level, leucocytosis, re-
cent antibiotic therapy)
20 10.5 (6.5–16.6)
Reason not specified 21 12.2 (6.4–22.2)
Pathogens identifieda (N=98)
Campylobacter spp. 57 50.8 (39.2–62.3)
Norovirus 8 10.9 (5.0–21.9)
Blastocystis spp. 6 9.6 (4.0–21.1)
Rotavirus 5 8.9 (2.9–24.2)
Clostridium spp. 7 7.3 (2.9–17.2)
Entamoeba spp. 4 5.4 (1.7–15.8)
Pathogenic E. coli 6 5.3 (2.0–13.1)
Candida spp. 3 4.8 (1.4–15.6)
Salmonella spp. 6 3.8 (1.7–8.2)
Other (Giardia spp., adenov-
irus, Aeromonas spp., hepat-
itis E)
4 4.0 (1.2–12.5)
a Two pathogens were identified in 11.5% (95% CI 5.4–22.9) of the 98
cases with a positive stool test result
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Table 11.4: Frequency of prescription of antibiotic and symptomatic treat-
ment, and reasons for prescription of antibiotic therapy among acute gast-
roenteritis patients consulting primary care physicians from the Swiss Sentinel
Surveillance Network, 2014
Number of
cases [n]
Percent [%] (95%
confidence interval)
Antibiotic therapy prescribed
(N=2’089)
195 8.5 (6.5–11.0)
Antibiotic class prescribeda (N=195)
Quinolone 123 60.2 (48.5–70.9)
Macrolide 30 15.0 (9.3–23.3)
Metronidazole 21 12.8 (7.7–20.5)
Aminopenicillin 22 11.6 (6.3–20.5)
Trimethoprim/sulfamethoxazole 7 4.5 (1.5–12.7)
Cephalosporin 5 3.1 (1.1–8.6)
Tetracycline 1 0.3 (0.0–2.4)
Not specified 5 1.6 (0.6–4.4)
Main reason for prescription of antibiotics (N=195)
Bacterial gastroenteritis 64 41.1 (25.0–59.5)
Duration of illness 12 9.0 (3.4–19.6)
Specific symptom 10 7.2 (3.4–14.8)
Expecting attitude of patient 6 4.5 (1.7–11.6)
Poor general condition 6 3.6 (1.3–9.2)
Immunosuppression 3 3.2 (0.9–11.0)
High, prolonged fever 5 3.1 (1.0–9.3)
Polymorbidity 4 2.7 (0.8–8.5)
Preventively 3 2.3 (0.6–8.5)
Other reasons (e.g. elevated
CRP level, leucocytosis, co-
infection)
22 13.3 (7.9–21.6)
Reason not specified 14 9.9 (5.2–18.2)
Recommended symptomatic treatmenta (N=1’909)
Fluid replacement with tea, broth 1’089 58.3 (53.0–63.3)
Probiotics 875 45.9 (39.1–52.8)
Antiemetics 851 45.4 (40.5–50.4)
Antidiarrhoeals 584 28.8 (23.6–34.6)
Analgesics 330 16.3 (12.8–20.5)
Spasmolytics 287 15.0 (11.5–19.2)
Rehydration solution 201 11.4 (7.8–16.4)
Intravenous rehydration 36 1.7 (1.1–2.6)
a Multiple answers possible
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Approaches for symptomatic and antibiotic therapy
In 92.0% (95% CI 89.8–93.8) of cases, Sentinella-physicians gave dietary
recommendations, or prescribed symptomatic and/or antibiotic treat-
ment. Most commonly, patients were advised to care for fluid replace-
ment by the intake of sufficient tea, broth etc. (58.3%, 95% CI 53.0–63.3)
(Table 11.4). Distinct rehydration therapies such as electrolyte solution
(11.4%, 95% CI 7.8–16.4) and infusion therapies (1.7%, 95% CI 1.1–2.6)
were less frequently prescribed. Symptomatic treatment included probi-
otics (45.9%, 95% CI 39.1–52.8), antiemetics (45.4%, 95% CI 40.5–50.4),
antidiarrhoeals (28.8%, 95% CI 23.6–34.6), analgesics (16.3%, 95% CI
12.8–20.5), and spasmolytics (15.0%, 95% CI 11.5–19.2). Antibiotics
were prescribed in 8.5% (95% CI 6.5–11.0) of cases (Table 11.4).
The Sentinella-physicians initiated stool testing and prescribed antibiot-
ics at the first consultation in 33 cases (unweighted results, table 11.5).
Stool diagnostics revealed the presence of a pathogen susceptible to an-
tibiotics in 20 of these cases. No antibiotics were prescribed in 22 cases
even though a pathogen which is theoretically susceptible to antibiotics
was identified.
The majority of patients receiving antibiotics was treated with quino-
lones (60.2%, 95% CI 48.5–70.9), followed by macrolides, metronidazole,
aminopenicillin, trimethoprim/sulfamethoxazole, cephalosporin and tet-
racycline (Table 11.4). Two or more antibiotic classes were reported to
be used for 8.5% (95% CI 4.6–15.2) of cases. No antibiotic class was
reported for 1.6% (95% CI 0.6–4.4) of cases treated with antibiotics.
Main reasons for the prescription of antibiotic therapy included (suspi-
cion of) bacterial gastroenteritis (41.1%, 95% CI 25.0–59.5), duration of
illness (9.0%, 95% CI 3.4–19.6), a specific symptom (7.2%, 95% CI 3.4–
14.8) and others (Table 11.4). Sentinella-physicians mentioned several
reasons for 23.9% (95% CI 16.6–32.2) of the patients despite being asked
to indicate only the main reason. When considering also multiple an-
swers, “poor general condition” was the third most frequently mentioned
reason for antibiotic therapy (data not shown).
Similar to stool testing, antibiotic prescription was associated with age
(p<0.001) and with the physicians’ specialty (p<0.001) but not with
sex (p=0.511) (data not shown). Again, children and adolescents were
less frequently treated with antibiotics compared to adults. Among the
>74-year-old age group, one-fifth of cases received antibiotics (20.0%,
95% CI 12.8–29.7). Nearly three-quarter of the antibiotic therapies were
prescribed at the first consultation (71.3%, 95% CI 60.5–80.1). These
patients had a lower general condition according to physicians’ impres-
231
11 Acute gastroenteritis in primary care, Sentinella
Table 11.5: Time point of prescription of stool testing and antibiotic treat-
ment among acute gastroenteritis patients consulting primary care physicians,
Swiss Sentinel Surveillance Network, 2014
No an-
tibiotics
prescribed
Antibiotic
prescribed
at first con-
sultation
Antibiotic
prescribed
at follow-up
consultation
No stool test initiated 1’713 70 11
Stool test initiated at first
consultation
68 33 7
Thereof with positive result
for a pathogen susceptible to
antibiotic therapya
12 20 5
Thereof with positive result
for a pathogen not
susceptible to antibiotic
therapya
4 1
Stool test initiated at
follow-up consultation
56 3 22
Thereof with positive result
for a pathogen susceptible to
antibiotic therapya
10 2 11
Thereof with positive result
for a pathogen not
susceptible to antibiotic
therapya
4 1
Unweighted results. Cases with missing information on (date of) antibiotic
prescription and/or (date of) stool test were excluded
a Not considering possible antibiotic resistances and treatment recommend-
ations
sion (median 5.0, 95% CI 4.0–6.0, IQR 4.0 [95% CI 3.0–5.0]–7.0 [95%
CI 6.0–8.0]) than patients receiving antibiotics later on (median 7.0,
95% CI 6.0–8.0, IQR 5.0 [95% CI 4.0–6.0]–8.0 [95% CI 7.0–9.0]) and also
suffered slightly more frequently from fever (44.7%, 95% CI 34.5–55.4 vs.
38.9%, 95% CI 24.0–56.2). However, both differences were not statistic-
ally significant. Patients with a recent history of travel had significant
higher odds to undergo antibiotic therapy (OR 1.75, 95% CI 1.06–2.88,
p=0.029).
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Discussion
This study underscored that acute gastroenteritis is common in Swiss
primary care: extrapolated annual consultation numbers (175’000 first
consultations) are comparable to those of influenza-like illness (ILI) dur-
ing an influenza season (varying between 107’000 and 276’000 ILI cases
in the last three seasons [18-20]). The majority of patients is sympto-
matically treated and does not require multiple consultations. However,
most episodes of AG lead to a sick leave of several days, though the phys-
ician-assessed general state of the patients is considered as “fairly good”.
Stool specimen testing is not systematically conducted and antibiotic
therapy is applied to less than 10% of patients.
Multiple factors influence physicians’ decision making
Sentinella-physicians reported more than one reason for stool testing in
a third of cases despite being explicitly asked for the main reason in the
questionnaire. This suggests that a combination of factors plays a role
in decision making. The same holds true for the prescription of antibi-
otic treatment where in around a quarter of cases several reasons were
mentioned albeit physicians were asked to indicate the main reason. The
reasons mentioned most frequently for stool testing – namely protrac-
ted course of disease, poor general condition, due to a specific symptom
and a history of recent travel – are in line with findings from other
studies: three of the aforementioned four factors (all except “specific
symptom”) were also mentioned by GPs participating in a qualitative
study in Switzerland [8] and in a study from Northern Ireland and the
Republic of Ireland [21]. The Irish study further reported that stool
testing is frequently prescribed if the illness is associated with an out-
break or if the physicians suspect a link with a particular consumed food
item or food premises (pub, restaurant, take away). Similarly, a qualit-
ative study among GPs in the UK found that long duration of illness,
recent travel, blood in the stool, patient being unwell and exclusion of
an infectious cause were the reasons mentioned most frequently for stool
testing [22]. Factors most strongly associated with requesting a stool
culture were bloody diarrhoea, diarrhoea lasting more than 3 days, and
a diagnosis of AIDS in a postal survey among physicians in the US [23].
Considering that protracted course of disease and poor general condi-
tion were mentioned most frequently as main reasons for stool testing
in our study, the difference in reported general condition at the time of
first consultation among tested and untested patients seems rather small
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(median 7.0, 95% CI 6.5–7.5, IQR 5.0 [95% CI 4.5–5.5]–8.0 [95% CI 7.5–
8.5] vs. median 8.0, 95% CI 7.5–8.5, IQR 6.0 [95% CI 5.5–6.5]–9.0 [95%
CI 8.5–9.5]). One explanation for this is that a “protracted course of
disease” does not necessarily equate with a poor general condition but
simply reflects the lack of improvement of symptoms with an average or
fairly good general condition. Most of the aforementioned studies [8, 21,
22] acknowledge that decisions for testing are subjective and depend on
the physicians’ experiences and attitudes.
AG, whether of viral or bacterial origin, is usually self-limiting [5]. An-
tibiotics are mainly recommended for severely affected patients and are
most effective if given early [5, 24, 25]. “Bacterial gastroenteritis” was
most frequently mentioned as main reason for antibiotic therapy in our
study. We cannot judge whether this reasoning was based on laboratory
results or on physicians’ experience. However, only two cases with pos-
itive stool test results for pathogens not susceptible to antibiotics were
prescribed antibiotics in our study. The second most common reasoning
for antibiotic treatment, namely duration of illness, was also reported
by Swiss GPs in an extensive qualitative assessment [8]. A study from
Poland concluded that factors associated with antibacterial drug admin-
istration included the work environment of the physician (working in
large practices and hospital wards favoured antibiotic prescription com-
pared to small practices), presence of fever, or mucus or blood in stool,
age of the patient and (rural/urban) residence [26]. The presence of
fever, or mucus or blood in stool could also be a factor leading to anti-
biotic therapy in our study as the third most frequent mentioned main
reason for antibiotic prescription was suffering from a specific symptom.
Some 62% of all cases with a laboratory-confirmed Campylobacter infec-
tion received antibiotic treatment in our study. This finding is important
in the context of antibiotic resistance development. More than half of
those patients received quinolones and one-third was treated with mac-
rolides – a finding confirming results from an earlier qualitative study
among Swiss GPs [8]. Given antibiotic resistance levels for fluoroquino-
lones as high as 55.3% for human Campylobacter isolates in Switzerland
in 2014 [27], these studies’ findings underscore the need for changes in
prescription practise in Switzerland. A similar level of resistance (60.2%)
was observed in Europe in 2014 [28]. Consequently, the European Food
Safety Authority and the European Centre for Disease Prevention and
Control do no longer recommend fluoroquinolones for the empirical treat-
ment of human campylobacteriosis.
234
Published article
Physicians’ case management impacts on the mandatory
surveillance system
A stool test was performed only for 11.6% of patients consulting a Sen-
tinella-physician due to AG. Of these, 19.8% (95% CI 15.1–25.6) had a
positive result for a notifiable pathogen. Hence, a very small propor-
tion of 2.3% (=11.6 × 19.8%) of AG patients consulting a Sentinella-
physician were actually reportable to the mandatory reporting system.
This is in line with Swiss physicians’ typical treatment pattern for AG
of “wait & see”, which can be followed by a “treat & see” approach or
a desirable (from the perspective of the NNSID) “test & see” or “test &
treat” approach based on illness progression [8]. Considering the (main)
reasons mentioned for stool testing, patients with a prolonged duration
of illness and patients reporting recent travel abroad are likely overrep-
resented among notified cases. The proportion of patients with stool
testing varies substantially between countries: it was found to be 4.3
or 9.1% in France [29], 6% in Italy [30], 7% in Ireland [31], 12% in the
Netherlands [32], 19% in the US [33] and 25% in Denmark [34].
The pathogen most often identified through stool testing in this study
(Campylobacter spp.) is also the pathogen most frequently reported to
Swiss national surveillance. Norovirus, which is not notifiable in Switzer-
land but in several countries of the European Union, was the second most
common identified pathogen.
Mild disease with high socio-economic burden
Physicians rated the general condition of AG patients as relatively good.
Nevertheless, a high proportion of 86.3% of employed patients was not
able to work due to the illness. Sick leave is considerable with a me-
dian of 4 days. The risk of transmission seems to play a subordinate
role as a reason for inability to work. Similar findings were reported in
a French study where 79% of working patients were on sick leave for a
median duration of 3 days [35]. In a Danish study, only 35% of patients
with AG reported having missed work or school as a result of illness
[34]. However, this Danish study was a population-based study in which
only 13% of patients were seen by a physician and/or hospitalised. In
our study, we did not observe a difference in time from symptom onset
to consultation between employed and unemployed patients (data not
shown). This indicates that the need of a medical certificate is unlikely
to be a main reason for consultation.
It is well known that some pathogens causing AG are easily transmitted
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from human-to-human, especially viruses, and contact with diarrhoea
patients has been described as a risk factor for AG previously [35, 36].
In our study, 28.6% (95% CI 24.9–32.6) of the patients had contact to
other people suffering from similar signs and symptoms in the 7 days
preceding symptom onset. Thus, it is possible that these patients had
a common source of infection or transmitted the disease among each
other.
In summary, our findings suggest that AG is a common, but gener-
ally mild disease which results, however, in a high social and economic
burden. The overall financial burden due to AG (including losses in
productivity) is likely a multiple of the healthcare costs estimated for
Switzerland in the range of e29–45 million annually [14].
Sentinella is invaluable to investigate current public
health issues
All information for this study was derived from physicians in the Swiss
Sentinel Surveillance Network. This study was specifically set up by the
FOPH to clarify current epidemiological questions about gastroenteritis
in Switzerland, using a national primary care sentinel surveillance plat-
form.
We consider it a strength of the study to have obtained information on
diagnosis and treatment directly from treating primary care physicians.
However, the actual duration of sick leave might have been longer or
shorter than reported or certified by the physician. Similarly, we could
not record the overall duration of the illness as in this study we could
not send out follow-up questionnaires at the end of an AG episode.
A limitation of our study is the change in sampling scheme for supple-
mentary questionnaires for the second half of the study period, especially
considering that AG is subject to seasonal variation. However, we be-
lieve that changing to full sampling and using weighted analyses to adjust
for the change in sampling scheme resulted in more reliable data than
continuing without changing the sampling scheme and obtaining far less
supplementary questionnaires.
We expected to observe a seasonality of case reports considering the lit-
erature [4, 36], results of a previous study [8] and surveillance data [12],
with a peak of AG in winter (December–March) and during summer
(June–September). Instead we found a decreasing number of initial con-
sultations per 1’000 PPCs over the year which we assume is partially due
to reporting fatigue of the Sentinella-physicians partaking in the study.
This is supported by a survey conducted among Sentinella-physicians in
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which they were asked about the time required for participating in the
sentinel network – in total and for the different research topics. Physi-
cians indicated that the study on AG was comparatively time-consuming
although the majority indicated that the total amount of time required
for notifying was acceptable [37].
Conclusion
Not to our complete surprise, this study has shown that acute gastroen-
teritis is a common disease in Switzerland with consultation frequencies
comparable to influenza-like illnesses. AG presented to physicians lead
to substantial sick leave in the employed, resulting in considerable socio-
economic costs due to productivity loss.
Furthermore, as suspected, the study confirms that the National Notific-
ation System for Infectious Diseases captures – if at all – only a fraction
of the scope of the problem (see introduction for currently notifiable
diarrhoea-causing pathogens). Hence, the Swiss Sentinel Surveillance
Network, Sentinella, represents a very important complementary sur-
veillance instrument to grasp principal dynamics of infectious disease
epidemiology at the primary care level.
The FOPH and the Federal Food Safety and Veterinary Office, being re-
sponsible to maintain population health and food safety in Switzerland,
are currently lacking effective tools for pinpointing and a comprehens-
ive national programme addressing the control of foodborne diseases and
AG. While there are efforts to increase food safety and consumer hygiene
including campaigns to increase awareness for food and kitchen hygiene
among consumers in Switzerland, prevention measures to reduce con-
tamination at food production or retail level are incomplete. Overall,
there is an imbalance in national disease prevention and control efforts
for AG considering that national strategies to reduce the burden of sea-
sonal influenza – an infection with a disease burden comparable to AG
– exist since many years.
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Summary
Rising numbers of campylobacteriosis case notifications in Switzerland
resulted in an increased attention to acute gastroenteritis (AG) in gen-
eral. Patients with a laboratory-confirmed Campylobacter infection per-
ceive their disease as severe and around 15% of these patients are hos-
pitalized. This study aimed at estimating healthcare costs due to AG
and campylobacteriosis in Switzerland. We used official health statistics,
data from different studies and expert opinion for estimating individual
treatment costs for patients with different illness severity and for extra-
polating overall costs due to AG and campylobacteriosis. We estimated
that total Swiss healthcare costs resulting from these diseases amount
to e29–45 million annually. Data suggest that patients with AG con-
sulting a physician without a stool diagnostic test account for e9.0–24.2
million, patients with a negative stool test result for Campylobacter spp.
for e12.3 million, patients testing positive for Campylobacter spp. for
e1.8 million and hospitalized campylobacteriosis patients for e6.5 mil-
lion/year. Healthcare costs of campylobacteriosis are high and most
likely increasing in Switzerland considering that campylobacteriosis case
notifications steadily increased in the past decade. Costs and poten-
tial cost savings for the healthcare system should be considered when
designing sectorial and cross-sectorial interventions to reduce the bur-
den of human campylobacteriosis in Switzerland.
Introduction
Since 1995 Campylobacter spp. has been the most frequently repor-
ted gastrointestinal bacterial pathogen in humans in Switzerland [1] and
since 2005 in the European Union (EU) [2]. An estimated 9.25 mil-
lion cases of campylobacteriosis occurred in 2009 in the 27 EU member
states, of which around 2% were reported [3]. Havelaar et al. estimated
the ‘true’ incidence rate of campylobacteriosis in these countries at 30–
13’500/100’000 population (350/100’000 in Switzerland).
In Switzerland, positive test results for Campylobacter spp. have to be
notified by diagnostic laboratories to the Federal Office of Public Health
(FOPH) since 1988 [4]. In 2012, 8’480 campylobacteriosis cases were re-
gistered within the National Notification System for Infectious Diseases
(NNSID), which is the highest number reported so far [1]. This corres-
ponds to a notification rate of 105 cases/100’000 resident population in
Switzerland. The extent to which campylobacteriosis contributes to the
public health burden of acute gastrointestinal illness is unknown. In The
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Netherlands, about twice the population size of Switzerland, approxim-
ately 4.8 million cases of gastroenteritis occur annually, whereby 220’000
patients need medical consultation [5].
A study among 69 general practitioners (GPs) concluded a rising aware-
ness of campylobacteriosis as a public health problem in Switzerland
(Supplementary material). Despite its mostly self-limiting nature, the
health burden of campylobacteriosis in the Swiss population may be sig-
nificantly higher than figures from the NNSID indicate. Severe cases
and complications such as Guillain-Barré syndrome, reactive arthritis
and post-infectious irritable bowel syndrome amplify the burden of dis-
ease and in particular the economic burden [6-8].
The estimated economic burden (equating healthcare costs at large, in-
cluding, e.g. loss of productivity and/or transportation and other direct
and indirect non-healthcare costs) of gastrointestinal infections or food-
borne illnesses in high-income countries varies between e14 (Australia
[9]) and e1’305 (United States [10]) per case in the community ([9-20]
in table 12.1). Thereby, healthcare costs account for e3–155/case in the
community [9-20]. This wide range is partially due to heterogeneity in
case definitions and definitions of economic burden. The yearly costs for
gastroenteritis due to 14 food-related pathogens and associated sequelae
in The Netherlands were estimated at around e468 million [11].
For campylobacteriosis, the estimated economic burden per case varies,
ranging from e117 (The Netherlands [17]) to e6’141 (United States [12])
([8,10-12, 17, 20, 26] in table 12.2). Healthcare costs of campylobacteri-
osis cases were estimated at e8/case in New Zealand, e82–280 in The
Netherlands and e163–253 in the United States ([8, 10-12, 20] in table
12.2). These numbers are difficult to compare as case definitions and
cost items included vary between studies. For example, sequelae due to
campylobacteriosis were considered in some studies while in others they
were not. Campylobacteriosis-associated acute gastroenteritis (AG)* ac-
counts for approximately 108’000 cases/year in The Netherlands, caus-
ing annual societal costs of about e81.5 million (including sequelae) [11].
In the EU, campylobacteriosis cases account for expenditures of public
health systems and for productivity losses of around e2.4 billion/year
according to the European Food Safety Authority [28]. The economic
burden highlights the importance of this widespread and common dis-
ease.
A quantification of healthcare costs due to AG and/or campylobacterio-
sis in Switzerland is lacking so far. Due to the rising number of campylo-
bacteriosis case notifications in recent years, we conducted several studies
which aimed at generating a better understanding of the epidemiology
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of campylobacteriosis in Switzerland. We investigated epidemiological
determinants [29], described time trends in notification data [1], the
campylobacteriosis-associated illness experience from the patients’ per-
spective [29, 30], the case management strategies of GPs (Supplementary
material) and laboratory positivity rates of Campylobacter spp. (Supple-
mentary material). In concert, these studies indicate that campylobac-
teriosis is causing a considerable burden of disease which considerably
impacts the health system in Switzerland and is likely associated with
high costs.
The aim of this study was to estimate the total annual costs for the
medical treatment of campylobacteriosis in Switzerland. However, given
that available data do not systematically distinguish campylobacteriosis
from AG we focused this analysis on available data of both conditions.
To the best of our knowledge, this is the first study estimating healthcare
costs due to AG and campylobacteriosis in Switzerland.
Methods
We developed patient management models and estimated their frequency
and associated costs from the perspective of the healthcare system.
Typology of patients: patient management models
Cost estimation was based on four different patient management mod-
els for AG which were derived from a broad expert consultation across a
purposive enquiry among practitioners in private general and specialized
practices (four), clinics and university hospitals (four), authors opinions
and data available to them: (i) patients consulting a physician without
stool testing (patient management model A), (ii) patients consulting a
physician with negative Campylobacter stool test results (patient man-
agement model B), (iii) patients consulting a physician and having a pos-
itive Campylobacter stool test result (patient management model C), and
(iv) hospitalized campylobacteriosis cases (patient management model
D).
Population figures as basis for modelling: sources and
approach
The number of notified campylobacteriosis cases occurring each year in
Switzerland was retrieved from the NNSID [1]. A study assessing the
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Table 12.1: Overview of selected studies estimating the cost of illness of gastrointestinal or foodborne illnesses
Costs includeda
First
author,
year
[ref.]
Nation Year Pathogens/disease
considered
(community cases,
unless specified
otherwise)
Cases
per
year
Dir-
ect
health-
care
costs
Pa-
tient
costs
(e.g.
travel
costs)
Prod-
ucti-
vity
losses
Oth-
ersb
Ex-
change
rate
used
(e1=
. . . )c
Dir-
ect
health-
care
cost,
per
case
(in
e)
Dir-
ect
health-
care
costs,
yearly
(in
mil-
lion
e)
Total
costs
per
case
(in
e)
Total
yearly
costs
(in
mil-
lion
e)
Hoffmann,
2015
[10]
United
States
2013 15 foodborne
pathogens
including
long-term
disabilities; only
domestically
acquired and
foodborne cases
8’914’713 X X X USD
1.34
155d 1’384 1’305d 11’636
Mangen,
2015
[11]
Netherlands 2011 14 foodborne
pathogens;
including sequelae
4’810’000 X X X EUR
1
31d 147 97d 468
Scharff,
2012
[12]
United
States
2010 All domestically
acquired,
foodborne illnesses
47’780’778 X X X USD
1.33
75 3568d 806–
1’227
38’506–
58’589
Friesema,
2012
[13]
Netherlands 2009 Gastroenteritis 4’600’000 X X X EUR
1
14d–
32d
63–
147
133–
151
611–
695
Gauci,
2007
[14]
Malta 2004/
05
Infectious
intestinal disease
164’471 X X X Lm
0.44e
72d 12 108 17
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Table 12.1: (continued)
Costs includeda
First
author,
year
[ref.]
Nation Year Pathogens/disease
considered
(community cases,
unless specified
otherwise)
Cases
per
year
Dir-
ect
health-
care
costs
Pa-
tient
costs
(e.g.
travel
costs)
Prod-
ucti-
vity
losses
Oth-
ersb
Ex-
change
rate
used
(e1=
. . . )c
Dir-
ect
health-
care
cost,
per
case
(in
e)
Dir-
ect
health-
care
costs,
yearly
(in
mil-
lion
e)
Total
costs
per
case
(in
e)
Total
yearly
costs
(in
mil-
lion
e)
Abelson,
2006
[15]
Australia 2004 Gastroenteritis
due to foodborne
illnesses
5’400’000f X X X AUD
1.69
22d 118 111d 598
Majowicz,
2006
[16]
City of
Hamilton,
Canada
2001 Acute
gastroenteritis
619’334g X X CAD
1.39
17d 11d 66 40
Van
den
Brand-
hof,
2004
[17]
Netherlands 1999 Gastroenteritis 4’476’399 X X X EUR
1
14 61 77 345
Roberts,
2003
[18]
England 1994 Infectious
intestinal disease
9’400’000h X X X GBP
0.66
(year
1999)
16d–
44d
153–
412
109d–
120
1’028–
1’128
Hellard,
2003
[9]
Australia 1999 Highly credible
gastroenteritis
15’173’430 X X AUD
1.65
3d 46 14d 208
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Table 12.1: (continued)
Costs includeda
First
author,
year
[ref.]
Nation Year Pathogens/disease
considered
(community cases,
unless specified
otherwise)
Cases
per
year
Dir-
ect
health-
care
costs
Pa-
tient
costs
(e.g.
travel
costs)
Prod-
ucti-
vity
losses
Oth-
ersb
Ex-
change
rate
used
(e1=
. . . )c
Dir-
ect
health-
care
cost,
per
case
(in
e)
Dir-
ect
health-
care
costs,
yearly
(in
mil-
lion
e)
Total
costs
per
case
(in
e)
Total
yearly
costs
(in
mil-
lion
e)
Lindquist,
2001
[19]
Municipality
of
Uppsala,
Sweden
1999 Foodborne
illnesses
500’000i
(Sweden)
X X SEK
8.81
117 58d 246 123
Scott,
2000
[20]
New
Zealand
1999 Foodborne
infectious disease
119’320 X X X X NZD
2.01
9d 1.0 229 27
Karve,
2014
[21]
United
States
2010/
11
Acute
gastroenteritis;
only cases
consulting a
physician, visiting
emergency
department and
inpatient care
setting
6’668’944j X USD
1.36
472d 3’151 472 3’151
a Categories represent only a very broad classification of costs included in the studies. Certain items may be included in different categor-
ies, depending on the study. For example, transportation cost was sometimes considered as ‘direct healthcare cost’ (when covered by the
health system) and sometimes included in ‘patient costs’.
b For example, food recalls, or intangible costs for reduced quality of life (intangible costs are monetary representations of pain, suffering
and fear which can be obtained through willingness-to-pay studies [22]), or value of statistical life for premature deaths.
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Table 12.1: (continued)
Costs includeda
First
author,
year
[ref.]
Nation Year Pathogens/disease
considered
(community cases,
unless specified
otherwise)
Cases
per
year
Dir-
ect
health-
care
costs
Pa-
tient
costs
(e.g.
travel
costs)
Prod-
ucti-
vity
losses
Oth-
ersb
Ex-
change
rate
used
(e1=
. . . )c
Dir-
ect
health-
care
cost,
per
case
(in
e)
Dir-
ect
health-
care
costs,
yearly
(in
mil-
lion
e)
Total
costs
per
case
(in
e)
Total
yearly
costs
(in
mil-
lion
e)
c Average exchange rates of the calendar year when the study was conducted (as indicated in the column ‘year’) were used and extracted
from [23].
d Calculated based on yearly case numbers and either costs per case (for calculating yearly costs) or yearly costs (for calculating costs per
case) as reported in the original publication.
e Exchange rate as indicated in the original publication (1 Maltese lira = e2.29)
f According to Hall et al. 2005 [24].
g Calculated based on a population size of 490’290 and 126’320 cases/100’000 population as reported in the original publication.
h Calculated based on total yearly costs (£742.8 million) divided by total costs per case (£79) as reported in the original publication,
rounded to the next 100’000.
i According to Norling, 1994 [25].
j Sum of estimated annual episodes of acute gastroenteritis in physician’s office (5’337’473), emergency department (1’032’064) and inpa-
tients (447’580) as reported in the original publication.
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Table 12.2: Overview of selected studies estimating the cost of illness of campylobacteriosis
Costs includeda
First
author,
year
[ref.]
Nation Year Pathogens/
disease
considered
(community
cases, unless
specified
otherwise)
Seque-
lae
con-
sidered
Cases
per
year
Dir-
ect
health-
care
costs
Pa-
tient
costs
(e.g.
travel
costs)
Prod-
ucti-
vity
losses
Oth-
ersb
Ex-
change
rate
used
(e1=
. . . )c
Dir-
ect
health-
care
cost,
per
case
(in
e)
Dir-
ect
health-
care
costs,
yearly
(in
mil-
lion
e)
Total
costs
per
case
(in
e)
Total
yearly
costs
(in
mil-
lion
e)
Hoffmann,
2015
[10]
United
States
2013 Campylobacter
spp.; only
domestically
acquired and
foodborne cases
GBS 845’024e X X X USD
1.34
253d 213 1710 1445
Mangen,
2015
[11]
Nether-
lands
2011 Campylobacter
spp.
GBS,
ReA,
IBS,
IBD
108’000 X X X EUR
1
280d 30 757 82
Scharff,
2012
[12]
United
States
2010 Campylobacter
spp.; only
domestically
acquired and
foodborne cases
GBS,
ReA
845’024e X X X USD
1.33
163 138d 1’392–
6’141
1’177–
5’189
Gellynck,
2008
[26]
Belgium 2004 Campylobacter-
associated
gastroenteritis
and sequelae
GBS,
ReA,
IBD
55’000 X X X EUR
1
n.a. n.a. 497d 27
Mangen,
2005
[8]
Nether-
lands
2000 Campylobacter
spp. and
sequelae
GBS,
ReA,
IBD
79’000 X X X EUR
1
82d 6.5 261d 21
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Table 12.2: (continued)
Costs includeda
First
author,
year
[ref.]
Nation Year Pathogens/
disease
considered
(community
cases, unless
specified
otherwise)
Seque-
lae
con-
sidered
Cases
per
year
Dir-
ect
health-
care
costs
Pa-
tient
costs
(e.g.
travel
costs)
Prod-
ucti-
vity
losses
Oth-
ersb
Ex-
change
rate
used
(e1=
. . . )c
Dir-
ect
health-
care
cost,
per
case
(in
e)
Dir-
ect
health-
care
costs,
yearly
(in
mil-
lion
e)
Total
costs
per
case
(in
e)
Total
yearly
costs
(in
mil-
lion
e)
Van
den
Brand-
hof,
2004
[17]
Nether-
lands
1999 Campylobacter
spp.
Not
con-
sidered
79’000f X X X EUR
1
n.a. n.a. 117d 9
Scott,
2000
[20]
New
Zea-
land
1999 Proportion of
foodborne
Campylobacter
spp.
GBS,
ReA,
HUS
75’345 X X X X NZD
2.01
8d 0.6 265 20
Roberts,
2003
[18]
England 1994 Campylobacter
spp.
Not
con-
sidered
n.a. X X X GBP
0.66
(year
1999)
n.a. 15 n.a. 106
GBS, Guillain-Barré Syndrome; HUS, haemolytic uraemic syndrome; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome;
n.a., not available; ReA, reactive arthritis.
a Categories represent only a very broad classification of costs included in the studies. Certain items may be included in different categor-
ies, depending on the study. For example, transportation cost was sometimes considered as ‘direct healthcare cost’ (when covered by the
health system) and sometimes included in ‘patient costs’.
b For example, food recalls, or intangible costs for reduced quality of life (intangible costs are monetary representations of pain, suffering
and fear which can be obtained through willingness-to-pay studies [22]), or value of statistical life for premature deaths.
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Table 12.2: (continued)
Costs includeda
First
author,
year
[ref.]
Nation Year Pathogens/
disease
considered
(community
cases, unless
specified
otherwise)
Seque-
lae
con-
sidered
Cases
per
year
Dir-
ect
health-
care
costs
Pa-
tient
costs
(e.g.
travel
costs)
Prod-
ucti-
vity
losses
Oth-
ersb
Ex-
change
rate
used
(e1=
. . . )c
Dir-
ect
health-
care
cost,
per
case
(in
e)
Dir-
ect
health-
care
costs,
yearly
(in
mil-
lion
e)
Total
costs
per
case
(in
e)
Total
yearly
costs
(in
mil-
lion
e)
c Average exchange rates of the calendar year when the study was conducted (as indicated in the column ‘year’) were used and extracted
from [23].
d Calculated based on yearly case numbers and either costs per case (for calculating yearly costs) or yearly costs (for calculating costs per
case) as reported in the original publication.
e According to Scallan et al. 2011 [27].
f Assumed, according to Mangen et al., 2005 [8].
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trend in Campylobacter positivity rates was conducted (thereafter re-
ferred to as the ‘Positivity study’). This study used data of eight Swiss
diagnostic laboratories on Campylobacter tests performed between 2003
and 2012. Positivity rates, defined as the proportion of Campylobacter-
positive to total number of Campylobacter tests, were calculated. The
number of Campylobacter tests performed in Switzerland was estimated
based on the preliminary positivity rate of 2012.
In 2013, a qualitative study among 69 GPs was conducted in Switzer-
land (thereafter referred to as the ‘Swiss GP study’). Using a semi-
structured questionnaire, physicians were interviewed about their case
management strategies for and general perception of AG and campylo-
bacteriosis. From this study, GPs’ estimates on the proportion of AG
patients with a stool test prescribed were available.
In 2014, the Swiss Sentinel Surveillance Network decided to study AG
for 12 months; 170 participating GPs reported all cases consulting due
to AG. This study (thereafter referred to as the ‘Sentinella study’) also
provides estimates on the proportion of patients with a stool test.
The results used for cost estimates from the ‘Positivity’, the ‘Swiss GP’
and the ‘Sentinella study’ are preliminary. Short summaries of these
studies including the preliminary results used for estimating healthcare
costs can be found in the supplementary material. Final results of all
these studies will be published separately.
We used the number of hospitalizations due to the ICD-10 code ‘A04.5
Campylobacter enteritis’ as reported in official hospital statistics pub-
lished by the Federal Statistical Office [31]. We compared this number
with estimates based on the hospitalization rate found in our case-con-
trol study on determinants of campylobacteriosis [29] and the number of
campylobacteriosis case notifications from the NNSID [1].
Population-level estimates
The number of campylobacteriosis cases registered at the FOPH was
assumed to correspond to the number of patients in management models
C and D in the whole of Switzerland. The number of hospitalizations in
Switzerland (patient management model D) was extracted from official
hospital statistics (hospitalizations due to Campylobacter enteritis, ICD-
10 code A04.5) [31].
Patients in management model D =
cases hospitalized due to ICD-10 code A04.5
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Patients in management model C =
cases in NNSID− patients in management model D
The proportion of positive to total number of campylobacteriosis tests
was used to estimate the number of patients in management model B
based on notified cases (hence, cases with a positive test result).
Patients in management model B =
cases in NNSID
positivity rate
(
= positive tests in x labs
all tests in x labs
) − cases in NNSID
The proportion of patients with stool testing (as opposed to consultation
without stool testing) was used to estimate case numbers for patient
management model A.
Patients in management model A =(
patients in management model B + cases in NNSID (= all tested)
proportion of patients with stool test
)
− all tested
The data sources used for the extrapolation from individual to popula-
tion-based costs are summarized in figure 12.1a.
Healthcare expenditures
Healthcare costs for each of the patient management models were estim-
ated by combining associated medical standard procedures with publicly
available respective rates for accounting. We extrapolated these indi-
vidual case management costs to estimate healthcare costs associated
with AG and campylobacteriosis in Switzerland in 2012.
Sources of cost data
We used different sources in order to calculate healthcare expenditure
due to Campylobacter infections: from the Swiss GP study, based on ex-
pert opinions and using preliminary results of the Sentinella study, treat-
ment schemes and standard approaches for case management (including
number and duration of consultations, laboratory tests performed and
medications prescribed) were identified. Consultation costs of GPs were
calculated using the number of points from the publicly available Swiss
medical tariff system, TARMED (as of June 2012) [32] and a point value
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Figure 12.1: Overview of data sources used for (a) extrapolation of treatment costs and (b) for cost estimation for acute
gastroenteritis and campylobacteriosis patients.
a Qualitative study about case management of campylobacteriosis patients among 69 general practitioners in Switzerland
(Supplementary material).
b Study on acute gastroenteritis conducted within the Swiss Sentinel Surveillance Network ‘Sentinella’ (www.sentinella.ch)
in 2014 (Supplementary material).
c Study on laboratory positivity rates of Campylobacter, Salmonella and Shigella diagnostic tests in Switzerland (Supple-
mentary material).
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of e0.7138 which is used in the canton of Bern [33]. Similarly, points for
laboratory diagnostics were extracted from the official tariff list (‘Ana-
lysenliste’; as of January 2012) using a point value of e0.83 applied
throughout Switzerland [34]. Costs for medications were extracted from
the list of pharmaceutical specialities (‘Spezialitätenliste’, version of 1
January 2012) [35]. Calculation of hospitalization costs was based on
the flat rates of the Swiss diagnosis-related group-based (DRG-based)
hospital reimbursement system and a base rate which is applied by sev-
eral regional hospitals in the canton of Bern, both for 2012 [36, 37].
Costs in Swiss francs were converted to Euros using an exchange rate
for the Euro of e0.83 per Swiss franc (average exchange rate January
2012–December 2012) [23]. The cost estimation process for the patient
management models is presented in figure 12.1b.
We obtained primary cost data from invoices for consultations of Cam-
pylobacter-positive patients, covering all patient consultations between
2011 and 2013 at the Swiss TPH travel clinic. This part of the study
was approved by the local ethical committee (Ethikkommission Nordw-
est- und Zentralschweiz ref. no. EKNZ: 2014–159).
Data analysis
Costs per patient treated
Differentiating by patient management model (models A–D), we evalu-
ated the costs for consultations, medication, laboratory tests and hos-
pitalization until conclusion of medical treatment. For all patient man-
agement models we defined two scenarios to account for some of the
heterogeneity of the patients and the case management strategies within
a given model: a minimal and an extended or prolonged scenario. The
proportions of patients treated with the minimal and the extended scen-
ario were estimated based on results of the case-control (e.g. proportion
of patients treated with antibiotics) [29] and the Sentinella study (e.g.
number of consultations; supplementary material). Afterwards, experts
were asked whether they considered the estimated proportions reason-
able. The two scenarios do not imply any chronology of the steps in-
volved.
Estimates for patient management model C were validated using real
patient records of the Swiss TPH travel clinic. Patient invoices were
entered in an electronic database and analysed using Stata v. 13 (Stata-
Corp., USA). Costs for laboratory tests or medication not primarily
associated with AG were excluded, i.e. tests for Echinococcus, Filaria,
flavivirus and Plasmodium, vaccines for rabies and tetanus, and electro-
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cardiograms. Laboratory tests performed in external laboratories were
invoiced by these laboratories and could, hence, not be considered in our
analysis. However, we added costs for one positive stool test for Cam-
pylobacter spp. as patients were selected based on having laboratory-
confirmed campylobacteriosis.
Results
Frequency of different patient management models in
Switzerland
In the NNSID, 8’480 cases of campylobacteriosis were registered in 2012
[1]. Preliminary results from the positivity study showed that 10.9%
of all campylobacteriosis tests were positive (Supplementary material).
Consequently, we estimated that 77’798 tests for Campylobacter spp.
were made in 2012, of which 69’318 had a negative test result (pa-
tient management model B). Estimates of the Swiss GP study indicated
that one in four AG patients has a stool test performed (Supplement-
ary material), suggesting that 233’394 patients consult a physician each
year without further stool testing (patient management model A). How-
ever, preliminary results from the Sentinella study suggest that only
11% (420/3’794) of patients had stool testing performed (Supplement-
ary material). In this case a total of 629’457 patients would be in patient
management model A.
The number of hospitalizations due to ‘Campylobacter enteritis’ (ICD-10
code A04.5) as reported in the official Swiss hospital statistics increased
steadily since 2004. In 2012, 1’348 hospitalizations were reported which
is the maximum so far (Figure 12.2). For comparison, 14.5% (23/159)
of interviewed patients in the recent case-control study, with laborat-
ory-confirmed campylobacteriosis, reported hospitalization due to their
illness [29]. Considering the case notification numbers of 2012 (8’480
cases), this proportion would result in 1’230 hospitalizations (patient
management model D). Patient management model C includes all no-
tified cases except those being hospitalized (1’348), resulting in 7’132
patients annually in Switzerland.
Individual case management costs for AG and
campylobacteriosis patients
The costs per case are highly variable ranging from e30 (patient man-
agement model A) to e4’828 (patient management model D). The cost
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Figure 12.2: Number of hospitalizations due to ICD-10 code A04.5 ‘Campylobacter enteritis’ in Switzerland from 2004
to 2012 (blue dotted line with circles, left axis, [31]), number of hospitalizations extrapolated from results of a case-control
study in Switzerland [29] assuming hospitalization of 14.5% of cases registered in the National Notification System for
Infectious Diseases (NNSID) (green dashed line with triangles, left axis) and number of case notifications from the NNSID
[1] (black solid line with squares; right axis).
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Table 12.3: Healthcare costs associated with the management of acute gastroenteritis and campylobacteriosis for four
patient management models with two scenarios each (values reflect costs in e)
Patient management
model A
Patient management
model B
Patient management
model C
Patient management
model D
Consultation without
stool test
Consultation with neg-
ative stool culturea
Consultation with pos-
itive stool culturea
Hospitalization
Minimal scenario 10 min
consultationb
19.02 15 min
consultationb
31.69 15 min
consultationb
31.69 15 min
consultationb
31.69
1 medicationc 10.79 Stool
culturea
(negative)
64.74 Stool
culturea
(positive)
128.65 Hospital stay
(DRG
G67Be)
4’727.36
Taking blood
sample
5.85 Taking blood
sample
5.85
Haemogramd
and CRP
18.26 Haemogramd
and CRP
18.26
1 medicationc 10.79 1 medicationc 10.79
5 min
reviewing
patient file
12.68 5 min
reviewing
patient file
12.68
5 min
telephone
consultation
12.68 5 min
telephone
consultation
12.68
Total, minimal scenario 29.81 156.68 220.59 4’759.06
Extended scenario + Taking
blood sample
5.85 + Antibiotic 24.90 + Antibiotic 24.90 + 5 min
reviewing
patient file
12.68
(costs additional to
minimal scenario)
+
Haemogramd
and CRP
18.26 + Pharmacy
feesf
6.27 + Pharmacy
feesf
6.27 + Taking
blood sample
5.85
+ 10 min
second
consultationb
19.02 + 10 min
second
consultationb
19.02 + 10 min
second
consultationb
19.02 +
Haemogramd
and CRP
18.26
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Table 12.3: (continued)
Patient management
model A
Patient management
model B
Patient management
model C
Patient management
model D
Consultation without
stool test
Consultation with neg-
ative stool culturea
Consultation with pos-
itive stool culturea
Hospitalization
+ 15 min
second
consultationb
31.69
Total, extended scenario 72.93 206.87 270.78 4’827.53
Proportion of patients
requiring extended
scenario:
20% 40% 65% 50%
Data sources
Expert opinion x x x x
TARMEDg [32] x x x x
List of pharmaceutical
specialities [35]
x x x x
Official laboratory tariff
list [34]
x x x x
Flat rates of Swiss DRG,
version 1.0 [36]
x
Swiss GP studyh x x x
Sentinella studyi x x x
Swiss TPH travel clinic x
CRP, C-reactive protein; NNSID, National Notification System for Infectious Diseases.
a Stool culture includes Campylobacter, Salmonella and Shigella.
b Or telephone consultation of same duration.
c Of the following medications: antidiarrhoeal, antiemetics, probiotics; average price of those medications: e10.79 (13 CHF).
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Table 12.3: (continued)
Patient management
model A
Patient management
model B
Patient management
model C
Patient management
model D
Consultation without
stool test
Consultation with neg-
ative stool culturea
Consultation with pos-
itive stool culturea
Hospitalization
d Including erythrocytes, leucocytes, haemoglobin, haematocrit, thrombocytes, and ≥5 subpopulations of leucocytes.
e For a patient with Campylobacter enteritis (ICD-10 code A04.5), aged ≥1 year, with a length of stay between 2 and 11 nights, the
DRG group ‘G67B’ is assigned. Cost weight: 0.573, base rate (applied by several regional hospitals in Bern): e8250.20 (9940 CHF) [37].
Quote from Swiss DRG version 1.0 [36] defining code ‘G67B’: [translated from German] ‘Oesophagitis, gastroenteritis and other diseases
of the digestive organs with a complex diagnosis or age <1 year or gastrointestinal bleeding, with very severe or severe complications or
comorbidities or age >74 years or peptic ulcer disease with severe complications or comorbidities or age >74 year, hospital occupancy >
1 day, without complicating diagnosis, without dialysis’.
f Fees include check of the prescription which can be invoiced once per item prescribed (‘Medikamenten-Check’; e3.57, CHF 4.30) and
check of the purchase which can be invoiced once per patient, per day and per provider (‘Bezugs-Check’; e2.70, CHF 3.25) [49]
g Costs vary among cantons; median costs are used (tariff point value e0.7138 or 0.86 CHF, e.g. canton Bern) [33].
h Qualitative study about case management of campylobacteriosis patients among 69 general practitioners in Switzerland (Supplementary
material).
i Study on acute gastroenteritis conducted within the Swiss Sentinel Surveillance Network ‘Sentinella’ (www.sentinella.ch) in 2014 (Sup-
plementary material).
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items attributed to the different patient management models and scen-
arios and associated costs are presented in table 12.3. (For a list of unit
costs see supplementary table S2.)
The healthcare costs of 41 patients with laboratory-confirmed Campy-
lobacter spp. infection were analysed. Costs for those 19 male and 22
female patients aged between 1 and 72 years were in the range of e179–
1’033 (median e464). The number of consultations varied between 1 and
8 per patient (median 2), the number of blood samples taken between 0
and 4 (median 1) and the time between the first and the last consultation
between 0 (only one consultation) and 65 days (median 3). Consulta-
tion costs and costs for laboratory testing of real patient data were higher
than estimated costs for patient management model C (Supplementary
table S3).
Healthcare costs due to AG and campylobacteriosis
Total healthcare costs for the management of the four different patient
management models combined in Switzerland in 2012 were estimated at
e29.5–44.7 million (Table 12.4). Costs for the different patient manage-
ment model groups (A–D) were e9.0–24.2, e12.3, e1.8 and e6.5 million,
respectively (Supplementary figure S1).
Costs separated by type/provider were: e11.1–20.6 million for GPs’
services (including medical assistants), e7.7–9.1 million for laboratory
diagnostics, e4.4–8.6 million for medications and e6.4 million for hos-
pitalizations (Supplementary figure S2).
Discussion
This study provides for the first time an assessment of total Swiss health-
care costs due to AG and campylobacteriosis by estimating the individual
costs of four types of patient management models and their frequency:
patients suffering from AG and seeking medical care without being tested
(model A); patients seeking medical care and having a Campylobacter-
negative stool test (model B); patients seeking medical care and having a
Campylobacter-positive stool test (model C); and patients with a severe
course of campylobacteriosis requiring hospitalization (model D).
Cases of campylobacteriosis increased in the last decade 1.5-fold, imply-
ing a contemporarily relevant public health problem. We estimated that
in Switzerland, each year 311’192–707’255 patients consult a physician
due to AG or campylobacteriosis, leading to annual healthcare costs ran-
ging from e29 to e45 million.
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Table 12.4: Estimated healthcare costs for the treatment of acute gastroenteritis and campylobacteriosis in Switzerland.
Costs for individual cases are based on resource use estimates presented in table 12.3
Patient
management
model
ASentinella
Patient
management
model
ASwiss GP
Patient
management
model B
Patient
management
model C
Patient
management
model D
Estimated number of
cases (n)
629’457 233’394 69’318 7’132 1’348
In minimal scenario 503’566 186’715 41’591 2’496 674
In extended scenario 125’891 46’679 27’727 4’636 674
Consultation e11’969’523 e4’438’134 e4’359’611 e448’552 e42’722
Laboratory diagnostics e0 e0 e5’753’394 e1’047’762 e0
Medication e6’791’841 e2’518’321 e747’941 e76’954 e0
Hospitalization e0 e0 e0 e0 e6’372’487
+Consultation e3’129’858 e1’160’517 e527’246 e88’156 e33’845
+Laboratory diagnostics e2’298’770 e852’359 e0 e0 e12’307
+Medication e0 e0 e864’154 e144’488 e0
Healthcare costs by
patient management
model
e24’189’992a e8’969’331a e12’252’346a e1’805’913a e6’461’362a
Total healthcare costs e29’488’953–44’709’613a
a Totals do not always add up because of rounding.
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The calculations were based on several assumptions as this study
provides the first estimates of healthcare costs due to AG and campylo-
bacteriosis in Switzerland. The country has no central database which
is based on diagnostic codes and where healthcare costs from outpatient
care are systematically recorded. Therefore, we tried to cross-validate
our estimates whenever possible by combining different data sources.
The real patient data which we used for comparison with cost estimates
for patient management model C originated from our own institution’s
(Swiss TPH) travel clinic. These real patient data suggested higher costs
for laboratory-confirmed, ambulatory patients than we used for our cal-
culations. Possibly consultation time in returning travellers was longer
because of the travel anamnesis and laboratory tests were more extens-
ive. Nevertheless, returning travellers are likely to be overrepresented
also in the patients with AG seen by GPs. When using the median total
costs of the real patient data of the travel clinic for patients in manage-
ment model C, the costs for this group would be e3.3 million (instead of
e1.8 million; Supplementary figures S1 and S2). Hence, we believe the
cost estimates used for patient management model C are conservative.
Some physicians reported performing a second stool test after a positive
result for certain patient groups (e.g. working in the food sector) before
allowing the patients to return to work. A few experts claimed that the
consultation times we applied in our models were rather short. They
suggested consultation times of 5–10 min longer for selected (but not for
all) consultations. The case-control study [29] found that about 10% of
campylobacteriosis patients in outpatient treatment received intravenous
therapy, which was not considered in our models. Furthermore, patients
requiring hospitalization may be transferred to the hospital by ambu-
lance causing additional costs. Taking all these points into account, we
believe that our estimates reflect rather conservative approximations.
Healthcare costs of laboratory-confirmed
campylobacteriosis patients
Campylobacteriosis cases as registered in the NNSID were estimated to
cost around e8.3 million/year (patient management models C and D).
The majority of these costs are attributable to hospitalizations. Compar-
ison of our estimates with actual patient data suggests that our estim-
ates (at least for patient management model C) underestimated actual
costs occurring in the health system. The number of hospitalizations
due to ‘Campylobacter enteritis’ (ICD-10 code A04.5) matches well with
the calculated number of hospitalized patients using the official notifica-
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tion data together with the hospitalization rate found in the case-control
study (1’348 vs. 1’230 cases). The hospitalization costs, which are based
on DRG flat rates, include all costs occurring during the hospital stay.
This flat rate is independent of the length of stay as long as it is within
2–11 nights (for DRG code G67B, according to DRG v. 1.0 [36]).
Healthcare costs of AG patients
The costs for AG patients without laboratory-confirmed campylobacte-
riosis varied significantly depending on the proportion of stool testing
we used to calculate patient numbers for patient management model A.
The proportion of stool testing is highly variable also in other countries:
it was found to be 12% in The Netherlands [38], 19–44% in the United
States [39, 40] and 27% in England [41]. Even though our estimate of
11% from the Sentinella study is lower compared to the proportions re-
ported in other countries we believe that this number is more accurate
than the semi-quantitative estimates obtained from the Swiss GP study.
Moreover, the figure from the Sentinella study represents the proportion
of patients for which the physician initiated stool testing. It is likely
that not all patients actually provided a stool specimen. Hence, using
the proportion of actually completed stool tests would increase case num-
bers in model A and our cost estimates. Additionally, our calculation for
patient management model A is based on the estimated number of tests
for Campylobacter spp. This may in fact underestimate the total num-
ber of stool tests as in some instances physicians might only test their
patients for viruses, for example. In this case, the number of patients in
management models A and B would be even larger.
Apart from Campylobacter both Salmonella and Shigella infections are
notifiable in Switzerland. Usually, basic stool bacteriology involves test-
ing for these three pathogens [42]. Under this assumption and ignoring
the chance of mixed infections, all Salmonella- or Shigella-positive pa-
tients were assigned to management model B (patients with Campylobac-
ter-negative stool test). This leads again to a rather conservative estim-
ate of costs since stool cultures with a positive result are more expensive
than negative stool cultures (e64.74 vs. e128.65) [34]. Additionally,
salmonellosis and shigellosis patients may also need hospitalization and
those patients are, therefore, more likely to create costs similar to those
estimated for campylobacteriosis patient management models C and D.
In 2012, 1’243 cases of salmonellosis and 159 cases of shigellosis were
reported [43, 44]. Moreover, AG patients with viral infections and pa-
tients without an identified causative agent might be hospitalized. The
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hospitalization costs for these patients were not considered in our study.
Patients consulting a physician not at all or only by phone and patients
seeking help in a pharmacy have not been considered in this study. Up to
60% of gastroenteritis patients calling the medical practice are managed
by phone, according to the Swiss GP study (Supplementary material).
Individual (healthcare) costs for these patients may be low. However,
the high quantity of these patients might still lead to considerable costs.
Comparison of cost estimates for Switzerland with
estimates of other countries
Various studies have been conducted in several countries to estimate
costs for gastrointestinal infections or campylobacteriosis (Tables 12.1
and 12.2). However, comparison of costs is very difficult due to vary-
ing case definitions used, heterogeneity in costs included, differences in
health systems and health-system use and time. We estimated that a
case of laboratory-confirmed campylobacteriosis costs on average e975
(average per case for models C and D). The extent of underreported
campylobacteriosis infections – defined as infections in individuals who
seek healthcare but whose infection is not captured by the surveillance
system [45] – is unknown for Switzerland. The multiplication factor due
to underreporting of campylobacteriosis was estimated at 1.3 in the UK
[46] and at 2.0–5.6 in The Netherlands [6, 47]. Applying the same factors
to Swiss data would result in 2’544–39’008 additional campylobacterio-
sis cases. Assuming that underreporting was due to under-diagnosis (as
opposed to under-notification), these cases are automatically included
in our patient management model A (where model A represents all con-
sulting AG patient without stool diagnostics.) Hence, costs in model
A attributable to under-diagnosed campylobacteriosis cases would range
between e0.98 and e1.50 million. Total costs attributable to campylo-
bacteriosis would then range between e8.4 and e9.8 million in Switzer-
land (representing 19–33% of total AG costs) or e206–759/case. Health-
care costs per case are higher than Dutch (e82–280/case, table 12.2) or
US estimates (e163–253/case). However, the latter two were based on
the yearly estimated number of campylobacteriosis cases in the popula-
tion while we considered only campylobacteriosis cases presenting to the
GP or being hospitalized.
On average, a case of AG (including campylobacteriosis) in Switzerland
was estimated at e63–95. Again, our cost estimates are based on cases
presenting to the GP while estimates from other countries usually are
presented for cases in the community. Hence, values are not comparable
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even though our cost estimates are within the range of cost estimates
from other countries (e3–155 [9-20], table 12.1).
Unknown socioeconomic burden
We only assessed direct healthcare costs for AG and campylobacterio-
sis. The average hospital stay of three nights and the median disease
duration of 7 days of campylobacteriosis patients which were found in
the case-control study [29] suggest that the socioeconomic burden due
to productivity loss and home care is a multiple of the healthcare costs.
Additionally, we neither considered costs arising from complications of
the disease (e.g. Guillain-Barré syndrome, reactive arthritis or irritable
bowel syndrome) nor did we include out-of-pocket expenses for medica-
tions of patients not consulting a physician or costs arising of patients
consulting the physician exclusively by phone. This further underscores
the conservative nature of our overall healthcare cost estimated at e29–
45 million.
The disease burden and economic consequences are further increased by
years of life lost due to premature mortality. The ICD-10 codes A02
‘other Salmonella infections’ and A04.5 ‘Campylobacter enteritis’ were
recorded only for four patients in 2011 as the main cause of death (Swiss
Federal Statistical Office, personal communication). When considering
also secondary causes of deaths, 104 deaths were registered in 2011. For
influenza it was shown that mortality is underreported in official statist-
ics [48]. We assume that such underreporting is also the case for deaths
due to campylobacteriosis (and salmonellosis).
AG and campylobacteriosis cause a marked public health problem gener-
ating considerable costs. To our knowledge, this is the first study invest-
igating healthcare costs due to AG and campylobacteriosis in Switzer-
land. Further research is needed for more accurate cost estimation. In
order to reduce the financial burden and suffering of patients, there is
a need for implementing health policy measures, sectorial and inter-sec-
torial public health interventions and increasing awareness in the popu-
lation at all levels.
Supplementary material
For supplementary material accompanying this paper visit http://dx.d
oi.org/10.1017/S0950268816001618.
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Abstract
Objectives: Acute gastroenteritis (AG) is a usually self-limiting, but
common disease worldwide. In Europe, incidence estimates range from
0.3–1.5 AG episodes/person-year. For Switzerland, available informa-
tion on AG is restricted to notifiable foodborne diseases and findings
from research studies starting at primary care level. The aims of this
one-year, population-based prospective cohort study are to assess the
incidence, burden of disease, aetiology and socio-economic impact of AG
in the Swiss general population. Additionally, the prevalence of bacterial
gastrointestinal pathogens and bacteria harbouring antimicrobial resist-
ances in the asymptomatic population shall be assessed.
Results: Weekly follow-up of the cohort consisting of 3’000 participants
will provide incidence estimates of AG. Furthermore, information collec-
ted will be used to assess risk factors for experiencing an episode of AG,
to explore determinants for help seeking, and to characterise the socio-
economic impact of AG including absence from work and inability to
perform daily activities. Aetiology of AG is determined by investigat-
ing stool samples from symptomatic participants. Finally, stool samples
from participants collected during an asymptomatic period will be used
to assess the prevalence of enterohaemorrhagic E. coli, Campylobacter
spp., Salmonella spp. and Shigella spp. as well as of resistance to dif-
ferent antibiotics (extended-spectrum beta-lactamase-, fluoroquinolone-
and carbapenemase-resistance).
Introduction
Acute gastroenteritis (AG)*, manifesting with signs and symptoms of
diarrhoea, vomiting, abdominal pain or cramps, fever, dehydration,
nausea and/or loss of appetite, is usually self-limiting, but leads to a
considerable burden of disease, health system use and socio-economic
impact. Studies in several European countries estimated the incidence
of AG at 0.3–1.5 episodes per person and year [1-14]. Furthermore,
it was found that a considerable 11% of patients with infectious en-
teritis develop post-infectious irritable bowel syndrome [15, 16]. Incid-
ence of AG for Switzerland is assumed to be comparable, but data is
limited to notifiable pathogens reported to the Federal Office of Pub-
lic Health (FOPH) based on the Epidemics Act. Several studies from
other European countries have shown that (i) only 6.4%–37.8% of all
AG episodes lead to consultation of a physician [1-9, 11, 12, 14], and
(ii) 0.2%–1.8% of episodes are reported to national surveillance systems
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[1, 11, 14]. These proportions are highly variable between countries and
pathogens due to different help seeking behaviour, case management and
surveillance systems [17]. From a study in the Swiss Sentinel Surveil-
lance Network, Sentinella, we estimated that around 175’000 individuals
consulted a physician due to acute gastroenteritis in Switzerland in 2014
[18]. Around 12% of cases were asked to submit a stool specimen and
hence, could potentially – if positive – be reported to the National No-
tification System for Infectious Diseases (NNSID) if their sample tested
positive for a notifiable pathogen and was reported by the diagnostic
laboratory. However, the proportion of AG patients consulting a phys-
ician is currently not known for Switzerland. Consequently, inference
from the above-mentioned frequencies and proportions to the incidence
and burden of AG at population level is not possible.
Therefore, the present study primarily aims at measuring the incidence
of acute gastroenteritis in the general population in Switzerland. Sec-
ondary objectives are to describe the burden of disease and the socio-
economic impact of AG, to assess its aetiology and to investigate the fre-
quency of selected risk exposures. Finally, the carriage rate of selected
pathogenic bacteria and bacteria harbouring selected antibiotic resist-
ances among the “healthy” (non-diarrhoeal) population in Switzerland
is assessed.
Main text
Study design and methodology
A one-year, prospective cohort study is conducted to determine the in-
cidence of AG in the general population in Switzerland. The study will
assess signs and symptoms of AG and exposure to selected risk factors
(incl. antibiotic use). In case of symptoms, the help seeking beha-
viour of patients, inability to work or to perform usual daily activities,
perceived illness experience and socio-economic consequences of the ill-
ness will be explored. Furthermore, the aetiology of AG is investigated
by examining stool samples from a subsample of participants report-
ing gastrointestinal symptoms. Finally, the prevalence of selected bac-
terial gastrointestinal pathogens (enterohaemorrhagic Escherichia coli
[EHEC], Campylobacter, Salmonella and Shigella) and bacteria with se-
lected antibiotic resistances (extended-spectrum beta-lactamase [ESBL],
carbapenemase, fluoroquinolone, and mobilised colistin resistance [mcr]-
1) is assessed among participants during an asymptomatic period.
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Study setting, recruitment process and eligibility
A representative sample of the Swiss population will be requested from
the Federal Statistical Office. The cohort is recruited by postal mail.
The procedure for cohort recruitment is shown in figure 13.1. Invitation
letters include a study information document, an informed consent form,
a contact information questionnaire (for obtaining participants’ contact
details and for selection of the preferred language and means of commu-
nication) and a short screening questionnaire to assess study eligibility.
Eligibility criteria for participating in the study are: living in Switzer-
land; speaking German, French or Italian; age ≥14 years; not suffering
from cancer of the bowel, irritable bowel syndrome, Crohn’s disease, ul-
cerative colitis, cystic fibrosis, coeliac disease or another chronic illness
with symptoms of diarrhoea or vomiting.
Data collection and management
Upon return of the signed informed consent and the completed contact
information and screening questionnaires, eligible study participants re-
ceive a baseline questionnaire, a stool sampling kit including an inform-
ation and instruction sheet on stool sampling, and the first weekly ques-
tionnaire. The content of each questionnaire is summarised in table 13.1.
Participants will continuously receive the weekly questionnaire during
one year (52 weeks; figure 13.2). Participants receive an additional ques-
tionnaire (“illness questionnaire”) in case of reporting gastrointestinal
signs and symptoms. Furthermore, participants are advised to imme-
diately report occurrence of diarrhoea and/or vomiting actively to the
study team by phone, e-mail or SMS (during the day, including week-
ends) (Figure 13.3). This “active reporting system” is used to select
AG episodes for microbiological investigation based on a pre-defined al-
gorithm considering moderate and severe cases of illness as defined by
Riddle, et al. [19]. In case the study subject’s AG episode is selected, the
study team will advise him/her to use the stool sampling kit received
at the beginning of the study and send a stool sample to the study
laboratory as fast as possible. After sending in a stool sample, the par-
ticipant’s stool sampling kit will be replaced. The list of diagnostic tests
performed on stool samples from symptomatic participants is provided
in table 13.1.
Each week, a pre-defined number of randomly selected participants (see
sample size calculation) will receive a stool sampling kit to send in a
stool sample immediately. Those stool samples will be tested for se-
lected pathogenic bacteria and presence of certain antibiotic resistances
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Figure 13.1: Operational flowchart of cohort recruitment for the burden of
gastroenteritis in Switzerland (BUGS) study
FSO: Federal Statistical Office; tbd: to be defined
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Table 13.1: Overview and content of different questionnaires used and other data collection for the burden of gastroenteritis
in Switzerland (BUGS) study
Data
collection
tool
Means of
application
Frequency Content
Contact
information
questionnaire
Paper-based 1x before
enrolment
Address, e-mail, phone number, language, preferred means of
communication (electronic questionnaire with link sent by
e-mail [default] or paper-based questionnaire sent by postal
mail)
Screening
questionnaire
Paper-based 1x before
enrolment
General demographic characteristics (age, sex), characteristics
to assess eligibility; for those not willing to participate: reason
for non-participation
Baseline
questionnaire
Electronic and
paper-based
1x at the
beginning of the
observation
period
Baseline characteristics: detailed demographic characteristics,
dietary habits, regular medication intake, chronic diseases,
permanent and long-term exposure risks (e.g. occupational),
general health seeking
Weekly
questionnaire
Electronic and
paper-based
Weekly (52x) Occurrence of gastrointestinal signs and symptoms and
short-term / transient risk exposures (e.g. food consumption,
travel)
Illness
questionnaire
Electronic and
paper-based
After
experiencing
gastrointestinal
signs and
symptoms
Disease determinants, health and help seeking, health care
utilisation, (self-)medication, consultations, absence from work,
ability to perform usual daily activities
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Table 13.1: (continued)
Data
collection
tool
Means of
application
Frequency Content
Stool sample
(sympto-
matic)
Sampling kit
sent to
participant at
baseline; upon
instruction by
study
personnel
participant
sends to study
laboratory
Selected
episodes of acute
gastroenteritis
Stool sample investigated for:
• Bacteria: Campylobacter spp., Salmonella spp., Shigella spp.,
Yersinia spp. (all culture & PCR); Clostridium difficile
(RDT & PCR); Plesiomonas shigelloides, Vibrio spp.,
EAEC, EPEC, ETEC, EHEC (all PCR)
• Viruses: adenovirus, astrovirus, norovirus, rotavirus,
sapovirus (all PCR)
• Protozoa & parasites: Cryptosporidium, Cyclospora
cyetanensis, Entamoeba histolytica, Giardia lamblia
• Selected samples (depending on risk profile): additionally for
cestodes, trematodes, nematodes and protozoa
Stool sample
(asympto-
matic)
Sampling kit
sent to
participant;
Participant
sends to study
laboratory
Max. 1x during
observation
period; random
selection
Stool sample investigated for:
• Antibiotic resistance: ESBL, carbapenemase,
fluoroquinolones; if carbapenemase-positive: MCR-1
• Bacteria: Campylobacter spp., Salmonella spp.,
Shigella/EIEC, EHEC (all PCR)
Stool sample
questionnaire
(asympto-
matic)
Electronic and
paper-based
Max. 1x during
observation
period; random
selection
Risk factors for carrying antibiotic-resistant bacteria, recent
antibiotic consumption, visits to or stay in medical institutions,
contact to animals and/or raw food
PCR: Polymerase Chain Reaction; RDT: Rapid diagnostic test; EAEC: enteroaggregative Escherichia coli; EPEC: en-
teropathogenic E. coli; ETEC: enterotoxigenic E. coli; EHEC: enterohaemorrhagic E. coli; EIEC: enteroinvasive E. coli
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Figure 13.2: Flowchart of cohort observation period for the burden of gastroenteritis in Switzerland (BUGS) study
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GI: gastrointestinal
286
with the aim to assess respective prevalences in the asymptomatic popu-
lation (Table 13.1). The stool sample will be discarded if the participant
reported diarrhoea with or without vomiting in the 4 weeks preceding
sampling. Sampling is conducted weekly throughout the observation
period to account for potential seasonal differences in prevalence. Each
participant is selected at most once for “asymptomatic sampling”.
All questionnaires apart from the contact information and screening
questionnaires will be available in electronic- and paper-format. By de-
fault, participants will receive an e-mail containing a personalised link
to the electronic questionnaires. However, during recruitment, they may
opt for paper-based questionnaires sent by postal mail. LimeSurvey, an
open source software set-up on a secured server at our institution (Swiss
TPH), will be used for electronic data collection. The software allows
completion of the questionnaire in a standard internet browser using
desktop or laptop computers, tablets or smartphones.
Electronic questionnaires will be programmed to require an answer to
ensure completeness of the data collected but will include an option “I
do not want to answer” or “not applicable” (where appropriate) in order
to prevent a forced-choice bias.
Paper questionnaires are entered by study personnel at the study centre
using a LimeSurvey data entry mask which is slightly adapted from the
one used by participants (e.g. containing an additional field “no answer
given” for each mandatory question). A sample of 10% of paper ques-
tionnaires is entered twice for data quality control. Discordant results
are checked against paper originals. A full double entry is conducted for
the “contact information questionnaire” as correct address details are
crucial for successfully contacting participants.
Quality control of data from study laboratories (stool sample results)
will be with the diagnostic laboratories, operating according to their
standard operating procedures in their daily routine. The study team
will only check plausibility of the data and values.
Electronic data are stored on secured network drives accessible only by
the study team. Data on the network drive is backed-up regularly, ac-
cording to institutional policy. Electronic data is stored in original file
formats and in comma-separated values (csv) format, where appropriate,
to ensure long-term accessibility.
Sample size calculation
We calculated the minimal sample size based on different parameter as-
sumptions for comparisons between two distinct groups and for within-
287
13 Burden of gastroenteritis in Switzerland (BUGS) research proposal
subject comparisons between two distinct periods. Underlying formulas
and results are provided in additional file 1 (Appendix E).
A cohort size of 3’000 individuals is envisaged to allow analysis of sec-
ondary outcomes and comparisons between groups and to assert enough
power in case assumptions were too optimistic based on the different
sample size calculations. We plan to start the observation period with a
cohort size of 3’500 individuals in order to achieve an average cohort size
of 3’000 after withdrawals and loss to follow-up during the 52 week study
period. Assuming a participation rate of 25% (including loss of people
not meeting the eligibility criteria) and a loss to follow-up of 20%, 15’000
people will be contacted initially. For planning purposes, we assume an
average cohort size of 3’000 throughout the one-year observation period.
The sample size (n) needed to reach a specific relative precision () for
the microbiological outcomes in asymptomatic participants (prevalence
of antibiotic resistances and selected pathogenic bacteria) was calculated
using the following formula (based on [20]):
n = 1.96
2 ∗ (1− P )
2 ∗ P
For the prevalence of ESBL, a relative precision of 20% is envisaged at a
95% confidence level. Assuming a prevalence (P) of 5–6% (based on [21,
22]), a sample size of 1’505–1’825 is needed. Considering that the previ-
ous prevalence estimates are from groups of potentially higher prevalence
than the general population (staff members of meat-processing compan-
ies with likely higher exposure risk; and primary care patients), we plan
to investigate 2’000 samples. Hence, every week 40 subjects are randomly
selected. Given the very low prevalence of Carbapenemase-resistance
(0.1%; personal communication) and mcr-1 (not found in 1’000 samples;
personal communication) it is questionable whether these resistances will
be found at all in our cohort. The prevalence of fluoroquinolone-resist-
ance in E. coli has not yet been investigated in the asymptomatic Swiss
population. Fluoroquinolone resistance prevalence in E. coli is at around
20% based on resistance data generated during routine medical care [23].
Hence, using the same sample size as for ESBL (N=2’000) should allow
for an estimate with a relative precision of at least 20% even if the pre-
valence in the general Swiss population is somewhat lower than 20%.
The presence of pathogenic bacteria (EHEC, Campylobacter spp., Sal-
monella spp., and Shigella spp.) can only be investigated in 1’600
samples of asymptomatic participants (of 2’000 collected) due to fin-
ancial constraints. For this investigation, the main interest is on EHEC
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prevalence in asymptomatic people. Considering that this prevalence is
expected at around 7–10% (personal communication) a sample size of
1’600 will still allow for a relative precision of 15–18%.
Approach to analysis
Definition of AG disease episode
The primary outcome of our study is presence or absence of an AG
episode and the incidence of AG in the general population. For this pur-
pose, an episode of AG is classified according to a modified version of
the definition suggested by Majowicz et al. [24]: a case of gastroenteritis
is an individual with ≥3 loose stools in 24 h, with or without vomiting,
but excluding those (a) with cancer of the bowel, irritable bowel syn-
drome, Crohn’s disease, ulcerative colitis, cystic fibrosis, coeliac disease,
or another chronic illness with symptoms of diarrhoea, or (b) who report
their symptoms were due to drugs, alcohol, or pregnancy. An episode
is defined to begin on the first day and end on the last day of reported
diarrhoea and/or vomiting, followed by a diarrhoea- and vomiting-free
period of 3 days [25].
Statistical analysis
Data cleaning and analysis will be conducted with the statistical soft-
ware Stata and/or R. All steps performed to clean and analyse the data
are documented in scripts (R) or do-files (Stata).
The cohort will be characterised in terms of demographic characteristics,
health status, dietary habits and permanent or long-term risk exposures
as reported at baseline. Similarly, cohort participants lost to follow-up
will be compared to those remaining in the cohort.
The primary outcome defined at the level of person-week is presence or
absence of an AG episode. Risk factors for experiencing an episode of AG
will be determined using multivariable mixed logistic regression analyses
with the individual included as a random effect. A basic multivariable
model including the biologically most plausible variables, region and
season will be defined a priori. Generalised estimating equation models
(GEE) will be considered in case of convergence issues of the mixed lo-
gistic regression models.
Secondary analyses will include calculating the incidence of AG as the
number of AG episodes per person-year under observation and the in-
cidence of gastrointestinal signs and symptoms (including episodes not
fulfilling the case definition of AG). Furthermore, transient risk factors
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for experiencing an episode of AG will be explored in uni- and mul-
tivariable mixed logistic regression models, including the individual as
random effect. Exposure information from the week preceding the AG
episode will be used. Determinants for presenting to the health system
(pharmacies, primary care, specialists or hospitals) in case of AG are also
investigated, again using uni- and multivariable mixed logistic regression
models (with the individual as random effect). Predictor variables in-
clude signs and symptoms, and perceived severity of AG, demographic
characteristics (age, sex, occupational status), co-morbidity, and type of
health insurance. Additionally, the socio-economic impact such as ab-
sence from work, inability to perform usual daily activities and the need
for care by family members or friends related to AG disease episodes will
be described.
Results from stool sample investigations from symptomatic participants
will be used to estimate pathogen-specific incidence rates of AG.
Finally, the prevalences of bacteria harbouring ESBL-, carbapenem- and
fluoroquinolone-resistance, and of EHEC, Campylobacter, Salmonella
and Shigella in the asymptomatic population is calculated.
Ethical considerations
Health-related personal data and stool samples from participants are
collected for this study. Therefore, the study is subject to the Federal
Act on Research on Human Beings and requires ethical approval. Ap-
proval will be sought from the responsible local ethical committee(s) for
a non-clinical trial study with minimal risks. All participants will be
asked for written informed consent before enrolment. The study will be
conducted according to the principles of Good Epidemiological Practice
[26] and the Declaration of Helsinki [27].
Participants will be advised to seek health care as they would do without
participating in this study. Similarly, it will be emphasised that invest-
igation of stool samples in the framework of this study does not replace
stool sample investigation potentially initiated by their health care pro-
vider. Results of stool investigations of symptomatic participants con-
ducted as part of this study are obtained with a time delay due to study
logistics. Hence, microbiological results will be known to the study team
too late to affect treatment considering the short disease duration of
most AG episodes and, therefore, will not be communicated to parti-
cipants or their physicians.
Participants are informed if antibiotic resistances are identified in their
stool samples during an asymptomatic period and advised to inform
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their physician in case of illness.
Operational issues
Data confidentiality and personalisation
Ideally, questionnaires should be anonymous as soon as they contain
health-related personal information. However, we must be able to link
the different questionnaires completed by each study participant. To
minimize the risk that unauthorised people are able to link the parti-
cipants’ names to their questionnaire data, we plan to implement several
measures: each participant is given a person identification code (“person
ID”) as well as a questionnaire identification code (“questionnaire ID”).
The person ID is used in all files/data sets containing personal inform-
ation. The questionnaire ID is used in all files/data sets containing in-
formation obtained from questionnaires or from laboratory testing. The
key file, linking the person ID and the questionnaire ID will be password
protected and stored separately from the other data sets. Access to this
key file will be limited to the principal investigator, the study coordinator
and an additional person (substitute of the study coordinator). For pa-
per-based questionnaires, both codes (person ID and questionnaire ID)
are printed on the empty questionnaires. However, as soon as receipt of
the completed questionnaires is registered in the study centre, the person
ID will be removed (cut off). In order to avoid that both codes are easily
visible and recognised as such by unauthorised persons, one of the codes
(the person ID) is printed in directly readable format (Arabic letters and
numerals) and the other code is printed as a QR- or bar-code. Also, the
two codes are not labelled with “person ID” or “questionnaire ID”. For
electronic questionnaires only the “questionnaire ID” will be used and
no names are stored in LimeSurvey (where questionnaire data is entered
and stored during the entire data collection phase). In order to complete
the questionnaire, participants will receive an e-mail including a link to
the questionnaire containing the questionnaire ID.
Active reporting system needed
For investigating the aetiology of AG, stool samples need to be obtained
quickly after disease onset as AG is usually a short, self-limiting disease.
Therefore, the information on signs and symptoms obtained through the
weekly questionnaire is too much delayed to be the basis for selection of
episodes for aetiological investigation (especially in those completing the
paper-based questionnaires; figure 13.3). We expect reporting delays of
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1–13 days in those completing electronic questionnaires and of at least
3–10 days (best case scenario) for paper-based questionnaires which will
severely impact the likelihood to detect pathogens. To address this lim-
itation, we plan to set up an “active reporting system” for participants
(see “data collection and management”). These parallel ways of collect-
ing data on diarrhoea and vomiting have advantages and disadvantages:
on the one hand, we can compare reporting completeness of the two
methods. On the other hand, participants are required to actively think
of the study when experiencing signs and symptoms, and have to report
their symptoms twice – potentially increasing reporting fatigue and re-
porting bias due to sensitisation. Further, the active reporting system
requires that study personnel being able to communicate in all three
study languages is on call every day, including weekends and public hol-
idays.
Limitations
Our study will be subject to limitations. Participation bias is likely to
occur. Considering the rather long observation period (one year with
weekly follow-ups), a certain amount of participants will be lost to fol-
low-up or withdraw from the study; these participants might differ from
those completing the entire follow-up period. Similarly, reporting fatigue
might occur, especially in those experiencing more than one episode of
AG. However, all those biases and limitations are unavoidable in cohort
studies and their mitigation is difficult. To address reporting fatigue, we
consider establishing a project newsletter to give participants feedback
about interim results of the study and additional information related to
the topic to highlight the importance of their contribution to research.
Inverse probability weighting will be considered if characteristics of our
final cohort differ from those of the general population.
Furthermore, compliance in actively reporting signs and symptoms as
well as in providing stool samples is crucial. Therefore, its importance
will be emphasised repeatedly to study participants. We suspect that
compliance might be associated with the (perceived) severity of the dis-
ease episode. However, we can only try to assess this bias at the end of
the study by comparing data from active reporting/stool sampling and
data from weekly questionnaires.
Recall bias and telescoping have been described as major challenges in
studies on AG. We believe that this bias might not be a notable problem
in our study considering the rather short recall period of 1 week.
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Participants travelling will still receive the electronic questionnaire but
those completing paper-based questionnaires will be able to complete
the questionnaire only once they returned. This might lead to different
compliance and recall bias in those two groups. On the other hand, it
provides an opportunity to assess potential differences in results between
the two methods.
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Surveillance of infectious diseases in Switzerland mainly relies on two sys-
tems: the National Notification System for Infectious Diseases (NNSID)
and the Swiss Sentinel Surveillance Network (Sentinella). However, both
systems are subject to different degrees of underestimation* of disease
frequency. There is insufficient knowledge on how disease incidence or
prevalence in the general population relates to the number of notified
cases in Switzerland. Therefore, the aim of this doctoral research was
to improve the understanding of this burden of illness pyramid using
the example of foodborne infections, exemplified in studying Campy-
lobacter , Salmonella and enterohaemorrhagic Escherichia coli (EHEC)
among others.
Trends in the frequency of Campylobacter and Salmonella were assessed
analysing data from the NNSID from 1988 to 2013 (chapter 4). The two
pathogens, presenting with similar signs and symptoms, showed inverse
trends pointing at changes in disease incidence. Indeed, several interven-
tions to control Salmonella spp. were implemented after the peak levels
in the early 1990ies and appear to have been successful. In contrast,
no limits at all for Campylobacter spp. in food were in place between
2006 and 2013 in Switzerland. Analysis of surveillance data of hepat-
itis A, another disease which may be transmitted through contaminated
food, revealed difficulties in interpreting long-term trends given frequent
changes in notification forms (chapter 5).
Results from positivity studies for Campylobacter and Salmonella, hence,
studies taking into consideration the number of tests conducted apart
from the number of positive results, lead to the same conclusions as
analysis of notification data alone: Campylobacter is increasing while
Salmonella is decreasing (chapter 6). At the same time, stool testing
frequency was found to be increasing for both pathogens. Part of the
increase in case numbers for Campylobacter can, therefore, be attributed
to increased testing while the observed decrease in Salmonella notifica-
tions seems even more significant considering this aspect. Understanding
diagnostic procedures and testing behaviour was consequently deemed
essential. Increased testing volume was also considered the main reason
for the observed strong increase in EHEC notifications since 2015, as
stated by laboratory experts (chapter 7). However, analysis of laborat-
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ory data suggested that increased testing only partially explained the
strong increase (chapter 8). We, hence, concluded that the occurrence
of epidemic events cannot be ruled out in the case of EHEC.
Swiss general practitioners (GPs) mostly follow a “wait & see” approach
when managing cases of acute gastroenteritis (AG)* as seen in a qualit-
ative (chapter 10) as well as in a quantitative assessment (chapter 11).
Both studies showed that only a minority of patients (one in four to one
in ten patients) is prescribed stool testing and hence, the illness has a
chance to be captured by the surveillance system if a notifiable pathogen
is found. In brief, there is already a rather small chance to start with
for an AG episode to proceed to higher levels of the burden of illness
pyramid and potentially being notified. Finally, all steps along the bur-
den of illness pyramid are associated with costs. In absence of available
data on costs associated with AG in Switzerland, we estimated that AG
and campylobacteriosis resulted in substantial healthcare costs of e29–
45 million in 2012 (chapter 12). Patients with AG neither approaching
a GP nor being hospitalised were not considered in these cost estim-
ates. Similarly, absence from work and other indirect costs were not
considered. Further research at the population level to understand the
full burden of disease of AG is urgently needed in Switzerland given the
large burden associated with AG identified through our research already
when looking only at levels starting from primary care. Consequently,
a research proposal was developed to explore the incidence, burden of
disease, social and societal impact of AG (chapter 13).
The research presented in this thesis was conducted in close collabor-
ation with and support of federal authorities (Federal Office of Public
Health (FOPH), Federal Food Safety and Veterinary Office (FSVO)).
This public-public partnership was mutually beneficial: it allowed us
(the researchers) to get direct and easy access to existing structures (e.g.
Sentinella) and data (e.g. disease notifications). Vice versa, our multi-
faceted research could be targeted to the needs of public authorities,
assuring that research is close to application. This improved accept-
ance of the research conducted, guaranteed support of our projects by
federal authorities and increased the chance of further use and dissem-
ination of research results by those stakeholders or consideration and
implementation of recommendations originating from our research. Fur-
thermore, our research supported the federal offices in several ways (e.g.
implementation of measures or recommendations, justify priorities) by
providing sound, scientific evidence of long-standing hypotheses and by
quantifying disease burden. Publication of results lead to media reac-
tions (Appendix, section F.1), raising attention to the topic by the public
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and increasing external validity of our research.
This chapter consists of three main parts. In the first part, the dif-
ferent levels of the burden of illness pyramid are discussed in the light
of the research results presented in this PhD thesis and findings from
other countries (section 14.1). The second part critically reflects on the
Swiss NNSID: whether the NNSID fulfils its purpose (subsection 14.2.1),
whether the purpose of the NNSID fulfils ‘our’ (the researchers’, epidemi-
ologists’, public health experts’) expectations (subsection 14.2.2), and fi-
nally suggestions for improving the NNSID are made (subsection 14.2.3).
The third part then illustrates how the ideal case management of AG
looks like from different perspectives and discusses the various and
partly conflicting wants and needs of patients (subsection 14.3.1), phys-
icians (subsection 14.3.2) and of the public health community (subsec-
tion 14.3.3).
14.1 Reconstructing the burden of illness
pyramid
14.1.1 From infection to disease notification
Several steps are involved until a case is reported to national surveillance,
as already mentioned in the introduction of this thesis (section 1.1 and
figure 1.1): after an individual is exposed to a certain pathogen, the
person has to be infected and/or develop (gastrointestinal) symptoms.
Then, the individual has to seek medical care. The physician has to
request a (stool) sample from his patient. The patient has to comply
with this request and the sample has to be sent to the diagnostic labor-
atory. At the diagnostic laboratory, the sample has to be analysed. If
a pathogen can be identified by the laboratory and if this pathogen is
notifiable, the laboratory has to report it to the FOPH. Finally, if the
laboratory complies with its obligation to report and the reporting form
is entered at the FOPH, only then, the case is registered in official dis-
ease surveillance statistics.
At each step, some cases are “lost” and hence, what is registered in
the NNSID does not reflect the actual disease incidence in the popula-
tion. However, the proportion of cases reaching the tip of the ‘burden
of illness pyramid’ depends on the pathogen, the patient, the physician,
the laboratory and the federal administration and hence, can neither
be compared across pathogens nor across countries or health systems.
The different levels of the burden of illness pyramid and factors associ-
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ated with the transition from one level to the next are discussed in the
following sections.
14.1.2 Before primary care: The “invisible” part of the
burden of illness pyramid
The lowest levels of the burden of illness pyramid, those before primary
care, are the most difficult to explore, understand and comprehend. At
this stage, no healthcare professionals are involved and hence, the health-
care system does not “see” those cases. Considering that most traditional
surveillance systems collect information from actors of the health care
system, i.e. physicians and/or diagnostic laboratories, these lower levels
are not captured. In Switzerland, the incidence of AG and the propor-
tion of individuals approaching a physician are not known but will be
explored in an upcoming prospective cohort study (Burden of gastroen-
teritis in Switzerland (BUGS) study; chapter 13).
A study in the United Kingdom (UK) showed that 533–1’530 cases of in-
fectious intestinal disease (IID) occurred per 1’000 person-years [Viviani
et al., 2016]. The incidence found in this retrospective telephone survey
differed depending on the recall period (7 vs. 28 days). Furthermore, in-
cidence rates found by Viviani et al. [2016] were higher than those found
in a prospective cohort study conducted in the UK at around the same
time (274 cases/1’000 person-years [Tam et al., 2012]). They concluded
that alterations in study design (e.g. recall period or case definition) can
strongly impact on study findings.
Tam et al. [2012] found that 25.3 cases per 1’000 person-years consulted
their GP in the aforementioned cohort study, hence, around 9% of com-
munity cases. A retrospective survey in the Netherlands found a com-
munity incidence of IID of 964 cases/1’000 person-years with 8% of cases
visiting a physician [Doorduyn et al., 2012]. Duration of symptoms of ≥3
days, blood in the stool and young age were predictors for consulting a
GP. Similarly, an Australian study found that disease duration, presence
of fever or chills, respiratory symptoms, and earache increased the odds
of visiting a physician due to infectious gastroenteritis while stomach
cramps decreased the odds [Chen et al., 2016]. In a study among cam-
pylobacteriosis patients in Switzerland, participants mentioned severity
and lack of improvement of symptoms as reasons for care seeking [Bless
et al., 2014]. One third of patients (32.7%) consulted the physician dir-
ectly, but some had consulted friends and family (42.8%), a pharmacy
(19.5%), the internet (14.5%) and/or called a medical hotline (5.0%) be-
fore visiting a physician. In the aforementioned Australian study, 36.1%
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of gastroenteritis cases visited any type of healthcare professional (e.g.
pharmacists or doctors) while 13.4% visited a physician [Chen et al.,
2016]. Similarly, our qualitative study among Swiss GPs provided evid-
ence that there is a substantial proportion of people with AG who do
either seek help at pharmacy level or by contacting the practice nurse,
apart from not seeking help at all (section 10.1 and Bless et al. [2016]).
As mentioned above, traditional surveillance systems (referred to as the
“indicator-based component” of epidemic intelligence* [Paquet et al.,
2006]) do not cover these lower parts of the burden of illness pyramid.
In recent years, numerous so-called “event-based internet surveillance
systems” have been developed. The “‘event-based component’ [of epi-
demic intelligence] refers to unstructured data gathered from sources of
intelligence of any nature” [Paquet et al., 2006]. Information sources in-
clude news feeds, social media, search engine queries, and users actively
reporting health events [O’Shea, 2017]. This has the advantage that they
do not rely on information from healthcare professionals [O’Shea, 2017]
and hence, also levels below primary care can be covered. Additionally,
processes for notification are shorter and therefore, faster. However,
so far, such event-based internet surveillance systems have mainly been
used for early detection of emerging infectious diseases or outbreaks.
Milinovich et al. [2014] found a correlation between a selected inter-
net search term and notifications for 17 infectious diseases in Australia.
However, they also highlighted that there is a complex interplay between
internet searches, media attention, and actual disease incidence. There-
fore, more detailed analyses are needed to further explore the potential
of using search terms for monitoring disease occurrence. It seems that
event-based surveillance is able to detect changes in disease occurrence.
By contrast, and similar to traditional surveillance, it is probably not
suitable to measure actual disease prevalence or incidence considering
that it is not possible to directly infer from baseline levels of search term
activity to disease prevalence. Syndromic surveillance is another option
for early detection of outbreaks. Syndromic surveillance can be based on
different data sources ranging from clinical observations over laboratory
data to drug sales and use of web pages and helplines [Dupuy et al.,
2013]. Clinical observations and laboratory data require contact with
the healthcare system and hence, are again subject to underestimation.
One example of syndromic surveillance based on clinical observations is
the study on AG conducted within Sentinella (chapter 11). The use of
data on drug sales, use of web pages and helplines are all subject to the
same limitations as discussed above: they are probably able to detect
changes in disease frequency but baseline levels of disease activity cannot
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be directly quantified. Finally, in the context of One Health*, surveil-
lance in the veterinary sector has been proposed for earlier detection
of outbreaks of emerging zoonotic diseases, thereby reducing costs for
outbreak control [The World Bank, 2012]. However, most surveillance
systems are passive and hence, rely on signs and symptoms of the disease
or syndrome under surveillance. Therefore, this One Health approach
using veterinary syndromic surveillance is not suitable for foodborne dis-
eases such as Campylobacter as this zoonosis is mostly asymptomatic in
poultry, cattle, and pigs which are important sources of human Cam-
pylobacter infections in Switzerland [Horrocks et al., 2009; Jonas et al.,
2015; Kittl et al., 2011]. Furthermore, human AG is frequently caused
by viruses having no animal reservoir (e.g. Norovirus, rotavirus) [Hall
and Lopman, 2015; Patel, 2015]. Therefore, in order to quantify the
lowest levels of the burden of illness pyramid, research studies such as
the BUGS study (chapter 13) are needed.
14.1.3 At primary care: physicians’ case management is
patient-oriented
Patients with AG consult a physician two days (median) after onset
of symptoms, according to the Sentinella study (chapter 11). Cam-
pylobacteriosis patients in a case-control study reported a median time
interval between first symptoms and consultation of three days [Bless
et al., 2014]. Nevertheless, physicians frequently report to follow a “wait
& see” approach for patients with AG (section 10.1 and Bless et al.
[2016]). This is in line with American guidelines for the management
of acute diarrhoea in adults recommending stool diagnostics “in cases
of dysentery, moderate-severe disease, and symptoms lasting >7 days”
[Riddle et al., 2016]. However, testing is also recommended according
to those guidelines “in situations where the individual patient is at high
risk of spreading disease to others, and during known or suspected out-
breaks”. Several studies reported that protracted or long course of dis-
ease, poor general condition, blood in stool, and reporting recent travels
were important factors favouring stool diagnostics [Bless et al., 2016;
Hennessy et al., 2004; McNulty et al., 2012, 2014; Scallan et al., 2005;
Schmutz et al., 2017a; Van Cauteren et al., 2015b; Van den Brandhof
et al., 2006]. Hence, physicians consider mainly patient characteristics
and patients’ well-being when deciding for or against stool testing. Pub-
lic health considerations play only a minor role in this decision, mainly if
the case is linked to the healthcare sector (either working or living in an
institution), or to the hospitality or food industry (section 10.1 and Bless
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et al. [2016]). Decisions for testing were also reported to be driven by
patient characteristics (e.g. age, length of hospital stay, clinical details)
in a study about the management of patients with suspected infectious
diarrhoea in hospitals in England [Buchanan et al., 2015].
Physicians estimated to request stool samples for 18% of patients (range:
5–60%) (section 10.1 and Bless et al. [2016]). The Sentinella study found
a slightly lower proportion of 12% (chapter 11). A wide range and het-
erogeneity in stool sampling rates were reported in other countries, with
individual physicians reporting stool sampling rates ranging from zero
per cent to 100% [McNulty et al., 2014; Van Cauteren et al., 2015b;
Van den Brandhof et al., 2006]. The number of stool tests conducted
varies also strongly throughout the year as seen in the positivity stud-
ies (chapter 6 and 8). Apart from seasonality in disease incidence, this
could also be due to seasonality in the prevalence of “risk factors for
stool testing” such as travel activity.
Stool sample investigation does not only depend on the decision of the
physician, but also on compliance of the patient. A qualitative study
in the UK revealed that embarrassment, fear of results and lack of in-
formation on why and how to collect the stool were barriers for patients
to providing stool samples [Lecky et al., 2014]. Fear of results might
be more strongly related to colorectal cancer screening than to acute
infectious gastroenteritis. Embarrassment was partly mentioned in con-
nection with handing over the sample to the receptionist, considering
that the reception is a public area where other people may listen to the
conversation or observe the situation. This factor might be different
in Switzerland as some physicians would instruct patients to directly
sending the stool sample to the diagnostic laboratory by postal mail.
Furthermore, participants mentioned concerns about hygiene (handling
faeces could contaminate own hands and objects; waste disposal) and
generally considered it “dirty” to handle their own stool. The Sentinella
study indicated that in 94% of cases where the physician decided to do
stool diagnostics a sample was actually sent to the laboratory (12.3%
vs. 11.6%) (chapter 11). Consistently, Swiss GPs reported that com-
pliance of patients to provide a stool sample is generally not an issue
(chapter 10). However, they also stated that if the patient would refuse
stool sampling, they would usually not insist as results are not crucial
for therapy in most cases of AG. For patients, there might be a trade-
off between embarrassment and perceived benefit of getting the results.
This trade-off might favour perceived benefit in case of acute infection
and suffering (in the case of AG) as opposed to preventive screening.
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14.1.4 After primary care: beyond sensitivity and
specificity of diagnostic methods
Traditional stool culture for gastrointestinal pathogens is increasingly
replaced by culture-independent methods such as multiplex PCR panels
in Switzerland (chapters 7 and 8) and elsewhere [Gibney et al., 2017;
Iwamoto et al., 2015; Marder et al., 2017; May et al., 2017]. This leads
not only to changes in diagnostic sensitivity and specificity but also
to changes in testing frequency, mainly due to co-testing for multiple
pathogens. For example, if the physician ordered tests for two or three
single pathogens, a laboratory using multiplex polymerase chain reac-
tion (PCR) panels is likely to test the sample using the panel (given the
requested pathogens are included in the panel) instead of using single
tests for each pathogen due to economic considerations (chapter 7). Test
results from pathogens included in the panel but not ordered by the phys-
ician would then usually be reported by the laboratory if positive due
to ethical reasons (chapter 7). However, there are also laboratories con-
sidering not to report results of tests not ordered to the physician (as
already routine in case of blood exams). Such information on co-testing
and ways of reporting of results from tests not ordered is usually not col-
lected by surveillance systems. However, it can impact on surveillance
data as shown at the example of EHEC in Switzerland, where it lead
to a strong increase in case numbers (chapters 7 and 8), and Campylob-
acter in the United States of America (USA), where culture-confirmed
cases decreased while notification rates adjusted for culture-independent
diagnostic tests remained stable [Gu et al., 2018].
It was mentioned that not only EHEC but also other pathogens caus-
ing diarrhoeal diseases should be detected more frequently with the in-
creasing use of multiplex PCR panels [Bundesamt für Gesundheit and
Nationales Referenzzentrum für enteropathogene Bakterien und Lister-
ien, 2015]. However, the authors hypothesised that this was not the
case because there is still enough expertise and equipment available to
confirm positive PCR results using culture-based methods. This is not
the only explanation for the lacking (strong) increase even though cul-
ture-confirmation was indeed required for Campylobacter to fulfil the
case definition of the NNSID (until 2017; in 2018, the FOPH changed
the case definition for Campylobacter to include also cases with PCR-
confirmation only. This change is valid retroactively for cases notified
since January 2013 [personal communication]). According to laboratory
experts, testing for EHEC was rarely specifically requested while Cam-
pylobacter , Salmonella and Shigella all were routinely tested. Hence, the
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use of multiplex PCR panels did probably not have a large impact on
test numbers for Campylobacter , Salmonella and Shigella while it had
a tremendous impact on test numbers for EHEC (and other pathogens
which are not notifiable). Therefore, it is conceivable that the increasing
use of multiplex PCR panels had a much larger impact on EHEC test
and case numbers than on the other three notifiable bacterial pathogens
included in most panels (Campylobacter , Salmonella and Shigella).
Nevertheless, also changes in diagnostic methods affecting sensitivity and
specificity must obviously be taken into account when interpreting sur-
veillance data, as described by Bless [2018]; Gu et al. [2018]; Hurd et al.
[2012] using the example of Campylobacter .
Statements from physicians and laboratory experts indicated that the
selection of diagnostic tests by the physician – both, concerning the in-
clusion of pathogens and the method applied – is not only dependent
on subject-specific or medical reasons but is also influenced by presenta-
tion of options on laboratory test order forms (unpublished observation).
Studies in Finland, Israel and the Netherlands have shown that phys-
icians’ ordering behaviour can be altered by changing how laboratory
test options are presented on order forms [Kahan et al., 2009; Seppänen
et al., 2016; Shalev et al., 2009; Zaat et al., 1992]. Hence, also changes
in something “simple” such as a laboratory test order form can influence
surveillance data. Given that diagnostic laboratories in Switzerland op-
erate in the private sector, harmonisation of order forms is hardly achiev-
able.
Furthermore, testing algorithms offered and used by diagnostic laborat-
ories are likely also influenced by economic considerations. It has been
shown that the workload at the laboratory and the overall turnaround
time of the sample can be reduced by screening samples first using PCR
followed by culture of PCR-positive samples (compared to culture only)
[Van Lint et al., 2016].
In summary, medical decisions and technical features such as sensitivity
and specificity of diagnostic methods are not the only factors influencing
under-diagnosis*. Laboratory test order forms and “translation” of phys-
icians’ laboratory orders into actual selection of tests at the laboratory
are also factors to be considered.
14.1.5 At the tip of the iceberg: the notification system
is not static
Finally, physicians and laboratories have to comply with their obligation
to report notifiable observations. Self-reported knowledge of physicians
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and employees of laboratories about the notification system is generally
“good” in Switzerland, according to an evaluation report of 2012 [von
Stokar et al., 2012].
Analysis of hepatitis A, B and C notification data showed that for all
three diseases, no report on clinical findings was received by the FOPH
for about 14–15% of cases (chapter 5, Richard et al. [2017, 2018]). This
is in line with previous analyses reporting that for 6% to 21% of cases
of gonorrhoea or invasive meningococcal disease reports from physicians
were missing [von Stokar et al., 2012]. Furthermore, a report on labor-
atory findings was missing for 6% of hepatitis A cases. Additionally,
for a study on EHEC, laboratories were asked to send stool samples or
EHEC isolates to the National Reference Centre for Enteropathogenic
Bacteria and Listeria (NENT). Comparison of samples received by the
reference laboratory and notifications recorded at the FOPH revealed
that for around 10% of 900 samples no corresponding notification could
be identified (personal communication). There might be other reasons
for those discrepancies apart from non-compliance in reporting. Never-
theless, it is reasonable to assume that there is some under-notification*
in Switzerland. Yet, a quantitative assessment of under-notification has
not been conducted systematically.
The challenges associated with surveillance systems do not end once
the notification arrives at the point of notification (in Switzerland: the
FOPH) and hence, the case is captured by the system (here: the NNSID).
Further issues include the reliability and validity of the data as well as
quality of data entry and proper documentation of changes in data entry
procedures, data entry masks, and notification forms (see also subsec-
tion 14.2.1). Analysis of hepatitis A notification data in Switzerland
(chapter 5) has shown that (a) changes in notification forms occur fre-
quently, (b) changes in both, data entry and forms are difficult to track,
and (c) certain sections of reports on clinical findings (e.g. assumed
place and source of exposure) are poorly filled in. The number of vari-
ables included in the surveillance system changed (increased) over time in
Australia [Gibney et al., 2017], indicating changes in notification forms
which may make interpretation of long-term trends difficult. Further-
more, notification forms used in Australia and Canada may even differ
between states (or province/territory) [Neave et al., 2016]. In Switzer-
land, notification forms are provided at national level (by the FOPH).
In conclusion, cases registered in the surveillance system are not only
subject to underestimation, resulting in a non-random selection of cases
occurring at population level. Heterogeneity in surveillance data is fur-
ther increased, and comparability reduced, by changes in notification
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forms and procedures, under-notification and incompleteness of data.
14.1.6 From disease notification back to infection
The research work presented provides insights into and quantitative es-
timates for the most important steps from attending primary care to
being notified to the NNSID. Figure 14.1 summarises the multiplica-
tion factors as we found them from our different studies for the different
levels of the burden of illness pyramid and extrapolation of NNSID case
numbers of Campylobacter , Salmonella and EHEC to consultation fre-
quencies at primary care level. Estimated multiplication factors did not
distinguish between pathogens except for positivity rates. When calcu-
lating backwards from pathogen-specific case numbers, estimated con-
sultation frequencies at primary care differ widely. This is not surprising
considering that prevalence and incidence of these pathogens, and the
proportion of cases seeking care, getting tested and finally notified differ.
Additionally, it has to be noted that estimated numbers at all except the
top two levels of the pyramid are not pathogen-specific and are, there-
fore, not cumulative. In other words, AG cases tested for Campylobacter
spp. and Salmonella spp. will be included in both, Campylobacter and
Salmonella estimates. Therefore, based on our extrapolation, “true”
consultation frequencies at primary care level are likely in the range of
230’000 (lowest estimate for EHEC) and 1.1 million (highest estimate
for Salmonella) per year. These estimates are substantial in size but
have to be interpreted with care as they are subject to several additional
limitations. Certain multiplication factor estimates did not include the
hospital setting. For example, the proportion of individuals requested to
provide a stool sample was taken from the Sentinella study (chapter 11).
This study involved GPs only. Physicians working in a hospital may use
a different case management strategy. Additionally, the positivity studies
on Campylobacter and Salmonella (chapter 6) did only include private
sector laboratories (no hospital laboratories). Positivity rates of hospital
laboratories may differ. Finally, multiplication factors and case numbers
used for this calculation originate from different years which could also
affect extrapolation results.
The Sentinella study (chapter 11) and the study on healthcare costs
(chapter 12) also provided estimates of consultations due to AG at pri-
mary care level: the Sentinella study estimates (174’610 first consulta-
tions due to AG) were lower while the estimates from the assessment of
healthcare costs (311’192–707’255 patients consulting due to AG or cam-
pylobacteriosis) were comparable to the “downward calculation” presen-
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Figure 14.1: Estimation of case numbers at different levels of the burden of illness pyramid for foodborne infections.
Note that numbers across pathogens are not cumulative and do not reflect estimated numbers for this specific pathogen.
Estimated multiplication factors are from different years
Positivity: see studies on positivity rates, chapters 6 and 8; Sentinella: see study within the Swiss Sentinel Surveillance
Network, chapter 11; Swiss GP: see study among Swiss GPs, chapter 10; BUGS: see study on burden of gastroenteritis in
Switzerland, chapter 13
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ted in this chapter (Figure 14.1). It has to be considered that the latter
two calculations were based on the same information sources (the health-
care cost estimations using mostly preliminary results of the same studies
as the calculation in this chapter). Additionally, those two calculations
started from the top of the pyramid and calculated downwards while the
Sentinella extrapolation relied on consultation frequencies at primary
care level in Switzerland considering the proportion of consultations by
Sentinella-physicians and the proportion thereof which is due to AG. All
calculations are based on several assumptions making it difficult to as-
sess which of them is most reliable and closest to reality. Furthermore,
estimates were calculated for different calendar years. Nevertheless, all
estimates point at a substantial burden due to AG at the primary care
level in Switzerland which is partly preventable. Furthermore, the es-
timates are indicative of a large, yet unquantified burden to the Swiss
economy and society.
14.2 The National Notification System for
Infectious Diseases: a critical reflection
14.2.1 Does the NNSID fulfil its purpose?
When judging about the performance of a system, its intended purpose
has to be taken into account. The purpose of the NNSID is the early
detection and surveillance of communicable diseases [Die Bundesvers-
ammlung der Schweizerischen Eidgenossenschaft, 2012b]. This should
support to prevent epidemics and further spread of those diseases, and to
evaluate if control measures were effective. Critique was raised that data
from the Swiss NNSID do not allow distinguishing between changes in
disease frequency at population level and changes in other factors influ-
encing case numbers [Bundesamt für Gesundheit and Nationales Refer-
enzzentrum für enteropathogene Bakterien und Listerien, 2015; Schmutz
et al., 2013, 2016]. The same was reported for surveillance systems of
other countries [Henao et al., 2015; Janiec et al., 2012; Lake et al., 2010].
In the subsequent paragraphs, the NNSID’s performance is assessed,
roughly following the handbook of the European Centre for Disease Pre-
vention and Control (ECDC) for surveillance system evaluation (chapter
3) [European Centre for Disease Prevention and Control, 2014]. These
guidelines were chosen as they were recent (from 2014) and developed
for the European Union (EU) with the aim to improve comparability of
country-specific data collected within The European Surveillance Sys-
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tem (TESSy). Switzerland does not belong to the EU and hence, does
not participate in TESSy but it still reports case numbers for selected
diseases to ECDC. Therefore, it would be ideal if the Swiss surveillance
system was comparable to those of the EU countries considering the geo-
graphic proximity and the (relative) similarity of health systems. Still,
guidelines of the Centers for Disease Control and Prevention (CDC) for
evaluating public health surveillance systems (task D) [German et al.,
2001] were considered in addition to complement the assessment.
External completeness – Under-notification
According to the ECDC handbook, external completeness refers to the
level of under-notification, hence, the cases correctly diagnosed by not
reported to the surveillance system (note, however, that the term “un-
der-reporting” is used in the handbook) [European Centre for Disease
Prevention and Control, 2014]. In contrast, sensitivity of a surveillance
system includes under-notification, under-diagnosis and under-ascertain-
ment* of cases. For a discussion on the sensitivity of the Swiss surveil-
lance system, please see the next section.
Both, the actual external completeness and the target level of external
completeness depend on the pathogen studied. Diseases for which a
high level of external completeness is important include highly conta-
gious diseases, diseases with high case-fatality, rare diseases, (re-)emer-
ging diseases, new strains, and diseases for which eradication or control is
envisaged [European Centre for Disease Prevention and Control, 2014].
For other diseases in the surveillance system, lower levels of external
completeness may be acceptable. Acceptable levels for external com-
pleteness of notifications should be defined before conducting a formal
evaluation.
One way to assess external completeness is comparison of notifications re-
ceived from physicians and from laboratories for diseases for which both
reports are required. Von Stokar et al. [2012] looked at five diseases in
Switzerland (invasive meningococcal disease, measles, gonorrhoea, tick-
borne encephalitis and hepatitis B) and reported that between 2.8% and
21% of cases missed physician reports in 2008 or 2009, depending on the
disease. Analysis of Swiss hepatitis A notification data revealed that a
report on clinical findings was missing for 14% of cases between 1988 and
2016 (chapter 5). Data for this kind of assessment is readily available at
the FOPH and hence, analysis should be conducted on a routine basis
for all notifiable diseases.
Another method for assessing external completeness is comparison of
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surveillance data with databases of data providers (i.e. laboratories and
physicians) or with medical records. For our positivity studies we re-
ceived data from diagnostic laboratories directly and compared it to case
numbers reported by the corresponding diagnostic laboratories accord-
ing to the NNSID database. Comparison of positive laboratory reports
received from the laboratories directly and cases recorded in the NNSID
for EHEC revealed that numbers differed by up to 21% annually for the
time period from 2007 to 2016 (chapter 8).
Capture-recapture studies are a third way of assessing external com-
pleteness. However, appropriate data sources are limited to compare the
NNSID data with. Only the subset of hospitalised cases reported in the
NNSID could be compared with hospital statistics. Mortality statistics
are not very suitable either as (fortunately) the majority of cases reported
to the infectious disease surveillance system will not be fatal. Sentinella
seems suitable in the first instance. However, case definitions often differ
between the NNSID and Sentinella – if the same diseases are surveyed
at all – and notifications lack a common identifier. Hence, the propor-
tion of patients captured by both systems cannot easily be quantified.
However, other countries have evaluated reporting completeness using
capture-recapture studies. For example, in Wallonia, Belgium, a com-
pleteness rate of 65% for notification of Legionnaires’ disease was found
[Jacquinet et al., 2015]. A similar rate of 60% was found for Creutzfeldt-
Jakob disease (CJD) in Belgium [Litzroth et al., 2015]. It was con-
cluded that the surveillance system was able to detect changes in CJD
incidence. Low reporting completeness was found in the Netherlands for
pertussis-related hospitalisations and deaths [Van der Maas et al., 2017].
Similar to Switzerland, cases must be reported to the Dutch notification
system upon laboratory-confirmation. Hence, hospitalisations occurring
after laboratory-confirmation may be missed. Despite limitations, cap-
ture-recapture studies should be considered to formally assess external
completeness of the NNSID.
Sensitivity and specificity
The ECDC handbook defines sensitivity as the “proportion of the ac-
tual cases that were reported to the system”; Specificity, on the other
hand, is the “proportion of non-cases identified as such and not reported
to the system” [European Centre for Disease Prevention and Control,
2014]. Therefore, sensitivity and specificity also depend on the disease
considered and are not universal to a surveillance system. Reconstruc-
tion of the burden of illness pyramid from consultation at primary care to
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disease notification using the example of foodborne infections has shown
that underreporting* is substantial in Switzerland (subsection 14.1.6),
and hence, sensitivity of the NNSID is low. However, diagnostic tests
used have changed: the increasing use of multiplex PCR panels – for
gastrointestinal infections but also for other diseases – increases test
numbers and case detections and, hence, sensitivity (chapter 7). On the
other hand, rare diseases may not be at the forefront of physicians minds
and hence, may not be considered at all or diagnosed with a substantial
delay (chapter 5), again at the cost of sensitivity. Considering that many
observations are notifiable upon positive laboratory diagnosis and that
diagnostic methods are of high quality in Switzerland, both, specificity
and positive predictive value (PPV) of the surveillance system are as-
sumed to be high.
Another aspect affecting sensitivity of the surveillance system is access
to healthcare. Access to healthcare is assumed high considering that
health insurance is compulsory in Switzerland and that 78% of the pop-
ulation reported having consulted a physician within the last 12 months
according to the Swiss health survey in 2012 [Bundesamt für Statistik,
2017b]. The BUGS study (chapter 13) will provide further information
for assessing sensitivity of the NNSID by looking at patients’ help seek-
ing behaviour and quantifying under-ascertainment.
The CDC guidelines define a second approach to measure sensitivity of
a surveillance system apart from underreporting: the “ability to detect
outbreaks, including to monitor changes in the number of cases over
time” [German et al., 2001].
Sensitivity to detect outbreaks or changes in disease frequency can still
be good even if underestimation is substantial as long as factors affecting
underestimation remain constant. A change in one or several of those
factors can either affect sensitivity or the PPV of the system. The PPV
of an outbreak or “alert” could be considered instead of looking at the
PPV of an individual case. However, no proportion of correct alerts can
be estimated in the absence of knowing the number of “true” changes
in disease occurrence (or outbreaks). However, experiences with EHEC
(chapters 7 and 8), Legionella [Fischer et al., 2017; Gysin, 2018] and
Chlamydia trachomatis [Schmutz et al., 2013] – all showing an increase
in notified cases which does not necessarily represent an increase in dis-
ease frequency at population level – point at a rather low PPV of the
NNSID.
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External validity
External validity is assessed by comparing data from the surveillance
system with data from another system, ideally from a source considered
the “gold standard”. A common method used is record linkage using
different data sources, e.g. medical records, or death certificates. A
study comparing measles case notifications concluded that the NNSID
had a lower sensitivity but a higher specificity compared to Sentinella
in terms of case detection [Richard et al., 2008]. However, the NNSID’s
performance was better for identifying outbreaks.
Hospital and mortality statistics are another source for comparison of
case numbers. However, different case definitions hamper easy compar-
isons. Furthermore, the three systems (NNSID, hospital and mortality
statistics) collect information at different time points during the course
of disease additionally complicating comparability. Comparison of data
on hepatitis A from the three aforementioned systems has shown that
case numbers from hospital statistics are comparable with the number
of cases reported to be hospitalised according to the NNSID – but only
when excluding secondary diagnoses from hospital statistics (chapter 5).
More deaths due to hepatitis A were recorded in mortality statistics than
in the NNSID.
Studies assessing external validity of data collected through the NNSID
are recommended.
Usefulness of the surveillance system
A system can be considered useful if it fulfils its purpose and results are
used for public health action. However, it can also be useful if it gen-
erates evidence for action beyond its intended purpose [German et al.,
2001]. Data from Swiss surveillance systems (NNSID and Sentinella)
have been used for several studies presented in this thesis (chapters 4, 5,
6, 8, 9, and 12). They stimulated research [Bless et al., 2014; Schmutz
et al., 2013], and served as basis for research articles [Richard et al.,
2017, 2018; Schuler et al., 2014] as well as for detection of outbreaks
[Delaporte et al., 2011; Knoblauch et al., 2015; Stephan et al., 2015].
Furthermore, notification data influenced policy. For example, the Swiss
national programme against human immunodeficiency virus (HIV) ex-
panded its scope to include also other sexually transmitted infections due
to the increase in Chlamydia trachomatis infections, syphilis and gonor-
rhoea [Federal Office of Public Health, 2010]. Finally, data from the
NNSID and from Sentinella, published in the “BAG Bulletin”, are reg-
ularly taken up by public media (Appendix, section F.2). These are all
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factors indicative of the system’s usefulness. Similarly, increasing Cam-
pylobacter case numbers lead to the establishment of the so-called “Cam-
pylobacter-Plattform” in 2008, a multi-stakeholder platform consisting
of representatives from research, from cantonal and federal authorities,
and from the poultry industry [Federal Veterinary Office, 2008], aim-
ing at reducing Campylobacter case numbers in Switzerland. However,
despite continuous high levels of Campylobacter case notifications, the
platform was abolished in 2016 [Bundesamt für Lebensmittelsicherheit
und Veterinärwesen, 2016].
Factors defining usefulness of a system vary between users [European
Centre for Disease Prevention and Control, 2014]. Therefore, a list of
intended and actual users of the systems would be required to formally
assess the NNSID’s and Sentinella’s usefulness.
Simplicity
The process of notification is shown in appendix B. Given the admin-
istrative structure of Switzerland, the reporting entities have to report
to one of 26 cantonal health authorities, and selected reports must be
sent to the federal health authority. Furthermore, the NNSID still relies
on paper-based notification forms transmitted to the cantonal physician
and/or the FOPH by postal mail or fax (or telephone in case of observa-
tions notifiable within 2 hours). Notifications received by the cantonal
authorities are forwarded to the federal authorities again by postal mail
or fax. The notification process could significantly be modernised and
simplified if notifications could be filled in directly in an electronic sys-
tem. This would then automatically and efficiently transmit the noti-
fication to the appropriate authorities (federal and concerned cantonal
authorities). Also Germany still uses paper-based notification for phys-
icians to report to local health authorities [Robert Koch-Institut, 2017].
In contrast to Switzerland, however, notification forms are entered into
an electronic system at the local level and forwarded to the state and
federal health departments electronically.
Information requested for reports on laboratory findings are mostly tech-
nical (such as type of specimen and diagnostic method) and therefore
routinely collected, known and easily recordable at the laboratory. How-
ever, reports on clinical findings also include information which may not
be known by physicians if they did not explicitly ask for during the
consultation (e.g. exposure history; see also “Data quality” in this sub-
section, 14.2.1, for a discussion of resulting consequences).
Furthermore, the Swiss system is rather complex when it comes to inter-
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vening in public health matters such as contact tracing and prophylaxis
among contacts: responsibilities are dependent on the circumstances.
The cantonal authority (cantonal physician) is responsible for case man-
agement of a case within his own canton [Der Schweizerische Bundesrat,
2015b]. Cantonal authorities may collaborate if several cantons are in-
volved (e.g. in case of small clusters or if the patient was travelling),
but the federal authority may also take over the responsibility. Finally,
the federal authority (the FOPH) is responsible if the case was travelling
abroad, hence, for communication with international authorities.
Flexibility – responsiveness to changing needs
Following reports of numerous countries of autochthonous transmission
of Zika virus disease and clusters of microcephaly and other neurologic
disorders in Brazil, the World Health Organization (WHO) declared a
Public Health Emergency of International Concern on 1st February 2016
[World Health Organization, 2016]. On 5th March 2016, a revised DHA
Ordinance entered into force declaring Zika virus a notifiable disease in
Switzerland [Das Eidgenössische Departement des Innern, 2015b]. Simil-
arly, notification of hepatitis E was introduced on 1st January 2018 in re-
sponse to the increasing awareness that hepatitis E is endemic in Europe
and not only travel-associated [Bundesamt für Gesundheit, 2017a; Das
Eidgenössische Departement des Innern, 2015a]. Hence, the NNSID is
able to quickly respond to changing needs – at least in case of emerging
diseases.
The obligation to reconsider the list of notifiable observations and the
content of the notifications at least once a year is stipulated in the “DHA
Ordinance on the reporting of observations on human communicable dis-
eases” [Das Eidgenössische Departement des Innern, 2015a]. Content (or
at least wording) of notification forms was changed quite frequently for
hepatitis A and Legionella (chapter 5; Gysin [2018]) – and likely also for
other diseases. For example, the clinical sign of jaundice was prompted
in at least three different ways: it was listed as one of the signs and
symptoms under the heading “clinical signs” from 1988–1990, it could
be checked as “reason for laboratory testing” from 1991–1998, and was
listed again under “manifestation” or “clinical manifestation” from 1999
onwards. Whether this kind of flexibility of the system is favourable is,
however, questionable considering that such changes can make interpret-
ation of long-term trends difficult. Case definitions were also changed
repeatedly. For example, in 2018 the case definition for Campylobacter
was adapted to include also cases with laboratory-confirmation using
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culture-independent methods as confirmed cases (personal communica-
tion). Case definitions used by ECDC are also regularly updated; also
at the European level, the case definition for Campylobacter newly in-
cludes laboratory-confirmed cases using nucleic acid detection methods
as confirmed cases in the 2018 update [European Commission, 2018].
Implementation of electronic reporting for laboratories was planned
already for 2012/13 [von Stokar et al., 2012] but is still pending (as
of August 2018).
In conclusion, the NNSID is responsive to changing epidemiological
needs. However, when it comes to adapting to technological advances,
the NNSID’s flexibility is limited.
Data quality
A substantial proportion of “unknown” or “not specified” responses to
certain variables has been noted for different notifiable diseases, espe-
cially regarding exposure information and risk factors (chapter 5, Gysin
[2018]). The assumed place of exposure was unknown or missing for
41% and 70% of acute and chronic hepatitis B cases, respectively and
for 25% and 68% of acute and non-acute hepatitis C cases recorded in
the NNSID [Richard et al., 2017, 2018]. Poor completion of suspected
country of exposure was also reported in Australia [Gibney et al., 2017].
The study among Swiss GPs has further shown that taking the exposure
history is not among the top priorities during a consultation for some
physicians – at least for diarrhoeal diseases (section 10.2). This is likely
also the case for other diseases which would explain the poor completion
of exposure information by the physician on notification forms.
The physician is required to complete the form as soon as the criterion
for notification is fulfilled [Das Eidgenössische Departement des Innern,
2015a]. Considering that this criterion for notification is often dependent
on laboratory-confirmation of the disease, the physician knows that he is
requested to complete the notification form only after the consultation.
The physician may not routinely collect all information requested on the
notification form, e.g. on exposure history, given that it is not required
for case management. Hence, filling in the form after seeing the patient
further contributes to incomplete information if no follow-up consulta-
tions are scheduled and not all information required was obtained and
recorded during the initial consultation. Extra efforts would be required
by the physician in order to be able to answer all questions on the noti-
fication form (e.g. “preventively” collecting the information needed even
though the suspected case might not be confirmed); else, data quality is
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at stake.
Moreover, considering the validity of data even if all information was
obtained, it reflects one point in time but certain factors such as hos-
pitalisation status could change. In this regard, also new diagnostic
methods providing faster results could change the time point of com-
pletion of the notification form because the criterion for notification is
fulfilled at a different point in time during the course of disease. This
could influence content of the notification.
For HIV, influenza and Legionella the number of tests conducted had
to be reported by diagnostic laboratories already before implementation
of the new Epidemics Act in 2016. For example, for Legionella this in-
formation is required since 2006 [Gysin, 2018]. However, reporting is
incomplete and has not been enforced. Sometimes even fewer tests than
cases (positive tests) were recorded for Legionella [Gysin, 2018]. Know-
ledge gaps on laboratory routine procedures in testing make it difficult
to evaluate data quality of reports on the “statistic of reports on labor-
atory findings” (i.e. the number of tests performed and the number of
positive tests thereof) which are notifiable since 2016 (chapter 9).
Acceptability of the surveillance system
The interviews with Swiss GPs and laboratory experts (chapters 7 and
10) indicated that there are differences between them concerning accept-
ability of the surveillance system but they generally see the need for a
notification system. On the other hand, they mentioned that they have
to provide a lot of information for little return (e.g. statistics as reported
in the bulletin of the FOPH, the “BAG-Bulletin”). Von Stokar et al.
[2012] found that some physicians would wait notifying a case until they
were reminded to report it by the cantonal physician (who sends remind-
ers based on reports from laboratories). Diagnosing a notifiable disease
is not everyday business for most physicians. Therefore, they might not
have a routine procedure and might not be aware of all notifiable dis-
eases. In contrast, in laboratories, reporting is frequently automated or
there is at least a defined procedure for reporting.
On the other hand, physicians in an Australian study reported that they
did not notify a case of Campylobacter because the laboratory would
notify it anyway, they did not know the reason for not reporting, or they
did not consider the notification important [Grills et al., 2010]. Hence,
increasing the physicians’ awareness that every single notification is im-
portant and that the information provided by physicians is complement-
ary to the laboratory notification are key to improve acceptability and
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compliance.
Another reason for higher acceptability and compliance by laboratories
compared to physicians could be that notification forms for laboratories
require fewer information and information which is easier to obtain (e.g.
age and sex of the patient) compared to physician notifications (e.g. risk
factors and exposure).
Acceptability of a system is subjective and its proper assessment would
require a separate study. Nevertheless, based on the indications dis-
cussed above, it can be concluded that the NNSID is accepted by Swiss
system actors. Despite, its acceptance could be improved by providing
feedback (e.g. in the form of more frequent, timely and targeted analyses
of notification data; more than “simple” tables with case numbers in the
weekly “BAG Bulletin”) and increasing awareness of the importance of
every single notification. In line, physicians in Australia reported that
improved feedback beyond “automatically generated summary reports”
would increase their compliance to notify [Grills et al., 2010].
Representativeness
Cases captured by the NNSID are unlikely to be representative of the
cases occurring in the general population in Switzerland – at least in
the case of foodborne diseases. The study among Swiss GPs and the
Sentinella study (chapters 10 and 11) have shown that, for example, pa-
tients reporting recent travel are much more likely to be tested in case
of AG and hence, are more likely to be captured by the system. Fur-
thermore, patients with severe disease, poor general health state or co-
morbidities are more likely to seek care and to be tested. Physicians’
(mis-)perception of risk factors can additionally influence their approach
to diagnosis as well as their awareness of a certain disease influencing
case-ascertainment.
Representativeness is likely to vary between diseases. The factor of un-
derestimation is probably lower for highly virulent pathogens and their
representativeness in the NNSID is higher. In contrast, the case as-
certainment bias is presumably higher for pathogens frequently causing
asymptomatic or mild infections.
Timeliness of reporting and outbreak detection
Timeliness is partly inherent to the system set-up (e.g. defined time
frame for reporting as stipulated in the Epidemics Act) and partly de-
pendent on the persons and processes involved. Notification is required
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within 2 or 24 hours or 7 days, depending on the pathogen [Das Ei-
dgenössische Departement des Innern, 2015a]. Furthermore, help seeking
behaviour of patients, diagnostic approaches of the physicians, specimen
collection and transportation, laboratory methods used by laborator-
ies, compliance with the reporting requirements and data processing at
the cantonal and federal authorities are influencing timeliness of report-
ing. New diagnostic methods such as multiplex PCR panels replacing
traditional culture-based methods for stool testing reduce the time to
diagnosis. However, patients with AG do not immediately seek help and
physicians frequently follow a “wait & see” approach (section 10.1 and
chapter 11), both delaying case detection. Richard et al. [2008] reported
that timeliness of case detection was better in Sentinella than in the
NNSID but it should be improved in both systems.
Another aspect of the surveillance system’s timeliness is the time to de-
tection of an “event” (a potential cluster or outbreak). This is dependent
on the processing of the data received, on data analyses and on informa-
tion sources used. In order to increase the chance to react timely in case
of a foodborne outbreak, the time frame for notification was reduced to
24 hours for most foodborne pathogens in Switzerland [Das Eidgenöss-
ische Departement des Innern, 2015a]. However, the timeliness of the
NNSID could certainly be further improved by introducing electronic
reporting, allowing for an almost simultaneous information of cantonal
and federal authorities and minimising time needed for data entry. Ad-
ditionally, automated outbreak detection tools could be applied for rapid
identification of clusters in case reports. First positive experiences are
reported from Germany where such a system was implemented in 2013
[Salmon et al., 2016].
Stability
Reliability and availability of the surveillance system itself (not the data
collected within the system) are key factors of stability according to the
CDC guidelines [German et al., 2001]. The studies conducted as part
of this thesis do not assess stability of the NNSID; however, no events
have been noted pointing at a lack of stability. Yet, the system’s stabil-
ity could potentially still be improved, e.g. by implementing electronic
notification, considering that data processing at the cantonal and fed-
eral authorities is mostly manual and hence, dependent on availability
of workforce.
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Conclusions on the system’s performance
This rough evaluation of the Swiss surveillance system showed that the
NNSID is a useful, well accepted and stable system. Sensitivity of the
system at case-level is low but sensitivity of outbreak detection still seems
acceptable. The system is able to adapt to changing epidemiological
needs but lacks flexibility to accommodate technical improvements such
as electronic reporting. Introducing electronic reporting could increase
timeliness of the system as well as simplicity and data quality. Combin-
ing and comparing notification data with data collected through other
systems (e.g. hospital and mortality statistics) is recommended to eval-
uate the data in terms of external completeness and validity, and to
further increase data use.
In summary, the NNSID does fulfil its purpose but should still be im-
proved in various aspects. It has to be noted that this is not a formal
evaluation of the Swiss surveillance system. A detailed evaluation fol-
lowing all steps described in the ECDC handbook [European Centre for
Disease Prevention and Control, 2014] goes beyond the scope of this
thesis but is strongly recommended. Furthermore, costs and cost effect-
iveness of disease surveillance were not considered but should be included
in a future evaluation.
14.2.2 Does the purpose of the NNSID match our
expectations?
A more refined definition of the NNSID’s purpose in combination with
targeted research systematically evaluating all system characteristics is
needed to further assess the system’s performance.
Critique about the NNSID which was raised may not only signal failures
of the system but could also be attributed to high or wrong expectations
towards the system. A surveillance system is not designed to provide
answers to all epidemiological research questions. Hence it cannot be
expected that it replaces epidemiological research. As discussed above
(subsection 14.2.1), simplicity is a key factor of a surveillance system.
Therefore, keeping the public health surveillance system simple, flexible,
acceptable, timely and stable and complementing findings by separate
research studies is likely more efficient and appropriate than overloading
the surveillance system with complementary research questions.
In that sense, it might be worthwhile considering alterations to the ex-
isting NNSID. For example, the burden of notification could be reduced
for physicians by decreasing the amount of data requested, especially
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for data with poor quality (e.g. exposure information). Complementary
research could be mandated using the resources saved to gather this in-
formation, when needed. This approach would have the advantage that
studies could be targeted to specific research questions circumventing
limitations inherent to surveillance systems such as case ascertainment
bias.
Additional possibilities to improve the NNSID are discussed in the fol-
lowing subsection.
14.2.3 How could the NNSID be improved?
An evaluation of the NNSID was conducted in 2011 based on a mandate
from the FOPH, as referred to already before [von Stokar et al., 2012].
The evaluation report concluded that the NNSID is a well functioning
and accepted system. Nevertheless, several recommendations to improve
the NNSID were given, mainly in terms of compliance and quality, some
of which are listed below:
• Regularly assess compliance of reporting taking into account other
information sources such as SwissDRG and medical statistics of hos-
pitals
• Simplify process of reporting by merging initial and complementary
report to improve compliance
• Implement an electronic notification system (which can ideally be
linked to practice-, hospital-, and laboratory-software information
systems) to improve compliance
• Improve knowledge about the NNSID among those required to no-
tify (e.g. on the selection of notifiable observations, time limit for
reporting and process of reporting)
• Actively inform about functionality and benefit of the NNSID through
different information channels
• Actively communicate changes in the NNSID to those concerned
• Specify contact persons who are readily available in case of questions
about technicalities of the NNSID
• Involve cantonal physicians to inform about the NNSID as they are
in close(r) contact with physicians
• Involve professional associations and stakeholders to act as role mod-
els and implement clear processes within institutions (hospitals, labor-
atories) defining responsibilities
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Optimising communication and increasing compliance
Some of the recommendations by von Stokar et al. [2012] have been
addressed. For example, initial and complementary reports have been
replaced by one notification form (report on clinical findings) for all but
four notifiable observations with the implementation of the new Epidem-
ics Act in 2016.
The benefit and importance of the NNSID was discussed controversially
among Swiss GPs participating in the qualitative study (section 10.2).
Both, laboratory experts and GPs from the stakeholder consultation
(chapters 7 and 10) mentioned the difficulty to identify and contact re-
sponsible persons at the FOPH. Hence, the FOPH should still try to
improve communication and specify personal contact partner(s). Fur-
thermore, the contacts established during the laboratory visits should be
maintained or even strengthened, and expanded to include more laborat-
ories, generating a community of practice of actors of the Swiss surveil-
lance system. Regular exchanges should be organised, e.g. as monthly
telephone conferences complemented by an annual meeting. If this ap-
proach proves successful, a similar network and exchange with physicians
should be considered.
The suggestion by von Stokar et al. [2012] to involve cantonal physi-
cians as mediators between physicians and the FOPH seems promising:
GPs participating in the qualitative study mentioned closer contact with
cantonal physicians than with the FOPH and perception of cantonal
authorities was generally more positive than perception of the FOPH
(chapter 10). It has to be noted, however, that the recommendations of
von Stokar et al. [2012] and most of the study findings originate from
times before introduction of the new Epidemics Act.
With the implementation of the new Epidemics Act, the FOPH released
a “manual on notifiable diseases” [Bundesamt für Gesundheit, 2018a] as
well as a poster with an overview of all notifiable diseases and pathogens
[Bundesamt für Gesundheit, 2018]. The latter was displayed in several
laboratories, as noted during the visits (chapter 7). This suggests that
the poster was considered attractive and acts as a good tool to increase
visibility of the notification system. Weekly reporting of influenza dur-
ing the influenza season was mentioned several times by Swiss GPs and
considered useful (unpublished observation). Communication of surveil-
lance data on influenza should, therefore, be used as a role model also
for other diseases considering that this reporting is well-known and per-
ceived positive by both, physicians and public media.
Findings from the qualitative study among Swiss GPs (section 10.2)
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suggest that events for continuous education and Swiss medical journals
(e.g. Swiss Medical Weekly or Primary Care) are suitable tools to reach
a high proportion of GPs in Switzerland. Therefore, these communic-
ation channels should be used more actively by the FOPH to inform
about issues related to disease surveillance, including changes in the
notification system but also to communicate results from analyses of no-
tification data. Publishing articles in existing local medical journals is
suggested rather than creating an own journal or newsletter considering
that physicians reported being overwhelmed by the flood of information.
In addition, active participation of staff from the FOPH at conferences
and events for continuous education should be increased to foster direct
personal contact between system actors.
Content of notification forms
Reliability and usefulness of risk factor and exposure information (per-
sonal risk factors, exposure risks, potential source and place of exposure)
collected in surveillance systems must be questioned: first, the informa-
tion is often incomplete (chapter 5; Gibney et al. [2017]; Richard et al.
[2017, 2018]). Second, the information relies on proper and systematic
anamnesis by the physician completing the form. However, the study
among Swiss GPs indicated that anamnesis on risk factors is not the most
important part of a consultation for some physicians, at least concerning
food anamnesis in case of diarrhoeal diseases (section 10.2). Further-
more, the physicians’ correct knowledge on incubation period, potential
sources of exposure and risk factors is crucial for accurate anamnesis and
completion of notification forms but must be questioned (section 10.2).
Neave et al. [2016] evaluated notification forms from Australia, New Zea-
land, the UK and Canada for selected diseases and made recommenda-
tions about which variables should be collected on notification forms to
inform public health policy in the context of imported infections. They
recommended the collection of at least the following variables: “Travel-
related information: recent international travel; reason for travel; dates
of entry to and departure from the countries visited during the disease
incubation period; and vaccination details. Demographic information:
traveller’s and parent’s country of birth; country of usual residence;
length of time resident in current country; postcode. There was no
agreement about whether ethnicity should be collected. Disease severity
information: hospitalisation; death.”
Following these recommendations, completely refraining from obtaining
information on possible exposure may not be appropriate. However,
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every variable of the notification form should be evaluated, carefully
considering validity, reliability and importance. Moreover, wording of
questions should be cautiously and deliberately chosen. For example,
there is a slight, but potentially important difference in asking “in which
country has the patient been during the incubation period” (objective
information) and “in which country has the patient likely been infected?”
(information with some subjective component, including interpretation
of the physician). Subtle changes in wording of notification forms can
influence responses, but the extent can hardly be quantified (chapter 5).
Therefore, it is recommended to refrain from those changes if ever pos-
sible. Collecting objective information (e.g. where has the person been)
rather than partly subjective information (e.g. where has the person
been exposed) is recommended to reduce heterogeneity in surveillance
data and increase reliability.
Electronic notification
Electronic notification has not been implemented in the NNSID yet, but
is still planned to be implemented in the future. Implementing electronic
notification can improve the NNSID in several ways: first, it is likely to
increase compliance by reducing the time needed for notification (less
paper handling; quicker search for appropriate form). Second, quality of
the data could be improved (e.g. automatically highlighting fields with
missing or erroneous information, no data entry of paper forms). Third,
under-notification could be reduced if the electronic reporting system
is linked to the practice-, hospital-, or laboratory information system
and generates automatic reminders that a certain diagnosis is notifiable.
Fourth, timeliness could be improved by simplifying the reporting pro-
cess. The Sentinella network offers both, electronic and paper-based
notification. Electronic notification was chosen by more than half of
participating physicians (chapter 11). Currently, the FOPH considers
switching to electronic notification only in the Sentinella system and
asked participating physicians still reporting on paper forms about their
willingness to switch [Sentinella, 2017]. More than a third of respond-
ents each were willing to switch immediately (26/70) or in case paper-
notification is ceased (25/70). One fourth of respondents still preferred
paper-based forms (18/70). For 14 of 70 respondents offering electronic
notification only would be a reason to quit Sentinella. These experiences
and results indicate that electronic notification would be well-accepted
among the majority of Swiss physicians. Nevertheless, there is still a
minority with a negative attitude towards electronic reporting. Proact-
326
14.2 The NNSID: a critical reflection
ive information of physicians (and others required to report) will, hence,
be very important when changing to electronic notification in other sur-
veillance systems, e.g. the NNSID.
In the Netherlands, introduction of an electronic reporting system
between the municipal and the national health services lead to improved
timeliness and completeness of notifications despite reports from clini-
cians and laboratories were still sent using conventional phone, fax or
e-mail to report to the municipal level [Ward et al., 2005]. Similarly,
Gibney et al. [2017] suggested that increasing case numbers seen in the
Australian surveillance system are partly attributable to changing from
manual notification of clinicians to automatic notification of laboratories.
Comprehensive vs. sentinel surveillance
During the evaluation of the NNSID it was also discussed if the nation-
ally compulsory notifications could be replaced by a sentinel surveillance
system [von Stokar et al., 2012]. It was shown that the NNSID is less
sensitive than Sentinella to detect cases of measles, despite the former
relying on two information sources (physicians and laboratories) while
the latter is exclusively supported by physicians [Richard et al., 2008].
Nevertheless, the NNSID was more sensitive to detect outbreaks. Ad-
ditionally, Sentinella lacked specificity and both systems showed weak
timeliness. Considering that outbreak detection is one of the main pur-
poses of disease surveillance, a comprehensive system such as the NNSID
should not generally be replaced by sentinel surveillance.
Collection of summary statistics (denominator information)
Knowledge of denominator information such as the number of tests per-
formed is important for interpretation of case numbers, as shown by our
positivity studies (chapters 6 and 8; Schmutz et al. [2013]). Reporting
of summary statistics for laboratories has been introduced more widely
with the new Epidemics Act: Laboratories have to report the number
of tests conducted for certain diseases once a year (chapter 9). Knowing
this denominator would allow rough analyses similar to our positivity
studies (chapters 6 and 8; Schmutz et al. [2013]). Repeated tests in the
same individual cannot be considered when analysing those data in con-
trast to our positivity studies where individual-based information was
collected. Experiences from the aforementioned studies suggest that in-
terpretation of findings do not change considerably if repeated tests are
not considered – at least when looking at trends. On the other hand,
preliminary analysis of summary statistics from the first two years of
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reporting has identified several limitations (chapter 9). One of those
limitations – confirmatory (“reflex”) testing – was not routinely applied
by diagnostic laboratories for the pathogens considered in our positivity
studies during the time periods studied. It is conceivable that systematic
reflex testing does affect positivity considerably and hence, should not
be ignored. In this case, collection of aggregated (vs. individual-based)
data on test numbers would no longer suffice. Furthermore, validity and
usefulness of data collected through current notification forms on “stat-
istic of reports on laboratory findings” must be questioned (chapter 9).
14.3 The ideal case management for acute
gastroenteritis from different perspectives
14.3.1 The patients’ perspective: reducing illness
duration and social impact
Laboratory-confirmed campylobacteriosis patients in Switzerland repor-
ted consulting a physician mainly due to severity, persistence or lack of
perceived amelioration of signs and symptoms [Bless et al., 2014; Suter,
2014]. The need for a medical certificate was spontaneously reported
as a reason for consultation in 4% of cases only. However, this finding
might be influenced by the fact that the study was conducted during
the festive season. Furthermore, the need for a medical certificate may
not be the primary reason for consultation in severely affected patients
(such as laboratory-confirmed campylobacteriosis cases) while it might
be a more prominent reason among moderately affected patients with
AG. The expectations of the patients towards the physician have not
been assessed in the aforementioned study. Swiss physicians reported
that patients rather expect some sort of “action” (e.g. treatment or
laboratory investigation) as opposed to what physicians called “watch-
ful waiting” (chapter 10).
Generally, little is published about patients’ expectations when consult-
ing a physician due to AG. Both, patients’ reported reason for consulta-
tion in the Swiss case-control study on campylobacteriosis [Bless et al.,
2014] and physicians’ perception of patients’ expectations (chapter 10),
point at a reduction of illness duration, and measures mitigating signs
and symptoms and therefore reducing suffering and social impact as the
main expectations of patients consulting a physician due to AG. A study
investigating antibiotic prescription in patients with acute diarrhoea vis-
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iting emergency departments in the USA found that 91% of patients
expected prescription of an antibiotic and/or another medication [Kar-
ras et al., 2003]. A study among participants of the Swiss inflammat-
ory bowel disease (IBD) national cohort revealed that individuals’ most
important expectations were good coordination between GPs and spe-
cialists, receiving information on adverse events of treatment, and easier
drug treatments [Pittet et al., 2018]. However, those expectations are
likely different in IBD patients compared to AG patients considering the
chronic nature of IBD. A study exploring reasons for attending an ur-
gent care centre in England found that patients with a “minor illness”
(as classified by a GP) mentioned quick access to care as a main reason
for consulting the centre (as opposed to a GP) [Amiel et al., 2014].
Furthermore, more than half of patients expected receiving prescription
medication.
Patients’ expectations towards the physician when consulting due to
AG will be explored in detail in the framework of the BUGS study
(chapter 13).
14.3.2 The physicians’ perspective: reducing suffering
and caring for the vulnerable
There are no Swiss guidelines on the management of acute diarrhoea.
The Swiss Society for Gastroenterology refers to international guide-
lines [Schweizerische Gesellschaft für Gastroenterologie, 2018]. American
guidelines for the management of acute diarrhoea in adults suggest initi-
ation of stool diagnostics “in cases of dysentery, moderate-severe disease,
and symptoms lasting >7 days” in line with common practice reported
by Swiss physicians (chapter 10; Riddle et al. [2016]). In those cases,
diagnosis serves to enable targeted treatment of the individual patient.
Assessing aetiology is usually not considered in mild to moderate and
recent cases as it hardly affects treatment for mainly two reasons: first,
AG is usually self-limiting and hence, symptomatic treatment and/or
dietary recommendations are generally sufficient (chapter 10). Second,
physicians want to help the (suffering) patient immediately rather than
in a few days when diagnostic results are available. In this perspective,
the use of new multiplex PCR panels seems to have advantages over tra-
ditional culture by providing results in hours rather than days (once the
stool sample arrived at the laboratory). Fast results provide the basis
to adjust treatment based on the aetiology of disease. Ideally, this then
helps to reduce both, suffering of the patient and empirical antibiotic
therapy. The latter should be avoided in the light of antibiotic resist-
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ances [Review on Antimicrobial Resistance, 2016].
The GP acts as the counterpart of the patient which is reflected in vari-
ous aspects of his attitude towards diagnosis, treatment and perception
of AG in general: as discussed above and in chapters 10, 11 and 14.1.3,
the decision for or against stool diagnostics is mainly dependent on the
patient’s health status rather than on public health considerations. Sim-
ilarly, the decision for or against prescription of antibiotics is based on
the individuals’ well-being rather than on the general aim to reduce an-
timicrobial use in the population (chapter 10; Review on Antimicrobial
Resistance [2016]). This leads to pragmatic decisions and empiric ther-
apy, and puts microbiological findings in the rear. A qualitative study
among English GPs found that high patients’ expectations for relief and
lack of time during consultation to explain inappropriateness of antibi-
otics were barriers for appropriate antibiotic prescription in the general
practice outpatient setting [Yates et al., 2018]. Furthermore, a recent
literature review concluded that the link between over-prescribing of an-
tibiotics by physicians and the increase of antimicrobial resistance is
neither immediate nor apparent to the physician while missed bacterial
infections with potentially serious patient outcomes are clearly coupled
[Krockow et al., 2018].
When asked about the importance of diarrhoeal diseases, many GPs re-
sponded that diarrhoea is not a problem because it is self-limiting, easy
to treat and generally not dangerous (chapter 10). They stated that
AG is frequent, but harmless. Hence, GPs’ reasoning suggests that they
did not consider the public health aspect of diarrhoeal diseases or their
economic impact in their response. Also when asked about the influence
of costs on their decision for or against stool diagnostics, GPs’ answers
were patient-focused (testing only if it is to the benefit of the patient to
reduce costs for the individual) rather than population-oriented (testing
for knowing the aetiology and typing to foster outbreak detection and to
plan targeted interventions) (chapter 10). Assessing potential exposure is
not a priority for some physicians (chapter 10). Similarly, McNulty et al.
[2014] reported that occupational risks and contact with farm animals
were frequently only recorded by physicians if spontaneously reported by
the patient. Furthermore, a study analysing data from a listeriosis out-
break investigation concluded that the physicians’ food history taking
appeared unstructured [Kiefer et al., 2016]. All above-mentioned factors
suggest that also physicians are mainly interested in AG (the syndrome,
as it presents as an illness/disease) as opposed to foodborne disease*
(with a focus on the transmission pathway).
Apart from reducing suffering of the patient, one of the physicians’ main
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concerns is to identify vulnerable patients and patients at risk of com-
plications and sequelae such as infants, elderly people and patients with
co-morbidities (chapter 10). Public health considerations seem to play a
minor role. In line, aetiological diagnosis is not generally recommended
[Riddle et al., 2016]. Furthermore, counselling on preventive measures is
only recommended for individuals at high risk of complications and for
travellers [Riddle et al., 2016]. This recommendation seems questionable
as contact with a person with acute diarrhoea was the only preventable
risk factor identified in a French study [Arena et al., 2014].
14.3.3 The public health or epidemiologists’ perspective:
identifying sources and outbreaks and preventing
spread of disease
From a public health perspective, investigating the aetiology of a disease
is central. In the case of AG, the aetiology should be assessed if there is a
high risk of human-to-human transmission and during outbreaks [Riddle
et al., 2016]. Knowing the aetiology is key to identify outbreaks, to check
if clustered cases are indeed linked to each other, to link outbreak cases
to suspected sources and/or to implement targeted interventions. There-
fore, the public health specialist concerned with prevention and control
of outbreaks is rather interested in foodborne disease (the aetiological
perspective) than in AG (the symptomatic perspective).
In terms of diagnostic methods, culture or a combination of culture
and culture-independent methods is preferred over culture-independent
methods alone from a public health point of view [Macfarlane-Smith
et al., 2018; Riddle et al., 2016]. Culture-based methods are crucial to
obtain isolates which are important for identifying clustered cases and
potential sources through typing. Shea et al. [2017] argued that isolates
are the “most effective tool” for maintaining and improving food safety.
In contrast, in the hospital setting, the use of multiplex gastrointestinal
(GI) panels could help infection control by quickly identifying patients
for which isolation (in the sense of quarantine) is indicated. A study
from the USA showed that among 158 patients with a negative test for C.
difficile and/or rotavirus using conventional methods, about a fifth was
positive for another GI pathogen using the FilmArray R© Gastrointestinal
(GI) Panel [Rand et al., 2015]. Among those, 60% were not isolated ap-
propriately. On the other hand, isolation could have been suspended for
25 patients testing negative with the panel. Also, culture-independent
methods help reducing the use of antibiotics as well as the length of hos-
pitalisation, and are, therefore, preferred from an economic point of view
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[Beal et al., 2018]. For laboratories, using culture-independent methods
such as multiplex PCR panels is financially attractive as well as already
mentioned before – even when followed by reflex testing in case of PCR-
positive results [Shea et al., 2017; Van Lint et al., 2016]. In conclusion,
from a public health perspective, there are factors favouring culture-
dependent methods and factors favouring culture-independent methods.
Screening samples with culture-independent methods followed by isol-
ation/culture-confirmation in case of positive screening results seems a
viable compromise. Nevertheless, the prolonged time delay from taking
the sample to starting bacterial culture must be taken into consideration
when choosing this approach [Shea et al., 2017]. In the future, next-gen-
eration sequencing (NGS) could be an alternative diagnostic approach
combining advantages of PCR (fast results) and culture-based meth-
ods (allowing epidemiological investigations, e.g. transmission dynam-
ics) [Gardy and Loman, 2018]. Gardy and Loman [2018] even suggested
that NGS could be used as a basis for a global surveillance system given
that the technology becomes affordable (both, in terms of money and
resources needed) and data is made available worldwide.
In Switzerland, laboratories mostly operate in the private sector. Hence,
the decision which diagnostic methods to apply is with the laboratories
themselves. Nevertheless, federal authorities could issue recommenda-
tions and guidelines. Furthermore, on a political level, testing procedures
can be influenced by adapting the official tariff lists for reimbursement of
costs by the compulsory health insurance. The potential impact of such
changes on laboratory diagnostics has been described using the example
of Aeromonas spp. [Tritten et al., 2014].
Aetiological assessment and susceptibility testing are highly recommen-
ded given the increasing problem of antimicrobial resistance and global
efforts to reduce antibiotic prescription [Review on Antimicrobial Resist-
ance, 2016]. Similarly, the Strategy on Antibiotic Resistance Switzerland
(StAR) aims at using antibiotics only in case of a proven bacterial infec-
tion without alternative treatment options [Der Schweizerische Bundes-
rat, 2015a]. The review on antimicrobial resistance highlighted the need
for rapid, low-cost point-of-care diagnostics [Review on Antimicrobial
Resistance, 2016]. Furthermore, they suggested that “high-income coun-
tries should make it mandatory that by 2020 the prescription of antibi-
otics will need to be informed by data and testing technology wherever
it is available”. Multiplex PCR panels provide faster results than tradi-
tional culture techniques. However, they are neither low-cost nor point-
of-care diagnostics. Furthermore, they do not allow antimicrobial sus-
ceptibility testing. Hence, other diagnostic tools are most likely needed
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to tackle the increasing problem of antimicrobial resistance. StAR also
mentions the need to develop new laboratory tests which are inexpens-
ive, provide rapid results and have “a strong practical emphasis” [Der
Schweizerische Bundesrat, 2015a]. “Competent learned societies, the
reference laboratories and industry” are responsible for the development
and implementation of these new tools according to the Swiss strategy.
Independently, financial responsibility needs to be clarified: can the pa-
tient be obliged to pay for diagnostics if diagnostics are performed for
the sake of population health – without immediate benefit for the indi-
vidual? Compliance of Swiss GPs in following such recommendations of
universal testing must be doubted given their patient-centred view and
their perceived unimportance of microbiological results for the majority
of individuals.
Knowing the aetiology of AG is not only important to identify outbreaks,
to adjust control measures (e.g. patient isolation) and to reduce anti-
microbial prescription but also to improve population health at large
by implementing targeted interventions for prevention. For example, it
is of utmost importance to know if the majority of AG is caused by
bacteria (the most common ones being zoonotic agents) or by viruses
(mostly with the human as main or sole reservoir). Similarly, the estim-
ated proportion of foodborne origin is highly dependent on the pathogen
(Table 1.1; [Hald et al., 2016; Havelaar et al., 2015]). For example, hu-
mans are the only known reservoir for norovirus. Its transmission occurs
mainly from person-to-person or via contaminated food or water (the
food and water being contaminated by infected individuals) [Hall and
Lopman, 2015]. Outbreaks are very common, especially in places where
many people convene, such as hospitals, nursery homes, schools, cruise
ships, restaurants and hotels. Prevention and control, therefore, relies on
proper hygiene including hand hygiene, disinfection of the environment
and patient isolation [Hall and Lopman, 2015]. In contrast, campylo-
bacteriosis cases are mostly sporadic and frequently linked to contam-
inated food (mostly meat, contamination originating from the infected
animal or spread during the slaughtering process) or infected animals
[Mahon and Patrick, 2015]. Direct transmission from infected humans
is considered rare. Consequently, prevention starts at controlling con-
tamination at animal level, throughout the food chain (“from farm to
fork”) and ends at the consumer level with campaigns on kitchen hy-
giene. In summary, while some prevention efforts (e.g. general hygiene
interventions) might help mitigating the risk of infection with several
foodborne or gastrointestinal pathogens for humans, others are patho-
gen-specific (e.g. mandatory freezing of poultry-liver for retail to reduce
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Campylobacter) and are, therefore, relying on aetiological assessment.
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The burden of illness pyramid for foodborne infections was investigated
using different research approaches. These have shown that the burden
of AG in Switzerland is considerable. Many cases seen at primary care
level are mild or moderate and can easily be managed by GPs. How-
ever, these cases still cause a considerable burden due to their frequency.
In line, healthcare costs of an individual mild case of AG may be low,
but the sum is still noteworthy and underestimated. Furthermore, even
mild cases result in work loss which could not be quantified within the
scope of this research but must be substantial. Cases seen in the no-
tification system do not represent a random selection of patients with
AG considering the rather sparing use of stool diagnostics. Hence, the
NNSID overrepresents severe or co-morbid cases and those with specific
risk factors for infection or testing, like recent travels. Furthermore,
there are many pathogens causing AG which are not notifiable, such
as norovirus and rotavirus. Cases appearing in the notification system
are much lower in numbers than those missed but individual healthcare
costs are higher. Strategies for saving healthcare costs should, there-
fore, target mild and severe cases as well as cases caused by notifiable
and non-notifiable pathogens. Assessment of non-healthcare costs such
as work loss is recommended to prioritise interventions and to evaluate
their cost-effectiveness.
The number of human Campylobacter and EHEC infections is increas-
ing while the number of Salmonella and hepatitis A infections is stable
or even decreasing in Switzerland according to notification data. The
trends observed for the first three pathogens mentioned are also suppor-
ted by positivity studies taking into account the number of tests conduc-
ted. Those analyses have shown that the NNSID is a useful system to
identify outbreaks but it is not sufficient for characterising the epidemi-
ology of foodborne diseases in Switzerland. It needs to be complemented
by research for confirming presence of and investigating suspected dis-
ease outbreaks. Furthermore, complementary research should be used for
assessing epidemiological determinants such as patients’ and physicians’
behaviour, the burden of disease at population level and obtaining other
supplementary information for setting priorities and informing policy.
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Sentinella is a useful sentinel surveillance system to complement find-
ings from the NNSID. It allows assessing the epidemiology of diseases
at primary care level including cases without laboratory confirmation.
Still, it does not provide the full picture as patients not approaching a
physician will be missed. Additionally, it does not cover patients seeking
help at emergency departments of hospitals directly.
National guidelines for the management of AG do not exist for Switzer-
land. Case management by the physician and processing of the stool
sample by the laboratory are very heterogeneous. National guidelines
could help to harmonise physicians’ and laboratories’ approaches towards
diagnosis and treatment of AG. It is important to consider the different
perspectives of patients, physicians, laboratory and public health experts
when developing diagnosis and treatment guidelines. Awareness of phys-
icians for the public health aspects of AG should be strengthened while
the public health specialist should consider the patient-focused view of
physicians.
Estimation of healthcare costs need to be updated and/or refined once
new findings are available, either from research studies (such as the up-
coming population-based cohort study on AG in Switzerland) or from
surveillance systems. Furthermore, indirect healthcare costs and non-
healthcare costs due to AG should be explored. Additionally, modelling
studies of healthcare and non-healthcare costs should be used to inform
development of AG case management guidelines and to evaluate their
economic impact.
15.1 Recommendations
The experiences from the different research projects which are part of
this thesis can be translated into recommendations for policy makers,
authorities and researchers:
For policy makers:
• The purpose and set-up of surveillance systems with their strengths
and limitations need to be considered when interpreting surveil-
lance data.
• The (disease-specific) burden of disease below the tip of the iceberg
(hence, beyond notification data) and its determinants must be
taken into account for planning and prioritising interventions.
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• Always include components of operations research when mandating
studies on specific infectious diseases in Switzerland to constantly
improve the Swiss infectious disease surveillance system.
For health authorities:
• Pilot testing of data collection tools and meticulous documentation
of changes therein is good practice for research studies. Pilot test-
ing should also be conducted when notification forms are changed.
Similarly, all changes potentially affecting surveillance data (e.g.
in data entry, case definition, notification forms, analysis) need to
be rigorously documented for accurate interpretation of long-term
trends.
• Strengthen personal contact between federal authorities and
healthcare personnel “on the ground” (physicians, laboratory ex-
perts). This will help improving compliance of reporting as well
as understanding of surveillance data. A community of practice
among actors of the Swiss surveillance system should be estab-
lished.
• Restrict information obtained on notification forms to minimum
essential and reliable data needed to decide if further action is
required (e.g. decision for or against contact tracing). Certain
information, e.g. on risk factors and exposures, can more reliably
be obtained through complementary research. Before changing
notification forms, research studies could be mandated to assess
validity of specific information.
• Consider conducting surveys among physicians and clinical labor-
atories to determine practices in case management on a regular
basis, either additional to or in replacement for collecting laborat-
ory statistics (number of tests conducted).
For researchers:
• Triage steps and approaches to case management of AG is likely
different in the outpatient and inpatient setting. Additional re-
search studies focussing on the hospital setting – from the emer-
gency (outpatient) department to intensive care – are needed to
assess the full (clinical) picture of foodborne diseases at the health
care system level in Switzerland.
• Combining authorities’ and scientists’ research needs is beneficial
for both sides: it can help to obtain funding (e.g. mandated re-
search), it can ease implementation of studies by providing access
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to existing structures (e.g. Sentinella), and it increases the likeli-
hood that findings are taken up by stakeholders. Therefore, seeking
close collaboration with health authorities is recommended.
• Explore best practices or ways to collect information on laboratory
statistics (number of tests conducted) allowing routine analysis
of data, or explore alternative approaches for taking into account
changing laboratory practices when interpreting surveillance data.
• Make use of and combine existing networks and data sets con-
sidering all surveillance systems (e.g. NNSID, Sentinella, Swiss
Pediatric Surveillance Unit (SPSU)) and data sources (e.g. pop-
ulation, hospital and mortality statistics) to increase validity of
results and effectiveness of surveillance systems.
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APPENDICES

Appendix A
List of notifiable observations in
Switzerland, as per January 2018
The following table provides an overview of all notifiable observations as
defined in appendices 1–4 of the “DHA Ordinance on the reporting of
observations on human communicable diseases” of 1st December 2015,
as per 01 January 2018 [Das Eidgenössische Departement des Innern,
2015a].
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Table A.1: List of notifiable observations for physicians and laboratories with time frame for notification in Switzerland,
as per 01 January 2018 [Das Eidgenössische Departement des Innern, 2015a]
Observation Time frame for
notification
Report on
clinical
findings
Supplementary
report on
clinical
findingsa
Report on
laboratory
finding
Statistics on
laboratory
findingsb
Cluster of
clinical/laboratory
findings
24 hours x x
Unusual
clinical/laboratory finding
2 hours x x
AIDS / Human
immunodeficiency virus
1 week x x
Anthrax / Bacillus
anthracis
2 hours x x
Botulism / Clostridium
botulinum
2 hours x x
Brucellosis / Brucella
spp.
1 week x x
Campylobacter spp. 24 hours x x
Carbapenemase-
producing
Enterobacteriaceae
1 week x x x
Chikungunya fever/virus 24 hours x x
Chlamydia trachomatis 1 week x x
Cholera/Vibrio cholerae 24 hours x x
Coxiella burnetii 1 week x
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Table A.1: (continued)
Observation Time frame for
notification
Report on
clinical
findings
Supplementary
report on
clinical
findingsa
Report on
laboratory
finding
Statistics on
laboratory
findingsb
Creutzfeldt-Jakob
disease / Prions
1 week x x x
Crimean-Congo
(haemorrhagic)
fever/virus
2 hours x x
Dengue fever/virus 24 hours x x
Diphtheria /
Corynebacterium
diphtheriae and other
toxin-producing
Corynebacteriaceae
(C. ulcerans,
C. pseudotuberculosis)
24 hours x x
Ebola (haemorrhagic)
fever/virus
2 hours x x
Enterohaemorrhagic
Escherichia coli
(infection)
24 hours x x
Gonorrhoea / Neisseria
gonorrhoeae
1 week x x x
(Invasive) Haemophilus
influenzae (disease)
1 week x x
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Table A.1: (continued)
Observation Time frame for
notification
Report on
clinical
findings
Supplementary
report on
clinical
findingsa
Report on
laboratory
finding
Statistics on
laboratory
findingsb
Hantaviral
diseases / Hanta virus
1 week x x
Hepatitis A (virus) 24 hours x x
Hepatitis B (virus) 1 week x x
Hepatitis C (virus) 1 week x x x
Hepatitis E (virus) 24 hours x x x
HIV infection / HI virus 1 week x x x
Influenza A HxNy (new
subtype)
2 hours x x
Influenza virus (seasonal,
non-pandemic types and
subtypes)
1 week x
Lassa fever/virus 2 hours x x
Legionellosis / Legionella
spp.
1 week x x x
Listeriosis / Listeria
monocytogenes
24 hours x x
Malaria / Plasmodium
spp.
1 week x x
Marburg fever/virus 2 hours x x
Measles (virus) 24 hours x x x
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Table A.1: (continued)
Observation Time frame for
notification
Report on
clinical
findings
Supplementary
report on
clinical
findingsa
Report on
laboratory
finding
Statistics on
laboratory
findingsb
(Invasive) meningococcal
disease / Neisseria
meningitidis
24 hours x x
Middle East respiratory
syndrome / MERS
coronavirus
2 hours x x
Plague / Yersinia pestis 2 hours x x
(Invasive) pneumococcal
disease / Streptococcus
pneumoniae
1 week x x
Poliomyelitis / Poliovirus 24 hours x x
Rabies (virus) 24 hours x x
Rubella (virus) 24 hours x xc x
Salmonella spp. 24 hours x x
Severe acute respiratory
syndrome / SARS
coronavirus
2 hours x x
Shigella spp. 24 hours x
Smallpox / Variola/
Vaccinia virus
2 hours x x
Syphilis / Treponema
pallidum
1 week x x
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Table A.1: (continued)
Observation Time frame for
notification
Report on
clinical
findings
Supplementary
report on
clinical
findingsa
Report on
laboratory
finding
Statistics on
laboratory
findingsb
Tetanus 1 week x
Tick-borne encephalitis
(virus)
1 week x x
Trichinellosis /
Trichinella spiralis
1 week x x
Tuberculosis /
Mycobacterium
tuberculosis complex
variabled x x x
Tularaemia / Francisella
tularensis
1 week x x x
Typhoid/paratyphoid
fever / Salmonella
Typhi/Paratyphi
24 hours x x
West Nile virus (disease) 1 week x x
Yellow fever (virus) 24 hours x x
Zika fever/virus 24 hours x x x
a Notifiable within 1 week
b Notifiable once a year until 31st January of the following year
c Congenital rubella
d Clinical findings: 1 week; laboratory findings: 24 hours
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Appendix B
Process of compulsory disease
notification in Switzerland
Figure B.1: Process map of disease notification of "report on laboratory
findings" in Switzerland
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Appendix B Process of disease notification in Switzerland
Figure B.2: Process map of disease notification of "report on clinical findings"
in Switzerland
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Appendix C
The influence of changes in diagnostic
approaches on disease surveillance
data: Time trend in positivity of EHEC
testing in Switzerland, 2007–2016:
Supplementary material
Seasonality
The positivity of enterohaemorrhagic Escherichia coli testing shows a
strong seasonality. The seasonality of the total number of tests and
the number of positives was calculated as the average number of tests
(positives) of all test years (2007–2016) per calendar month. The number
of total tests performed increased by 68% from February with 553 tests
until September with 928 tests. The number of positively tested cases
follows a similar seasonal pattern with 6 cases detected in February and
16 in August. Positivity peaked in July with 1.9%. The seasonality has
been incorporated into the mixed effect logistic regression using sine and
cosine functions, in the form of sin(d ∗ 2 ∗ pi/T ) and cos(d ∗ 2 ∗ pi/T ),
where d is the time period (e.g. January, February) and T is one year,
as described by Stolwijk et al. [1]. The predicted probabilities for a
positive test outcome of the univariable logistic regression are shown in
figure C.1.
References
1. Stolwijk AM, Straatman H, Zielhuis GA. Studying seasonality by using sine
and cosine functions in regression analysis. J Epidemiol Community Health
1999; 53:235–238.
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Figure C.1: Predicted probability per calendar month for a positive test outcome of an enterohaemorrhagic Escherichia
coli infection for the univariable model using sine and cosine functions, 2007–2016, Switzerland
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Appendix D Statistic of reports on laboratory findings 2017
Appendix D
Notification form: Statistic of reports
on laboratory findings 2017
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Appendix E
The burden of gastroenteritis in Switzerland (BUGS) study: a
research proposal for a one-year, prospective cohort study:
Additional file 1
Sample size calculation for the burden of gastroenteritis in Switzerland
(BUGS) study based on different parameter assumptions, including
derivation of underlying formulas
Comparison between two distinct groups (exposed and unexposed)
Power calculations were based on Hayes and Bennett [1], with adjustment for the situation of unequal group sizes.
Let
λ = average event rate among exposed persons (expressed as number of events per person year)
dλ = hypothesized difference in average event rate between exposed and unexposed persons
λ1 = average event rate among exposed persons
λ0 = average event rate among exposed persons
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q = proportion of exposed person
Then,
λ1 = λ+ (1− q)× dλ and λ0 = λ− q × dλ.
The corresponding weekly event rates are λ′1 = λ152 , λ′0 =
λ0
52 .
Let y = average number of weeks of observation per subject.
Then, formula (2) of Hayes and Bennett [1] was adapted and slightly simplified to provide the minimal total
number N of subjects required as
N = (1.96 + z1−β)2 ×
[(
λ′1
q
+ λ
′
0
1− q
)
/y + CV 2 ×
(
λ′21
q
+ λ
′2
0
1− q
)]
/ (λ′1 − λ′0)2
where β denotes the accepted type II-error probability. In case of q = 0.5, N equals 2× (c− 1), where c = number
of clusters per group according to formula (2) of Hayes and Bennett [1].
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Table E.1: Sample size calculation for the burden of gastroenteritis in Switzerland (BUGS) study for a comparison of
the mean number of events per person and year between two distinct groups (exposed and unexposed) based on different
parameter assumptions
Parameters specified / assumptions Comparison of mean number of
events per person and year between
two distinct groups (exposed and
unexposed)
Mean num-
ber of
events per
person and
year
Difference in
mean number of
events per person
and year between
exposed and un-
exposed
Power
Pro-
portion
exposed
ICC
Average
number
of weeks
observed
Calculated sample size needed
1 0.3 0.9 0.2 0.2 40 1’162 (n1= 929, n2= 233)
0.75 0.3 0.9 0.2 0.2 40 909 (n1= 727, n2= 182)
0.75 0.3 0.9 0.2 0.2 26 1’384 (n1=1’107, n2= 277)
0.75 0.3 0.9 0.2 0.2 52 705 (n1= 564, n2= 141)
0.75 0.2 0.9 0.2 0.2 40 1’908 (n1=1’526, n2= 382)
0.75 0.2 0.8 0.2 0.2 40 1’425 (n1=1’140, n2= 285)
0.75 0.1 0.8 0.2 0.2 40 5’295 (n1=4’236, n2=1’059)
0.75 0.2 0.9 0.2 0.5 40 2’172 (n1=1’737, n2= 435)
0.75 0.2 0.9 0.2 0.5 26 3’172 (n1=2’537, n2= 635)
0.75 0.2 0.8 0.2 0.5 26 2’369 (n1=1’895, n2= 474)
0.75 0.3 0.9 0.1 0.2 40 1’722 (n1=1’549, n2= 173)
0.75 0.2 0.9 0.1 0.2 40 3’552 (n1=3’196, n2= 356)
0.75 0.2 0.8 0.1 0.2 40 2’653 (n1=2’387, n2= 266)
0.5 0.3 0.9 0.2 0.2 26 1’008 (n1= 806, n2= 202)
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Table E.1: (continued)
Parameters specified / assumptions Comparison of mean number of
events per person and year between
two distinct groups (exposed and
unexposed)
Mean num-
ber of
events per
person and
year
Difference in
mean number of
events per person
and year between
exposed and un-
exposed
Power
Pro-
portion
exposed
ICC
Average
number
of weeks
observed
Calculated sample size needed
0.5 0.3 0.9 0.2 0.2 40 660 (n1= 528, n2= 132)
0.5 0.3 0.8 0.2 0.2 26 753 (n1= 602, n2= 151)
0.5 0.3 0.9 0.2 0.5 40 733 (n1= 586, n2= 147)
0.5 0.2 0.9 0.2 0.5 40 1’484 (n1=1’187, n2= 297)
0.5 0.1 0.9 0.2 0.5 40 5’299 (n1=4’239, n2=1’060)
0.5 0.1 0.8 0.2 0.2 40 3’634 (n1=2’907, n2= 727)
ICC = intraclass correlation coefficient
bold: Calculated minimal sample size exceeds envisaged cohort size of 3’000 individuals
Within-subject comparison between two distinct periods (high and low risk period):
Longitudinal comparison of rates
Let X(1)ij = number of events in subject i during unit interval j (e.g. week j) in low risk period
Let X(2)ij = number of events in subject i during unit interval j (e.g. week j) in high risk period
X
X
Assumptions:
(1) X(1)ij = Pois (λ1 + dλi0 + dλi1), j = 1, . . . , m1
(2) X(2)ij = Pois (λ2 + dλi0 + dλi2 + dλi3), j = m1 + 1, . . . , m1 +m2
where λ1 and λ2 denote the average rates in the low and high risk period, respectively,
dλi0 denotes a subject-specific random effect with E (dλi0) = 0 across both periods,
dλi1 and dλi2 denote subject-specific random period effects with E (dλi1) = E (dλi2) = 0 and E
(
dλ2i1
)
= E
(
dλ2i2
)
,
and dλi3 denotes an additional subject-specific random effect in the high risk period with E (dλi3) = 0.
All random effects are assumed to be mutually independent.
We define:
Ui =
1
m2
m1+m2∑
j=m1+1
X
(2)
ij −
1
m1
m1∑
j=1
X
(1)
ij
The variance of Ui conditional on fixed values of the random effects then becomes:
V ar (Ui|random effects) = 1
m2
(λ2 + dλi0 + dλi2 + dλi3) +
1
m1
(λ1 + dλi0 + dλi1)
giving
E [V ar (Ui|random effects)] = 1
m2
λ2 +
1
m1
λ1 (E.1)
Moreover,
E (U1|random effects) = (λ2 + dλi0 + dλi2 + dλi3)− (λ1 + dλi0 + dλi1) = (λ2 − λ1) + (dλi2 − dλi1) + dλi3
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implying that
E
[
E (Ui|random effects)2
]
= (λ2 − λ1)2 + V ar (dλi2) + V ar (dλi1) + V ar (dλi3)
and
V ar [E (Ui|random effects)] = V ar (dλi2) + V ar (dλi1) + V ar (dλi3) (E.2)
For the variance of Ui, which is the sum of E.1 and E.2, we thus obtain
V ar (Ui) =
1
m2
λ2 +
1
m1
λ1 + 2× V ar (dλi1) + V ar (dλi3) (E.3)
If we assume that V ar (dλi1) = V ar (dλi2) = V ar (dλi0) and relate V ar (dλi0) to λ1 through
V ar (dλi0) = (λ1 × CV1)2
where CV1 is the coefficient of variation of λ1 + dλi0, and V ar (dλi3) to |λ2 − λ1| through
V ar (dλi3) = (|λ2 − λ1| × CV2)2
where CV2 is the coefficient of variation of |λ2 − λ1|+ dλi3, then we finally obtain
V ar (Ui) =
1
m2
λ2 +
1
m1
λ1 + 2× (λ1 × CV1)2 + (|λ2 − λ1| × CV2)2 (E.4)
In our power calculations we chose CV1 = CV2 = 0.25. If all random effects were normally distributed, this
would imply that dλi1, dλi2 ∈ (−0.5× λ1, 0.5× λ1) and dλi3 ∈ (−0.5× |λ2 − λ1| , 0.5× |λ2 − λ1|), each with a
probability of 95%.
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Table E.2: Sample size and power calculation for the burden of gastroenteritis in Switzerland (BUGS) study for a
comparison of the mean number of events per person and year between two distinct periods (high and low risk period)
based on different parameter assumptions
Parameters specified / assumptions Comparison of mean num-
ber of events per person
and year between two dis-
tinct periods
Mean num-
ber of
events per
person and
year
Difference in
mean number of
events per person
and year between
high and low risk
period
Power Proportion
observed
weeks at
high risk
Indi-
vidual
coeffi-
cient of
variation
Average
number
of weeks
observed
Calculated sample size needed
1 0.3 0.9 0.2 0.25 40 1’133
0.75 0.3 0.9 0.2 0.25 40 890
0.75 0.3 0.9 0.2 0.25 26 1’365
0.75 0.3 0.9 0.2 0.25 52 687
0.75 0.2 0.9 0.2 0.25 40 1’875
0.75 0.2 0.8 0.2 0.25 40 1’400
0.75 0.1 0.8 0.2 0.25 40 5’219
0.75 0.2 0.9 0.2 0.5 40 1’926
0.75 0.2 0.9 0.2 0.5 26 2’926
0.75 0.2 0.8 0.2 0.5 26 2’186
0.75 0.3 0.9 0.1 0.25 40 1’678
0.75 0.2 0.9 0.1 0.25 40 3’472
0.75 0.2 0.8 0.1 0.25 40 2’593
0.5 0.3 0.9 0.2 0.25 26 996
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Table E.2: (continued)
Parameters specified / assumptions Comparison of mean num-
ber of events per person
and year between two dis-
tinct periods
Mean num-
ber of
events per
person and
year
Difference in
mean number of
events per person
and year between
high and low risk
period
Power Proportion
observed
weeks at
high risk
Indi-
vidual
coeffi-
cient of
variation
Average
number
of weeks
observed
Calculated sample size needed
0.5 0.3 0.9 0.2 0.25 40 649
0.5 0.3 0.8 0.2 0.25 26 744
0.5 0.3 0.9 0.2 0.5 40 659
0.5 0.2 0.9 0.2 0.5 40 1’354
0.5 0.1 0.9 0.2 0.5 40 4’905
0.5 0.1 0.8 0.2 0.25 40 3’595
bold: Calculated minimal sample size exceeds envisaged cohort size of 3’000 individuals
References
1. Hayes RJ, Bennett S: Simple sample size calculation for cluster-randomized trials. Int J Epidemiol 1999, 28:319–326.
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Appendix F
Selected media articles
F.1 Selected media reactions on studies
presented in this thesis
Figure F.1: Newspaper article in response to publication on healthcare costs
of acute gastroenteritis and campylobacteriosis; Source: Volksblatt Liechten-
stein, 13.08.2016, page 32
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Appendix F Selected media articles
Figure F.2: Newspaper article in response to publication on acute gast-
roenteritis in Swiss primary care, Sentinella; Source: Corriere del Ticino,
05.08.2017, page 5
Figure F.3: Newspaper article in response to publication on acute gastroen-
teritis in Swiss primary care, Sentinella; Source: Walliser Bote, 05.08.2017,
page 19
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Figure F.4: Newspaper article in response to publication on acute gastroenteritis in Swiss primary care, Sentinella; Source:
Tages-Anzeiger, 26.08.2017, page 58
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Appendix F Selected media articles
F.2 Selected media reactions on surveillance
data
Figure F.5: Newspaper article in response to interview aired on Swiss TV,
based on weekly situation report on influenza-like illnesses published in the
“BAG Bulletin”; Source: 20 Minuten (issue region Basel), 09.03.2018, page 9
Figure F.6: Newspaper article in response to weekly situation report on tick-
borne diseases published in the “BAG Bulletin”; Source: 20 Minuten (issue
region Basel), 10.07.2018, page 11
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